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ABSTRACT
From the 1980s onwards pharmaceutical manufacture evolved from a fragmented 
industry to a global oligopoly. In the ecology literature coevolution theory proposes that 
competing species (incumbent firms) interact and shape each others’ development, and 
that this in turn potentially shapes the community (industry) structure. This suggests that 
when exploring how firms’ strategies changed during a period of significant industry 
change it is important to understand processes of both strategy evolution and 
coevolution in order to understand the dynamics of strategic change. This led to the 
research question 'How did the realised strategies of a heterogeneous set of firms 
coevolve during the period of pharmaceutical industry consolidation from 1992-2002?’ 
In order to answer this a categorisation of strategic actions realised by firms in the 
pharmaceutical industry was developed. This was used as the basis of a methodological 
framework which used qualitative document analysis to longitudinally analyse how the 
grand strategies and strategic actions of a set of six pharmaceutical firms evolved and 
coevolved. These firms had arrived at different strategic outcomes and were selected 
using purposive sampling and replication logic. For the period 1992-2002 it was found 
that each firm realised unique patterns of grand strategy evolution. Further, the strategic 
actions that formed realised strategies coevolved both with the strategic actions of other 
firms and with the structure ot the pharmaceutical industry as it became increasingly 
consolidated and globalised. Contributions to theories surrounding the environmental 
determinism versus strategic choice debate have been made with the findings supporting 
theories of coevolution, incremental and emergent strategy, and temporal patterns in 
strategy development. New contributions to knowledge were the development of a 
theory of pharmaceutical industry coevolution, development of a methodological 
lramework tor understanding strategic change in the pharmaceutical industry, and the 
creation of techniques to aid strategic decision making.
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CHAPTER ONE
INTRODUCTION TO THE THESIS
1.1 Introduction
The aim of this thesis is to make a contribution to the existing body of knowledge about 
strategic change by exploring processes of strategy evolution and coevolution. The 
thesis explains how the realised grand strategies and strategic actions for a set of firms 
evolved and coevolved as the pharmaceutical industry underwent significant structural 
change. This thesis contributes to existing knowledge in the strategic change literature 
with regard to theory, method and practice. This chapter provides an overview of the 
thesis. The research rationale explains the reasons for focusing upon the subject of 
strategy processes and strategic change in the pharmaceutical industry. This is followed 
by details of the assumptions underpinning the thesis which leads into an outline of the 
research question and sub questions that are addressed. As the acaderhic literature 
contains different interpretations of the key themes discussed, a section outlining the 
definitions has been included. The chapter closes with a summary of the relevant 
literature that is reviewed and details about the structure of the thesis.
1.2 Research Rationale
According to the Structure-Conduct-Performance (S-C-P) paradigm changes in industry 
structure influence strategy evolution in incumbent firms (Bain, 1956; Mason. 1959) 
and that those strategies shape industry structure (Scherer. 1980). The S-C-P paradigm 
suggests that firm strategies lead to industry consolidation which leads to changes in 
incumbent firm strategies; and so a cycle continues. As an industry consolidates, 
incumbent firms arrive at different strategic outcomes such as being acquired, merged 
or liquidated, which leads to an increased concentration of larger firms. Yet this 
relationship between strategic outcomes and industry structure has not been explored.
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possibly because the S-C-P model emphasises industry structure (Baumol. 1982) and 
not the evolution of individual firm strategies.
From the 1980s onwards the pharmaceutical industry structure has undergone 
significant structural change as it evolved from being highly fragmented to being a 
global oligopoly accompanied by a high number of small new entrants (Jones and 
Cockerill. 1984; Kettler, 2001a). The industry has seen several ‘megamergers' and the 
disappearance of smaller biotechnology firms as they have either been acquired or failed 
to survive. In 2000 the Office of Health Economics hosted a conference that focused on 
"Consolidation and Competition in the Pharmaceutical Industry” (Kettler, 2001a). 
Among the issues explored were "the role of external networks in the pharmaceutical 
R&D process” (Kettler, 2001b:29), “changing market dynamics and industrial 
structures” (Grabowski and Vernon, 2001:62) and “Investors’ Views on Merger and 
Acquisition. Alliance and Licensing Activity in the Pharmaceutical Industry” (Walton. 
2001:80). However, what this conference did not explore, and what appears not to have 
been explored in the existing strategic change literature, was how' the realised grand 
strategies and strategic actions of individual firms have evolved and coevolved during 
the changes in industry structure. Specifically, how these evolved and coevolved for 
firms that arrived at different strategic outcomes.
Population ecologists and corporate demographers have focused upon types of strategic 
outcome in their studies of births, deaths and transformations, tracking these for a 
complete industry or population from the start of its life (Carroll and Hannan, 2000). A 
main weakness of this approach, which will be addressed in this study, is that it was 
rarely feasible to provide depth to the factors that had preceded ending events (Davis. 
1996). There is also significant debate as to whether it is strategic choice or the 
environment that determines the fate of organisations (Astley and Van de Ven, 1983). 
Strategic outcomes can also be related to Glueck's (1976) grand master strategies. For 
example, he classes liquidation as a retrenchment strategy. By focusing upon a detailed 
breadth of grand strategies and associated strategic actions this thesis bridges a gap in 
coevolution studies that have had a narrower focus, for example strategic “adaptations” 
(mergers, acquisitions and divestitures) and “strategic partnerships and alliances” 
(Lewin and Volberda 1999:528). Also, there are few longitudinal studies that have 
tracked the coevolution of industry and individual firm strategies (Lewin and Volberda,
1999). Therefore, this thesis aims to contribute to a current gap in our knowledge and 
understanding relating to how firm strategies have coevolved for a group of 
pharmaceutical firms that have arrived at different strategic outcomes as the industry 
structure has become increasingly consolidated and globalised.
1.3 Assumptions Underpinning the Thesis
As will be discussed in the literature review there are a number of endogenous and 
exogenous factors that have the potential to shape the strategies of firms. Due to the 
variety and nature of these potential forces for change it is not possible to accurately 
forecast how they will all impact upon strategic actions. Therefore, one of the main 
assumptions of this thesis is that, in order to understand what strategy is, one has to look 
at the strategic actions that firms have actually implemented, i.e. those that were 
realised, in order to identify patterns that show consistent behaviour.
A second assumption is that it is possible to identify the strategies that were realised. In 
other words, it is possible for a researcher to reconstruct the real world of strategy 
implementation and extend this to identify links between how the strategic actions of 
each firm have coevolved with those of incumbent firms and changes in industryO  J
structure.
A third assumption is that if people are asked to recall events there is a process of 
justification or problems with memory recall, which affects their perceptions when 
recalling events that have happened. This suggests that, when examining strategy 
decisions, it would be best to use documentary sources to collect data on the strategic 
actions that were realised in order to identify the grand strategies and strategic actions 
that were realised.
A fourth assumption is that in periods of consolidation and globalisation firms cannot be 
grouped on the basis of overall strategic thrusts as argued in the strategic group 
literature. Rather that, as the industry is undergoing significant change the strategies of 
all firms in an industry undergo some process of coevolution which can be 
demonstrated through the chronological tracking and analysis of strategic actions.
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Finally, the fifth assumption is that the strategies of firms cannot be understood by 
focusing upon a limited number of strategic variables or at a limited number of levels. 
All strategic actions that have been implemented by a firm need to be identified as far as 
is feasible during the data collection process. Therefore quantitative techniques that lead 
to the forced clustering or reduction of variables are of limited value to this type ot 
research. A qualitative approach is more informative as it involves interpretation of the 
findings as they emerge and leads to the identification of patterns through methods such 
as chronological ordering (Mintzberg and Waters, 1982), pairing and pattern matching.
1.4 Research Questions
The purpose of this thesis is to explore how the realised strategies and strategic actions 
of incumbent firms in an industry have evolved and coevolved during a specific period 
of industry change. The literature so far has not focused upon how firms' realised 
strategies, at the level of the strategic action, have both evolved and coevolved prior to 
different strategic outcomes. This research aims to contribute to the field of strategy by 
developing further a theory of strategic coevolution for the pharmaceutical industry.
The research is guided by the conceptual framework (Figure 1.1) which illustrates the 
lines of inquiry that were undertaken in order to understand this process.
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Figure 1.1 Conceptual Framework of the Coevolution of the
International Pharmaceutical Industry: 1992 - 2002
Environmental Forces Coevolving 
With Firms’ Strategic Actions
Industry structure starts to undergo
change:
Globalisation and consolidation
Realised Strategic Actions 
of Heterogeneous Set of Incumbent
Firms
Strategic outcomes 
(realised strategic actions) Realised strategic actions of a 
heterogeneous set of 
incumbent firms
Industry continues to 
consolidate and moves closer 
to becoming a global 
oligopoly
Source: Compiled by the author
This model was developed from the literature and is discussed in more detail in Chapter 
Four. The review of the literature and the subsequent development of the conceptual 
framework led to the research question:
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‘How did the realised strategies of a heterogeneous set of firms coevolve during the
period of pharmaceutical industry consolidation from 1992-2002?
In order to answer this question a number of sub questions also needed to be addressed 
These were:
Rl: What strategic actions were realised by firms in the pharmaceutical industry
during 2001-2002?”
R2: How did the realised grand strategies of a heterogeneous set of firms evolve 
during the period of pharmaceutical industry consolidation from 1992-2002?
R3: How did the realised strategic actions of a heterogeneous set of firms 
coevolve with each other’s strategic actions during 1992-2002?
R4: How did a heterogeneous set of firms realise internationalisation strategies
during the period of pharmaceutical industry consolidation from 1992-2002?
The rationale for these sub questions, and how they were derived from the conceptual 
framework, is discussed in Chapter Four.
1.5 Definitions of Key Terms
The following key terms are used in this thesis.
Strategy In this study strategy is considered as “a sequence of united events which 
amounts to a coherent pattern of business behaviour” (Kay, 1993:9) and “a 
pattern....consistency in behaviour over time" (Mintzberg et al., 1998:9) with the 
strategy being underpinned by the actions that were implemented.
Planned linear strategy is the “determination of the basic long-term goals of an 
enterprise, and adoption of courses of action and the allocation of resources necessary 
for carrying out these goals" (Chandler, 1962:13).
Emergent strategy has been defined as “patterns or consistencies realised despite, or in 
the absence of, intentions"(Mintzberg and Waters, 1985:257).
Realised strategy can either be emergent or intended, as in planned linear strategy, but 
the key point is that realised strategy is “what the organisations actually did"(Mintzberg 
and Waters, 1985:257). This can be understood through identifying the strategic actions 
that were actually implemented.
Strategic actions This thesis has adopted the definition used by Miller and Chen 
(1994:9) when they identified competitive actions as “implemented, public, market- 
oriented decisions, those significant concrete actions taken by an organisation that are 
observable by customers, competitors, and other industry participants." In other words, 
those that were publicly reported.
Evolutionary theory The emphasis of this thesis with regard to the research design 
incorporates the view that “evolutionary theory places dynamics, process 
transformation at the centre of the analysis" (Malerba, 2004:15). Hence the research 
design has focused upon using a longitudinal design to collect data so that changes in 
the strategy process can be analysed for firms that arrived at different strategic 
outcomes, i.e. that transformed themselves from their original organisational form.
Coevolulion theory Lewin and Volberda (1999:527) proposed that coevolution is
“conditions of simultaneous evolution that persist over long time periods”. Futuyma and
Slatkin (1983:3) believed that “the study of coevolution is the analysis of reciprocal
genetic changes that might be expected to occur in two or more ecologically interacting
species and the analysis of whether the expected changes are actually realised”. This is
extended to focus upon how “coevolution may influence several interacting species and
possibly even an entire community” (Roughgarden. 1983:57). The thesis encompasses
the coevolution of species and community by identifying how the selection forces that
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shape the community (industry structure) can be shaped by the incumbent species and 
vice versa. In other words how the species (incumbent firms) and community (industry 
structure) coevolve.
Strategic outcomes The definition of strategic outcomes for this study is adapted from 
the corporate demography literature relating to ‘vital events* (Carroll and Hannan, 
2000:45). The term ‘strategic outcome* is used to define how firms evolve into a 
different species, for example as a result of being merged, demerged, acquired or 
liquidated.
The Pharmaceutical Industry “The pharmaceutical industry may be defined as being that 
part of the chemical industry which is concerned with the manufacture and marketing of 
products for the prevention, diagnosis and treatment of diseases in humans'* (Bremner, 
1992:17). For this study the definition has been extended in order to encompass the 
symbiotic relationships that traditional pharmaceutical firms have developed with 
biotechnology organisations (Kurdas. 1998; Rothaermel, 2000). Therefore, the term 
‘pharmaceutical industry* used in this thesis is the same as that referred to as 
‘biopharmaceuticaf in some academic papers.
1.6 Structure of the Thesis
The theoretical underpinning of this thesis has been shaped by literature from the fields 
of strategic management, economics, organisation theory and ecology and is specifically 
guided by coevolution theory. The literature review can be broadly categorised under 
the headings: strategy, forces for change and the pharmaceutical industry, as illustrated 
in Figure 1.2
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Figure 1.2 The Overlap of Relevant Literature
Source: Compiled by the author
Chapters Two and Three review the literature shown in Figure 1.2 and present
conclusions as to why the pharmaceutical industry provides a suitable context for
understanding processes of strategy and evolution and coevolution of strategic actions.
Chapter Four presents a methodological framework for qualitatively analysing how
firms’ strategies and strategic actions evolve and coevolve. It explains the process for
selecting six firms for the sample, each of which had arrived at a different strategic
outcome. Chapter Five chronologically presents the results of the strategic actions
realised by each of the firms in the sample during 1992-2002. Chapter Six discusses
these results in relation to grand strategies and related internationalisation strategies. It
explores the strategies that were selected by each firm and how they evolved. The
chapter also presents an Empirical Typology of Grand Strategy Evolution and
contextualises the strategy evolution process. Chapter Seven discusses temporal patterns
in strategy development for the firms in the sample. It also explores how the realised
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strategic actions coevolved and discusses issues relating to interdependence and path 
dependence with regard to the coevolution process. A theory of pharmaceutical 
industry coevolution which is presented in the form of a model is also developed. 
Chapter Eight presents the main conclusions of the study and discusses the 
contributions of the thesis with regard to theory, method and practice. Limitations of the 
work are acknowledged and suggestions are given for future research which could 
develop the findings. Chapter Eight also includes a reflection of the journey travelled 
during the doctoral studies for this thesis.
1.7 Chapter Summary
Chapter One has set the context for this thesis. It has provided a rationale for the study 
and the research question and sub questions that will be explored. Definitions 
underpinning the research and the structure of the thesis were presented. The next 
chapter reviews the literature with regard to strategy and change.
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CHAPTER TWO 
LITERATURE REVIEW: 
STRATEGY AND CHANGE
2.1 Introduction
The main themes of the literature review were outlined in Chapter One. This chapter 
explores the literature with regard to strategy, forces for change, and industry evolution. 
It begins with a discussion of the concept of strategy and the continuum of strategy 
processes. A view that underpins this thesis is that strategy is not an isolated process 
but one that develops as a result of various evolving endogenous and exogenous factors. 
The literature review explores what these factors are. how they can evolve, and how 
they have the potential to influence the strategy process and the strategic outcomes of 
individual firms. This leads to a review of the environmental determinism versus 
strategic choice debate; concluding that coevolution theory can provide a new' 
understanding of what determines the fate of organisations. '
2.2 The Concept of Strategy
All organisations have broad goals of some form ranging from short-term survival to 
long-term visions (Ansoff. 1968; Suarez and Utterback, 1995). In broad terms, strategy 
is the overall guiding framework that enables an organisation to work towards its vision 
and goals and it should be designed to provide consistency in strategic actions 
(Hambrick and Fredickson. 2001). Although it has been suggested that strategies are the 
routes to decision making, such as which businesses should be in the portfolio, how the 
businesses should compete and how the firm should achieve growth (Ansoff. 1968; 
Hrebiniak et al., 1989; Thomas and Pollock. 1999). it should be noted that there is no 
general consensus about the meaning of the term strategy (Huff et al.. 1994; Lynch, 
1997; Markides, 2001). Despite this there is some consensus that strategy guides the
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overall direction of an organisation as it seeks to maintain a strategic fit with its 
environment (Henderson, 1989; Barney, 1991; Porter, 1996).
It has been argued that the ultimate objective of strategy development is to achieve 
advantage over competitors that will lead to the long-term maximisation of profits 
(Porter. 1985) with organisations placing a priority on achieving a competitive 
advantage that can be sustained whatever the economic conditions (Bogner et al., 1999). 
If an organisation does not achieve a fit with its environment and subsequent advantage 
over its competitors, its ability to earn profits will be restricted. Profits are needed for
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re-investment into the organisation so that it can continue to grow (Porter, 1996). 
Organisations that do not develop strategies to adapt to changing environments risk 
being selected out; in other words they fail to survive (Carroll and Hannan, 1995). So, 
firms should strive to implement strategies that differentiate them from their 
competitors whatever the environmental conditions (Henderson, 1989) in order to 
maximise their chances of survival; in other words, the achievement of competitive 
advantage. In order for competitive advantage to be achieved it has been proposed that 
the focus should be on strategy as a balancing unifying process in which organisations 
seek to find (albeit often temporarily) a unique position, vis-a-vis their competitors, i.e. 
the achievement of competitive advantage (Mintzberg and Lampel, 1999; Hambrick and 
Fredrickson, 2001; Markides, 2001).
During the past 40 years there have been various perspectives on where organisations
A
should focus when formulating strategies in order to achieve strategic objectives. In his 
seminal paper Chandler (1962:383) explained that "strategy has been the plan for the 
allocation of resources to anticipated demand."’ Alfred Chandler's description of 
strategy in 1962 summed up the relative simplicity of the environment that 
organisations had been operating in during the first half of the last century. 
Organisations initially started-up to sell a standard product which was produced in 
sufficient quantities to meet demand. As Chandler's (1962) work illustrated, 
organisations and their products gradually became more complex. It was recognised 
that existing products could be sold in new markets overseas and that standard products 
could be produced in different formats. This has led to growth in both the size of 
organisations and the level of competition.
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Appearing to build upon the descriptive work of Chandler (1962), Ansoff (1968) 
developed a prescriptive model of how strategic decisions should be made. He proposed 
that resources should be maximised through the development of budgets, with strategies 
designed to achieve the budget’s objectives. The focus of corporate strategy was upon 
defining the current business and the potential for new businesses. Emphasis was placed 
upon decisions relating to product and market development. Analysis focused upon the 
viability of various options with emphasis given to the return on long-term investments. 
Subsequent selection decisions could be made in order to develop a portfolio of 
complementary products and markets. Emphasis was placed upon long-term planning 
and ensuring that the organisation was in control with regard to making strategic 
choices that allowed adaptation to a changing environment. Strategic decisions were 
based upon an analysis of the extent of risks posed by threats in the external 
environment and the capabilities and resources of the organisation in relation to 
opportunities (Andrews, 1991). This leads to the development of corporate level 
strategy which is focused upon defining the mission of the organisation, the corporate 
objectives, and policies that lead to it achieving its purpose (Hitt and Ireland, 1985; 
Andrews, 1991; Lynch, 1997). It defines the nature of its external relationships 
(Andrews, 1991; Kay, 1993) and the businesses, markets and activities that it is in or 
will engage in (Ansoff. 1968: Kay 1993). In order to achieve this mission, plans are 
developed to achieve corporate objectives to ensure fit with the external environment 
whilst utilising internal resources (Lynch. 1997). This strategic planning approach has 
been advocated for use by small and medium-sized enterprises (Analoui and Karami,
2003).
The overall purpose of corporate level strategy is to create synergy throughout the
businesses controlled by the corporate parent in order to maximise profits. Profit
maximisation has its roots in economic theory which suggests that the primary objective
of organisations is to maximise profit (Penrose, 1959; Porter, 1980). Penrose (1959)
argued that managers are motivated to maximise profits because they received benefits
such as increased status and pay as a result of profits being reinvested back into the
organisation, leading to increased growth. Although writers such as Chandler (1962)
appear to assume that the objective of strategy is to ensure organisational growth there
is no consensus that growth is the only objective of strategy. For example, Greer and
Hoggett (1999:239) defined strategy as being concerned with "survival and/or growth.”
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2.3 The Continuum of Strategy Processes
Chandler (1962), Ansoff (1968) and Andrews (1991) were the main proponents of the 
view that strategy is a logical process based upon linear planning or design. However, 
there are other schools of thought concerning the extent to which the strategy process is 
planned or incremental. Whether strategy should be viewed as being an incremental, 
revolutionary, emergent or realised process is now considered.
2.3.1 Strategy> as an Incremental Process
Lindblom (1959; 1979) argued that policy (or strategy) decisions cannot be made in a 
linear, one direction, process. Rather, the process involves frequent refinement with 
decisions needing to be re-visited in order to redefine the problems, objectives and how 
the issues can be resolved. The suggestion was that long-term decisions cannot be 
planned but involve the organisation making changes step-by-step as it comes across 
new situations. Further, that strategies should be changing processes of refinement in 
light of new information. Although each decision is relatively small, over time, the 
actions will amount to major changes (Baden-Fuller et al., 1994). This process has been 
termed incrementalism and thus enables the organisation to maintain fit with its 
changing environment (Lindblom. 1979; Quinn, 1991). Johnson (1988) disagreed, 
proposing that over time a gap develops between the strategic decisions and the changes 
in the environment leading to what he termed ‘strategic drift' which would lead to a 
mismatch between the organisation's strategic decisions and its environment. As Strebel 
(1992) argued, this step-by-step form of change is not effective for all organisations all 
of the time. For example, if there is a sudden major change, what he termed a 
breakpoint, either in the organisation's immediate or competitive environment then 
incremental changes in strategy would not be sufficient for a firm to maintain strategic 
fit with its environment. Taking this further Ansoff and McDonnell (1990) argued that 
incremental change is reactive, that it focuses upon problems after they had occurred, 
rather than pre-empting them.
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2.3.2 Strategy> as a Revolutionary Process
Criticising the incremental approach. Hamel's (1996) view was that rather than being 
reactive to fast changing environments successful organisations are those which are 
proactive. Hamel and Prahalad (1993) suggested that organisations in which managers 
were focused upon attaining success over more powerful rivals were able to accomplish 
this by thinking outside of the normal mindset of what is achievable. The desire to 
succeed motivates them to stretch resource capabilities to their maximum in order to 
outpace the strategies of competing organisations (Hamel and Prahalad. 1993). Hamel 
(1996) considered that for organisations wanting to succeed, strategy should be 
groundbreaking, encompassing all members of the organisation and ignoring existing 
industry rules. However, Porter (1996) argued that the revolutionary approach prevented 
the long-term focus necessary for sustained competitive advantage as a firm seeks to 
develop its position within a specific industry. Hamel (1996) countered this, suggesting 
that by thinking outside industry rules the revolutionary approach may help a firm to be 
a driver of industry change.
Hamel (1996) prescribed guidelines in order for a firm to undertake this revolutionary 
approach. However, he does not appear to propose what an organisation should do if the 
revolutionary strategy actually leads the firm into a strategic drift away from its 
environment. In order to prevent potential strategic drift Tushman and O'Reilly (1996) 
argued that the key to long-term organisational success is the ability to combine both 
the incremental and revolutionary approaches. This could enable the firm to maintain 
fit with its environment whilst being sufficiently innovative to maintain competitive 
advantage. This is a view similar to that discussed with regard to Mintzberg’s (1987) 
concept of emergent strategy which will now be discussed.
2.3.3 Strategy as an Emergent Process
Mintzberg (1994) suggested that although strategies could be deliberate there are
problems if the focus is only upon planned strategic decisions. For example, the
planned approach to strategy is based upon anticipated changes in the environment
rather than focusing upon changes as they occur. Organisations may not always be
effective in their judgement of the impact of changes in the environment (Kiesler and
15
Sproull. 1982) and the risk is that adherence to the plan is rated more highly by 
management than the need to change (Johnson. 1988). This would suggest that 
strategies cannot be planned too far in advance but instead need to emerge as 
management becomes aware of new information and identifies how its organisation can 
maximise the opportunities and minimise the threats as they arise (Sawy and Pauchant, 
1988; Mintzberg, 1994).
Penrose (1959) argued that an organisation needs to be entrepreneurial in order for it to 
grow, that rational decision making is not sufficient if an organisation is to maximise 
the opportunities for growth. As part of his critique of the long-term planning focus, 
and appearing to build upon Penrose's (1959) view, Mintzberg (1987; 1994) proposed 
that formal long-term planning in isolation stifled the creative process. This prevents the 
organisation from adapting its strategy to maximise the opportunities resulting from 
new, unexpected discoveries. In other words, formal planning prevents the emergence 
of ideas that would lead to the development of the unique strategies required to give an 
organisation competitive advantage (Mintzberg, 1994). This is based upon the proposal 
that a synthesis of shared ideas leads to the development of unique products which 
provide organisations with an advantage over competing product offerings (Mintzberg. 
1994). Mintzberg and Lampel (1999) argued that this could be enhanced through 
collaboration with other organisations as information is shared.
2.3.4 Strategy as a Realised Process
In this chapter so far, four perspectives about the process of strategy along a continuum
■term to step-by-step incrementalism, from adapting to
changes in the environment to ignoring existing rules have been considered. Each of 
these approaches to strategy may be suitable at different times and to different 
organisations. What appears to be important is that organisations seek continual success 
whilst facing changing environments. Organisations evolve over time and so do their 
environments, suggesting that strategy should be an evolutionary process with different 
strategic processes required at various times.
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Other authors have attempted to classify strategy. For instance. Whittington (1995) 
chose to categorise strategy schools based upon whether they were focused on profit 
maximisation or pluralism along one continuum and were deliberate or emergent on the 
other continuum. This provided four generic perspectives on strategy which he classed 
as the Classical approach (profit maximising and deliberate), the Processual approach 
(emergent and pluralistic), the Evolutionary perspective (profit-maximising and 
emergent) and the Systemic perspective (deliberate and pluralistic). Mintzberg el al. 
(1998) produced ten categories of strategy formation based upon the relevant processes, 
for example that strategy is a process of negotiation or a visionary process. They 
proposed that each of the ten 'schools' had focused on a different part of the strategy 
process rather than considering strategy as a unifying concept, although they did add 
that recent work had moved towards focusing upon a more integrated rather than 
segmented approach.
There is an emerging view in the current literature that the different perspectives of 
strategy are not as different as the various ‘schools’ would suggest (Mintzberg and 
Lampel. 1999; Hambrick and Fredrickson, 2001; Markides. 2001). Ideally the purpose 
of strategy is to guide organisations towards the achievement of long-term, advantage 
over competitors (i.e. competitive advantage) and that this advantage should be 
sustainable (Henderson, 1989; Barney, 1991; Porter, 1996) with the ultimate objective 
being to achieve long-term profit maximisation (Porter. 1985) with organisations 
placing a priority on achieving competitive advantage that can be sustained whatever 
the economic conditions (Bogner et al., 1999).
Although scholars may agree that strategy should lead to the achievement of long-term
objectives Porter (1996) argued that as firms had sought to maximise profits in
increasingly fast changing environments they had moved their focus from strategy to
organisational efficiency. Although efficiency is important for profit maximisation.
Porter (1996) argued that by reacting to change rather than long-term strategic
positioning the result had been continually low profits with a reduced ability to make
long-term investments. He suggested that this shift in perspective away from strategy
meant that organisations no longer had the ability to undertake strategic thinking,
although this appears quite a generalisation. As defined in Chapter One realised
strategy can be considered as “what the organisations actually did" (Mintzberg and
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Waters, 1985:257) rather than their intentions or plans. By exploring how realised 
strategies evolved researchers can start to develop an understanding of what actually 
happened. This suggests that "real world' research into strategy should examine how 
organisations have actually implemented strategies over a period of time in order to 
develop understanding of the strategy process rather than focusing upon plans. As the 
next sections will demonstrate, there are a wide variety of factors that have the potential 
to shape how strategies evolve, and thus lead potentially to differences between planned 
and realised strategies.
2.4 The Relationship Between Strategy and Competition
It has been proposed that if an organisation does not have competitors it does not need a 
strategy (Ohmae, 1982). Thomas and Pollock (1999) suggested that there has been a 
major focus in the strategy literature on how organisations should compete and who 
they are competing with. Organisations can face competition as a result of market forces 
or be protected by government actions such as public ownership (Mason. 1959). 
Competition limits the power of individual organisations by preventing them from 
charging excessive prices or limiting supply to the detriment of the public. It has also 
been argued that defining the scope of competitors is important for an organisation to be 
able to develop appropriate strategies (Campbell-Hunt. 2000). Literature regarding the 
nature of competition and competitors is now' reviewed.
2.4.1 Perfect Competition
Perfect competition, a hypothetical concept, underpins traditional economic theory and 
is based upon a series of assumptions (Cohen and Cyert. 1975; Scherer, 1980). For 
example, many organisations operate in an industry with an homogenous product, 
w'hich all firms produce to the same standard (Cohen and Cyert. 1975) and that, if above 
normal profits are seen to be earned, this will attract new entrants which will return the 
industry to equilibrium (Scherer. 1996a). According to the concept of perfect 
competition, no seller has monopoly power to protect, incumbent firms face no barriers 
to resource mobility, and potential entrants face no barriers to entry (Cohen and Cyert,
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1975; Scherer, 1980). The concept of perfect competition has attracted criticism 
because it is not a reflection of real life situations (Baumol. 1982; Cohen and Cyert. 
1975; Henderson. 1989). For this reason various models have been developed for 
undertaking competitive analysis, many of which are underpinned by the S-C-P 
paradigm, which will now be discussed.
2.4.2 The Structure-Conduct-Performance (S-C-P) Paradigm
Many of the models for competitive analysis are based upon the theory that there is a 
causal link between the structure of an industry, the strategies developed by 
organisations (organisation conduct) and the level of profits that can be earned (Bain, 
1956; Mason. 1959). Scherer (1980) proposed that not only did structure have the 
ability to shape the conduct of firms but also that firms had the ability to shape the 
structure of the industry. This causal relationship was identified by Industrial 
Organisation Economists with the key concepts pioneered by Bain (1956) and Mason 
(1959) and is referred to as the Structure-Conduct-Performance (S-C-P) paradigm 
(Scherer, 1980; Bogner et a/., 1998; Thomas and Pollock. 1999). Structure refers to 
factors such as the number of sellers and buyers, barriers to entry, cost ^structures, 
product differentiation and vertical integration. Conduct (strategy) refers to factors such 
as pricing behaviour, product strategy, advertising, research and innovation, plant 
investment and legal tactics. Performance includes measures such as levels of 
efficiency, progress, full employment and equity (Scherer, 1980; Bogner et al., 1998).
A criticism put forward by Baumol (1982) was that the S-C-P model places more
emphasis on industry structure than it should do. His alternative perspective on the
relationship between structure, conduct and performance was the theory of the
‘contestable market’. He argued that a particular type of industry structure does not
necessarily equal a particular type of performance. For example, new entrants alter the
structure of an industry and its composition. According to the contestable markets
theory it is merely the threat of new entrants that can make organisations change their
conduct. The industrial organisation perspective places emphasis on the effect of
conduct on industry performance and structure rather than structure having the main
effect, although a large emphasis is placed upon market concentration using precise
neoclassical models such as monopoly and oligopoly. However a criticism of this
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approach is that its focus is very narrow which gives it a limited application to real life 
situations. It does however suggest that government policies focusing on industry 
structure in order to change conduct may be misplaced (Ferguson and Ferguson. 1994). 
The S-C-P model has provided a valuable basis for much of the competitive strategy 
literature (Jones and Cockerill, 1984; Faulkner and Johnson. 1992; Grant and Cibin. 
1996) and was utilised by Porter (1980) in his pioneering work into generic competitive 
strategies. These strategies are discussed in Section 2.4.4.
2.4.3 Identification o f Competitors
Market structure studies provide a basis for analysing how firms compete with each 
other. The unit of analysis is firms that have been allocated to an industry on the basis 
of their products being close substitutes leading to a high cross elasticity of demand. 
Measures of analysis can focus upon barriers to entry, level of demand and the 
associated price and income elasticities, concentration of buyers and sellers and product 
differentiation (Jones and Cockerill. 1984; Ferguson and Ferguson. 1994). Flowever. it 
is important to note the difference between markets and industries. Markets are 
groupings based upon the buyer’s perspective, what the buyer perceives as being close 
substitutes which equates to there being a high cross elasticity of demand. Therefore, 
firms that are in the same industry do not necessarily compete in the same markets. 
Thus. Scherer (1980) proposed that competitors are rivals that are directly competing 
for the same customers or resources.
It has been argued that defining the scope of competitors is important for an 
organisation to be able to develop appropriate strategies (Campbell-Hunt, 2000) as it 
seeks to differentiate itself from competitors in order to increase sales and maximise 
profits. A firm thus seeks to achieve advantage over rivals as it develops potential new 
customers, captures rivals’ customers and competes for shared customers (Warren. 
1991). Makowski and Ostroy (2001) conceptualised perfect competitors as those who 
could create intense rivalry by undertaking any actions necessary to increase profits. 
Through measures such as bargaining, perfect competitors would take every action 
possible to maximise profits in an industry until there is no surplus to be earned by other 
firms. In other words, any firms in an industry could be classed as a rival. However.
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Porter (1996) argued that if firms undertake actions to stay ahead of all competitors they 
risk becoming all things to all people leading to persistently low profits.
Companies can focus too much on meeting the needs of core customers, which places 
them at risk for example from potential new entrants (Porter. 1980). Incumbent firms 
may be unprepared for new technology offerings from organisations outside the 
industry that they had not previously considered as competitors, who then target their 
core customers (Bower and Christensen. 1995). As these new organisations steal 
customers there is a loss of income for the incumbent organisations, w hich could lead to 
difficulties in accessing the necessary resources for survival and growth. Even if the 
sales orders of a company exceed those of rivals if they do not have sufficient resources 
to meet the orders then they cannot be converted to actual sales. Therefore, a company 
needs to focus on both acquiring customers and resources in order to achieve 
competitive advantage. Both researchers and firms have perspectives as to how they 
identify who the competing firms are. This review considers the perspectives of 
industry positioning and structural analysis, competitive strategies and the related 
concept of strategic group analysis (SGA).
<
Porter (1996) proposed that in order to achieve competitive advantage organisations 
should focus upon developing a unique, long-term strategic position within an industry 
that would allow them to achieve superior performance. The focus of competitive 
strategy is how each business competes in its market(s) as it seeks to achieve advantage 
over competitors (Day el al., 1987) through the development of an industry position that 
leads to profit maximisation (Porter, 1980; Kay, 1993).
In order to identify a niche in which a firm could develop its industry position. Porter
(1985) developed a structural analysis model adapted from the S-C-P paradigm to
understand the forces that can affect the level of rivalry in an industry. This was
designed to provide an analytical framework for strategists to understand the impact of
the bargaining power of suppliers and buyers and the threats posed by substitutes and
new entrants together with the extent of industry rivalry. Porter (1985) argued that
different industries had different levels of attractiveness based upon the profits that
could be earned. The structural analysis model was designed to provide a framework for
organisations to develop generic strategies that would enable them to identify the best
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strategic position in an industry in order to achieve sustainable competitive advantage 
and maximise profits. In essence importance was placed upon how the firm positioned 
itself in an industry vis-a-vis its competitors and it was suggested that changes in this 
industry structure affected the conduct of managers, i.e., how they formulate strategies.
2.4.4 Generic Competitive Strategies
Porter (1980) argued that competitive advantage could be achieved through 
implementing one of three generic competitive strategies after industry structural 
analysis had been undertaken. According to Porter (1980; 1985) a firm has a choice 
between three forms of generic competitive strategy that it should adopt in order to 
achieve sustainable competitive advantage, which would lead to profit maximisation 
within an industry. These strategies were overall cost leadership, differentiation and 
focus. Analysis of each stage of the value chain would enable a business to pursue a 
cost leadership strategy that allows it to provide products or services at the same quality 
or price as competitors. The emphasis on cost leadership allows it to earn superior 
profits. These can then be used to increase marketing intensity, invest more than 
competitors in research and development or reduce prices to customers. Differentiation 
could be achieved through the development of distinctive competences within the 
organisation allowing it to be more innovative than competitors. This could allow the 
firm to either achieve first mover advantage and/or to achieve premium prices thus 
maximising profits. The focus strategy involves a firm concentrating on the needs of a 
small niche of customers with a specialised product. Porter (1980) warned that most 
firms would only be able to adopt one type of strategy in order to maximise success but 
he did agree that some firms could possibly combine two of the generic strategies.
Porter's (1980:1985) model of generic competitive strategies has attracted criticism 
both with regard to its theoretical contribution and that it is focused upon only three 
types of strategy. Chrisman et c//.(1988) argued that Porter had not considered how 
firms should differentiate themselves within segments. Criticisms such as this led to 
various academics seeking to refine and/or extend the generic strategy concept (Wright, 
1987; Chrisman et al., 1988: Mintzberg, 1991). Yet despite the criticisms Porter’s 
(1980; 1985) concept of generic competitive strategies became, and continues to be. the
focal model for competitive strategy research as researchers have sought to understand
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the sources of sustainable competitive advantage (Hendry, 1990; Campbell-Hunt, 
2000) .
2.4.5 Strategic Groups
The term "strategic groups" was originally coined by Hunt (1972) and reconceptualised 
the widely held school of thought that the structure of the industry influenced the 
conduct of organisations and thus their performance (the S-C-P paradigm). He found
that rather than the structure of the industry influencing the way that organisations
0
performed it was actually the thoughts and actions of those managing the companies, 
through their strategies, which affected not only the performance of the company but 
also of the industry. These actions impact on the structure of the industry by dividing it 
into subsets of organisations, strategic groups, which appear to share very similar 
characteristics in the way that they operate. This led to the development of an extensive 
literature using Strategic Group Analysis (SGA) (Porter. 1979; Mascarenhas, 1989; 
McGee and Segal- Horn, 1990; McGee et a l , 1995; Thomas and Pollock, 1999; Leask 
and Parker, 2004; Leask and Parnell, 2004).
In its simplest terms Strategic Group Analysis involves clustering groups of companies 
that have similar (generic) strategies based upon 'strategic dimensions*, for example 
geographical coverage and marketing intensity (McGee and Segal-Horn, 1990). Porter 
(1979) focused on the issue of mobility barriers that surround and protect strategic 
groups. Mobility barriers are assets that a firm has acquired which are difficult for 
others to imitate and prevent or at least minimise the entry into the strategic group from 
those already in the industry. Porter's (1979) argument was that mobility barriers make 
it difficult for members of one strategic group to cross into another and that strategic 
group membership was related to levels of performance. McGee et al. (1995:257) 
defined strategic groups as follows:
"The strategic groups concept directs attention to those groups o f organisations 
in an industry which may actively compete with each other by virtue o f their 
investment in apparently similar distinctive assets, strategic resources and core
competences. * i
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In other words groups of firms can be clustered together on the basis of how a group of 
homogeneous firms competes, with each strategic group having distinct differences 
from the others in the industry. Thomas and Pollock (1999) considered strategic groups 
in relation to asset configuration, how an individual firm assembles together assets, 
resources and competences into a package which it hopes cannot be easily copied by 
other organisations. It is the way that these are weaved together that can provide a firm 
with its competitive advantage. Thomas and Pollock's (1999) concept of Strategic 
Group Analysis raises the question of how similar characteristics have to be in order to 
cluster organisations together. Their work emphasises that parameters and/or strategic 
dimensions need to be identified, decided upon, explained and justified very clearly by 
any SGA analyst early in the study because otherwise the work could be open to 
criticism for being too vague. It could be argued that similarities were not sufficient for 
organisations to be clustered and therefore each firm has its own individual strategic 
group. That would tend to make the SGA concept obsolete for analytical purposes.
A major weakness of SGA has been the number of static studies that have looked at a 
snapshot in time rather than the changes resulting from industry dynamics, although 
some researchers have sought to address this weakness. For example, McGee and 
Segal-Hom (1990), in their study of the European food industry, researched industry 
dynamics by developing the concept of strategic space. This involved identifying gaps 
in firm strategies that were not being occupied by the operational strategies of 
organisations at the time of their study. This allowed them to predict potential gaps in 
the marketplace that companies could adapt their strategies to fill in the future by 
extending the period of time in which the strategic variables are examined. Bogner et al. 
(1996) used SGA to track changes in pharmaceutical industry structure as a backdrop 
for exploring the competitive positions and entry paths of European firms operating in 
the American market. Schwittay and Carr (2001) also used SGA to conduct a 
longitudinal study into changes within the spirits industry as it moved from being a 
multi-domestic to a global industry. SGA studies that focus upon changing industry 
dynamics have the potential to be further developed to provide answers to the following 
questions set by Huff et al. (1994:36):
• Which organisations are most likely to change strategic position?
• When is a change in strategy most likely to occur?; and
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How is the firm likely to reposition itself vis-a-vis its competitors, given a 
change in strategy?
The SGA concept has been the subject of much debate and the reader is directed to 
several comprehensive reviews of the research in this field that have been published 
(McGee and Thomas, 1986; Thomas and Venkatraman, 1988; McGee el al., 1995). 
What the concept illustrates for this thesis is that some strategists have agreed that 
groups of firms follow similar strategies and that these are different from the strategies 
of firms operating in the same industry but in different strategic groups. Thomas and 
Venkatraman (1988) suggested that rather than focusing upon strategic groups it may be 
more beneficial to define strategic groups by moving away from an industry perspective 
and instead group organisations according to 'environmental types’ or ‘profiles’ 
according to the environmental conditions faced by the groups as they develop their 
competitive strategies. Porac el al. (1994) agreed that groups of organisations in an 
industry follow similar strategies but suggested that the notion of identifying similar 
organisations is more than an economic entity and that it also has a psychological and 
sociological basis. They suggested that managers have mental maps of who they 
consider to be in their “primary competitive group” (Porac el al., 1994:135) and that 
these perceptions form the basis of how they develop competitive strategies.
The review of the literature about strategic groups, environmental types and primary 
competitive groups has highlighted the lack of academic agreement as to how 
competitors can be identified. What it has highlighted is the emphasis to 'group' firms 
together on the basis of similar attributes. Yet Deephouse (1999) argued that a strategic 
balance needed to be achieved between the extent that firms were similar in order to 
maintain legitimacy and the extent to which they differentiated themselves in order to 
increase competitiveness. Although groups of organisations may follow different 
strategies to those of rivals it should not be forgotten that every organisation is unique
(Penrose, 1959; Hannan and Carroll, 1995; Kaplan and Johnston, 1998). The
uniqueness of organisations results from various factors such as their history, the way in
which they were started as well as their consequent evolution. Other factors include the
services that the organisation provides, its resources, the collective experience of
management working as a team, its decision making process and its culture (Penrose,
1959; Hannan and Carroll, 1995; Kaplan and Johnston, 1998). This uniqueness means
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that organisations in the same industry, even when they appear to be similar, will not 
necessarily react in the same way to changes (Hannan and Carroll. 1995).
2.4.6 Network Level Strategies
It has been argued that partnerships can provide more value than a single firm acting 
autonomously, and that the source of competitive advantage lies in the network of 
alliances that a firm develops. These network relationships lead to the joint development 
of the inimitable resources necessary for sustainable competitive advantage (Dyer and 
Singh, 1998; Gulati. 1998; Gulati et al., 2000). The increased trend in developing 
network relationships has been driven by firms’ continued pursuit of competitive 
advantage in fast changing environments that have included increased global 
competition and "rapidly changing technology and fragmented markets”(Lei. 1993:36). 
These relationships include strategic alliances, joint ventures and licensing agreements 
(Gulati et al., 2000). can be with competitors, suppliers and customers (Thomas and 
Pollock. 1999), and can transcend industry boundaries (Gulati. 1998; Gulati et al. 2000).
These strategic networks enable firms to share skills, resources, knowledge, costs and 
risks (Lei. 1993; Thomas and Pollock. 1999; Gulati et al., 2000) for the "co-
development of products, technologies or services” (Gulati, 1998:293) which allow 
them to gain access to new markets and technologies. Incumbent firms and potential 
new entrants may find it mutually beneficial to form linkages that allow the sharing of 
resources and competences (Jones and Cockerill. 1984: Malerba and Orsenigo. 1996). 
So a good partnership could be a large firm that has established a high reputation in an 
industry with a small firm that has leading-edge technological resources which ideally 
can lead to increased status and social recognition (Stuart, 2000). If a firm partners with 
another firm that has a strong status in the industry this reputation can be transferred to 
the partner and thus elevate their social status. This can enhance their ability to network 
with other firms. Firms may collaborate with certain 'competitors' in certain markets 
whilst continuing to compete in other areas (Dyer and Singh, 1998: Thomas and 
Pollock, 1999).
There are risks with entering into such strategic alliances. Strategic alliances are based
upon trust as firms share and access different areas although this inadvertently causes
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risks. This may not have been intentional but the skills and competences that have been 
developed in one area may inadvertently have been transferred to another market where 
the firms compete rather than co-operate (Lei. 1993; Thomas and Pollock, 1999). This 
may occur as information becomes tacit corporate knowledge, although information that 
does not relate to specific projects can be kept secret from the partner firm (Thomas and 
Pollock. 1999). Sometimes firms may prematurely end alliances when they feel that they 
can take the information to other areas and have learnt all that they need to know. There 
is also the risk that as the relationship continues the level of learning decreases and 
firms can become dependent upon each other rather than working as partners (Lei, 
1993). Firms may become locked into unproductive relationships and there is also the 
risk that existing partnerships may prevent a firm from collaborating with other partners 
(Gulati, 1998; Gulati et al., 2000). Therefore a firm needs to decide the extent to which 
it needs to balance the risks associated with partnerships together with the degree of 
competitive advantage that it requires.
2.4.7 Strategic A ctions
Kay (1993:9) described strategy as ‘‘a sequence of united events which amounts to a 
coherent pattern of business behaviour" and Mintzberg et c//.(1998) used the term a 
"pattern of actions" that allows researchers to track “consistency in behaviour" 
(Mintzberg et al., 1998:9). This would suggest that in order to understand the strategies 
realised by firms it is necessary to identify the ‘strategic actions' that contribute to the 
different levels of strategy within an organisation. This underpins one of the main
9
arguments of this thesis that if a comprehensive understanding of a firm’s strategy is to 
be developed it is necessary to identify the strategy or strategies that were realised by 
tracking the strategic actions that were actually implemented to identify consistency in
actions.
Strategic actions refer to singular actions undertaken by firms that will affect their
overall strategic direction. For example, strategic actions that contribute to co-operative
strategies include entering into and exiting from joint ventures, entering into merger
talks and successful completion of mergers, licensing-out and licensing-in products. In
essence, strategic actions and tactics may be the same thing. Tactics are “the short-
duration. adaptive, action-interaction realignments that opposing forces use to
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accomplish limited goals after their initial contact" (Quinn. 1980:9) which is why there 
is the need to identify whether actions contribute to a ‘consistency in behaviour'. In 
their study of competitive inertia Miller and Chen (1994) identified a number of 
strategic actions for firms in the airline industry in order to track the level of 
competitive inertia. The tracking of strategic actions, which can also be referred to as 
strategic variables, has also been undertaken in SGA in order to identify similarities 
between different strategic groups. For example Bogner et al. (1996) applied SGA to 
strategic variables such as the use of internal development versus licensing and the 
establishment of 'generics’ divisions to identify the strategies of European 
pharmaceutical firms.
As discussed in the previous section, firms are lighting to maximise advantage over 
other firms in order to access resources. The purpose of strategy is to guide 
organisations towards the achievement of long-term advantage over competitors (i.e. 
competitive advantage) in order to maximise profits (Porter. 1985; Henderson, 1989; 
Barney, 1991; Porter, 1996). It has been emphasised that corporate and competitive 
strategies should not be implemented in isolation from each other. Together they should 
lead to an overall strategy (Kay, 1993) that interrelates with the organisational structure 
including the key functional areas, the capabilities of the firm and the external 
environment (Chandler, 1962; Hitt et al., 1982a, 1982b; Kay. 1993). Organisations 
should place a priority on achieving competitive advantage that can be sustained 
whatever the economic conditions (Bogner et a l, 1999).
So far in this chapter focus has been on the development of an understanding of 
strategy, competition and competitive advantage. An explanation about how the 
external and internal environment have the potential to shape a firm's ability to realise 
competitive advantage will now be considered.
2.5 The External Environment and Strategic Fit
As has been discussed in the overview' of the strategy process, the majority of scholars 
have talked about the relationship between strategy and the environment. The impact of 
the external environment upon strategy has been the focus of study for population and
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organisational ecologists (e.g. Hannan and Carroll, 1995) economists (e.g. Bain, 1956; 
Porter 1980) and organisational change theorists (e.g. Pfeffer and Salancik, 1978; 
Pettigrew and Whipp, 1991). Environmental factors impacting upon how strategies 
evolve can be related to socio-political institutions, industry structure, economic issues 
(e.g. levels of inflation and stages in the economic lifecycle), innovation, customer 
demand, competitor actions and threats posed by potential new entrants (Bain, 1956; 
Lawrence and Lorsch, 1967; Porter, 1980; Nelson and Winter. 1982; Hrebiniak ct al., 
1989; Carroll and Hannan, 2000).
It is becoming increasingly difficult for organisations to develop long-term strategies as 
environments are changing at a rapid pace, leading to an increase in competitive 
pressures for many organisations (Child. 1977; Smart and Vertinsky, 1984; Ansoff, 
1994; Leavy, 1997; Liedtaka. 2000). The impact of environmental changes can vary and 
while not all of them will be relevant to all organisations (Pfeffer and Salancik, 1978) 
they will affect the competitive environment in which a firm operates as well as its 
ability to survive and grow (Smart and Vertinsky, 1984). Environmental factors create 
the context for competition which has the ability to limit the power of individual 
organisations in order that organisations do not charge excessive prices or limit supply 
to the detriment of the public (Mason, 1959). It has been argued that firms have the 
ability to shape how the competitive environment evolves. For example, they can 
implement strategic actions that can lead an industry from fragmentation to 
consolidation (Porter, 1980) or form policy networks to influence regulatory decisions 
(Nunan. 1999). Some of these factors are discussed in more detail in the following 
sections which start with a focus on industry evolution.
2.6 Industry Evolution
Industry structure and incumbent firm strategies and factors such as technology and
regulation evolve over time. As various interacting factors reach different stages of the
lifecycle (introduction, growth, maturity, decline) at different times it is important to
realise that how these factors interact today is linked to the history of each, and the
actions and processes that occurred in the past (Nelson and Winter. 1982). As each
factor evolves in its own way it is difficult to identify how the paths will cross over to
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impact upon the present, making analysis a complex process. This therefore suggests 
that a strategy based upon a long-term linear plan, as prescribed by the planning school 
(Ansoff, 1968; Porter, 1980), is not feasible in practice.
Further, as Porter (1980) commented, there is a risk in pursuing a strategy where the 
value risks being eroded by industry evolution. Scherer (1980) in his refinement of the 
structure-conduct-performance (S-C-P) paradigm proposed that firms have the ability to 
shape industry structure and both Porter (1980) and Hamel (1996) argued that it could 
be in the firms’ interest to adopt appropriate strategies to do this. Yet as shown by the 
S-C-P paradigm, industry structure also has the ability to shape firm strategies (Bain. 
1956; Mason, 1959; Scherer. 1980) and it has been argued that firms conform to 
industry recipes or culture (Spender, 1989; Pettigrew and Whipp, 1991) rather than 
attempting to create new rules. Three factors that have been identified as playing key 
roles in industry evolution are technology, regulation and globalisation. These are 
discussed in the following review of the literature which aims to highlight the ability of 
firms to implement strategies that shape these factors.
2.6.1 Industry Evolution Theory
Standard evolution theory suggests that an industry follows an S-curve pattern similar to 
that of the product lifecycle's introduction, growth, maturity and decline curve. The 
theory is that industries proceed through stages of introduction, growth, maturity and 
decline (Porter, 1980; Kaplan and Johnston, 1998; McGahan, 2000). But there are 
various factors that can impact upon this process so that the industry does not follow the 
suggested pattern. Examples include new products that are the result of emerging 
technologies or an industry in the maturity stage can still undergo changing patterns in 
both supply and demand (Baden-Fuller et ai, 1994). Models have been developed to 
help strategists understand and predict these changing dynamics in order that they can 
develop appropriate strategies (McGahan, 2000). The ability of the models to forecast 
industry change is not the subject of this study. What such models do highlight though 
is that there are many factors that can impact upon an industry and shape its evolution.
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2.6.2 Industry Evolution and Strategic C ’ho ice
The evolution of an industry affects the strategic choices available to firms, significantly 
altering the ways in which they seek to achieve competitive advantage. An 
understanding of how an industry will change together with the factors that drive 
changes in the industry, is important for an organisation when developing strategies as 
industry can shape the actions of organisations (Scherer. 1980; Hannan and Carroll 
1995). The basis for this argument is that it allows an organisation to make the most 
appropriate strategic decisions in light of environmental changes and anticipated moves 
by rivals (Warren, 1991; Kaplan and Johnston, 1998; Ghobadian and Viney. 2001). For 
organisations that operate in competitive environments forces for change to strategy can 
result from structural changes to the industry such as barriers to entry, level of demand
9
and the associated price and income elasticities, concentration of buyers and sellers and 
product differentiation (Jones and Cockerill. 1984; Ferguson and Ferguson. 1994) and 
the firms’ strategies can shape these structural changes (Scherer, 1980). For example, 
Jones and Womack (1986) identified three major factors that shaped the evolution of the 
automotive industry. The first was the move towards mass manufacturing in the early 
part of the 20th Century. The second occurred in the 1950s as European manufacturing 
sought to combine mass production with product differentiation in order to achieve 
advantage over American competitors. The third was the entry of Japanese 
organisations in the 1960s that sought to achieve competitive advantage through 
innovative organisation of production processes. What this highlights is that industries 
can be shaped as the result of organisations pursuing new ways to develop competitive 
advantage and that this can have continuing effect on how each of the organisations 
develops future strategies.
2.6.3 Technology Evolution
An understanding of technological change can lead to an understanding of both
environmental and organisational evolution (Tushman and Anderson. 1986) and thus
how technology changes the shape of industries (Suarez and Utterback, 1995).
Economists have recognised that changing technologies impact upon the competitive
environments of firms in various industries, including, the pharmaceutical industry
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(Nelson and Winter, 1982). It was suggested earlier that organisations seek to develop 
distinctive competencies in order to achieve competitive advantage. Developing these 
competences can take many years. It has been argued that the key to having the right
0
distinctive competencies to deal with a changing environment is the ability of managers 
to identify changes in the environment very much in advance of the organisation being 
able to realise the benefits of the change (Cockburn et al. ,2000).
Yet, the extent that new technologies will impact upon industry evolution is inclear as 
their application is affected by the unique factors that make up the firms in an industry 
and how they develop and utilise new technology (Nelson and Winter, 1982). 
Incumbent firms may implement actions in order to try to prevent the entry of new 
firms. The S-C-P paradigm is based upon the assumption that as part of their strategy 
firms can seek to erect barriers to prevent the entry of new firms. In his seminal work. 
Bain (1956) argued that incumbent firms erect barriers to entry through measures such 
as patents and product differentiation in order to protect profits. 1 Iowever. incumbent 
firms may decide to adopt or ignore a new innovation and the impact of a new 
innovation may have been unanticipated if. for example, it had been developed in a 
seemingly unrelated industry (Rogers, 1983). Technological changes can be either
competence enhancing or competence destroying for incumbent organisations
(Tushman and Anderson, 1986; Malerba and Orsenigo. 1996). For example, Remington 
Rand, although very competent in typewriters was not able to transfer this competence 
to the emerging computer industry (Malerba and Orsengio, 1996).
Consequences of innovation can be both desirable and undesirable and can affect both 
individual firms and the industry as a whole (Rogers, 1983). It has been suggested that 
technology follows a pattern of incremental change punctuated with major changes that 
create technological discontinuities (Tushman and Anderson, 1986). The technological 
development can be so dramatic that it creates an acute discontinuity in the operating 
environment of organisations. This appears to build upon the view suggested by 
Schumpeter (cited in Mason, 1959) that technology leads to the creative destruction of 
an industry. In other words the creation of technology can lead to the destruction of an 
industry as it had previously existed with a subsequent negative impact upon incumbent 
organisations. This can lead to a fall in industry concentration as innovative new
entrants steal market share from the market leaders (Geroski and Pomroy, 1990) or be
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so radical that customers may be slow to adopt the products that result from new 
technologies (Bower and Christensen. 1995). Technological development has the 
potential to completely change the structure of an industry and can even lead to the 
creation of a new industry (Tang and Thomas, 1994; Malerba and Orsenigo. 1996; 
Kaplan and Johnston, 1998; Rothaermel, 2000). Incumbent organisations may be 
reluctant to embrace new technology. This encourages new entrants, leading to a 
dynamic process of change as new technologies are developed (Tang and Thomas, 
1994) which is probably encouraged by incumbent organisations continuing to ignore 
the dangers presented by emerging technologies (Bower and Christensen, 1995). The 
reluctance of incumbent organisations to adopt new technology may actually make 
entry easier for new organisations (Tang and Thomas, 1994). The pace of innovation 
can be self-perpetuating with it increasing as the number of new entrants increases 
(Scherer. 1980; Geroski and Pomroy, 1990; Tang and Thomas, 1994; Rothaermel. 
2000). The result can be that new entrants to an industry can change its shape and have 
the potential to make it more competitive (Malerba and Orsenigo. 1996). This explains 
why the threat of competition from potential entrants to an industry has the largest 
impact upon the development of competitive strategies (Bain. 1956; Baumol, 1982; 
Barney, 1991). It has also been argued that although some new entrants are able to 
become industry leaders many will exit quickly (Malerba and Orsenigo, 1996). 
Established firms may make a strategic decision to exit the industry if they feel it will 
be beneficial to use their competences or investments in more suitable industries 
(Burgelman. 1994).
2.6.4 Industry Regulation and Policy Networks
Having focused upon how technology has the potential to shape the evolution of an 
industry the chapter now proceeds to review the role of government policy, in particular 
regulation. The extent to which government policy changes have influenced firms has 
been debated in the academic literature. Chandler (1962:384) in his seminal work on the 
development of large business corporations in the United States, suggested that public 
policy issues had substantially less impact on major firms than “the market, the nature 
of their resources, and their entrepreneurial talents.” In contrast Ansoff (1984). whose 
work covered a later period, suggested that socio-political issues had increasingly
impacted on the decisions of firms, giving managers progressively less freedom in their 
decision-making. It has been suggested that because governments placed emphasis in 
the policy making process on the short-term attainment of political goals, this had made 
the formulation and realisation of long-term strategies for firms more complex and 
difficult.
Pressure for changes in regulatory regimes have increasingly been the result of action 
taken at the European level (Majone. 1994). Rhodes (1999) argued that this delegation 
of functions away from central national governments, together with increased control of 
certain activities by the European Elnion, meant that the central core of national 
governments was effectively facing a reduction in control over matters relating to policy 
implementation.
Regulation is also being increasingly influenced at the global level due to factors such
establishment bodies such as the World Trade
Organisation (WTO). There has been an increase in the number and power of multi-
national corporations and 'stateless' organisations who are able to exert increased 
influence on policy decisions (Grant, 1993). Smith (1999) makes a cautionary note that 
although international factors may affect the natural policy process it is national factors 
which are more likely to influence policy decisions. For example, governments may 
undertake policies to protect the competitiveness of national industrial champions 
(Jones and Cockerill, 1984).
Majone (1994:81) discussing the role of regulatory agencies in Europe, suggested that 
regulation was more than legislation, and therefore "it requires detailed knowledge of. 
and intimate involvement with, the regulated activity". This, therefore, suggests that it is 
mutually beneficial for policy decision makers, including regulatory bodies, to interact 
with the various interested parties. Network relationships can be interdependent as civil 
servants rely on information from interest groups such as technical input and statistical 
information. This is an exchange process as government officials can gain information 
which will, for example, support arguments where departmental objectives are in 
conflict with those of another department (Grant, 1993). The information which has 
been gained from firms and trade associations helps to supplement the information that
government collects from other sources and helps officials to reduce errors made in the 
policy process.
The interactions of influencers upon policy decisions have been described as ’webs of 
influence’ (Braithwaite and Drahos, 2000) or 'policy networks’ (Rhodes, 1999). The 
main thrust of the concept of policy networks is that there are groups that interact in 
order to influence and direct the policy decisions made by the Core Executive on a 
specific area of policy. Interest groups tend to be a formalised representation of actors 
who seek to influence and direct how government designs and implements its policies. 
These can include formal coalitions such as trade associations which represent the views 
of an industry or specific sector and trade unions which represent certain sectors of 
employees. It can also include individual firms, societies and religious organisations 
(Greenwood and Thomas, 1998; Grant, 2000). A major strength of interest groups can 
be in how they develop relationships with government departments and thus have the 
ability to influence and steer policy decisions away from the control of the Minister and 
the Core Executive (Smith, 1999). It should be noted, however, that this concept has 
been criticised for not appearing to consider what Majone (1994) refers to as the traits 
of secrecy that can still surround the policy making process.
The application of network theory helps in the identification and understanding of the 
various interdependent relationships of the different actors who can exert power and 
influence over policy making and regulation. Early research into networks was 
criticised because it was descriptive and did not explore the dynamics of change 
(Dowding. 1995). However, later research highlighted how the various groups evolve 
over time, re-grouping and re-forming as differing needs change (Nunan, 1999). This 
may involve different levels of power within the network, and its membership and 
structure may differ dependent upon the specific policy issue (Rhodes, 1999). Rhodes 
(1999) also suggested that some professional networks are limited to the specialists 
operating within them. He cited the NHS as a classic example of this because of its self- 
contained nature, but the sector has changed as governments have moved towards 
introducing a management culture with an increased focus on cost control (Rhodes, 
1999). This helps to explain why there has been a growth in policy networks as 
managers operating in the new public sector need to share responsibility and gain
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knowledge from those who may be able to help them achieve their objectives (Atkinson 
and Coleman, 1992).
Interest groups can have competing interests and the efforts of one can cancel out those 
of another. For example, where there have been food scares, . those representing 
members of the public concerned about safety have competed against those representing 
producers whose prime concern has been business objectives. Even though the public 
will represent a larger number the producers' representative would normally be in a 
position to exert greater political influence (Pilkington, 1998). However, in recent years 
there have been occasions when the industry position has been weakened as the media 
has influenced public concern by promoting the interests of consumers. Again, this is 
illustrated by the food safety issue when the normally close community of industry and 
civil servants has been forced into the open by the media so that public opinion has 
influenced policy decisions from a stronger position than on other, less media friendly, 
issues (Grant, 1993).
2.6.5 Industry Concentration
V
Microeconomics suggests that industry types can be classified into four kinds based 
upon the number of organisations in the industry (Jones and Cockerill, 1984). These are 
perfect competition, monopolistic competition, oligopoly and monopoly. The 
implication is that the greater the industry concentration the less competitive it is. There 
are various ways of measuring concentration but essentially it is concerned with the 
amount of market share held by organisations and sometimes the number of 
organisations operating in an industry. The difference in size of organisations in an 
industry can affect how they behave (Jones and Cockerill. 1984). Firm size can be 
measured by factors such as number of employees, capital employed and turnover. 
Different measures of size can be more appropriate to different industries. Firms in a 
fragmented industry can potentially make strategic choices that move the industry 
towards consolidation and thus increased concentration (Porter. 1980). But. as 
Lawrence (2002) suggested, industries are becoming increasingly concentrated.
One of the ways in which firms in a fragmented industry can work to increase market
power is through merger and acquisition activity within an industry (Porter. 1980). This
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decreases the number of firms and increases the size and power of those involved in 
mergers and acquisitions. Firms also have the ability to shape the globalisation of an 
industry. It has been argued that industry concentration and internationalisation, which
have been partially driven by increasing financial concentration, lead to the
0
globalisation of industries (Chesnais, 1993). Several other factors that have been 
discussed so far in this literature review have also contributed to industry globalisation. 
These are the globalisation of regulation, the evolution of multinational corporations, 
emerging technologies, cross border strategic alliances, merger and acquisition activity 
and new forms of global communication such as the world wide web (Chesnais, 1993; 
Braithwaite and Drahos, 2000; Tolentino, 2000). One important aspect of industry 
consolidation is that incumbent firms face different strategic outcomes as the number of 
firms reduces. This is discussed in Section 2.7.3.
Another important factor that needs to be considered in relation to industry evolution is 
the impact of environmental discontinuities. Although firms may make strategic choices 
in order to achieve competitive advantage, a major environmental discontinuity that 
alters an industry's structure can severely reduce the impact of any competitive 
advantage (Barney. 1991; Porter, 1996). The suggestion is that factors impacting upon 
an industry can be so severe that they create an environmental discontinuity (a sharp 
break in the operating environment). These factors can result from competitive actions 
such as new technology developments, price wars, major economic changes, or 
government actions such as deregulation and privatisation (Strebel, 1990; Smith et 
al., 1999). The resulting discontinuities can potentially erase an incumbent firm’s 
source of competitive advantage, necessitating the identification and development of 
other sources in order to sustain competitive advantage in the newly defined industry 
(Barney. 1991).
It may be in the interests of incumbent organisations to trigger the major discontinuity, 
for example if they have developed a suitable product or competence enhancing 
technology (Strebel. 1992). But, as Strebel acknowledged, major discontinuities are 
increasingly out of the control of individual organisations. However, Smith et al. 
(1999) argued that environmental discontinuities such as deregulation do not suddenly 
present themselves to organisations without any warning. It is suggested that there are 
signs of potential change such as deregulation creating a time lag between the potential
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discontinuity and its impact thus allowing the firm sufficient time to take pre-emptive 
action (Strebel. 1990; Smith et al., 1999). For example with regard to public policy 
decisions it has been argued that organisations can be very influential in shaping policy 
decisions before they are implemented through involvement in policy networks (Nunan, 
1999; Rhodes, 1999).
Tushman et c//.(1986) have argued that those organisations that continued to be 
successful after a major environmental change or discontinuity are those that swiftly, 
almost simultaneously, undertake strategic reorientation in all areas in order to realign 
the business with the new environment. However, Dean et al. (1999) disagreed with 
this view, arguing that organisations should only undertake punctuated change 
programmes if incremental programmes have failed to realign the organisation with its 
environment. Miller and Friesen (1980) conducted a study investigating change in 26 
companies including the Ford Motor Company and The Singer Company. Overall they 
found that although organisations undertook frequent incremental change, complete 
reorientations were sporadic. Whatever the arguments as to how swiftly internal change 
programmes should be undertaken other researchers have found that unless changes in 
the external environment were particularly significant, possibly leading the organisation 
to a crisis situation, the majority of companies would be slow in realigning their 
strategies with the changed environment (Chandler, 1962; Miller and Friesen. 1980; 
Grant and Cibin, 1996; Viney, 200F). Having reviewed factors in the external 
environment that have the potential to shape strategy evolution, factors in the internal 
environment will now be explored.
2.7 The Internal Environment
2.7.1 Internal Activities and Resources
The strategies that are realised do not fully explain the origins of competitive advantage. 
In order to understand the factors that underpin these strategies it has been argued that 
the internal sources of competitive advantage need to be understood. These can include 
the internal resources of the firm (Penrose, 1959; Barney, 1991). core competences 
(Hamel and Prahalad, 1990), dynamic capabilities (Teeee and Pisano, 1994) and the
ability to learn (Bogner et al., 1999). But in order to understand how these evolve into 
sources of competitive advantage it is necessary to understand the activities (Porter, 
1985) or actions that are implemented and precede the achievement of competitive 
advantage. In other words it is necessary to understand how each of these factors 
interact in order to understand the unique process that each firm implements to realise 
the strategies that lead to competitive advantage.
A large body of literature has developed during the past twenty years relating to how a 
firm’s internal resources, capabilities and activities can be the source of sustainable 
competitive advantage (Porter. 1985; Hamel and Prahalad, 1990; Barney, 1991; Teece 
and Pisano. 1994; Bogner et al., 1999). Rather than focusing upon industry positioning 
in order to achieve competitive advantage proponents of the resource-based view argued 
that it is how an organisation develops its internal resources, capabilities and 
competences in a unique way that leads to the achievement of competitive advantage 
(Barney, 1991). Hoskisson et al. (1999) suggested that the literature about how firms 
can use internal resources to create competitive advantage has its foundations in the 
work of Penrose (1959) and has been termed as the Resource Based View (RBV) 
(Barney. 1991).
Bogner et al. (1998) proposed that the strategic group and resource based perspectives 
have parallels in terms of origin and concept development. For example, two of the 
main RBV proponents (Penrose. 1959; Barney, 1991; 2001) and the main champion of 
the industry positioning concept, who has also promoted the strategic group concept 
(Porter. 1979; 1996) have similar perspectives about the importance of internal 
activities. They stress that it is the way in which an organisation develops resources or 
assets, skills, capabilities and competences into unique packages that enables it to 
achieve competitive advantage (Penrose, 1959; Barney, 1991; Porter. 1996). In order for 
competitive advantage to be sustainable, strategy must be value adding so that activities 
cannot be easily imitated (Barney, 1991; Porter. 1996).
One way in which advantage can be created from internal resources is through the
development of core competences which have been referred to as the collective learning
of the organisation (Hamel and Prahalad. 1990). It is argued that by identifying how it
can develop distinctive competences or capabilities i.e. those competences that cannot
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be copied by other organisations, an organisation can achieve competitive advantage 
(Hamel and Prahalad. 1990; Teece and Pisano, 1994; Bogner et a l , 1999). The key to 
these distinctive competences results from the unique way that an organisation bundles 
together its resources, together with a level of organisational learning that is sufficient 
to keep competences distinct in changing environments (Bogner et al., 1999) which 
Teece and Pisano (1994) classed as dynamic capabilities. Eisenhardt and Tabrizi (1995) 
argued that fast new product development is a strategic competence that allows 
organisations to adapt to rapidly changing environments. This concept of time-based 
strategies suggests that the faster an organisation carries out certain activities (such as 
bringing new products to market) the better it is able to achieve competitive advantage.
Both Porter (1996) and Stalk et al. (1992) argued that time-based strategies, such as 
rapid new product development, are only subsets of what they term as the need for 
organisations to develop strategic capabilities. They argued that in addition to speed, 
organisations need to consistently produce goods that satisfy customers, be able to 
clearly understand the changing competitive environment, be able to deal with the 
differing needs of multiple markets and to be innovative both in terms of product 
development and processes. Porter (1996) also emphasised the need to focus upon the 
interdependence of the pieces (e.g. core competences, key resources, value adding 
activities) and how they fit together in a way that is consistent with the overall strategy 
in order to create sustainable competitive advantage. Success is dependent upon the 
synergy created from the individual parts resulting from the system of integrating all of 
the activities (Porter. 1996). But, Porter also argued, this needed to be combined with 
an ability to adopt a strategic position in an industry that could be developed and 
defended over a timeframe in excess of ten years, rather that the short-term approaches 
advocated by proponents of time-based competition.
Mintzberg and Lampel (1999) criticised Porter (1996) for ignoring the need for strategic
learning. A lack of learning can lead to the risk of management continually making the
same mistakes. This suggests that unless barriers to learning are overcome firms may
never be able to achieve sustainable competitive advantage. Top management can
develop distinctive core competences by exploring linkages through the organisation
that when combined provide a unique advantage to the business, the focus being upon
the collective learning of the organisation (Hamel and Prahalad, 1990: Burgelman,
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1994; Bogner et al., 1999) which is similar to Mintzberg’s (1994) view that the sharing 
of ideas can lead to the development of entrepreneurial strategies.
In addition to the views discussed so far, Lindley and Wheeler (2000:361) stressed the 
need for goals to be “multidimensional” i.e. referenced to external, internal and time- 
related factors. Bogner et al. (1998) proposed that learning at the management level was 
a key to sustaining competitive advantage. Referring back to Penrose (1959) there are 
some differences in her original work from those suggested above. Instead of learning 
she spoke about the collective experience of the managerial team, and so although the 
focus is on collective learning she did not necessarily consider the benefits of collective 
learning throughout the organisation. Penrose (1959) stressed that it is not the resources 
themselves which are the important factor but the output from the resources i.e. the 
services that they provide which make an organisation unique and provide it with 
competitive advantage.
2.1.2 Internal Threats to Survival and the Achievement o f Competitive Advantage
It has been argued that it is the dynamic interrelationships between internal and external 
environments that persuades organisations to respond to change (Ghobadian et 
al, 1997). Hamel and Prahalad (1993) suggest that organisations in which managers are 
focused upon achieving success over more powerful rivals are able to achieve success 
by thinking outside the normal mindset of what is achievable. The desire to succeed 
motivates them to stretch resource capabilities to their maximum capacity in order to 
outpace the strategies of competing firms (Hamel and Prahalad. 1993). But not all firms 
are able to incorporate this type of thinking. For example, in a study of the oil majors 
Grant and Cibin (1996) found that most major organisations did not undergo strategic 
reorientation until 10 years after the 1974 oil crisis and that the trigger to this change 
was declining profitability. For this reason this section continues the review with a 
focus upon internal threats to survival and the achievement of competitive advantage.
Despite being an advocate of strategic choice, Porter (1996) emphasised that the
greatest threat to the achievement of competitive advantage comes from within the
organisation itself. The strategic choice literature has tended to assume that firms will
maximise their strengths and opportunities in order to achieve competitive advantage in
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order to maximise profits. For example. Porter (1980; 1985; 1996) and Hamel (1996) are 
very prescriptive about strategy formulation and implementation and their views appear 
to be based upon the assumption that firms want to profit maximise. Economic theory 
has suggested that the primary objective of organisations is to maximise profit (Penrose, 
1959; Porter. 1980) although others have argued that this hypothesis is not always true 
(Ansoff. 1968; Scherer. 1980). Penrose (1959) argued that managers are motivated to 
maximise profits because they receive benefits such as increased status and promotion 
as a result of profits being reinvested back in to the organisation which lead to increased 
growth. Profit or wealth maximisation will also be the goal of the majority of 
stockholders (Hill and Snell, 1988).
Greer and Hoggett (1999:239) defined strategy in the following terms:
"an organisation is concerned with strategy whenever it pursues courses o f  
action which are either means towards the organisation’s survival and/or 
growth or towards the private advantage o f organisational actors. ”
Greer and Hoggett’s (1999) definition raises the question of whose goals strategy is 
trying to achieve -  whether it is those of the organisation or of the individual actors. To 
explore this in more detail it is necessary to refer to organisational behaviour and 
organisation theory literature which focuses upon the behaviour of people in an 
organisation rather than considering it as a rational economic entity. An organisation is 
reliant upon directors and managers which can be considered as a collective coalition to 
move the organisation towards its goals. It is managerial actions within the organisation 
rather than the market that it operates in that affect organisation profitability (Cohen and 
Cyert, 1975; Amel and Froeb, 1991). Organisational ecology literature suggests that 
managers may not always be working towards the pursuit of goals such as profit 
maximisation but. rather, the main focus is upon making life easier for organisational 
members. Hence it is suggested that each manager has his/her own goals and that they 
are not necessarily the same as those of the organisation (Hannan and Carroll, 1995). It 
has also been suggested that there is a frequent trade-off between the achievement of 
organisational goals and those of the individual, for example, to gain resources for a 
department irrespective of the cost implication for the organisation (Cohen and Cyert, 
1975).
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There are various other internal factors which can weaken a firm’s ability to compete in 
its external environment. Management teams benefit from the collective experience of 
working together in the same situation (Penrose, 1959) and these cognitive thoughts 
may be framed with reference to their beliefs of what is and is not achievable (Hamel 
and Prahalad, 1993). Managers have perceptions or an 'image' (Penrose, 1959:42) of 
how the internal and external environments can impact upon the organisation. They 
use these perceptions in order to decide how to make changes that will lead to profit 
maximisation (Penrose. 1959). However, perception is not necessarily the same as 
reality and this can affect how managers respond to changing situations (Smart and 
Vertinsky, 1984). Jarzabkowski (2001) argued that it is how the organisation internally 
views itself that provides its strategic orientation, an intangible framework of how 
decisions should be made and how it should react to change. This orientation explains 
why some organisations are entrepreneurial, attempting to break into new areas and 
realise unique strategies (Mintzberg, 1987) and why others appear unable to react to 
major changes until a crisis situation is reached (Leavy, 1997). It may also affect the 
degree of management control exerted in the realisation of strategies (Kald et al., 2000).
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Analoui and Karami's (2002) study of Small and Medium Sized Enterprises (SMEs) 
found that those that were successful undertook environmental scanning as part of the 
strategy process. However, strategic inertia may be a barrier to an organisation’s 
recognition of the need to develop strategies to adapt to the changing environments 
(Miller and Chen, 1994; Leavy, 1997). Possible causes of inertia can include the 
structure of the organisation being too bureaucratic and/or large for change to be easily 
implemented. Child (1977) argued that large organisations with bureaucratic 
mechanistic structures in particular may need to change their structures in order to be 
able to adapt more easily and quickly to environmental cues about change. The 
emphasis being that the structure should be conducive to the organisation being able to 
respond quickly to environmental cues (Child, 1977). Hannan and Freeman (1997) 
suggested that firms could be dominated by a culture that felt change was unnecessary 
because they had been successful in the past.
In addition to inertia, major changes in the environment mean that a management team
cannot plan or make decisions based upon previous experience, and may be unable to
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change as a result of institutionalisation because they are committed to previous plans 
even if they are no longer appropriate (Pfeffer. 1981; Kald et al., 2000). There may also 
be a failure in the ability of managers to either recognise or correctly define problems as 
a result of their misinterpreting cues from the environment (Kiesler and Sproulh 1982) 
and how they perceive the environment (Smart and Vertinsky, 1984). It has also been 
suggested that middle management, when picking up on cues from a changing external 
environment may choose to act in a way that is not consistent with the corporate 
strategy, but that it is important for them to identify when is the correct time to realign 
the official strategy with the strategic actions that have been undertaken 
(Burgelman,1994).
2.7.3 Strategic Outcomes
As has been discussed in this chapter so far there are various factors that can affect the 
strategy process in a firm and its ability to achieve competitive advantage. During this 
process some firms will fail to survive and others will change their organisational form, 
for example as a result of merger and acquisition activity. The term 'strategic outcome'
V
is used to define how firms can either exit an industry or evolve into a different species. 
Population ecologists focus upon a type of strategic outcome in their studies of births, 
deaths and transformations but there are three weaknesses in their approach. Firstly, as 
they were tracking these for a complete industry or population from the start of its life it 
was rarely feasible to provide depth to the factors that had caused these beginning and 
ending events (Davis, 1996). This suggests that the lack of depth meant that it was not 
feasible to track and identify the realised strategies that preceded each of the events. 
Secondly, with the exception of birth the focus appears to upon ending events, for 
example disbanding, acquisition, merger, exit to another industry, nationalisation and 
being taken over by creditors (Carroll and Hannan. 2000). What is argued in this thesis 
is that there is a need for a more fine grained approach to understanding the strategic 
outcomes of firms in an industry than those used by population ecologists if we are to 
understand the strategy process and how it relates to strategic outcomes. Table 2.1 lists 
a number of strategic outcomes that it is felt should be identified if a study of changes in 
industry structure and firm strategies is to be understood in more detail than previous 
studies have allowed. In the majority of these cases strategic outcomes could also be 
classified as strategic actions.
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Table 2.1 Selected Strategic Outcomes
S t r a t e g i c  O u t c o m e R e f e r e n c e s
Strategic exit from an industry Burgelman (1994), Carroll and Hannan (2000)
Acquired by creditors, disbanded or liquidated Glueck (1976), Carroll and Hannan (2000)
Acquired by another firm Carroll and Hannan (2000)
Merged Carroll and Hannan (2000)
Survived in the industry without being acquired or 
merged
Chandler (1962), Jones and Womack (1986), 
Grant and Cibin (1996)
Divested or demerged Glueck(1976)
Privatised Dean e t al. (1999), Ghobadian and Viney 
(2001), Viney (2001)
Source: Compiled by the author
Strategic outcomes relate to discontinuities in the firm's activities. Firms enter and 
strategically exit industries, they merge or make acquisitions, are acquired, firms 
survive without being acquired, they can be privatised and they can also be liquidated. 
So, for example, if a firm is merged it has changed its form and as a process of further 
mergers continue there may be no links left that relate it to its original form (Carroll and 
Hannan. 2000).
v
These strategic outcomes can be related back to Glueck’s (1976) grand master strategies 
of growth, combination, stability and retrenchment. Although Glueck (1976) classified 
retrenchment through, for example, liquidation of a business, as the least popular 
strategic choice it was still a strategic action chosen by the firm rather than externally 
decided by the environment. In other words, strategic outcomes such as liquidation of a 
business are not necessarily negative but may form part of an overall plan. However, 
the literature has failed to identify how the strategies that have evolved during a period 
of industry evolution differ dependent upon the strategic outcome of a heterogeneous 
set of firms. If a firm is entering into a merger or making acquisitions it can be 
classified under Glueck's (1976) strategic choice of growth as it will increase the size of 
the organisation.
2.8 Evolutionary Theory, Strategic Choice and Environmental
Determinism
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Evolutionary theory has its roots in the field of biology where the emphasis is upon how 
species evolve and how a process of natural selection occurs with the environment 
selecting which species will survive and which will die (Nelson and Winter, 1982; 
Henderson, 1989; Hodgson, 1995). The theory, which Lynch (1997) termed as survivor 
theory, underpins the concepts of incremental and emergent strategies (Lynch. 1997; 
Mintzberg et al., 1998) and strategic choice (Child, 1995). The prescriptive views about 
strategy development (Ansoff, 1968; Hamel, 1996; Porter, 1996) strongly advocate that 
the firm has the ability to make strategic choices. These views focus upon learning from 
changes that are taking place in the environment and adapting strategies in order to 
maintain strategic fit. A major debate in the literature is the extent to which it is the 
strategic choices that are made or the environment which determines the fate of an 
organisation. Astley and Van de Ven (1983:247) summarised these opposing 
perspectives as:
• The natural selection view which was classified at the macro level (i.e. the 
industry), with the environment determining firm actions. This is 
underpinned by the literature relating to population ecology and industrial
V
economics.
• The strategic choice perspective of strategic management which was 
classified as residing at the micro level with a voluntaristic orientation.
The theory of natural selection proposes that the fate of the organisation is determined 
by the environment, ‘environmental determinism’, rather than purely the strategic 
choices made by the organisation. (Astley and Van de Ven. 1983; Hrebiniak and Joyce. 
1985). Although Child (1995:2) argued that proponents of environmental determinism 
supported an •‘essentially mechanistic paradigm” whilst strategic choice was closely 
related to concepts of organisational evolution. Henderson (1989:139). drew upon 
ecology theory relating to "Gause's Principle of Competition" and argued that firms (the 
species) in the same environment, in this situation an industry, need to differentiate 
themselves in order to survive and achieve advantage over competitors. The biological 
perspective of evolutionary theory proposed that species fight to seek competitive 
advantage in their environment in order to survive because there is only limited room
and so all of the species cannot be accommodated. Different species emerge with some 
replacing the former incumbents, a process of natural selection (Henderson, 1989).
Firms compete with each other, not just for sales but for resources as well. Few 
organisations are self sufficient with regard to resources and it is argued that the 
organisation is reliant upon other organisations and institutions to acquire the necessary 
resources (Pteffer and Salancik, 1978). The population ecology perspective suggests 
that if firms are competing for scarce resources not all will be able to access sufficient 
resources and therefore cannot survive (Hannan and Freeman, 1977). Therefore an 
organisation is reliant upon successful interactions with both suppliers and buyers in 
order to survive, as well as the extent to which rivals are trying to access either of these. 
Organisations that do not develop appropriate strategies enabling them to adapt to 
changing environments risk being selected out, in other words they fail to survive
(Carroll Hannan, 1995). Hannan Freeman (1997) argued because
organisations are unable to undertake the necessary changes it is the environment that 
selects which organisations will be successful and which will fail. The issue of 
dependence upon resources and processes of natural selection underpin evolutionary 
theory and the related resource-based theories of the firm (Nelson and Winter, 1982; 
Hodgson, 1995). Hannan and Freeman (1997:201) further argued that during industry 
evolution medium-sized companies can become ‘trapped" as they seek to develop 
strategies to fend off large organisations. The position of these middle-sized companies 
is subsequently weakened, leading to them being unable to survive. They suggest that 
small organisations do not face the same problems because they are not being subjected 
to the same competitive threats from the large organisations.
The important issue appears to be that adaptation is a continual and complex process 
that results from a variety of internal and external forces exerting pressure on the 
organisation (Astley and Van de Ven, 1983). Hrebiniak and Joyce (1985) proposed that 
approaches to firm adaptation could not be illustrated by these two opposing views but, 
instead, that adaptation should be viewed as a continuum that influences the strategic 
options available to firms. In other words, that neither is mutually exclusive.
Coevolution as a Theoretical Lens
As has been discussed there are various interpretations of what is meant by the term 
strategy. In this review strategy has been explored as a process that could be planned, 
incremental, revolutionary or emergent. Both Porter (1996) and Hamel (1996) argued 
that firms have complete freedom of choice in how they implement and formulate 
strategies that will lead to the achievement of competitive advantage, as long as they 
follow certain prescribed guidelines. Porter (1996) prescribed a long-term strategic 
approach whilst Hamel (1996) focused upon ignoring existing industry rules. In 
comparison, proponents of emergent (Mintzberg. 1987; 1994) and incremental strategy 
(Lindblom. 1959; Quinn. 1991; Lindblom, 1979) have proposed that strategies need to 
frequently redefined in order to take advantage of opportunities and maintain 
strategic fit with the external environment. Evolutionary theory underpins the concepts 
of incremental and emergent strategies, with the suggestion that firms can adapt their 
strategies in light of changes as they arise. Strategy evolutionists, such as Barnett and 
Burgelman (1996), proposed that strategy research should focus upon the strategies that 
have been realised and how they evolved, rather than being prescriptive about how 
strategies should be implemented.
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In this chapter focus has been given to the different aspects of evolutionary theory; in 
particular, relating them to issues of strategic choice, environmental determinism and 
industry evolution. When discussing the debates in organisation theory that focused 
upon strategic choice and environmental determinism. Astley and Van de Ven (1983) 
suggested that future research could result in identifying that firms are both proactive 
and reactive in adapting to the environment. In other words instead of focusing upon 
defending different schools of strategic choice and environmental determinism, a 
unifying theory should be adopted in order to understand this process. As already 
discussed in this chapter, both the strategic choice and environmental determinism 
perspectives are underpinned by evolutionary theory. In particular, this literature review 
has explored interacting factors such as firm strategies, technology, regulation and 
changing industry structures (concentration and globalisation). As these reach different 
stages of their lifecycles at different times how these factors interact today is linked to 
the history of each, the actions and processes that occurred in the past (Nelson and
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Winter, 1982). But. as each factor evolves in its own way, it is difficult to identify how 
the paths will cross over to impact upon the present, making analysis a complex 
process.
Evolutionary theory has been criticised by Child (1995:21) for not considering the 
“actors within the firm** and therefore ignores the processes that lead to firm outcomes. 
But Child's (1995) emphasis upon internal political issues limits his consideration of the 
actions of external actors in competing firms. For example, SGA has identified how 
firms have followed the strategies of those they consider to be competitors. As has been 
shown industry evolution results from changing factors such as technology, regulation, 
concentration and globalisation. Each of these factors can be influenced and shaped by 
the conduct of firms. Coevolution theory has been developed in the ecology literature 
which has proposed that competing species interact and shape each others’ 
development, and that this in turn this can potentially shape the community structure 
(Futuyma and Slatkin.1983). Coevolution theory has underpinned an emerging number 
of papers in the management and strategy literature. This area of research has covered a 
number of topics including coevolution theory in relation to changes in organisational 
form (Djelic and Ainamo, 1999; Lew in and Volberda. 1999; Lampel and Shamsie. 
2003), patterns of coevolution between the environment and firms’ strategies (Carney 
and Gedajlovic, 2002), the coevolution of a specific network with its environment 
(Koza and Lewin. 1999) and processes of coevolution with regard to strategic renewal 
actions, regulatory and technological change (Flier et al., 2003). It can therefore be said 
that the conduct of firms coevolves with changes in industry evolution. In addition, as 
was discussed, firms enter into network agreements with partners and it has been argued 
these strategic alliances also coevolve (Koza and Lewin. 1998). The literature on 
competitive dynamics has proposed that "actions triggered by one firm may trigger a 
series of actions among the competing firms’* (Tloskisson a  a/., 1999:428). In other 
words, firm strategies may coevolve with those of competing firms and the industry 
structure. This thesis therefore adopts the proposal of Lewin and Volberda (1999) that 
coevolution provides a theoretical lens that will unify studies into understanding 
processes of adaptation and determinism.
2.10 Chapter Summary
It has been argued that, in order to contribute to our understanding of how strategies are 
realised, it is necessary to understand that various endogenous and exogenous factors 
can influence the strategy process. From the literature reviewed in this chapter it is 
concluded that firms should strive to achieve strategic fit with their environment. Yet, as 
the literature review has shown there are a variety of evolving factors that mean that the 
ability of the firm to forecast how the environment will change is limited. Examples of 
factors shaping the industry structure that can impact upon a firm’s strategies include 
technology, regulation and globalisation. Like the moves on a chess board each action 
that is undertaken can potentially impact upon a competitor’s next move.
Henderson (1989) proposed that all firms seek to differentiate themselves in order to 
achieve competitive advantage. But various endogenous factors, such as inertia and 
management perceptions can limit or prevent the ability of an organisation to profit 
maximise and achieve competitive advantage. All of these factors have their own 
evolutionary processes making it extremely difficult, if not impossible, to forecast how 
they will coevolve with each other, and the subsequent impact upon each individual 
firm.
This may explain why sustainable competitive advantage is such an elusive objective 
for most firms. As this chapter has shown exogenous factors can be influenced by firms. 
For example, they can introduce new technology that is competence destroying for other 
firms or they can form policy networks in order to exert influence on political decisions. 
Internationalisation strategies can lead to industry globalisation as more firms need to 
act globally. Similarly merger and acquisition activity can lead to industry
consolidation and policy networks can seek to shape the policy decisions that affect 
other firms.
There have been few longitudinal studies that have tracked industry and individual firm 
strategy evolution simultaneously (Lewin and Volberda. 1999). In addition, studies into 
the coevolution of firm strategies have tended to focus upon a narrow area of strategic 
activity, such as strategic alliances (Koza and Lewin. 1998. 1999) and no papers were
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identified that explored these processes for firms in the same industry that arrived at 
different strategic outcomes. Therefore, a contribution to the gap in the literature could 
be made by using the theoretical lens of coevolution in order to identify how strategies 
can coevolve with a particular emphasis upon strategic outcomes. In order to explore 
this further it is felt necessary to identify an industry which met certain criteria in order 
to provide a suitable context for studying this phenomena. The criteria were that:
• The industry structure needed to have undergone significant structural change so 
that relationships between industry evolution and firm strategies can be 
identified.
• The changes in structure needed to be those that could be related to specific 
types of strategy, such as merger and acquisition activity.
• The firms in the industry needed to have implemented a variety of different 
strategies so that strategic actions could be identified for each firm and then 
compared with those of other firms. This would allow for empirical research to 
identify how the strategies had coevolved.
• The firms in the industry needed to have arrived at a variety of different strategic 
outcomes. This meant that the empirical research could focus upon how the 
strategies had coevolved for a heterogeneous sample of firms rather than 
assuming that they were all homogeneous.
In the next chapter it is explained how the pharmaceutical industry provides an 
appropriate context for meeting the above criteria.
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CHAPTER THREE
THE PHARMACEUTICAL INDUSTRY
3.1 Introduction
The purpose of Chapter Three is to explain the reasons why the pharmaceutical industry 
provides an appropriate context for exploring how strategies and strategic actions 
evolve and coevolve. As the following review shows, the industry has undergone 
significant changes as a result of technology evolution, regulatory changes and 
globalisation. The result has been that the industry has evolved from being a 
fragmented industry to a global oligopoly (Jones and Cockerill. 1984; Kettler, 2001a). 
This chapter provides a history that explains how the industry has evolved since its
thinception in the 17 Century through to the early 21 Century. This includes a review of 
how firms have pioneered new technologies and entered into cooperative strategies to 
exploit them. It also reviews realised pharmaceutical firm strategies that have lead to 
industry globalisation and consolidation and the resulting range of different strategic 
outcomes that firms have arrived at. Other strategies that have been implemented by 
incumbent firms are also discussed in order to illustrate the range of strategic choices 
that are available to firms in the pharmaceutical industry.
3.2 An Overview of the Pharmaceutical Industry
The pharmaceutical industry is technology intensive and it has been argued that product 
innovation is the key to competitive success for its firms (Kettler. 1998; Kurdas, 1998). 
Various Research & Development (R&D) strategies have been identified in the industry 
including a bias towards the development of minor local products (Thomas III. 1996), 
'me-too' R&D strategies (Kettler. 1998) and focusing efforts upon therapeutic classes 
that were not being sufficiently targeted (Taggart, 1993).
The pharmaceutical R&D process incurs high costs coupled with a high risk of failure 
meaning that many lead drug candidates are not successfully developed or
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commercialised (Kettler. 1998; Cunningham, 2001; Orsenigo el a l , 2001). The drug 
discovery process can be driven by factors such as government policy initiatives, 
scientific breakthroughs and the commercial exploitation of new technologies (Kettler, 
1998). The innovations that are successful can range from being blockbuster drugs to 
those that have been classed as 4me-toos‘ which are incremental developments of 
existing products. Due to the uncertainty in the R&D process it is usually not possible 
to identify which of these two categories new innovations will fall into (Kettler. 1998). 
Even when a product has passed through the various regulatory stages relating to safety, 
efficacy and quality and it has been brought to market it may still have to be recalled 
due to unexpected problems (Taggart, 1993; Bhandari el a l , 1999). It has been
estimated that lead time from discovery of a new compound
commercialisation as an approved new drug takes an average of 15.3 years (Heracleous 
and Murray, 2001), although this figure is open to debate. Despite several periods of 
change in the technological trajectory the industry has been characterised by the 
longevity and success of established pharmaceutical firms in areas such as size of 
market share and the ability to bring new products to market. Some of these have 
survived more than one hundred years despite the introduction of pioneering 
technologies by potential new entrants (Kurdas, 1998).
The pharmaceutical industry has a history of being relatively unconcentrated with a 
large number of organisations involved in R&D (Jones and Cockerill, 1984; Grabowski 
and Vernon. 1994; Matraves, 1999). Based upon data from the 1980s the industry was 
described as fast-growing with the market being structured in a way that enabled 
oligopolies to exist in many sub markets as firms competed on the basis of drugs for
treating specific illness (Jones Cockerill, 1984; Taggart, 1993). Matraves
(1999:191) identified the main pharmaceutical therapeutic markets. These are shown in 
Table 3.1.
Table 3.1 Therapeutic Classes Served by the Pharmaceutical Industry
Therapeutic Class Drug Treatments and Illnesses
Cardiovascular Anti-coagulants, haemophilia, beta-blockers, diuretics, 
hypertension, cholesterol reducers
Respiratory system Anti-histamines, asthma, cough medicines, bronchitis, 
cystic fibrosis
Anti-infectives Antibiotics, antimalarial, anti-virals, vaccines, AIDS
Pain control Analgesics, anaesthetics, anti-arthritics, anti-gout, 
migraine, bone products (for rheumatism etc )
Internal medicine Antacids, anti-nauseants, contraceptives, enzymes, 
hormones, laxatives, digestants, anti-ulcerants, immuno-
suppressants, anti-obesity
Mental Health/CNS Anti-convulsants, sedatives, Parkinson's disease, 
Alzheimer's , anti-depressants, multiple sclerosis
Topical Dermatologicals, haemorrhoids, feminine hygiene 
preparations, ophthalmic
Cancer Therapy Cancer therapy (oncology), anti-emesis in cancer treatment
Miscellaneous Nutrients, vitamins, diabetes, diagnostics
Source: Matraves (1999:191)
For example, both Lilly and Aventis produce insulin to treat diabetes. At this market 
level neither firm would necessarily compete with the manufacturer of cardiovascular 
drugs. However. Scherer (1996b:270) argued that monopolies did exist as "drug 
companies seek and win dominant positions in new therapies”. As will be discussed 
later, the pharmaceutical industry entered a period of consolidation at the end of the 
1980s, largely as a result of increased merger and acquisition activity. This was 
accompanied by increasing moves toward the global harmonisation of pharmaceutical 
regulation and the industry has become a global oligopoly (Matraves, 1999; Kettler. 
2001a).
Rogowsky (1996) commented that the competitive success of pharmaceutical firms was 
not just driven by the external factors such as government policy, which all firms face, 
but also by internal factors such as the entrepreneurial nature of those directing the firm. 
He argued that it was not just the creativity of the scientists that was important to the 
success of firms, but also the commercial focus of the organisation as it seeks to carve 
out a competitive niche in the global pharmaceutical industry. In recent times 
pharmaceutical firms have developed strengths in areas such as competences based 
around the R&D process, as well as in external relationships through the formation of 
networks (Bower, 1993; Henderson and Cockburn, 1994; Kettler, 1998). This chapter
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continues by focusing on specific factors that have impacted upon the evolution of the 
pharmaceutical industry, and reviews the strategic choices available to incumbent firms.
3.3 Technological Trajectories Prior to the 1970s Biotechnology
Revolution
thThe origins of the pharmaceutical industry can be traced back to the 17 Century when 
apothecaries were responsible for making and dispensing different medicines. The 
process became more refined during the 18lh Century due to advances in chemistry. In
ththe 19 Century some apothecary retailers, for example Allen & Hanburys and Merck, 
diversified into becoming manufacturing chemists. In the following years there were 
two main types of pharmaceutical product development. The traditional approach, used 
by apothecaries, was based upon extraction and purification techniques, which was the 
main approach adopted by US and British firms. The second was based upon a 
technique originally used by dyestuff manufacturers, known as synthetic organic 
chemistry, which was mainly pioneered by Swiss and German firms. This led to firms
such as Hoechst and Bayer becoming new entrants to the pharmaceutical industry. The 
UK and US had been happy to import the drugs produced by German firms rather than 
develop their own, but they were forced to change this approach during the outbreak of 
World War I when they were cut off from the supply of German products (Owen 1999).
World War I resulted in two significant changes for the US and UK pharmaceutical 
industries. Firstly, governments recognised the need for the industry to develop its 
pharmaceutical capabilities. Secondly, at the end of the war assets that had belonged 
previously to German firms were sold to US firms and these helped to stimulate the 
domestic (US) pharmaceutical industry. The period of the First World War saw the 
development of sulphur drugs and penicillin. Although penicillin had been discovered 
by accident, the development of sulphur drugs (for example Prontosil by Bayer) 
demonstrated a move towards a focused and well organised drug development process 
(Owen. 1999). Following World War 11 the antibiotics revolution started, with the drug 
discovery process continuing to be based upon a trial and error approach (Kurdas, 
1998). This was the main approach used until the biotechnology revolution of the 
1970s.
55
3.4 1970s Onwards -  the Biotechnology Revolution
A large proportion of pharmaceutical companies had traditionally been focused upon 
the development of ‘chemical* pharmaceuticals and the industry had been defined as 
being part of the chemical industry (Bremner, 1992). This started to change in the mid- 
1970s with the start of the ‘biotechnology revolution‘(Pammolli and Riccaboni, 2001). 
The biotechnology revolution refers to what Walsh and Galimberti (1993:189) classed 
as “third generation’* biotechnology. This resulted from the discovery of recombinant 
DNA in 1973 and its application to the genetic engineering of micro-organisms (Owen, 
1999). This led to the application of biotechnology to the development of biological 
medicines. Biological medicines date back to the 17th Century and rather than being 
derived from chemicals are the product of living organisms such as plants (Morris, 
2001). The introduction of biotechnology techniques led to the replacement of some 
traditional biological medicines. For example, animal insulin was replaced by the 
genetically modified human insulin1 (Owen 1999, Morris 2001). The biotechnology 
revolution also led to the introduction of completely new products such as growth 
hormones (Morris, 2001). The development of biotechnology together with other 
technologies has also led to a more rational approach to the drug discovery process than 
the trial and error method previously used (Matraves, 1999; Ramani, 2002).
Dedicated Biotechnology Firms (DBFs) were the first to commercially exploit the third 
generation biotechnologies (Walsh and Galimberti, 1993). It had been assumed that 
firms pioneering the new technology would replace the incumbent chemical-based 
pharmaceutical firms (Owen, 1999), particularly as chemical processes were being 
increasingly replaced by biotechnology manufacturing techniques (Matraves, 1999). As 
discussed in Chapter Two (Section 2.6.3) technological changes can be either 
competence enhancing or competence destroying for incumbent organisations
(Tushman and Anderson, 1986; Malerba and Orsenigo, 1996). It has been suggested
%
that competence enhancing technologies are introduced by incumbent organisations 
whilst competence destroying technology is introduced by new organisations (Tushman 
and Anderson, 1986). It would appear that the introduction of biotechnology had the
9
1 Although animal insulin has continued to be manufactured by pharmaceutical firms
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potential pharmaceutical
industry. However, it enabled incumbent firms to develop drugs that could not 
previously be made and to treat illnesses that were previously untreatable. Established 
pharmaceutical firms that had a long history of developing competences within the 
dominant design preceding this biotechnology revolution could have easily become 
locked into their established way of thinking and competences, leaving them unable to 
adapt to the new' technology (Walsh and Galimberti. 1993). However, pharmaceutical 
firms have long histories surviving various changes in the past (Walsh and Galimberti, 
1993). There is also debate with regard to how biotechnology and genetic engineering 
have been classified in the literature as either competence enhancing or competence 
destroying. This has led to a view that biotechnology was not the basis of a 
technological discontinuity. Instead it should be viewed as a technological trajectory 
that is only one of several technologies used by the pharmaceutical industry (McKelvey,
1996).
The introduction of biotechnology in the mid 1970s led to tentative strategies being
undertaken by incumbent pharmaceutical firms in relation to the new technology.
Bayer, for example, created a molecular biology group (Walsh and Galimberti. 1993).
But the first main strategic thrust relating to biotechnology began in the early 1980s
with incumbent pharmaceutical firms entering into alliances with the pioneers of
biotechnology. This led to the development of symbiotic relationships in which
biotechnology firms benefited from the strength of the pharmaceutical organisations in
commercialising the new technologies. This allowed biotechnology firms to benefit
from the pharmaceutical firms’ existing networks, particularly their relationships with
regulatory and licensing authorities (Walsh and Galimberti, 1993; Kurdas, 1998:
Rothaermel, 2000). The trend of entering into network relationships extended into other
areas and included R&D alliances, sharing competences to develop patents and
licensing strategies. These are examples of the external network relationships that
pharmaceutical firms entered into with the biotechnology pioneers (Taggart, 1993;
Kettler. 2001b; Chiesa and Toletti. 2004). For example, Sandoz entered into research
cooperation agreements in biotechnology, with firms such as Repligen and Amrad. and
similarly in the area of genetic engineering with firms such as Genetic Therapy
(Schmidt and Ruhli, 2002). There have been exceptions to biotechnology firms using
network relationships as their main route to accessing the industry, with some
57
biotechnology firms, such as Amgen, developing themselves into fully-fledged 
pharmaceutical firms (Owen. 1999).
There was a change in the trend of cooperative relationships in the early 1990s as 
traditional pharmaceutical firms focused on developing in-house competences in 
biotechnology and as the industry saw the entry of a large number of small 
biotechnology organisations (Grabowski and Vernon, 1994; Kettler, 2001a). Until the 
early 1990s pharmaceuticals had been considered as a unique and fiercely protective 
industry. Until the arrival of biotechnology firms at the end of the 1980s there had been 
no new entrants to the industry for more than twenty years (Balance et al., 1992). This 
signalled the start of a period of intense consolidation, which is discussed in the 
following section.
3.5 1980s Onwards Towards Consolidation and International
Harmonisation of Pharmaceutical Regulation
Jones and Cockerill (1984) described the pharmaceutical industry as highly fragmented.
V
Taggart (1993) proposed that one of the reasons for this fragmentation was that because 
of the inherently volatile nature of the R&D process, few firms would contemplate 
taking the additional risks associated with merger and acquisition (M&A) activity. 
Consolidation of the larger pharmaceutical firms started in the late 1980s, with the 
formation of organisations such as SmithKline Beecham and Bristol Myers Squibb, and 
increased pace during the 1990s (Pursche. 1996; Matraves, 1999; Heracleous and 
Murray, 2001). This was followed by a number of "megamergers' which resulted in the 
formation of firms such as GlaxoSmithKline and Novartis (Matraves, 1999; Schmidt 
and Ruhli, 2002) leading to “consolidation of firms at the top" (Matraves, 1999:188). In 
addition, as the biotechnology organisations have grown to medium size they have 
either been acquired by the larger organisations or ceased to survive (Kurdas 1998). 
This relates to the theory proposed by Hannan and Freeman (1997) that there is a limit 
to the growth potential of medium-sized organisations. This also appears to suggest that 
the pharmaceutical industry is heading towards bipolarisation, a trend Lawrence (2002), 
commenting upon studies by ESC Lyon, referred to as occurring in other industries such 
as brewing and publishing.
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As has been discussed, the key to competitive success in the pharmaceutical industry is 
the ability to successfully innovate. Therefore access to new technologies and new 
successful products can improve the competitiveness of firms. Yet the ability to 
achieve this in-house, in an industry in which there is a high level of product failure, is 
limited. As a result firms may have weaknesses in their product line with gaps that need 
to be filled (Belcher and Nail. 2000; Henderson, 2000). Alongside the need to be 
innovative, pharmaceutical firms have been put under pressure as a result of healthcare 
reforms. These have included increasing costs of clinical trials and measures to reduce 
healthcare expenditure (Boscheck, 1996). This pressure on profits has been 
accompanied by a rise in price competition, particularly from generic manufacturers as 
patents expire. The industry faced a high level of patent expirations from 1992 through 
to the beginning of this century. Therefore incumbent firms needed to identify ways in 
which to reduce costs, strengthen the product pipeline and maximise revenue if they 
were to remain competitive. These appear to be the main factors that have driven the 
intense period of global industry consolidation that began in the early 1990s. 
Acquisition of biotechnology firms meant that the pharmaceutical firms were able to 
exploit the new technology in-house. There have also been increased competitive 
pressures at the global level and firms have sought to increase size in order to compete. 
Cross-border mergers and acquisitions gave firms the mass needed to compete at the 
global level, which was felt necessary as the industry evolved from being international 
to global. This in turn provided cost savings in areas such as marketing, and meant that 
products could be sold in countries where the patents had not yet expired. It has been 
proposed that the ability of a firm to be able to innovate is arguably increased by the 
size of the firm yet. Henderson (2000) argued that the larger pharmaceutical firms had 
exceeded the size where scale economies could be achieved.
3.6 Regulation of the Pharmaceutical Industry
As was suggested in the previous section, one of the factors that has potentially driven 
industry consolidation is the introduction of healthcare reforms to reduce government 
expenditure on pharmaceutical products. The pharmaceutical industry is strongly 
regulated, possibly more so than any other industry (Earl-Slater. 1993). Policy makers
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have several roles to play with regard to the pharmaceutical industry. The purpose ol 
this section is to provide an overall picture of regulatory changes that have potentially 
impacted upon the pharmaceutical markets where firms compete. Although there has 
been a move towards increased globalisation of regulation, national markets still tend to 
have some aspects of individuality. For example, unlike most other countries, the US 
Government had a long history of not regulating pharmaceutical prices (Green, 1997)". 
For this reason the case of the UK has been adopted to explain some of the national 
aspects of regulation. The UK Government acts as a champion of the national industry 
in order to encourage its competitiveness (Kettler, 1998). The pharmaceutical industry 
can be very important to a nation's economy. For example in the UK, pharmaceuticals 
has consistently been one of the country's top three industries with regard to trade 
surplus. According to ABPI (2003) figures two UK companies, GlaxoSmithKline 
Beecham and AstraZeneca were in the top four global pharmaceutical companies in 
2001, with a combined global share of 11.6%, although there were no other British 
firms in the top 20. This reflects changes that have occurred as a result of merger and 
acquisition activity. For example, of the top UK pharmaceutical firms in the 1990s, 
Fisons was acquired by Rhone-Poulenc Rorer and Boots by BASF (Matraves. 1999). 
But despite this, in 2001 the industry contributed a trade surplus of £2.9 billion and 
directly employed 65.000 people (PICTF, 2002; ABPI, 2003). Therefore, it is in the 
government's interest to support and protect the industry.
Governments, in their role as purchasers of healthcare products, seek to control and 
reduce healthcare expenditure. If they do not achieve the right balance between cost 
control and championing the industry, firms can threaten to withdraw from a country 
and relocate to another (McDonald, 2000). In addition governments are also responsible 
for the regulation of pharmaceutical products relating to safety, efficacy and quality 
(Earl-Slater, 1993; Taggart, 1993; Thomas 111, 1996; Kettler, 1998).
2 Although the Clinton administration did propose the introduction of price capping regulation (Abbott, 
1995)
3.6.1 Pharmaceutical Regulation Relating to Safety, Efficacy and Quality
The pharmaceutical industry develops products which require regulatory approval at 
various stages of the product pipeline from the development of New Chemical Entities 
(NCEs), through to marketing issues such as advertising and labelling restrictions post-
launch (Earl-Slater, 1993). Regulatory intervention in pharmaceutical markets can 
therefore be aimed at product composition, manufacturing, labelling, packaging, 
marketing and distribution. Issues of pharmaceutical regulation relating to safety, 
efficacy and quality have becoming increasingly stringent since the Thalidomide 
disaster of the 1960s (Earl-Slater, 1993; Matraves, 1999; Owen, 1999). Safety is an 
issue because governments want to ensure that new medicines, which are intended to 
improve people's health, do not cause unforeseen damage as in, for example, the case 
with Thalidomide. Governments also seek to minimise public concern about treatments 
such as those surrounding possible links between the MMR vaccination and autism. It 
has been argued that these aspects of regulation have both increased the costs related to 
the pharmaceutical R&D process, and have also raised barriers to entry (Green. 1997).
V
In addition to safety, efficacy and quality a fourth regulatory criterion has arisen in 
some countries. This relates to issues of cost and reimbursement, affecting how a 
product is supplied to the market (Kanavos and Mossialos. 1999). It would appear that 
this fourth stage has been driven through increasing pressure on health service 
expenditure. There are industry concerns in the UK that this was the aim behind the 
establishment of the National Institute for Clinical Excellence (NICE). For example. 
NICE guidance in 1998 focused upon the explicit rationing of Viagra although a court 
case by Pfizer overturned this decision. It was argued that doctors should not be 
prevented from making clinical decisions on the basis of cost-effectiveness (McDonald, 
2000).
3.6.2 Patent Protection, Generic Products and Marketing Strategies
In many countries the argument to support government intervention has been based on
the uniqueness of the pharmaceutical industry. This means that competition is not
subjected to the same market forces as other industries, particularly because of patent
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protection. The purpose of patent protection is to protect the incomes earnt by 
pharmaceutical companies for newly developed products. This is meant to allow firms 
sufficient time to both recoup the money spent on R&D, and raise finance for further 
development, before cheaper generic products can be sold on the market as a substitute. 
But although patent protection prevents competition from generic products, firms still 
compete with substitute branded products that have been produced to treat the same 
therapeutic class (Green. 1997). Although a patent is typically granted for twenty years, 
the development time that elapses prior to commercial launch effectively reduced this to 
approximately ten years in the 1990s, although legislation has been passed to extend 
patent length in some countries (Green, 1997; Matraves, 1999). Patents are becoming 
increasingly important for pharmaceutical firms. There have been moves to encourage 
prescribes to prescribe generic products whenever possible, or for a pharmacist to 
dispense a generic substitute even if a doctor has prescribed a branded product (Taggart,
1993; McDonald, 2000).
Pharmaceutical firms are increasingly facing generic competition as patents expire. 
This opens up the market to competition from generic products which can be up to 50%
V
cheaper than the branded equivalent (Griliches and Cockburn, 1996). Scott Morgan 
(2000) suggested that two strategies were available to the original producer of the 
branded product, advertising and pricing. Jones & Cockerill (1984) identified price, 
along with product development and promotion as being the three main competitive 
weapons used in the industry. These can all be considered as key parts of a marketing 
strategy. Marketing strategies are an important source of competitive advantage for 
pharmaceutical firms as they seek to commercialise their products. As discussed, there 
are regulatory restrictions on the marketing of pharmaceutical products. In the United 
States, for example, prior to Food & Drug Administration Agency (FDA) approval 
potential purchasers of a new drug (prescribers) mainly obtain information through 
reviews in medical journals. Manufacturers cannot actively promote the indications of a 
drug until after FDA approval has been granted. However, once this approval has been 
obtained there appears to be a positive correlation between promotional expenditure and 
the number of patients treated (Howard Beales 111. 1996). Marketing strategies have 
ranged from developing a niche national market to marketing an existing product line 
globally and ‘co-operative’ marketing (Taggart, 1993). Marketing is mainly conducted
through pharmaceutical representatives who ‘detail the product to the prescriber and to 
medical magazines (Matraves, 1999).
3.6.3 Globalisation of Pharmaceutical Regulation
Global regulatory issues relating to prescription pharmaceutical drugs had been led by 
the World Health Organisation and the United States until the early 1980s. Their 
leadership in this area has since been superseded by harmonisation implemented by the 
European Union and the International Conference on Harmonisation (ICH) (Braithwaite 
and Drahos, 2000). Pressure for changes in regulatory regimes were increasingly the 
result of action taken at the European level starting with the 1965 EC Directive on 
Medicinal Products. This directive focused on issues relating to safety, quality and 
efficacy (Braithwaite and Drahos, 2000). The European influence has also affected 
decisions relating to areas such as pricing and reimbursement, and has initiated a drive 
towards European rather than national approval of new drugs reaching safety standards 
(Kanavos and Mossialos, 1999).
At the European level there has also been a move towards establishing a single market
t
in pharmaceuticals. This was started with a 1975 Directive that led to the establishment 
of a Committee for Proprietary Medicinal Products (CPMP) in Brussels (Taggart. 1993; 
Braithwaite and Drahos, 2000). Amendment of the Directive in 1983 started a voluntary 
mutual recognition scheme. This means that if a pharmaceutical drug has been 
approved in one country it could be marketed in other European Union (EU) member 
states, with some exceptions (Earl-Slater, 1993; Braithwaite and Drahos. 2000). This 
scheme was not widely adopted and changes in 1987 meant that the new products had to 
be approved by CPMP before they could gain national regulatory approval (Braithwaite 
and Drahos, 2000). The year 1999 saw the establishment of the European Medicines 
Evaluation Agency (EMEA) whose role included the coordination of European wide 
technical approval of pharmaceutical products rather than them having to gain approval 
in each individual country, although this centralisation is only compulsory for 
biotechnology products (Matraves, 1999; Braithwaite and Drahos, 2000).
At the international level there has been a move towards harmonisation with the 
establishment of the International Conferences on Harmonisation of Technical
Requirements for the Registration of Pharmaceuticals for Human Use (ICH) which were 
established in 1990 (Matraves, 1999; Braithwaite and Drahos, 2000). The original 
concept of ICH was to build upon the move towards a single pharmaceutical market in 
Europe and bilateral agreements between countries such as Japan and the US, in order 
to move towards international harmonisation of the development and registration of new 
medicines. The initiative involves consultation between representatives of regulatory 
bodies. The overall aim was to speed-up the process from drug development to patient 
delivery. (Matraves. 1999; ICH. 2002). Despite the progress made in pharmaceutical
A
regulation both in terms of improvements in safety, efficacy and quality, and the 
harmonisation of pharmaceutical regulation there are still regulatory issues that need to 
be developed. Unresolved issues in Europe relate to parallel trade, price liberalisation
standardisation (Kanavos Mossialos, 1999). been argued
globalisation of pharmaceutical regulation has been hampered by the long history that 
the regulation has in developed national markets (Braithwaite and Drahos, 2000). 
Examples of recent changes include the European Court of Justice ruling in favour of a 
pharmaceutical firm with regard to parallel importing (ABPI, 2004) and the decision of 
World Trade Organisation (WTO) member governments to enable poorer countries to 
import cheaper generic pharmaceutical products (WTO, 2003).
1990s Onwards - The Creation of a Global Oligopoly
Along with the increasing trend towards globalisation of pharmaceutical regulation it 
has been argued that the pharmaceutical industry has evolved into a global industry 
(Rogowsky, 1996; Kettler, 2001a). As discussed, governments have sought to reduce 
the profits earnt by pharmaceutical firms, which has been combined with issues relating 
to shortening product lifecycles. In order to overcome the resulting financial pressures, 
pharmaceutical firms have sought to increase profit through the development of new 
products, and through geographical expansion (Taggart. 1993; Walsh and Galimberti, 
1993; Matraves, 1999). Although each geographical market may present different 
regulatory hurdles', the research and development technology itself is not difficult to 
transfer (Matraves, 1999). This can be achieved through various strategies including the
' Although this is reducing as the result of increasing international harmonisation of pharmaceutical 
regulation
establishment of wholly owned marketing and distribution networks, entering into co-
operative arrangements such as joint ventures and co-marketing agreements, 
outsourcing of activities or the establishment of overseas R&D facilities (Walsh and 
Galimberti, 1993; Matraves. 1999; Schmidt and Ruhli, 2002). Outsourcing activities can 
include the use of Contract Research Organisations with firms sometimes only 
maintaining a small internal R&D facility (Balance el al., 1992; Piachaud, 2002). 
Strategies such as international cooperative strategies and Foreign Direct Investment 
have led to increasing global flows of finance which has been reinforced by the 
globalisation process (Walsh and Galimberti, 1993). The result has been that the 
leading pharmaceutical firms operate either internationally or globally (Matraves, 1999) 
but this does not apply to all pharmaceutical firms. For example, Thomas III 
(1996:110-111) identified a significant number of pharmaceutical companies that had 
the discovery of “minor local products’’ as the main focus of their R&D activity. This 
indicates that although incumbent firms may be facing the same exogenous forces they 
are not necessarily evolving their strategies in the same way.
3.8 2000 Onwards -  Decoding of the Human Genome, Genomics
and Proteoniics
June 2000 saw the initial decoding of the human genome (Jones, 2001). In 
pharmaceutical terms this is referred to as genomics. There is also another layer to be 
unravelled to fully understand the genetic sequences. Each gene provides instructions as 
to how proteins should be constructed, and when this is further understood it could lead 
to the next major technological revolution in pharmaceuticals (Jones, 2001). Genomics 
studies are focused upon gene expression and proteomics upon protein expansion. 
These technologies are being developed in the hope of addressing the issues of 'target 
identification’ and 'lead candidate optimisation’ (Cunningham. 2001). So. for example, 
genomics can potentially lead to the development of drugs tailored to meet the 
therapeutic needs of either a group of people or even for each individual (Bhandari el 
a/.,1999; Ileracleous and Murray, 2001). Current technological developments have 
started to focus upon identifying how the product success rate can be improved through 
the application of genomics and proteomics technologies (Bhandari, 1999; 
Cunningham, 2001). Such developments could lead to better understandinu of how-
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pharmaceuticals react within each individual and lead to higher levels of product safety. 
The deciphering of the genetic code, although still at its initial stages, means that there 
is the potential to create medications for illnesses that were previously unbeatable. This 
could potentially be extended to the development of bespoke drugs for each individual 
(Jones, 2001).
Bhandari el al. (1999) suggested that different operational strategies will be needed for 
pharmacogenomics. from the drug discovery stage through to commercial exploitation. 
However, all of the strategic options to exploit this new technology are not yet clear. 
Potentially a new industry will emerge as a result of the new technologies relating to 
genomics and proteomics. If, as Porter (1980) argued, there are no rules when a new 
industry emerges then it would suggest that industry recipes (Spender, 1989) no longer 
apply and firms may either be setting new industry rules (Hamel, 1996) or more likely 
to imitate the strategies of other firms in order to avoid strategic drift. This therefore 
suggests that the pharmaceutical industry will continue to provide an interesting context
for exploring how firms' strategies and strategic actions coevolve in light of the
0
technological changes that have shaped the industry.
Defining the Modern Pharmaceutical Industry
The history of change that has been discussed so far brings us to the modern 
pharmaceutical industry and this section outlines the key aspects of that industry. The 
modern pharmaceutical industry comprises of firms who, in various forms, are 
responsible for legally producing and/or marketing medicinal products that are 
consumed by humans (this therefore excludes veterinary products). This is an industry 
that has become increasingly globalised and one which has expanded from its original 
base of R&D-focused pharmaceutical firms to one that encompasses a heterogeneous 
composition of firms (Comanor, 1996; Henderson and Cockburn. 1996). Contemporary 
players in the industry are the traditional major pharmaceutical companies as well as 
specialised biotechnology companies, academic and public research institutions, 
contract sales organisations and contract research organisations (Kettler, 2001a).
There are two main types of pharmaceutical products: 'branded' which are produced by 
pioneering R&D based pharmaceutical manufacturers and ‘generic'. Generic products 
are extremely similar to the branded products and are launched when the patent for the 
branded product has expired. The generic bioequivalent can sometimes be produced by 
a firm affiliated to the original manufacturer but more often it results from 
manufacturers focused upon the production of generic medicines (Griliches and 
Cockburn, 1996; Scott Morton. 2000). Tables 3.2 and 3.3 show the major players in the 
pharmaceutical industry for 1992 and 2001, which have been ranked on the basis of 
global sales. Separate tables are used as the high level of merger activity within the time 
period makes direct comparisons difficult.
Table 3.2 Top 10 Pharmaceutical Firms in 1992 - Ranked by Global Pharmaceutical Sales
Company Country of 
Origin
1992
Share of Global 
Pharmaceutical 
Sales
Rank
Glaxo Wellcome UK 3.8 1
Merck USA 3.6 2
Bristol-Myers Squibb USA 2.8 3
Hoechst Marion 
Roussel
GER 2.6 4
SmithKline Beecham UK 2.2 v5=
Ciba-Geigy SW1 2.2 5=
Roche SWI 2.1 1=
Sandoz SWI 2.1 7=
American Home 
Products
USA 2.0 9=
Pfizer USA 2.0 9=
Source: Matraves (1999:188)
Table 3.3 Top 10 Pharmaceutical Firms in 2001 - Ranked by Global Pharmaceutical Sales
Company Country of 
Origin
2001 Share of 
Global
Pharmaceutical
Sales
Rank
Pfizer USA 7.5 1
GlaxoSmithKline UK 7.0 2
Merck USA 5.3
AstraZeneca UK 4.6 4
Johnson & Johnson USA 4.4 5
Bristol-Myers Squibb USA 4.3 6
Novartis SWI 4.0 7
Aventis FRA 3.5 8
Pharmacia Corp USA 3.4 9
Abbott USA 3.1 10
Source: ABPI (2003)
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Two firms that were in the top 3 in 1992 still held top slots in 2001; Merck & Co., and 
GlaxoSmithKline (in its merged form). A sharp jump over the period was seen by Pfizer 
which had risen from 9th position in 1992 to number one in 2001. The following section 
provides an overview of the strategies that have been undertaken by the firms in the 
pharmaceutical industry, followed by an overview of strategic outcomes in the industry.
3.9.1 An Overview’ o f Realised Strategic Actions by the Pharmaceutical Industry
The technological and regulatory factors that have been discussed so far have the 
potential to affect the realised strategies of incumbent firms. Regulation can affect both 
R&D and marketing strategies. As well as the exogenous forces that have been 
discussed the modern pharmaceutical industry has also been shaped by the strategies 
that have been realised by incumbent firms. As has been demonstrated the emergence 
of biotechnology has led to increased levels of both network strategies and M&A 
activity. In addition, other corporate level strategies identified within the industry have 
included retrenchment, divestment of a division, diversification, vertical integration and 
the creation of spin-off companies (Taggart, 1993; Schmidt and Ruhli, 2002). 
However, literature on pharmaceutical strategies has tended to focus on the business 
level, which may be because there are few 'pure' pharmaceutical firms, with many 
parent firms traditionally operating in a range of industries such as the chemical and 
pharmaceuticals industries.
Pharmaceutical industry researchers have tended to focus upon two types of strategy 
that create competitive advantage for pharmaceutical firms, those of R & D and 
marketing (Jones and Cockerill, 1984; Balance et al.. 1992). As discussed in Chapter 
Two, researchers in other industries have also identified internal competences and the 
development of network relationships as sources of competitive advantage. This still 
applies to the pharmaceutical industry, but the literature appears to indicate that this is 
only because these sources can strengthen the advantage achieved through R&D and 
marketing. However, it is not clear whether firms seeking to achieve competitive 
advantage should place emphasis upon the R&D process or marketing. For example, 
Drews (1997) placed emphasis upon R&D productivity as the key to pharmaceutical 
success. Yet, as Kettler (1998) emphasised, there has been an increase in •me-too'
products which would suggest that firms are having to market more aggressively if they 
are to differentiate these products.
However. R&D and marketing are just two of the many strategies that pharmaceutical 
firms seek to implement as they choose from the available strategic choice set. As 
Balance et al (1992) illustrated, pharmaceutical firms have many strategic options 
available to them although they argued that each firm will usually only implement a 
few. They proposed that strategic options relate to decisions about which products to 
develop for the product pipeline, markets to be served (both therapeutically and 
geographically), outsourcing, distribution methods, cooperative arrangements and 
merger and acquisition activity (Balance et al 1992). Due to the long term focus needed 
to bring products from development to being profitable, finance and investment 
strategies are also important to the pharmaceutical industry. These have focused upon 
both raising additional funds and investment in other firm's operations (Taggart. 1993; 
Henderson and Cockburn, 1996).
Strategic actions that have been discussed in the pharmaceutical literature can be 
grouped under the strategy headings of corporate, marketing^ Research and 
Development (R&D), investment, network and global (Table 3.4). These categorisations 
are not mutually exclusive, for example a firm may implement a strategic action that fits
isation and marketingthe criteria for both global
Table 3.4 Mapping of Pharmaceutical Strategic Actions with Related Strategies
Strategic Actions Related Strategy References
Mergers, acquisitions, vertical 
integration, retrenchment, 
divestment, diversification, 
creation of spin-off companies
Corporate strategy
Balance et al.
(1992) ,Taggart
(1993) , Pursche 
(1996), Matraves 
(1999), Heracleous 
and Murray (2001), 
Schmidt and Ruhli 
(2002).
Niche marketing, advertising, 
‘detailing’ by sales 
representatives, marketing and 
distribution networks, co- 
marketing agreements
Marketing strategy
Balance et al.
(1992) , Taggart
(1993) , Walsh and 
Galimberti (1993), 
Matraves (1999), 
Schmidt and Ruhli 
(2002).
Licensing agreements, R&D 
alliances, establishment of 
overseas R&D facilities, 
outsourcing of the R&D function, 
focus upon ‘minor local products', 
‘me-too' R&D strategies
Research &  
Development 
(R & D ) strategy
•
Balance et al. 
(1992), Walsh and 
Galimberti (1993), 
Piachaud (2002), 
Schmidt and Ruhli 
(2002).
Raising additional funds, investing 
in other companies Investment
strategy
Taggart (1993), 
Henderson and 
Cockburn (1996).
Licensing strategies, outsourcing, 
strategic alliances, joint ventures, 
co-marketing agreements
Network strategy
Balance et al.
(1992) ,Taggart
(1993) , Walsh and 
Galimberti (1993), 
Kurdas (1998), 
Matraves (1999), 
Rothaermel (2000), 
Schmidt and Ruhli 
(2002).
Establishment of overseas 
subsidiaries and R&D facilities, 
cross border mergers and 
acquisitions, cross border 
cooperative arrangements, co- 
marketing agreements
Global strategy
Walsh and 
Galimberti (1993), 
Matraves (1999), 
Schmidt and Ruhli 
(2002).
Source: Compiled by the author
3.9.2 Strategic Outcomes
So far this chapter has discussed the history of the pharmaceutical industry, the 
evolution of its structure and firm strategies that have been implemented. It has also 
illustrated how the industry has undergone significant changes in its technological 
trajectories. During this process biopharmaceutical firms have arrived at a number of 
different strategic outcomes. Referring to Tables 3.2 and 3.3, Merck, which was
th fi rm sestablished prior to the 20 
in the top 20 have been the result of significant megamerger activity, in particular 
Aventis. Novartis and GlaxoSmithKline. Whilst Amgen evolved from being a new 
biotechnology firm into a pharmaceutical company other middle sized pharmaceutical
firms were acquired or failed survive (Kurdas 1998; Owen, 1999). These
demonstrate examples of pharmaceutical firms that have arrived at different strategic
outcomes. Further evidence that firms in the pharmaceutical industry arrived at a variety 
of different strategic outcomes is provided by the information contained in Table 3.5. 
which is based upon data from the Department of Trade and Industry (DTI). This is a 
summary of firms registering and de-registering in the UK from the manufacture of 
pharmaceuticals and medicinal chemicals. It confirms that 290 firms had de-registered 
during the period 1994 -  2000, and thus they arrived at different strategic outcomes 
from firms that had survived in the industry without being acquired or merged. This 
therefore suggests that a large number of firms in the pharmaceutical industry undergo 
periods of transformation that result in them arriving at different strategic outcomes.
Table 3.5 Number of New Pharmaceutical/Biotechnology Businesses Created
Minus Existing Such Businesses Closing
1994 1995 1996 1997 1998 1999 2000 Sub
totals
Stock4 (as at l sl Jan) 425 430 420 415 405 405 380 -45
Registrations 40 30 40 25 35 35 35 +240
De-registrations 35 40 45 35 35 60 40 -290
Net change 5 -10 -5 -10 0 -25 -5 -50
Source: PICTF (2002:21) based upon data from the DTI
4 Stock is the number of firms registered as manufacturers of pharmaceuticals and medicinal chemicals on 
1sl of January each year
3.10 The Research Question
1 he purpose ot this chapter was to demonstrate that the pharmaceutical industry
provides a suitable context lor understanding the processes of evolution and coevolution
relating to firm strategies and strategic actions. The criteria for a suitable industry were
outlined in Section 2.10 and the pharmaceutical industry meets these criteria in the 
following ways:c  -
The industry structure lias undergone significant structural change as it has 
evolved from being highly fragmented to a global oligopoly, accompanied 
by a high number of small new entrants.
The changes in structure can be related to specific firm strategies. For
example, merger and acquisition activity can be linked to industry
consolidation and strategies such as cross-border co-operative arrangements
have resulted in industry globalisation.
The firms in the industry have implemented a wide range of strategic 
actions. Those reviewed in this chapter were categorised in Table 3.4 and 
showed that there is a wide range of strategic actions that can be tracked in 
order to identify the realised strategies of individual firms and to identify 
how these strategies and strategic actions have evolved and coevolved.
The firms in the industry have arrived at a variety of different strategicJ J w
outcomes. These have included firms merging, being acquired, failing to 
survive and surviving without being acquired or merged. Accompanying 
this, the industry consists of' a heterogeneous set of firms that include 
branded pharmaceutical manufacturers, biotechnology firms, generics 
manufacturers, Contract Research Organisations and Contract Sales
Organisations.
Although not exploring coevolution processes. McKelvey et til's. (2004:113) findings 
into sectoral innovation in the pharmaceutical industry proposed that there is a
simultaneous interaction among firms; specificities, sectoral actors, national contexts 
and international trends . I his suggests that the pharmaceutical industry provides a 
particularly interesting context for exploring coevolution processes. Carney and 
Gedajlovic (2002) suggested that path dependency is an important component for 
understanding the coevolution process. 1 hey argued that the outcomes of organisational 
strategies can shape the local environment which in turn affects the actions of other 
actors altected by this environment. This can be related to the issue of strategic 
outcomes that was discussed in Chapter Two and the changes to the structure of the 
pharmaceutical industry that were outlined in this chapter as it evolved into a global 
oligopoly. I his leads to the specihc research question that guides the empirical research 
for this thesis: ’How did the realised strategies of a heterogeneous set of pharmaceutical 
firms coevolve during the industry consolidation of 1992 - 2002?’
3.11 Contribution to Theory and Practice
As has been discussed there have been a variety of studies into pharmaceutical 
strategies (Balance et al., 1992; Taggart, 1993; Walsh and Galimberti, 1993: Henderson 
and Cockburn, 1996; Pursche. 1996; Kurdas, 1998; Matraves, 1999; Rothaermel, 2000; 
Heracleous and Murray, 2001; Kettler. 2001b: Piachaud. 2002; Schmidt and Ruhli, 
2002) but there appears to have been limited empirical research into how the strategies 
of individual pharmaceutical firms have evolved longitudinally. This has been partially 
addressed by Strategic Group Analysis (SGA) studies (Bogner et al., 1996; Leask and 
Parker, 2004; Leask and Parnell, 2004) but. by its nature, this approach grouped firms 
rather than focusing upon individual patterns of strategic change. There has also been 
some recent research into strategy formation and processes in large pharmaceutical 
firms (Schmidt and Ruhli, 2002). However, there has been little examination of either 
strategy evolution or coevolution in the middle sized pharmaceutical firms, or factors 
that may have impacted upon their strategy processes prior to different strategic 
outcomes. Specifically, the thesis contributes to existing knowledge about coevolution 
with regard to addressing a gap about how the grand strategies coevolved for medium 
sized pharmaceutical firms who arrived at different strategic outcomes during 
significant change to the structure ot the pharmaceutical industry.
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This thesis encompasses Pettigrew s (2001) view that quality academic research also 
needs to be relevant by making the study context specific, i.e. by focusing upon a 
specific industry. 1 his enables the researcher to focus on strategy in a single industry 
and understand how realised strategies have preceded the strategic outcomes of firms. A 
study ot the type proposed tor this thesis means that the academic work can be based
fi r m s
pharmaceutical industry on issues relating to strategic change.
3.12 Chapter Summary
The aim of this chapter was to explore whether the pharmaceutical industry provided a 
suitable context for exploring how firm strategies and strategic actions have evolved and 
coevolved. The chapter explored factors that have impacted upon the industry as it has 
undergone significant structural change with it appearing to move towards 
bipolarisation Also reviewed in this chapter are the strategies realised by firms in the 
industry, identifying that some of these could specifically be related to changes in
V
industry structure, for example cross border mergers. It was also found that firms in the 
industry had arrived at a number of different strategic outcomes. As summarised in 
section 3.10 the pharmaceutical industry met the criteria set out in Chapter Two for 
deciding whether it provided an appropriate context for exploring how firm strategies 
and strategic actions had evolved and coevolved. This led to the development of the 
research question followed by the proposed contributions of the thesis to both theory 
and practice. The contributions that the thesis makes are discussed further in Chapter
Eight.
In the next chapter the research design for the thesis is discussed. Lewin and Volberda 
(1999:528) proposed that the understanding of coevolution processes would be 
advanced with more studies using data to analyse “microstate adaptation data 
sequences* and they referred to the work of Webb and Pettigrew (1999) who tocused 
upon “strategic adaptations such as mergers, acquisitions [and] divestitures (Lewin and 
Volberda. 1999:528). As the next chapter shows a methodological framework has been
developed which adopts this proposal. I his was achieved through focusing upon and 
developing a categorisation ol strategic actions realised by firms in the pharmaceutical 
industry. I his could be applied qualitatively to longitudinally track and analyse the 
evolution and coevolution ol strategic actions and grand strategies for a set of 
heterogeneous pharmaceutical firms that arrived at different strategic outcomes.
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CHAPTER FOUR
RESEARCH DESIGN
Introduction
The purpose of C hapter Four is to explain the research design that was used to guide the 
collection and analysis of empirical data to explore the research question. As was 
discussed in Chapter Three this thesis aims to contribute to the existing body of 
knowledge in the strategy field by exploring a gap in the current literature about how 
the strategic actions and strategies of pharmaceutical firms that arrived at different 
strategic outcomes evolved and coevolved during the period 1992-2002. The research 
question that was developed to address the gap is: ‘How did the realised strategies of a 
heterogeneous set of firms coevolve during the period of pharmaceutical industry 
consolidation from 1992-2002?’ The research for this thesis is guided by coevolution as 
a theoretical lens, a conceptual framework, and the philosophical perspective of realism.
The chapter starts with an introduction to the parameters of the research. An explanation 
is given of the context, level and unit of analysis for the empirical research. This is 
followed by an explanation of the sub questions and conceptual framework that will 
guide the research in order to address the research question. Attention is then focused 
more specifically on the issues that surrounded the research design for this study. As the 
chapter explains, a flexible (qualitative) research perspective was adopted as this met 
the criteria necessary for addressing the requirements of the conceptual framework and
A
the desire for the research to have a realist underpinning that combined aspects of both 
positivism and interpretivism. It discusses how a methodological framework was 
developed for analysing strategic change in the pharmaceutical industry. Also 
explained is how this methodological framework was adapted in order to longitudinally 
collect data to address the research question through the use ot text analysis. This was 
applied to a sample of six pharmaceutical firms selected by purposive non-probability 
sampling and replication logic. The chapter then provides an overview of the methods 
of data analysis and concludes with a reflection on issues relating to research bias and
limitations of the research design.
The Research Parameters
There have been different perspectives as to whether emphasis should be placed upon 
the firm as the unit of analysis or the industry (Hoskisson et al9. 1999). The economics- 
based Structure-Conduct-Performance (S-C-P) paradigm proposed that industry 
structure shapes firm strategy and that firm strategy shapes industry structure (Scherer, 
1980) but has been criticised tor only paying limited attention to firm strategy (Spanos 
and Lioukas, 2001). Porter (1980) adapted the S-C-P model but moved the focus to the 
firm strategies and performance levels, the firm also being the main point of interest for 
evolutionary economics (Child. 1995). But as Porter (1985) acknowledged, as the
internal activities of a firm can provide its unique competitive advantage, firms are
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unlikely to provide access to researchers to all of the factors that contribute to their 
competitive success. Therefore researchers have tended to focus upon the strategic 
actions that firms have implemented in order to understand the strategies that have been 
realised, what have been termed as “strategies-in-action” (Campbell-Hunt, 2000:151).
Although scholars have placed different emphasis on whether to focus upon the firm or 
the industry it has been recognised that each has the ability to shape the other and yet 
the strategic management literature is lacking in studies that have emphasised how firm 
strategies coevolve with the strategies of other incumbent firms and how these strategies 
coevolve with changes in industry structure. Therefore, the research design for this 
thesis focuses upon the pharmaceutical industry as the level of analysis and the 
pharmaceutical firm as the unit of analysis.
The level of analysis is the pharmaceutical industry as this represents the community 
(Roughgarden. 1983). It is important to understand the level of analysis because factors 
that affect this level, such as consolidation and globalisation have an impact on the 
pharmaceutical firms, which are the unit ol analysis. I he unit ot analysis is the 
incumbent pharmaceutical firm so that it is possible to compare the coevolution ot 
different types of firm within the industry (Roughgarden. 1983). 1 his is the level at 
which realised strategies and strategic actions can be analysed. Importance was placed 
upon comparing and contrasting the realised strategies ol lirms that had arrived at 
different strategic outcomes. From the literature review it was shown that strategy 
relates to the achievement of competitive advantage, coevolution theory relates to
competing species and in the strategy literature the S-C-P paradigm has tended to be 
adapted in models of competitor analysis. However, it is becoming increasingly difficult 
to identify who a firm s competitors are, particularly with the increasing emphasis upon 
developing cooperative networks, as demonstrated in Chapters Two and Three. This is 
particularly pertinent to the pharmaceutical industry where incumbent firms have 
entered into symbiotic relationships with new entrants, particularly biotechnology firms. 
Therefore this thesis has not focused upon firms that "compete” but those that have 
arrived at different strategic outcomes. By focusing upon the strategic actions and 
strategies of individual firms it was possible to track changes in how these evolve for 
each firm and also compare the strategic actions to those of other firms in the sample in 
relation to temporal patterns of strategy development (Webb and Pettigrew. 1999) and 
coevolution (Lewin and Volberda. 1999).
The emphasis of the research design will be upon identifying patterns in firms’ realised 
strategies and strategic actions with regard to how they evolved and coevolved. In order 
to answer the research question it was felt that four sub questions also needed to be 
addressed. As this chapter will explain, initial exploratory research illustrated that the 
categorisation of strategic actions outlined in Chapter Three (Table 3.4) needed to be 
developed into a methodological framework in order to address the research question. It 
explains how this methodological framework makes a contribution in the way that it can 
be applied to provide new knowledge and understanding about the evolution and 
coevolution of strategic actions in the pharmaceutical industry whilst addressing 
limitations in existing analytical tools used to explore strategic change. Specifically it 
addresses the question:
• R l: What strategic actions were realised by firms in the pharmaceutical industry 
during 2001-2002?
From Chapters Two and Three a conceptual framework was developed to guide the 
research design in order to identify and analyse patterns of evolution and coevolution.
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This is illustrated in Figure 4.1 and indicates the lines of inquiry that were translated 
into three further sub questions in order to address the research question.
Figure 4.1: Conceptual Framework of the Coevolution of the
International Pharmaceutical Industry: 1992 - 2002
Source: Compiled by the author
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The conceptual framework is based upon the principles of the S-C-P paradigm. It 
proposes that as the pharmaceutical industry structure evolved into a global oligopoly 
the changing structure shaped the strategies (conduct) of incumbent firms, and their 
strategic actions (strategies) in turn shaped the structure of the industry. These can be 
analysed to show how patterns have occurred in realised strategies at the grand level. 
The research question is based upon the proposal that a heterogeneous set of firms in the 
pharmaceutical industry arrived at different strategic outcomes that altered the structure 
of the industry as it moved towards being a global oligopoly. Coevolution theory 
suggests that during a period of time certain strategic actions implemented by 
incumbent firms shaped the strategic actions of other firms in the industry and also the 
industry structure. I he literature reviewed also suggested that the emergence of new 
technology and regulatory changes may have both led to changes in industry structure, 
namely globalisation and consolidation, and impacted upon the realised strategies of 
incumbent firms. This process has then led to strategic outcomes that have in turn 
coevolved with the realised strategies of competing firms, and to further changes in the 
industry structure. For example following an initial period of merger and acquisition 
activity by a limited number of firms, increasing numbers of firms became involved in 
the process, either by being acquired or by engaging in M&A activity themselves. This 
in turn would have increased the concentration ratio of the industry as firms became 
larger, leading the industry from being fragmented to becoming a global oligopoly 
(Jones and Cockerill, 1984; Kettler. 2001a). In order to understand how the strategies of 
firms evolve as the industry structure changed the strategic actions of firms can be 
identified and chronologically mapped to identify the strategies that were realised. This 
will be achieved by addressing the question:
R2: How did the realised grand strategies of a heterogeneous set of firms evolve 
during the period of pharmaceutical industry consolidation from 1992-2002?
The conceptual framework focuses upon the realised strategies ot incumbent firms. In 
order to identify if there were patterns of coevolution between firms the following 
question will be addressed:
R3: How did the realised strategic actions of a heterogeneous set of firms
coevolve with each other’s strategic actions during 1992-2002?
As discussed in Section j .10 certain strategic actions, for example cross border mergers.
specifically had the ability to shape the pharmaceutical industry structure as it became
ineieasingly globalised, in other words there was a process of coevolution between the
stiategic actions that were realised and the evolving industry structure. The research
design will therefore focus upon the collection and analysis of empirical data that can 
address the question:
• R4: How did a heterogeneous set of firms realise internationalisation strategies
during the period of pharmaceutical industry consolidation from 1992-2002?
4.3 Overview Of The Research Approach
4.3.1 Overview o f Research Philosophies
The key philosophical paradigms that have been discussed in the literature are those 
relating to positivism (Lincoln and Cuba. 2000; Thietart et al., 2001). interpretivism 
(Miles and Huberman. 1994; Thietart et al., 2001), constructivism (Lincoln and Cuba. 
2000) and realism (Levy, 1981; Miles and Huberman, 1994; Patton. 2002; Robson, 
2002).
The positivistic paradigm is based upon the application of scientific techniques in order 
to generate hypotheses. These lead to law-like generalisations that can be applied to the 
complete population. The subject being studied is assumed to be independent of the 
researcher. It employs a logical approach with quantitative techniques and a highly 
structured methodology. This objectivity is demonstrated by tests of reliability and 
validity (Lincoln and Cuba. 2000; Thietart et al., 2001). The positivistic paradigm could 
not fully guide the research for this thesis. Firstly because the research is exploratory 
and, secondly, the research cannot lead to a law-like generalisation because it is very 
context specific. However, positivism can be applied to this thesis in that it is argued 
that the process of how the data is collected can be applied to other industries in order to 
understand the strategies that have been realised.
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In contrast to positivism, interpretivists believe that the world is too complex to be 
explained through law-like generalisations, particularly as each case studied could be
considered as unique. Rather than one truth believe that there are many
possibilities that can be identified through research. Rather than being objective the 
research is subjective through, for example, studying people’s motivations. 
Interpretivists believe that the researcher cannot be truly independent of the researched, 
and that part of the reseaichei s interpretations are the result of his/her interaction with 
the subject being studied (Thietart et a l , 2001). This thesis does involve some 
interpretation ol the articles that appeared in the press about firms and their strategies. 
Although the reseaicher sought to be as objective as possible in recording the strategic
actions that were implemented, including • •writing coding rules, some
interpretation had to be applied. For example, there were two issues relating to the 
interpretation ol merger activity. A firm may refer to the action as a merger and then 
refer to it as an acquisition at another point in time. It was accepted that there would be 
anomalies in the way that strategic actions are reported, and yet, through the 
development of a coding book, sought to minimise the effect. But the acceptance of 
potential anomalies rather than saying this is a true reflection again represents the 
standpoint between positivism and interpretivism.
4.3.2 Realism as a Guiding Philosophical Perspective for this Research
In Chapter Two different perspectives of strategy were discussed. Planned strategy can 
be real in the mind of the chief executive because it steers the organisation towards its 
vision and steers the organisation's plans. If s/he was to be asked what the strategy of 
the organisation was the planned version would probably be the one that he would 
discuss. But, as Mintzberg et al. (1998) noted, realised strategy is the action that was 
undertaken, and this may not be the same as the planned strategy. This concept of 
realised strategy is related to the paradigm guiding this study, w hich is one of realism. 
Having a ‘common-sense ontology’ in the way that it takes seriously the existence of 
things, structures and mechanisms revealed by the sciences at different levels of reality, 
realist research derives knowledge from experience (Outhwaithe,1998:19). As such 
realism is ‘concerned with developing methods appropriate to the particular subject 
matter of the social sciences’ (Blaikie, 1995:58). What were the strategies that were
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realised? How did they coevolve? How does this relate to the strategic outcome of the 
organisation? Realism as a guiding paradigm both encompasses aspects of positivism 
and interpretivism whilst rejecting other aspects. This view of realism underpins this 
study which seeks to identify the realised strategies of firms which may be different 
from those that were planned. There are various perspectives of realism with terms used 
such as historical realism and critical realism (Robson. 2002) and transcendental realism 
(Miles and Huberman. 1994). Rather than being aligned within one of these subsets the 
leseaicher has adapted Robson s (2002) conceptualisation of realist research as follows:
• Action - realised strategies
• Mechanism -  strategic actions
• Outcome -  strategic outcome
• Context -  the period of pharmaceutical industry consolidation 1992 - 2002
The research shows how realised strategies precede strategic outcomes. The research is 
underpinned by the assumption that the strategic outcomes of firms follow from the 
strategic actions that had been implemented. The mechanism for identifying the realised 
strategies is the identification and analysis of the strategic actions implemented by 
firms. The context is the period of pharmaceutical industry consolidation. 1992 -  2002. 
The attention to detail, in this case identifying every publicly reported strategic action, 
is a key aspect of realist research (Robson 2002). “At the heart of realism is the 
assumption that there is a reality which exists independently of our awareness of it” 
Robson (2002:29). Robson's (2002) comment illustrates how researchers can probe in 
order to reveal realities that had not been previously visible. As the philosophical 
positioning of this research is that of realism (Miles and Huberman, 1994; Robson, 
2002), the research for this thesis seeks to identify the underlying mechanisms (e.g. 
strategic actions that preceded the strategic outcomes that led to industry consolidation) 
and is 'methodologically open' (e.g. it does not define a specific method). Hence, a 
qualitative methodological approach has been adopted for this research. The 
philosophical underpinning of this study is that a form of reality can be identified, 
namely the strategic actions that were implemented and reported in the press. Yet, 
when they were reported, they were not reported for the purposes of identifying the 
strategies that firms realised, but instead were reported as singular events or summaries
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of a year's activities. By tracking these strategic actions it was possible to reconstruct 
them in order to identify the strategies that were realised. These may be different from 
how they would be reported by the company as it seeks to justify and explain its actions. 
This leseaich provides one aspect of the reality which is under study.
In oidei to increase the objectivity of the research the researcher maintained a distance 
from those being leseaiched — in keeping with the positivistic stance, and contrasting 
with the interpretivistic need to get fully involved with those being studied. But, in 
relation to this perspective, the researcher immersed herself in the trade publications and 
other relevant hteiature. together with initial interviews, in order to become familiar 
with the industiv undei study, and as a result this has led to an emergent research 
design. The underpinning realist philosophy, that there is more than one reality, means 
that it was tempting to make the scope of the study too wide for the time limitations that 
are placed on a thesis. Ideally, the research would have involved tracking all of the 
publicly reported strategic actions lor every pharmaceutical firm during the whole 
period of its life. I he analysis would have then focused upon analysing how the 
strategic actions for all of the firms had coevolved. This would have been followed 
through with in-depth interviews and various other case study approaches, including 
analysis of financial data, product pipelines and so forth, in order to paint what could be 
considered as nearer to a ‘true’ picture of the evolution and coevolution of firm 
strategies and strategic actions in the pharmaceutical industry. But research needs to be 
manageable and this would not have been feasible. However, the underpinning 
philosophy of realism indicates the great amount of additional research that can be 
undertaken after completion of the thesis in order to further develop the answer to a 
broader research question, by both adding depth to the analysis that was undertaken, and 
by adding breadth to the number of firms analysed and the length of time that is placed
upon tracking the history of each firm. Until such time though, the research is guided
%
by realism, achieving a balance between the strengths and weaknesses of positivism and 
interpretivism.
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4.4 Methodological Choices and Research Design for an
Exploratory Study
4.4.1 Research Strategies
The research strategy is guided by the philosophical underpinning of the research 
(realism), the research question and the conceptual framework. This research 
encompasses the multiple theoretical lens approach that has been proposed by 
researchers in strategy (Hoskisson et al. 1999. Thomas and Pollock 1999) and studies 
into adaptation and selection by using coevolutionary theory as the theoretical lens 
(Lewin and Volberda 1999). The research strategy guides decisions as to how 
information was collected and analysed in the way that was most appropriate for 
addressing the research question. Errors in research findings can occur as a result of 
giving inadequate consideration to research design. For example, by not correctly 
defining the research question or assessing how data collection will address that 
question. It has been suggested that consideration be given to analysis before the data is 
collected (Miles and Huberman. 1994; Yin, 1994) otherwise a mass of data can be 
collected that is either insufficient for addressing the research question or the researcher 
does not have the time to analyse the data.
Robson (2002) proposed focusing upon two overarching types of research strategy; a 
flexible design strategy (principally qualitative) and a fixed design strategy (primarily 
quantitative). He also considered a combined research strategy which is similar to that 
of Yin's (1994) description of case studies as a research strategy. Yin (1994) 
highlighted that case studies should not be confused with qualitative research strategies, 
but instead should be considered as a strategy in its own right that can encompass both 
quantitative and qualitative techniques. This section, therefore, reflects upon the 
adoption of both quantitative and qualitative research methods before explaining why a 
flexible, predominantly qualitative, research strategy was adopted (Patton, 2002; 
Robson. 2002).
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In general terms quantitative research is closely aligned to positivism. (Robson, 2002) 
Quantitative designs are highly structured, and considered by their proponents to be 
logical and objective. The research design is tightly prespecified (Bryman, 
1993;Robson, 2002) and is suited towards dealing with a large number of cases, with 
the aim being to generalise research findings to a complete population. This is achieved 
through the application of mathematical equations and statistical techniques, and is 
normally associated with numerical data (Miles and Huberman, 1994; Robson, 2002). 
Quantitative designs are theory driven, focused upon hypothesis testing. Data collection 
methods include experiments and questionnaires.
Qualitative research designs are more closely aligned with postpositivistic paradigms 
such as interpretivism and constructivism (Miles and Huberman, 1994; Robson. 2002). 
Data is normally provided in the form of words (Miles and Huberman. 1994; Robson, 
2002). Qualitative research strategies are highly flexible meaning that research 
questions can be redefined as the findings emerge. Qualitative strategies focus upon a 
small number of cases, which leads to increased depth and richness of findings (Miles 
and Huberman. 1994). Qualitative data is about context specific actions (Miles and 
Huberman. 1994) in contrast to quantitative approaches which have been criticised for 
being context stripping and thus prevent analysis from being relevant (Guba and 
Tincoln, 1998). Qualitative approaches can include naturalistic inquiry, in-depth 
interviews and documentary analysis.
Both qualitative and quantitative approaches can be used to map events in a
chronological order. Miles and Huberman (1994) illustrated how this could be done
with qualitative data. Quantitative techniques can include time series analysis and event
history analysis. Both quantitative and qualitative approaches can also be used for
clustering cases on the basis of specific variables in order to identify firm heterogeneity.
They can also both be used to identify causal relationships. Miles and Huberman
(1994; 10) also highlighted one of the strengths of qualitative research being that it
provides a “real world" perspective, although it should be noted that in Real World
Research Robson (2002) appears to indicate that this can be achieved through both
quantitative and qualitative approaches. Therefore despite the extensive literature that
debates quantitative versus qualitative approaches there are similarities in what they can
achieve. It has been highlighted that there is a need for the researcher to identify which
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approach is more suitable, in particular whether a research design needs to be highly 
structured (quantitative) or very flexible (qualitative) for the research that is to be 
undertaken ( I hietart el a/., 2001; Robson, 2002). Of course, as highlighted by Yin 
(1994) a case study approach can incorporate both of these methods.
4.4.2 Re\ iew of Research Design Issues in Previous Strategic Change Research
This section locuses upon specific aspects of previous strategy content research, namely 
those relating to time horizons, the numbers of strategic variables that have been 
consideied and stiategic actions. 1 he purpose of this section is to explain how a review
of research methodologies in the strategy literature influenced the research design lor
this thesis.
Longitudinal studies are considered important in strategy research in order to 
understand the dynamics of industries that result from firms changing their strategies 
(Mascarenhas, 1989; Bogner et al., 1996). Tushman and Anderson (1986) suggested 
that studies into changes of organisational strategy over time in competitive 
environments have been few. Subsequent literature searching appears to support this 
view, noting that longitudinal studies have also tended to focus upon large organisations 
(Grant and Cibin. 1996; Dean et al.. 1999; Ghobadian and Viney. 2001).
Many studies that claim to be longitudinal have actually employed cross-sectional 
analysis rather than focusing upon the process of changes in strategy (Ginsberg 1988). 
For example, the quantitative method of strategic group analysis (SGA) developed from 
snapshot studies to those of a more longitudinal nature. Bogner et al. (1996) and 
Schwittay et al. (2001) undertook a longitudinal approach but the data collection was 
actually cross sectional, with the research focused upon identifying industry breakpoints 
in which to group the firms on the basis of their strategic actions. SGA was evaluated 
as a method for analysing changes in strategies in an industry over time. However, this 
strategy was on the basis that it grouped firms at specific times dependent upon them 
following similar strategies and therefore did not allow the richness of explanation that 
would result from tracking the strategic actions of individual firms. This lack of depth 
was recognised in a study by Bogner et al. (1996) when tracking the entry paths of
European firms into the US pharmaceutical industry and so they supplemented their 
research method with historical analysis.
In order to undertake longitudinal research the issue of timescales with regard to 
efficiency needed to be considered. Other studies that have involved studying strategy 
and strategic actions have analysed text for 8 - 1 0  years (Miller and Chen. 1994; Viney, 
2001). It was felt that as the focus of the thesis was strategic change that it was 
necessary to collect data that was contemporary but that also included a timescale that 
encompassed a major breakpoint in the structure of the pharmaceutical industry. In 1994 
the Scrip Yearbook reported that the pharmaceutical industry had undergone its highest 
level of merger and acquisition activity for several years. In addition, during this period 
25% of patents were facing expiry (PJB Publications. 1995). Thus in order to include a 
lead time to this period it was decided to collect continuous data for the two years 
preceding this major breakpoint through to the last day of data collection for this stage
of the study i.e. January 1st 1992 to December 31st 2002.
Strategic content research, such as that discussed in the last section, has continued to 
focus upon a limited number of strategic variables, for example Mascarenhas (1989) 
focused upon seven. This was a development as it provided a wider picture than other 
SGA work that had only grouped companies on the basis of two variables (McGee and
Segal-Horn 1990). Qualitative studies have focused upon a smaller sample of firms and
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tracked the strategies in more depth than that allowed for in quantitative approaches 
(Mintzberg and Waters. 1982; Viney, 2001). These qualitative methods do not, 
however, allow for a qualitative researcher to track the number of firms that quantitative 
analysis allows for. It does not allow for differences between a wide variety of firms to 
be compared, for example for measuring relative levels of strategic activity or strategic 
inertia between a set of firms, or to compare how different firms have shaped their 
strategic actions in light of changes in the industry environment. However, the 
advantage over quantitative analysis is that it does allow for a richness ol data about 
each firm that allows the findings to be contextualised.
In order to understand how the realised strategies and strategic actions have evolved and
coevolved it is firstly necessary to identify an appropriate way ol identifying the
strategies that were realised. This can be achieved through tracking strategic actions.
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These categorisations can be used to track the strategic actions and industry 
themes/influences through a longitudinal study. Miller and Chen (1994), focusing upon 
stiategic inertia in the airline industry, used strategic actions to compare a larger number 
of firms i.e. j j  in the airline industry over a longitudinal study which tracked the 
stiategic actions of firms using a single source trade publication. Regression analysis 
was used to measure lex els of strategic inertia. But again there were weaknesses with 
this study, f iistly, it appeared to assume that all of the firms in the airline industry were 
homogeneous, there was no evidence that they had attempted to explain differences 
between the organisations. 1 his may not have been necessary, but it does mean that the 
method is difficult to apply to an industry where the incumbent firms may have very 
distinct diffeiences. This means that analysis based upon considerinu firms as 
homogeneous is weak. Secondly, their analysis did not consider reversal of the strategic 
actions, so for example it a firm started a collaborative agreement no consideration 
given to whether the collaborative agreement had been prematurely ended.
was
It was therefore considered important to design a methodological framework that could 
explore how strategic actions actually change, through both advancement and 
retrenchment, over a sustained period of time. Advancement means the implementation
V
of a strategic action, such as entering into an R&D agreement. Retrenchment means the 
premature cancelling of an R&D agreement. Another example would be expansion of 
the workforce followed by redundancies. This is at odds with the objective of the 
planning school of strategy which focuses upon moving forward in a linear direction, 
with no consideration given to premature termination of strategic actions. In addition it 
is important to understand the extent to which strategic actions are undertaken that 
allow the organisation to achieve strategic fit with the external environment, which is 
the view advocated by the incremental school of thought. If this is to be explored then
• . •
it is necessary to know what the external changes in the environment are and how these 
could relate to the strategic actions of a firm.
In summary, the review of papers into strategic content research highlighted that the 
majority of them had one or more of the following limitations:
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A limited number of strategic variables was usually selected:
The lesearch took a snapshot or cross sectional approach rather than a 
longitudinal approach;
1 he lesearch did not consider the potential influence of specific 
environmental factors on specific strategic actions;
The research did not consider reversals in the strategic actions that had been 
implemented;
The studies considered all firms to be homogenous.
In order to outline a more detailed picture of strategic change for firms in an industry it 
is argued that it is first necessary to develop a research design that allows for these 
limitations to be overcome and that allows for the study to include the following:
A wide range of strategic content variables to be considered that apply to the 
industry, in other words the strategic choices available to firms;
That these strategic choices can be tracked during a longitudinal study;
That it is possible to identify how potential influences and themes in the 
industry environment can be related to strategic actions.
As outlined in this thesis such limitations can be overcome once a categorisation of 
strategic actions and industry influences/themes has been identified and developed. In 
their paper reviewing research into how companies compete and why, Thomas and 
Pollock (1999) suggest that whilst a study of competition at different levels such as at 
the strategic group and firm levels should be adopted, that it may also be beneficial to 
look at the overlap of networks in order to provide some form of triangulation in order 
to focus on the issue of competence.
These gaps therefore suggest that a valuable contribution could be made to the existing 
academic literature by the development of an appropriate research method. The research 
design outlined and developed in this chapter shows how the limitations of previous 
research can be overcome through the development of a classification of strategic 
actions that details the externally oriented strategic choice set of an heterogeneous group
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ot companies, in this case the international pharmaceutical industry. The collection of a 
large number of variables makes data collection and analysis more complicated than by 
focusing on a tew selected variables but the inclusion of all relevant strategy variables 
provides a richness ot data that enables a more accurate understanding of strategy 
(Ginsberg 1988). Although Ginsberg (1988) did warn, however, that a risk of using too 
many variables is that changes in strategic direction may be overlooked. This limitation 
has been overcome in the research design for this study because it has also recorded the 
termination or retrenchment of strategic actions that had been previously implemented.
I his reseaich design aims to overcome the following limitations of previous research 
into strategic change:
By allowing a detailed range of externally reported strategic actions to be 
considered. It has therefore not limited the number of strategic variables 
considered in the analysis which is often the case in quantitative analysis;
By allowing the analysis to include both when individual strategic actions 
were started and. if appropriate, when they were prematurely terminated;
By allowing continuous longitudinal analysis to be undertaken and so
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prevents the risk of important events being omitted, a risk of cross sectional 
research;
The analysis allowed consideration to be given to the heterogeneous nature 
of the firms in the study.
4.4.3 A Qualitative (Flexible) Research Strategy
It has been proposed that exploratory research is more suited to an unstructured 
(qualitative) approach whilst descriptive and explanatory/causal research is more suited 
to a fixed/structured (quantitative) research design (Thietart et al., 2001; Robson, 2002). 
1 his thesis is focused upon developing an understanding of strategy processes putting 
emphasis on realised strategic actions, not plans or intentions. Further, the research 
question is focused upon ‘how did firm strategies coevolve?* The realist philosophical 
underpinning has been demonstrated in the research design for this study through a 
qualitative approach that involves the development of a methodological framework
which avoids interaction with the people that form part of the study. This approach is
akin to a positivistic quantitative approach and yet it is qualitative in that it has
deconstructed documentary sources in order to identify the strategic actions
implemented in the pharmaceutical industry. It focused upon words, the strategic
actions that were reported in the trade press {Scrip)1, the Financial Times and a database
of merger and acquisition activities (Mergerstat). This framework is then used to
collect data on the firms in the sample in order to identity patterns in how the strategic 
actions evolved and coevolved for each firm.
Further leasons why the research design needed to be flexible are given below.
• The research was context specific and was not aiming to produce law like 
generalisations but to generate theory.
• The thesis is exploratory and changes needed to be incorporated in light of the 
findings as they emerged. 1 he methodological framework needed to be refined 
as more strategic actions were identified so that they could still be coded.
• As strategy is not necessarily a linear process the research design needed to 
include aspects of strategic actions being terminated as well as started.
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• The results that emerge from focusing upon one firm may lead to a 
reinvestigation of the strategic actions implemented by another firm. If a static 
data collection instrument was used, such as that in quantitative analysis, this 
would not be possible.
1 The pharmaceutical industry has a publication called Scrip which is produced twice each week 
with approximately 16-20  pages focusing upon the strategic actions of firms in the 
pharmaceutical industry. Scrip has been used by researchers who have tracked changes in the 
pharmaceutical industry (Matraves, 1999). The objective of Scrip is to report on the strategies 
and activ ities of firms in the pharmaceutical industry and has subsequently published a detailed 
list of articles that are relevant to this research and so can form the sampling frame. It is 
justifiable in content and text analysis studies to use a sampling frame that has been developed 
by an entity that is not the researcher (Nuendorf, 2002)
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4.5 Development of a Methodological Framework 
Strategic Change in the Pharmaceutical Industry
I his section outlines one ot the key contributions of this thesis: the development of a 
methodological framework to analyse strategic changes in the pharmaceutical industry 
and addiesses the sub question Rl. 1 he analytical method developed overcomes the 
limitations ol other techniques and can be adapted to analyse how firm strategies and 
strategic actions have evolved and coevolved over a period of time. The literature 
review relating to the pharmaceutical industry (Chapter Three) indicated that a large 
proportion ot pharmaceutical strategy researchers have tended to focus upon specific 
aspects of strategy rather than the overall strategy of a firm, with the most 
comprehensive coverage of academic strategies found in the work of Taggart (1993). 
Taggart (1993) explored the development ol the world pharmaceutical market with 
particular emphasis upon the application of multinational theory, technology and the 
competitive environment of the industry. This was complemented with case studies 
focusing upon companies in the United States. Europe and Japan. However, no
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publications were found that contained a detailed categorisation of strategic actions that 
firms in the pharmaceutical industry have implemented.
Having identified from the literature review that there was a gap with regard to 
identifying how firm strategies and strategic actions in the pharmaceutical industry had 
evolved and coevolved it was necessary to identify a suitable method for data collection 
and data analysis. But this was not straightforward and required the development of a 
data analysis instrument. This section outlines the stages involved in this process.
4.5.1 Pharmaceutical Industry Background
In order to become orientated with the industry, to understand the major changes that 
had affected its structure and the firms’ strategies, the researcher immersed herself both 
in the strategy literature and the trade press for the pharmaceutical industry . This was
" These publications included academic papers on strategies in the pharmaceutical industry, publications 
by the ABPI trade association, issues of Scrip, the Scrip Yearbook, the Financial Times, Fortune and 
reports by the Financial Times and Mintei
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an emergent process as the researcher sought to identify the strategies that had been 
implemented and to produce a focus for the thesis. When initially reading about the 
pharmaceutical industry, particularly the trade journal Scrip, there appeared to be a mass
of inforrnation about the actions of individual firms, but little in the way of being able to 
compare and contrast the strategic actions of different sets of firms. As the reading 
continued it was not immediately clear that there were variations of what appeared 
initially to be the same strategic action. So, for example, ‘entering into a licensing 
agreement could actually be broken down into 'licensing-out’ or ‘licensing-in‘. the 
licensing agreements may or not involve equity investments and could relate to various 
different types of technologies, for example proteomics, genomics or information 
technology. This can be likened to Boyatzis’ (1998:3) concept of the "codable 
moment . In other words the researcher is presented with a random mass of data, in this 
case news in a trade journal, which eventually the researcher realised could be coded, in 
this case into strategic actions. Reading of the printed sources led to the formation of 
ideas about changes in strategies in the pharmaceutical industry that could be potentially 
addressed through interviews. This led to a decision to conduct some exploratory 
interviews in order to develop the information that had been collected from printed 
sources. Two interview schedules were written. The first was designed to gain the
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views of the UK pharmaceutical industry's trade association, the ABP1. on changes that 
had affected the industry during the past twenty years. The second was designed for 
those actually operating within and/or advising the industry. A copy of the interview 
schedules is contained in Appendix A.
Five interviews were undertaken in order to explore changes in the pharmaceutical 
industry during the past twenty years. Two members of the trade association (ABPI) 
were interviewed, an interview was conducted with a consultancy specialising in 
regulatory issues and two were undertaken with biopharma organisations. The initial 
purpose of these interviews was to explore how the impact of regulation had affected 
the industry and the competitive strategies of incumbent firms in light of it being 
heavily regulated.
It emerged from these interviews that there was an overall perspective that government 
and the pharmaceutical industry were working closely together in the United Kingdom. 
This had meant that with the exception of clinical safety, regulatory issues had not
become any stricter, in other words they had not impacted upon the strategies of the 
turns. The main theme relating to change that emerged was that the industry was 
becoming increasingly bipolarised with the formation of five very large companies, a 
large amount ot small, mainly biotechnology organisations and that other organisations 
as they grew to middle size were usually being bought by the large firms, if they were 
able to survive. This informed the literature search that was reviewed in Chapter Three.
What also emerged from the interviews was the inability of respondents to remember in 
detail events that had occurred during the past twenty years. Interviewees made 
statements such as "that was before my time” and "I can't remember”. There was a 
rationalisation ot what they felt was correct but that they could not guarantee this. The 
other important issue was that, unless commenting upon their own strategies, the 
impression was that the information they provided had been what they had read
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themselves in trade publications and other similar sources so the views were quite
limited. Also, the range of strategies that they had reported upon in the industry was
quite limited. Yet change was occurring as the industry globalised and bipolarised
suggesting that a wide variety of strategic actions could have been implemented in order 
for this to occur.
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4.5.2 Summary of the Findings of the Initial Exploratory Research
Returning to the text sources that had been initially read, together with the information 
gained from the interviews, the initial text analysis was started. This enabled the 
researcher to identify in excess of 50 strategic actions that had been realised by firms in 
the pharmaceutical industry . This raised two issues. Firstly, that interviewees were only 
able to recollect a small subset of strategic actions that had been implemented in the 
industry. Secondly, that scholars researching the pharmaceutical industry had been 
limited in the number of strategic variables that they had included in any one study 
(Table 3.4). It was therefore necessary to identify sources for collecting data that would 
identify if there was more detailed information about the strategic actions that had been 
realised by firms in the pharmaceutical industry.
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4.5.3 Data Collection for Developing the Methodological Framework
I he researcher found that when conducting the exploratory interviews how easy it was 
to guide the answers in certain directions as a result of the reading that the researcher 
had already done. For this reason the researcher wanted the process of data collection 
and recording to be systematic and uninfluenced by my own views, or at least to reduce 
this as tai as possible. Therefore a data collection process was preferred where the 
researcher would not be able to influence the decisions that were made by the subjects 
of the study. In addition, analysis of qualitative published data prevents the biases and 
problems ot memory recollection that could result from interviews (Plewis, 1985). This 
influenced the decision to select text analysis as the main form of data collection. It has 
been accepted that how the information was reported in the press was the result of the 
subjective judgement ol both those in the organisations that provided the media with the 
information and the subjective interpretation of this information by the media.
This data collection needed to be able to overcome these weaknesses of previous 
research by accessing data that could identity a detailed number of strategic actions that 
had been implemented by firms in the pharmaceutical industry. It needed to be 
produced in a way that did not have problems with memory recall, and could enable the 
data to be collected longitudinally. Upon reviewing the possible data collection methods 
the researcher felt that in the initial exploratory research, publications had provided a 
good source of information that could be used for data collection. Researchers who have 
used documentary sources to track the strategies or strategic actions of firms in an 
industry have used trade journals (Miller and Chen, 1994) or a quality newspaper such 
as the Financial Times (Viney, 2001).
The main source of empirical data was the ‘companies’ pages of Scrip from January 1st 
2001 to December 21st 2002. As was discussed previously Scrip is a major 
pharmaceutical industry trade journal. In order to check whether Scrip was a more 
suitable source of relevant data than the Financial Times a sample of 20 pharmaceutical 
company news stories that were reported in Scrip in the first quarter of 2001 were 
checked against the 2001/2002 editions of the Financial Times. Only 7 of the items
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were reported in the Financial Times. This, therefore, supported a
oi data on strategy in the pharmaceutical industry .
when
1 here were three main problems with using Scrip encountered during the study. Firstly, 
when underaking this form of documentary analysis it is best to have paper copies of the 
articles to leier back to. This was not initially possible as the copies were held in the 
British Library and were covered by copyright which prevented photocopying of all of 
the relevant articles. In order to overcome this limitation the researcher attempted to 
code the strategic actions as the researcher read the articles, making a note of the issue 
and page numbers, and a few brief words about the article. Initial codes have to be 
frequently lefined and so coding without having the articles to return to means that the 
task cannot be carried out in a comprehensive manner. Boyatzis (1998) stressed that
identifying themes, in this case strategic actions, efficiency is a primary 
consideration in decisions about sampling. The reason for this is that the time that it 
takes to read the aiticles is multiplied possibly three to four times as the researcher 
assimilates the information and identifies codable moments. For this reason it was 
necessary for the researcher to be able to revisit the pages of Scrip that were being used 
to identify the strategic actions and undertake coding. This was not feasible if the
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copies were only available in the British Library. Photocopying was not an option 
because copyright laws meant that all the relevant pages of Scrip could not be 
reproduced.Several alternative ways of overcoming this problem were considered 
including only sampling a limited amount of journals (for example every other issue) 
but the researcher felt that this would reduce the likelihood that the resulting 
categorisation would be comprehensive. The researcher identified that the best way to 
overcome this problem would be to have all of the articles available in a printed format 
that could also be scanned in order that a computer based search and retrieval process 
could be used. After various negotiations with the publishers the researcher was allowed 
to access the relevant data.
4.5.4 Data Analysis for the Methodological Framework
Analysing the data from Scrip proved to be an emergent process. Repeated reading of
Scrip identified patterns showing how •ent strategic actions could
constructed and then re-constructed in different wavs. This concurs with the view that a
process of realisation leads to coding and analysis of patterns (Boyatzis, 1998). For
example, licensing agreements could relate to co-operative strategies, investment raising
strategies or R&D strategies for exploiting a new technology such as proteomics. This
identified the need lor strategic actions to be more tightly defined than the headings
used in Table 3.4 if the categories were to be mutually exclusive. For example, as
discussed earlier in this chapter, ‘licensing’ could be coded as ‘licensing-in’ or
licensing- out . In addition it also highlighted the need to refine the names of each
stiategy thus leading to the creation of additional categories. So. for example.
Research and Development divided into 'Cooperative Product Development (R&D)’
and 'Organic Product Development (R&D)’. This led to a process of utilising various
techniques in order to develop the categorisations. The stages for undertaking this are 
outlined in the following paragraphs.
In order to overcome the limitations ol the iirst set of codes, techniques used in text 
analysis and content analysis were applied. Content analysis has been regarded as an 
important way of acquiring historical quantitative data (Ginsberg, 1988). Many of the 
quantitative approaches to text analysis involve interpreting messages and “counting” 
how many times a word or phrase appears. This study is more focused upon the breadth 
ol strategic actions that are reported rather than the frequency of certain words or 
phrases and therefore takes the approach of coding certain words that appear in the text 
into themes (Boyatzis. 1998) which for this study were strategic actions.
Categorisations are more appropriate to analyses that focus upon identifying single or a
few words rather than in the analysis of free-flowing text such as Scrip (Plodder. 2000).
Techniques used in thematic analysis were also used in order to develop the
categorisations (Boyatzis. 1998). This was accompanied by a process of text analysis
and the development of a code book describing how the strategic actions could be
identified. A coding dictionary was developed of words/concepts/phrases that meant the
same as the strategic action variables in order to help with the coding process
(Neuendorf, 2002). There are debates in the literature about whether, when conducting
content analysis, coding should be done by people or by software (Neuendorf, 2002)
which can also be applied to text analysis. As approximately 1500 pages of Scrip were
to be reviewed, NUDIST5 (N5) software was used to import the data so that it could be
stored in an electronically searchable format. N5 facilitated data display and systematic
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searching. Content and text analysis were used with N5 used purely as a tool to aid the 
retrieval of data. 1 he coding dictionary was used for searches undertaken. The data 
could be displayed in a report format and also on screen, allowing the researcher to view 
the complete Scrip article when necessary for understanding the context of the selected 
text. The relevant sections were coded, added to the categorisation and the dictionary 
developed as knowledge was increased during the coding process.
In order to develop the categorisation further, the previous draft versions were re-
conceptualised. Conceptualisation is an important part of the categorisation process if 
the categoiisation is to have purpose (Riedel, 2000). As the strategic actions were being 
identified in order to explain patterns in the strategies of firms, data was organised 
through a set of mind maps. Putting down onto paper the main strategy headings 
together with the strategic actions that had been identified helped to organise the 
information on the mind map. This allowed the linking of strategic actions in different 
categories and aided memory recollection of actions that had been read about but had 
not been noted down in the initial draft of the strategic actions.
These strategic actions were initially mapped with the six strategy headings identified in
V
lable 3.4. This led to the identification of subcategories for the original strategy 
headings, for example, marketing subcategories included pricing, branding, sales and
advertising strategies. In addition, notes were made of strategic actions that appeared in
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more than one category. For example, launching products in new geographical markets 
appeared in both the product launch category and the internationalisation/globalisation 
category. With these diagrams it was possible to see how each of the strategic actions 
formed part of a specific strategy and therefore illustrated how these parts added up to 
the implementation of a specific type of strategy.
Following one of the key principles of high quality qualitative research that data 
collection should be thorough, the next stage of development of the categorisation 
involved a fine grained analysis of the issues of Scrip. This was to identify all of the
strategic actions that had been reported during the period January 1 2001 -  December
31st 2002 by electronically scanning the articles from Scrip and importing them into
N5. The coding dictionary was further developed to include all words that were
relevant to the strategic actions that had already been identified, and these were
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recorded in the form of tree nodes using the N5 software. This led to a process of
identifying further strategic actions and assigning them to an interpretation of the most 
appropriate strategic heading.
4.5.5 Categorisation o f the Strategic Actions
Once the strategic actions had been empirically identified through the text analysis it 
was necessary to identify a framework that was suitable for classifying them so that
they could be coded in order to identify the strategies that had been realised. Detailed 
reading of the literature suggested that the adoption and adaptation of Pearce II and 
Robinson s (1994) identification of 14 grand strategies was a suitable framework. This 
had also been used by Viney (2001) when he tracked the strategies of the major 
Regional Electricity Companies through content analysis. As the pharmaceutical 
industr) had evolved into a global oligopoly it was preferable to apply an additional 
coding as to whether the strategic actions could be related to globalisation rather than 
how firms had competed. Grand strategies can be understood as the packages of 
strategies that firms had planned and/or realised in order to achieve long-term 
objectives. It was necessary to develop Pearce II and Robinson's (1994) framework so 
that the strategic actions that had been identified in the empirical research could be 
allocated to mutually exclusive categories. This is an important factor in developing a 
taxonomy (Child and Faulkner. 1998) and/or categorisation.
The empirical research had identified strategic actions relating to the external raising of 
finance and the use of information technology. This resulted in the addition of two new- 
grand strategies. The empirical data had also highlighted that various cooperative and 
acquisition based strategic actions had been implemented. This led to the reassigning of
some categories and the creation of new categories to reflect that certain strategies may
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be focused on acquisitions, co-operative arrangements or organic development. Finally, 
taking into consideration the main emphasis of pharmaceutical firms the market 
development category was redefined to focus upon therapeutic markets. This resulted in 
an extension of Pearce II and Robinson's (1994) original categorisation of 14 grand 
strategies to 23 for the pharmaceutical industry as illustrated in Table 4.1.
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Table 4.1 Overv
2001-2002
Grand Strategics
Cooperative 
concentration (market 
penetration)
Organic concentration
iew of Gran(l Strategies Implemented by Firms in the Pharmaceutical Industry
Cooperative market 
development 
Organic market 
development
M&A market 
development 
M&A product 
development
Cooperative product 
development (R&D)
Organic product 
development (R&D)
Cooperative innovation 
(R&D)
Organic Innovation 
(R&D)
Cooperative innovation 
(Information 
Technology)
Organic innovation 
(Information 
Technology)
Horizontal integration
Vertical integration
M&A concentric 
diversification
Organic concentric 
diversification
Conglomerate
diversification
Retrenchment
Organic growth
Divestiture
Definitions and Criteria for Inclusion/Exelusion
Actions relating to an existing product in an existing therapeutic market that involves some form of 
Z r V%a9T 8Tehmem' M,T b e ‘bcused uP°n an exisli"g dominant technology (Pearce II and 
S ' o r S e m e s '  3 PllarmaCeUlicals Producl and not involving biotechnology,
d t e Z  2 n t m ^ ' h iS,finS P HdUCl in 311 CXiS“nS ,herapcutic nlarket thal have been implemented bv 
994) t  “ 1 ,  k *  '° CUSedUp,on an cx,stm§ dominallt technology (Pearce II and Robinson, '
proteomics b 3 pharmaceut,cals Product and not one involving biotechnology, genomics or
Strategic actions relating to entry into a new therapeutic market through a cooperative arrangement 
J j ie source must make reference to this being a new therapeutic market for the firm.
frm itself Cll° nS l° entry int0 a new th*rapeutic market that have been implemented by the
j j ie source must make reference to this being a new therapeutic market for the firm.
Strategic actions relating to entry in a new therapeutic market as a result of Merger and Acquisition 
£ c ivity. The source must make reference to this being a new therapeutic market for the firm
i l T h f r 1 fr.alherTt’la n 'ntemal development of a product or process using technology that was already 
ed b\ the firm. I Ins does not include biotechnology, proteomics, genomics or gene libraries. The 
source must not state that the technology was new to the firm_______
I lie cooperative development of an existing product or process using technology that was alreadv used
b> the firm. I lus does not include biotechnology, proteomics, genomics or gene libraries. The source 
must not state that the technology was new' to the firm.
The development of an existing product or process using technology that was already used by the firm.
his does not include biotechnology, proteomics, genomics or gene libraries. The source must not 
state that the technology was new to the firm._________
Development ol a product or process, through a cooperative arrangement, relating to biotechnology.
proteomics. genomics and gene libraries or any technology that the source states as being new to the 
firm.
This can also include development of a new chemical entity (NCE), and development of a class of
p roduct that had not existed prior to the beginning of the study ( lsl January 1992) e.g. a super statin
Internal development of a product or process relating to a change in technology from those that were
already used, relating to biotechnology, proteomics, genomics and gene libraries or anv technology that 
the source states as being new to the firm. '
This can also include development of a new chemical entity (NCE), and development of a class of
iroduct that had not existed prior to the beginning of the study ( lsl January 1992) e.g. a super statin.
Actions that relate to information technology, ecommerce or ebusiness through a cooperative 
arrangement
Actions that relate to information technology, ecommerce or ebusiness through internal development
Liquidation
Merger or acquisition involving a firm that is broadly similar but that is not in the same supply chain
e.g. a pharmaceutical firm acquiring a pharmaceutical firm. This is focused upon the merger or partial 
or full acquisition of a business____________________________
Merger or acquisition involving a firm that is a customer or supplier e.g. a pharmaceutical firm 
acquiring a marketing organisation.__________________________
Merger or acquisition of a firm that "may be related to some distinctive competence or asset of the core 
business" (Mintzberg, 1991:79) e.g. a pharmaceuticals firm acquiring a generics business.
It does not include a business that is broadly similar or part of the supply chain______
The spin off or creation of a new business which must be solely ow ned by the company
Merger and acquisition activity involving a firm that is completely unrelated to the pharmaceutical 
technology or healthcare industry and that does not fit the criteria for concentric diversification.
A strategy focusing upon restructuring, asset and cost reduction but does not include the sale of any 
'arts of the firm_________________________________
Corporate expansion activities which include an increase in assets and expenditure.
This does not include the acquisition or merger of businesses or increases that are product specific 
The sale of complete businesses ie business units, subsidiaries etc as going concerns. This does not 
include the selling off of parts of the linn e.g. a plant or a product line.This does include a demerger.
Joint venture
The selling off of parts of a company as a result of the actions of an administrator.
This includes the sale of complete businesses le business units, subsidiaries, spin offs, or w holly ow ned 
businesses as going concerns as well as plants and product l i n e s . ____________________________
External finance raising
The creation of a third "daughter" firm by two or more partner firms._________________________
Strategic actions that focus on financing arrangements through external organisations. These can 
include equity partnerships and/or licensing agreements. This includes any cooperative arrangement 
where the firm has had equity placed into it by the partner firm. This does not include the selling 
(liquidation or divestment) of assets
Source: Author after Pearce II and Robinson (1994)
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The categorisation shown in I able 4.1 was developed so that it contributed to high 
quality research by adapting some of the criteria proposed by Boyatzis (1998) for good 
identification of themes (realised strategies) together with Miles and Huberman’s 
(1994) recommendations for coding. The finalised categorisation therefore consisted of
• A label (the grand strategy )
• A definition ot what the theme concerns (the characteristic or issue constituting 
the theme)
• A description of how to know when the theme occurs (indicators on how to 
"flag' the theme (i.e. relevant strategic actions)
• A description of any qualifications or exclusions to the identification of the
Figure 4.2 shows an extract ol the text that was analysed. I he final categorisation is 
contained in Appendix B.
products, a topical anti-infective 
Crystacide, and Micanol (dithranol) for 
psorisasis, are based on Bioglan’s 
Crystalip topic drug delivery
system.....Bioglan expects its
agreements with Medeva to generate
other a representative of a pharmaceutical trade association. Both experts felt that the 
framework was sound and comprehensive with no amendments necessary.
theme
Figure 4.2 Example of text from Scrip
revenues of more than £10m
Source: Scrip April 2nd 1996:13
A detailed version of the finalised categorisation was shown to two pharmaceutical 
industry experts, one was a General Manager of a biopharmaceutical company and the
Application of the Categorisation of Strategic Actions as a
Methodological Framework
The next stage ol the research tor this thesis was applying the methodological
framework so that it could be used to address the research question and sub questions 
R2-R4.
4.6.1 Data Collection
As Mintzberg and Waters (1982) stated, trying to track strategies over a period of time 
is difficult. There are limitations as to the work that can be achieved for a thesis, in 
particular these are with regard to financial factors and access to resources. When the 
categorisation was developed it was on the basis that all firms could be analysed using 
the same data collection instrument. However, extensive searching identified that there 
was a limit as to the amount of data that could be found tor all of the firms in the sample 
going back to 1992. An email to the British Library suggested" that the most 
comprehensive data would be on the Lexis Nexis database, but for example with regard 
to Bioglan the earliest annual report that Lexis Nexis professional database held was for 
1998. Searches for annual reports were conducted using the databases held at the British 
Library and Company Annual Reports On-Line (CAROL) but again it was found that it 
was not possible to obtain annual reports for every firm in the sample for each of the 
eleven years being studied. Some detailed information was found using the LexisNexis 
database but again it was not possible to find the same sources for each firm for the 
timescale. However, some of these sources were used to provide background 
information about the firms.
For this reason it was decided to continue using Scrip as the main source for collecting 
data on the strategic actions and grand strategies that were realised during 1992-2002. 
When the data on the strategic actions for each sample firm had been collected using all 
issues of the ‘companies section’ of Scrip January 1st 1992 -  December 31st 2002 it 
was triangulated with the Financial Times using the same process of classifying
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strategic actions over the same time period and this was supplemented with data from
Mergerstat about merger and acquisition activity that each firm in the sample had been
involved with. Information was also collected from other various sources in order to
contextualise the data for each of the firms. In particular, this was focused upon gaining
a background to each firm’s establishment and to identify any potential breakpoints in 
each firm s operating environment during 1992-2002.
4.6.2 Population Selection
As discussed in C hapter Three the pharmaceutical industry has evolved into a global 
oligopoly with consolidation at the top and the entry of a large number of small
;y firms (Grabowski and Vernon, 1994; Kettler, 2001a). December 27thbiotechnolo
2000 was the first day of operating for the firm that had resulted from the last
c
megameiger to date in the pharmaceutical industry with the creation of 
GlaxoSmithKline, the world's largest pharmaceutical firm (GSK, 2004). As discussed 
earlier in this chapter this was one of a number of major megamergers that shaped the 
changing structure ot the pharmaceutical industry as it evolved during the 1990s 
moving towards being a global oligopoly. But with this thesis I have chosen to focus on 
the "middle ground" (Lawrence, 2002:43) firms that had arrived at different strategic 
outcomes rather than the largest ten firms in the pharmaceutical industry as they were 
listed in Table 3.3 . There were various reasons for this which are outlined below.
"Middle sized" pharmaceutical firms appear to have been rather neglected in the 
pharmaceutical literature. Studies into the changing structure of the pharmaceutical 
industry (Grabowski and Vernon, 1994; Matraves, 1999) and various aspects of 
competitive strategies (Bogner el a/., 1996; Helms, 1996) have tended to focus on the 
larger organisations. Although Bogner el al. (1996) initially selected 25 of the largest 
pharmaceutical organisations, after consultation with the pharmaceutical industry they 
increased the number to 36. This included five generic firms and also meant that they 
were focusing upon middle sized pharmaceutical firms as well as the very largest ones. 
As discussed in Chapter Three as the biotechnology companies have grown to medium 
size they have either been acquired by the larger organisations or ceased to survive 
(Kurdas, 1998). As also discussed in the literature review (Chapter Three), Hannan and 
Freeman’s (1997) view was that there is a limit to the growth potential of medium-sized
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enterprises. 1 he reason for this is that as an industry evolves (bipolarises) middle sized 
companies are either acquired by large growing organisations or fail to survive as a 
result of competitive processes. For this reason it was decided to select the sample from 
medium sized pharmaceutical firms that had arrived at different strategic outcomes.
As has been discussed this research is qualitative and this approach underpins the
sampling strategy used for the research. Specifically it led to the purposeful selection of
a small number of cases (Patton, 2002). Purposive sampling is not statistically
representative but can be used to identify key themes and aspects of uniqueness which
is appropriate to a thesis that focuses upon the evolution and coevolution of strategic
actions tor a heterogeneous set of firms. The cases selected through the purposive
sampling were those considered to be “information rich" (Patton, 2002:46) in that they
represent ditterent strategic outcomes and could therefore contribute to our
understanding of how realised strategies precede these different strategic outcomes.
Forms ol probability sampling, traditionally used in quantitative analysis, although
allowing for generalisations, would have risked omitting key cases that were needed for
exploring how the realised strategies and strategic actions of a heterogeneous firms have 
evolved and coevolved.
v
laking the end of 2000 as its starting point the sampling frame for this research focused
upon the firms that were in the pharmaceutical industry top 200 by turnover at the end
of 2000. This was achieved by using the Scrip Pharmaceutical League Table which lists
the top 200 pharmaceutical firms in the world in 2000. ordered by turnover (PJB
Publishing, 2001). The reason for selecting firms as they were in 2000 was so that data
about the firms could be analysed in order to identify their strategic outcome at the end
of the research period which was December 31st 2002. This two year period was
judged to be sufficient in order for the firms sampled to have arrived at a number of
different strategic outcomes during this period of pharmaceutical industry consolidation.
From this a geographical cluster was identified which consisted of all European
pharmaceutical firms in this sampling frame. The European firms were selected as they
have to develop strategies in a different regulated trade bloc from firms in the United
States and Japan, and were therefore operating in a unique environment from other
pharmaceutical firms but together were affected by the same exogenous forces. In
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addition the literature has shown that the strategies of Japanese pharmaceutical firms are
very different from those of European firms and so this factor was isolated out of the 
research. This resulted in 73 firms being selected (Appendix C).
Using copies of Scrip from January 1st 2001 to December 31st 2002 a search was 
conducted to identify firms that had arrived at different strategic outcomes. As
term
define how firms evolve into a different species, for example as a result of being
merged, demeiged, acquired or liquidated. Therefore searches were carried out to
identify firms which had arrived at any of the strategic outcomes divested, acquired.
merged, demerged and liquidated. The results of the coding are shown in Appendix D.
In qualitative research there is often the temptation to collect more data than is
necessary to address the research question. As Miles and Huberman (1994:56)
highlighted it is important to “resist overload -  but not at the price of sketchiness”.
Each ol these strategic outcomes contributed either negatively or positively to the
number of firms operating in the pharmaceutical industry, which can be related to the
conceptual framework (Figure 4.1) with regard to issues of strategic outcomes relating 
to industry consolidation.
In order to maximise the credibility of the analysis a multiple case replication approach
was chosen which increased the stability of findings whilst allowing for generalisability
across cases (Miles and Huberman. 1994). Yin (1994:51) argued that replication and
sampling are not the same, and stated that “any use of multiple-case designs should
follow a replication, not a sampling, logic and an investigator must choose each case 
carefully”.
Yin (1994:51) also suggested that a replication approach should be
“in a manner similar to multiple experiments, with similar results (a literal 
replication) or contrasting results (a theoretical replication) predicted explicitly 
at the outset o f the investigation. ”
Therefore, in this research purposive sampling (Patton, 2002) was combined with 
replication logic (Yin, 1994).
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fi rm
stiategies it was felt important to include in the analysis firms that had arrived at 
different stiategic outcomes. In order to select the firms and to develop the strength of 
the analysis a liteial replication approach was applied where each firm in the chosen 
sample shared at least one similar characteristic with other firms in the sample. From 
these a purposive sample was selected, based upon the strategic outcomes of the firms
fi rm s
Table 4.2.
Table 4.2 Firms in the Thesis Sample
Name Country of Origin
Asta Medica 
Pierre Fabre
Strategic Outcome Position in the Scrip 
Pharmaceutical 
League Tables for 
2000
Shire
LEK
Galen Northern Ireland
Bioglan England
Survived without being 
merged or acquired 
Liquidated 143
Asta Medica was the only firm in the sample that on January 1st 2001 was owned by a 
parent company and was also a parent company itself. Asta Medica’s strategic outcome 
was that it was disbanded and divested by its parent company Degussa. Pierre Fabre 
merged with bioMerieux and then subsequently demerged from the company. Shire 
merged with the Canadian pharmaceutical firm Biochem. LEK was acquired by 
Novartis whilst Bioglan was chosen because it had arrived at the strategic outcome of 
being liquidated. Finally it was felt that in order to develop the analysis it was 
important to include a European firm in the sample that had stayed in the same form 
from January 1st 2001-December 31st 2002. When selecting this firm it was felt that it 
would be beneficial to ideally select a firm that had not changed its parent, been the 
subject of merger activity or been acquired during the period for analysing strategic 
actions i.e. from January 1st 1992 to December 31st 2002, although it was acceptable if 
the firm itself had acquired other organisations. The firm Galen met this criteria. Two 
particular factors made the researcher feel that it would add depth to the research 
findings. The first was that the Financial Times had described Galen as being similar to 
two other firms that had already been chosen for the sample, Shire and Bioglan.
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That leaves a space in the middle. It is a niche being exploited by a new 
corporate beast, speciality pharmaceutical company. Also known as emerging
pharmaceuticals, group which includes Shire, Galen, Bioglan
Pharma.............  Acquisitive, pragmatic and nimble, they pride themselves on
marketing niche drugs considered too small by “big pharma Unlike flashier
biotechs, they do not waste money on speculative, long-term research that may 
never bear fruit ”
(Guerrera and Pilling, 2000:36)
The second factor that made Galen interesting to the research and with regard to 
replication logic was that it was in a very similar position to Bioglan in the 2001
pharmaceutical league table with regard 
pharmaceutical sales with Bioglan ranked 1
ranking leading firms 
40. A third factor
was that Bioglan, Shire and Galen all originated in the United Kingdom. Therefore, it 
was possible to use replication logic to compare the strategies of these three similar 
firms with each other and with the other firms that had specific differences such as
V
country of origin and not being labelled as ‘speciality’ pharmaceutical firms.
It was felt that the approach taken to selecting firms strengthened the firm analysis 
undertaken by enabling the analysis to identify patterns and differences across the cases 
in order to identify aspects of coevolution (the underpinning theory for this research). It 
was felt that this replication is important in research that is focusing upon how firm 
strategies had coevolved.
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4.6.3 C hoice of Qualitative Data Analysis Methods
Before undertaking the analysis to identify the strategies realised by each firm N5 was
c
used to retrieve all of the articles relating to the firm being analysed. The stages
undertaken in order to identify and record the strategic actions implemented by the
firms in the sample are given below, fhe analysis required considerable interpretation
by the researcher in order to identify whether each retrieved item actually related to a
strategic action relevant to a grand strategy. In order to increase the reliability and
validity ot the findings the following stages were followed for coding each strategic 
action:
1) The relevant articles were retrieved using each of the words in the coding dictionary 
for the specific grand strategy being identified
2) The articles that had been retrieved were read to identify if they related to 
the strategic actions that had been identified for this form of grand strategy and/or
V
the definition of the theme concerned
3) If they met this criteria each article was coded as being relevant to the grand strategy.
4) The articles that had been coded were read again to check if they matched any 
qualification or exclusions for the relevant grand strategy. If they included any 
exclusions for the theme then the coding was removed.
5) The relevant data from the coded articles were then recorded on the spread sheet as 
shown in Table 4.3.
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Table 4.3 Example of Recorded Data: Galen’s Organic Growth Strategic Actions
Year Strategic Action 
Code
Strategic Action Geographical
Locations
1992 ORG1 New antibiotics plant Northern Ireland
1994 ORG2 £7.3 million expansion programme -
1995- 1997 ORG3 3 year £17.4 million expansion 
p r o g r a m m e ____________
-
1997 ORG4 Establishment of a clinical trials 
operation
"us
2000
| |i
ORG5 Expansion of UK salesforce • UK
The categorisation ot strategic actions was designed so that each strategic action has 
been allocated with a code and a description of the rules as to what does and does not 
constitute each type ot strategic action. These codes were used in the transcription of the 
text data so that a record was made of each strategic action that the firm implemented, 
the year in which it was implemented and the number of times in each year it 
implemented that specific strategic action. In order to cross-check any information when 
this information was initially recorded it also included the journal, the date and the page 
number of where the strategic action w as reported in order to be able to'gain easy access 
to the information if further information is needed to explain certain aspects of the 
findings.
One of the problems with the data collection was a lack of historical data that this 
presented as it was primarily focused upon the period 1992-2002. Webb and Pettigrew 
(1999) also acknowledged in their study that the timescale for data collection means that 
the researcher can only refer to actions that occurred during the period under study. 
Problems that were encountered with this meant that the researcher was unable to 
identify the products owned by firms and the therapeutic markets served as at 1st 
January 1992. This therefore impacted upon the preciseness of the analysis regarding 
the grand strategies relating to concentration, market development and product 
development in the original categorisation used for the methodological framework 
(Table 4.1). For example, it was not possible to distinguish between internal product 
development, product acquisition and cooperative product arrangements. Therefore, for
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the puiposes of this thesis these were reduced to the one category of ‘network and 
acquisition based product development strategy.’
The market development strategy was also removed from the classification as there is 
no base line data to identify the therapeutic markets served by the firm prior to 1992. 
However, any mention made in the Financial Times or Scrip of the firms entering into a 
new therapeutic market were included in the commentary about each organisation’s 
strategic actions. Maiket development relating to geographical markets were referred to 
in the globalisation coding. Finally a new categorisation was created that related to 
I roduct Divestment and Licensing Out . 1 his had originally been included within the 
external finance raising strategy, but further reading of the pharmaceutical literature 
highlighted that firms may implement relevant strategic actions for reasons other than 
just raising finance, for example, to streamline the product pipeline. The products can 
either be divested or the rights to marketing the product licensed out. The adapted 
categorisation that was used for the final coding and resulted in the headings shown in 
Table 4.4 is contained in Appendix E.
Table 4.4 Grand Strategies Used in the Final Analysis
Grand Strate;______________________________________
Network and acquisition based product development strategy 
Cooperative innovation (Information Technology) strategy 
Organic innovation (Information Technology) strateg 
Merger &Acquisition strategy 
Organic concentric diversification strategy
Conglomerate diversification strategy 
Retrenchment strategy 
Organic growth strategy 
Liquidation strategy
Divestment & demerger strategy
Joint venture________________
External finance raising strategy 
Product divestment and licensing out strategy
Source: Compiled by the author
The choice of qualitative data analysis methods is outlined in Table 4.5. which relates 
the sub questions R2 to R4 to the stage of qualitative analysis and analytical methods.
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Table 4.5 Choice of Qualitative Data Analysis Methods
Sub Question
R2: How did the realised grand 
strategies of a heterogeneous set of 
firms evolve during the period of 
pharmaceutical industry 
consolidation from 1992-2002?
R4: How did a heterogeneous set 
of firms realise internationalisation 
strategies during the period of 
pharmaceutical industry 
consolidation from 1992-2002?
R3: How did the realised strategic 
actions of a heterogeneous set of 
firms coevolve with each other's 
strategic actions during 1992- 
2002?
Source: Compiled by the author
Stage of Qualitative 
Analysis
Reconstruction and 
longitudinal tracking of 
strategic actions in order to 
identify the realised grand 
and internationalisation 
strategies of firms.
Longitudinal tracking and 
matching of realised 
strategic actions in order to 
understand how they 
coevolved.
Analytical Methods
Chronological ordering, thematic 
analysis, text analysis
Pattern matching
Miles and Huberman (1994) advocate the use of matrices so that the data can be easily 
manipulated and used for different purposes. Several matrices have been developed to 
record the information contained in the texts in formats that can be adapted for various 
types of analysis and so that the information can be easily manipulated for other uses. 
For example, the evidence has been recorded chronologically and can be tabulated in 
order to calculate the frequency of different events. In order to analyse the timing of the 
strategic actions the data was put into chronological lists which, when suitable, were 
depicted in graphs, for example by pictorial representation on timescales in order to 
apply labels relating to patterns or sequences of events (Mintzberg and Waters. 1982). 
This allowed for the identification of linked sequences between strategic actions in 
order to identify patterns that could be classed as realised strategies. These were also 
used to compare the strategic actions implemented by different firms in order to identify 
temporal patterns in strategy development through the use of pattern matching. This is a
method similar to that used by Webb and Pettigrew (1999) when they explored temporal
patterns in strategy with their study of the insurance industry. Webb and Pettigrew
(1999) further developed their analysis through the used of a time series based approach
but for the reasons discussed previously this thesis has focused upon the use ol
qualitative analysis. The final stage of the analysis tocused upon how the realised
strategic actions of the firms in the sample had coevolved during 1992 -  2002. Using a
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development of the chronological mappings discussed earlier these were compared for 
each type of strategy for each of the six firms using pattern matching.
Having deconstructed the text in order to categorise strategic actions, data analysis 
methods were identified in order to use this information to address the research 
question. Additional coding was applied to the article if it met the criteria for a 
globalisation strategy and/or a retrenchment ot the strategic action. Matrices were used 
to record the data from the text analysis in formats that can be adapted for various types 
of analysis and so that the information can be easily manipulated for other uses (Miles
1994). In order to analyse the timing of the strategic actions the data 
was put into chronological lists which were then depicted in bar charts in order to apply 
labels relating to patterns or sequences of events (Mintzberg and Waters, 1982). Figure 
4.3 shows the bar charts that relates to Table 4.3.
Huberman
Figure 4.3 Summary of Galen’s Organic Growth Strategic Actions
1993 1998 1999 2000 2001 2002
= years that the strategic actions were not realised
= years that the strategic actions were realised
This allowed for the identification of linked sequences between strategic actions in 
order to identify patterns that could be classed as realised strategies.
4.7 Criteria for Judging the Quality of Qualitative Research
Robson’s (2002, after Cresswell, 1998) recommendations as to a ‘good* flexible design 
were adapted as follows. Detailed methods of both data collection and analysis were 
undertaken. Considerable time and rigour were applied in developing a categorisation 
of strategic actions that was adapted to collect data to identify the strategic actions and 
strategies realised by the firms in the sample. The categorisation of strategic actions 
evolved from an initial exploratory approach through to a categorisation that was 
developed through a process of fine grained analysis. This multistage approach is also 
adopted in the analysis stage as the realised strategies ol firms are identified first. This
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then followed thiough to an analysis of how strategic actions formed strategies and the 
strategic actions coevolved.
As well as adopting Robson s (2002) guidelines for a "good" qualitative research design, 
various ciiteiia weie applied in order to maximise the quality of the research, its data 
analysis, collection and writing. It is important to be guided by a philosophical 
paradigm, such as realism, so that it can be used to guide each stage of the research 
piocess in older to improve the quality. However, there are proponents of the view that 
researchers can achieve quality of research whilst accessing a plurality of paradigms 
(Mingers and Brocklesby, 1997). Robson (2002:18) emphasised that realism does not 
reject the scientific principles of positivism but incorporates a “scientific attitude". This 
means that research should be conducted “systematically, sceptically and ethically.” As 
demonstrated in this chapter the research was conducted in a systematic manner, as 
shown by the stages involved in designing the methodological framework, the 
development of the sample and the stages involved in the data analysis. The nature of 
the research design for this thesis means that there are no ethical considerations because 
the documents are publicly available. Robson (2002) argues that these criteria are likely 
to improve the quality of research. The criteria identified in Table 4.6 were also met by 
the research design in order to maximise the quality of the research.
Table 4.6 Criteria for Ensuring High Quality Research
Criteria
Construct 
Validity
Objectivity
Biases made
explicit_____
Empirical 
findings 
emphasised in 
reporting
Adequacy of 
theorisation
References
Yin (1994), 
Robson(1999) 
Patton (2002)
External validity Yin (1994)
Patton (2002)
Patton (2002)
Patton (2002)
Robson (2002:62)
Methods employed in the research design
With regard to the categorisation of strategic actions and grand 
strategies for each strategic action that was identified an 
example was included together with the date that it appeared in 
the lelevant documentary source. Every stage of developirm 
the stiategic action data collection instrument has been noted. 
With regard to the strategic actions reported for each of the 
firms in the sample a copy of the relevant text was recorded, 
fhiee souices of evidence were used for identifying the 
realised strategies and strategic actions of the firms in the 
sample (Scrip, the Financial Times and Mergerstat). Audit 
trails have been employed with each stage of analysis available 
for review that provides evidence of how the analysis was 
conducted through a series of building blocks.
1 he categorisation of strategic actions means that the data 
collection was replicated for each of the sample firms._______
The design of the data collection instruments identified for the 
categorisation of strategic actions reflect the positivistic 
influence upon me. 1 hey have been developed in a format so 
that the information that is collected can be standardised and is 
objective with the researcher being independent of those that 
are being researched.________________
A section on research bias has been incorporated into the 
thesis._____________________
I he aim was to emphasise the empirical findings, rather than 
personal beliefs, in the findings. For this reason all of the 
strategic actions that were identified were tabulated usine 
chronological ordering.________________________
Coevolution theory has been employed as a theoretical lens in 
order to generate a theory as to how the strategies of a 
heterogeneous set of firms coevolve.
Research Bias and Research Limitations
One of the issues that needs to be dealt with when dealing with the analysis of 
qualitative data is the issues regarding the researcher’s concepts (Miles and Huberman, 
1994) and so this thesis has included definitions that describe the main terms that are 
used in the analysis. In addition the guidelines suggested by Boyatzis (1998) for 
developing themes has also been used. However, unlike qualitative research that 
involves interviewing people and asking them to recall events the use of written text for 
data collection to some extent means that the data is not being changed, for example 
because of recollection issues. Verification is undertaken in ensuring that the list of 
strategic actions only refers to actions that have been implemented by firms in the 
pharmaceutical industry and this has been done through providing specific company
examples for each strategic action. In addition the worthiness of the data was checked 
through various forms of triangulation.
There is also a risk of error as the coder collects information and codes it. for example 
the omission of a strategic action or the insertion of a wrong code (Neuendorf, 2002) 
but two measures were undertaken to negate the impact of such errors. Firstly the data 
was triangulated. Secondly, after coding all of the text on N5 the information was 
printed out to check and recode the data as necessary. Thirdly, each of the strategic 
actions that was coded was then matched up with the evidence from the relevant sources 
of Snip, the Financial Times and Mergerstat. It would have been beneficial to have 
used a second coder but the high costs associated with the data collection meant that 
there were not sufficient resources to employ a second person to cross-check the coding.
Another limiting factor of the research is the reliance upon strategic actions that were 
reported in the media. This means that the data is subjective for two reasons. Firstly, it
is relying upon firms to accurately, and substantially, release information about strategic
0
actions to the media. Secondly, the information released by the firms has to have been 
selected by the journals’ editorial staff for inclusion and is also subjected to their 
interpretation of events. The researcher aimed to minimise this aspect of bias by only 
including actions that were reported as actually having been implemented rather than 
those that may potentially happen, an approach used by Webb and Pettigrew (1999). So, 
for example, information would not have been recorded for data analysis if it was about 
merger talks, but would be if a merger had been agreed.
4.9 Chapter Summary
The research design has been developed in order to answer the following research 
question "How did the realised strategies of a heterogeneous set of pharmaceutical firms 
coevolve during the industry consolidation of 1992 - 2002?’’ The research design was 
underpinned by a conceptual framework and the philosophical underpinning of realism. 
A detailed categorisation of strategic actions realised by firms in the pharmaceutical 
industry was used as a methodological framework for analysing how the grand strategic 
actions and grand strategies of firms evolved and coevolved. This Chapter discussed 
how the methodological framework was applied to a sample of six pharmaceutical firms
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that arrived at different strategic outcomes. I he results of the strategic actions that they 
realised during 1992-2002 are presented in the Chapter Five.
CHAPTER FIVE 
RESULTS:
REALISED STRATEGIC ACTIONS 1992-2002
Introduction
Chapter Four categoiised the strategic actions that were realised for all pharmaceutical 
firms as they were reported in Scrip for the period January 1st 1992 to December 31st 
2002. This chapter narrows these down to focus upon the strategic actions realised by 
the firms in the sample. Using the adaptation of the methodological framework 
discussed in Chapter Four this chapter presents the results that were obtained from the 
text analysis and coding of Scrip, the Financial Times and Mergerstat for the period 1st 
January 199— to December 31 2002. This was conducted for the six firms in the
sample in order to identify the strategic actions that were realised. The strategic actions 
were chronologically mapped in order to provide the empirical data needed to address 
the sub questions R2 to R4. 1 his will provide the basis for the discussions on strategy 
evolution and coevolution in Chapters Six and Seven.
Four categories have been removed from the original set as they were not reported as 
being implemented by any of the firms in the sample. These were cooperative
t #
innovation (IT) strategy, organic innovation (IT) strategy, conglomerate diversification 
strategy and liquidation. This left strategic actions relating to nine types of grand 
strategy that were evidenced as having been realised by the firms in the sample. The 
finalised categorisations are shown in Table 5.1 along with an abbreviated codename for 
each of the strategies.
1 IK
Table 5.1 Grand Strategy Strategic Actions Realised by Firms in the Sample
Grand Strateg;
Merger and Acquisition
Network and Acquisition Based Product Develo 
Organic Concentric Diversification 
Organic Growth
Joint Venture
Divestment and Demerger______
Product Divestment and Licensing Out
Retrenchment 
External Finance Raising 
Source: Compiled by the author
Code Name
M&A
ment NABPD
OCD
D&D 
PD&LO
EFR
This chapter is structured to present the strategic actions that were realised for the 
following firms:
Pierre Fabre 
LEK
Asta Medica 
Shire 
Galen 
Bioglan
5.2 Pierre Fabre
Laboratoires Pierre Fabre was a French privately owned company established by 1961 
by Monsieur Pierre Fabre (Pierre Fabre, 2003). It evolved into being "France's second 
largest privately owned pharmaceutical firm” (Scrip, 1994a: 13). By 2002 Pierre Fabre 
felt that because it was “present in all pharmaceutical sectors [that it gave it] an edge 
over [its] competitors in the face of regulatory changes” (Pierre Fabre, 2003:6). As 
Table 5.2 shows Pierre Fabre demonstrated consistency in strategic actions with regard 
to the implementation of Network & Acquisition Based Product Development 
(NABPD) strate «ic actions.
Table 5.2 Pierre Fabre’s Network & Acquisition Based Product Development (NABPD) Strategic 
Actions
Year
1992
1992
1992
1996
1998
1999
1999
1999
2000
2000
2001
2001
2001
2001
2001
2001
2002
Strategic Action
Marketing and 
development agreement 
Development, 
manufacture and supply 
agreement
Licensing in agreement
1993 1 Co-marketing 
| agreement
1993 1 R&D agreement
1994 1 Development and 
marketing agreement
1994 1 Letter of intent for 
exclusive licence to 
manufacture Pedvax 
H1B for sale in France
1995 I Distribution agreement
1996 1 Licensing in/marketing 
| agreement
Firm
Haw Par Brothers 
International Ltd 
R P Scherer
Pfizer
Warner-Lambert
A & S Biovecteurs
Product
• •Baume du Tigre" (Tiger
Balm)
Sigma-Tau
Merck & Co and Pasteur 
Serumset Vaccins (PMSV)
Licensing in agreement: 
Registration, marketing 
and promotion 
Agreement to enter a 
research partnership
Research collaboration
Gerolymatos
Biovail
The benign prostatic 
hypertrophy product. 
doxazosin 
The antiviral. Vidarabine
A number of Pierre 
Fabre's pharmaceutical 
______products_____
Geographical Location
Europe
France
N/A
Pharmaceutical products 
containing propionyl L- 
carnitine
France and French 
speaking African 
countries
Pedvax H1B France
Applied Pharma Research
Licensing in of sales and 
development rights
Licensing in
Licensing in of 
exclusive development 
and marketing rights 
Joint marketing 
agreement
Five year alliance
Cancer research contract
The French scientific council
CNRS
French Institute de Pecnerche 
de Developpement
/\llergan
All of Pierre Fabre's 
products in Greece 
Tiazac
10% gel formulation of 
the antiviral, idoxuridine. 
for herpes simplex 
Research into 
pharmaceuticals derived 
from natural substances 
Potential therapeutic 
substances
Greece
France
Several European 
countries
Orphan Medical
Zorac
Busulfex
Continental Europe
21 European countries 
plus Argentina and South
Africa
Glaxo Wellcome
Recordati
The anticancer 
comb i nat ion eni 1 uraci 1/5
_____ fluorouracil_____
Recordati s calcium 
antagonist, lercanidipine
EU and certain French 
speaking African 
countries
France
Exonl lit Therapeutics Defining of genetic 
signatures for biopsies 
and blood samples
Celera Genomics For the examination of 
tubulin gene 
polymorphism
License agreement University of California San
Francisco
Yellow fever virus 
technology
Worldwide
Co-research agreement Gen fit
Co-marketing
agreement
Lilly Eflucimibe (F-12511)
Co-marketing
agreement
Lilly Raloxifene
Worldwide
France
Development
collaboration
UroGene Novel therapeutic targets 
and drugs in onco- 
_______ urology
Source: Compiled by the author from various issues of Scrip, the Financial Times and Mergerstat, 1992 
2002
Relevant NABPD strategic actions were reported as being realised in all years apart 
from 1997. The strategic actions related to marketing, development, research.
Also see Table 5.5
manufacturing, distribution and licensing-in agreements. At least two of the cooperative 
arrangements were with genomics firms; Genfit and Celera Genomics. There has been 
detailed literature about how pharmaceutical firms increasingly interacted with 
biotechnology firms (Kettler, 2001a) but Pierre Fabre’s relationships with Genfit and 
Celeia suggest that future research could be conducted to ascertain if pharmaceutical 
firms will entei into the same symbiotic relationships with genomics firms as they did 
with the biotechnology films. Piene Fabre was involved in agreements with a variety of 
different types of organisation including the French scientific council CNRS. the 
University Of California San Francisco and university hospitals. This confirms the work 
of Bower (1993) with regard to the different types of organisation that can appear in a 
pharmaceutical firm s network and also adds weight to the view that pharmaceuticals 
can be viewed as a “system or network” (McKelvey et al., 2004:112). Pierre Fabre also 
entered into five joint ventures during 1994-2001 (Table 5.3).
Table 5.3 Pierre Fabre’s Joint Venture (JV) Strategic Actions
Year Strategic action JV Partner JV Name Countries
1994 Establishment of 
an international 
centre to study 
skin ageing
A Toulouse 
university 
hospital
France
v
2000 Establishment of 
a JV
Arriani
Pharmaceuticals
Pharma Fabre SA
•
Greece
2000 JV production 
plant
Novo Nordisk Aldapn Tizi Ouzou 
region
2001 Joint research 
centre
CNRS, the 
French National 
Scientific 
Research 
Centre
France
2001 Joint centre for 
pharmacological 
screening
CNRS France
Source: Compiled by the author from various issues of Scrip and the Financial Times 
1992-2002
Pierre Fabre’s Joint Ventures were with pharmaceutical firms, a university hospital and 
the CNRS (the French National Scientific Research Centre). As was seen in Table 5.2 
prior to the joint venture with CNRS Pierre Fabre had already been in involved in a 
research partnership with the organisation. Of the five reported JVs only two of these 
were with other commercial pharmaceutical organisations, i.e. Arriani Pharmaceuticals
1 1
and Novo Nordisk. As shown in Table 5.4 Pierre Fabre made a number of acquisitions 
that were outside its home country of France.
Table 5.4 Pierre Fabre’s Merger & Acquisition (M&A) Strategic Actions
Year
1993
1995
1998
1999
2000
2001
2001
Firms acquired or 
merged with
Ellem
Acquired the 
Algerian business 
of Biogalenique
Acquired Dolisos
Tema Medical
Merger with 
bioMerieux2 
Acquired Organon 
Teknika
Transgene
Notes
Acquisition of a majority share
Pierre Fabre acquired a 51% 
stake in Tema Medical
from 52.8% to 70.3%
Geographical locations
Algeria
France
South Africa
France
Holland
Source: Compiled by the author from various issues ot Scrip, the Financial Times and Mergerstat 1992- 
2002
With regard to its home country the reason for the acquisition of Dolisos in 1998 was so 
that Pierre Fabre. together with the existing Pierre Fabre Plantes & Medecine 
subsidiary, could develop its strength in homeopathic medicine (Scrip* 1998a). Pierre 
Fabre entered into one merger, with the French diagnostics firm bioMerieux in 
December 2000, creating “France's largest independent pharmaceuticals group'’ 
(Halpem 2002:15). As shown in Table 5.5 all of Pierre Fabre’s PD&LO strategic 
actions related to licensing out agreements.
This subsequently resulted in a demerger
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Table 5.5 Pierre Fabre’s Product Divestment & Licensing Out (PD&LO) Strategic Actions
1997
2001
2001
2002
Licensing out 
of rights to 
Navelbine
Licensing out 
agreement 
Licensing out 
agreement
Exclusive 
worldwide 
agreement 
which 
included 
Immuno- 
Designed 
Molecules 
making 
payments to 
Pierre Fabre 
in order to 
use Pierre 
Fabre's 
compounds
Firms Involved
Synthelabo
Cypress Bioscience
Immuno-Designed
Molecules
Products 
involved
Milnacipran
Milnacipran
Elfucimibe 
(F-1251 1)
Bacterial
membrane-
based
compounds
Countries
European 
marketing 
rights 
(excluding 
France) plus 
some Latin 
American 
and Asian 
territories 
US and 
Canada
Lilly gained 
exclusive 
rights to 
markets 
including 
Latin
America and 
the UK 
Worldwide
Source: Compiled by the author from various issues of Scrip and the Financial Times
1992-2002
The licensing out agreements related to products in the pipeline ranging from those at 
the developmental stage to others that were already being marketed. For example, the 
agreement with Lilly was for a product in Phase 1 trials whilst with Cypress Bioscience 
it involved the already marketed Milnacipran. As Table 5.6 illustrates Pierre Fabre's 
Organic Concentric Diversification (OCD) strategic actions were focused upon 
establishing UK subsidiaries and new businesses in France in 1997.
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Table 5.6 Pierre Fabre’s Organic Concentric Diversification (OCD) Strategic Actions
Year
1997
1997
1997
1997
Strategic Action
Establishment of a UK 
subsidiary Pierre 
Fabre Oncology 
Establishment of UK 
R&D division 
(subsidiary): Pierre 
Fabre Research 
Creation of a new 
business: Pierre Fabre 
Medicament 
Creation of a new 
business: Pierre Fabre
Country
United
Kingdom
Dermo-Cosmetique__________
Source: Compiled by the author from various 
issues of Scrip and the Financial Times 1992-2002
Pierre Fabre already had various overseas subsidiaries in other parts of the Europe and 
the US (Scrip, 1997a). The establishment of the two new French companies was part of 
a restructuring process "to give the two businesses more freedom to develop in their 
specific market areas, and make it easier for them to forge alliances" (Scrip, 1997b: 12). 
As shown in fable 5.7 Pierre Fabre only realised one strategic action relating to organic 
growth, although this was for a three year investment programme.
Tabic 5.7 Pierre Fabre’s Organic Growth (OG) Strategic Actions
Year Strategic Action
1995 Fr200 million investment 
programme for 
manufacturing facilities
Source: Compiled by the author from various 
issues of Scrip and the Financial Times 1992-2002
The 1999 restructuring highlighted in Table 5.8 was focused upon remaining 
competitive during tough trading conditions (Scrip, 1999c).
Table 5.8 Pierre Fabre’s Retrenchment (TR) Strategic Actions
Year Strategic Action
1994 Restructuring of Italian operations
1994 Closure of Swiss site
1999 Cutting of almost 200 jobs and other restructuring
Source: Compiled by the author from various issues o f Scrip and the 
Financial Times 1992-2002
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As illustrated in table 5.9 a recurring theme for Pierre Fabre was its strategic actions
relating to divestment and demerger with this pattern continuing through to the 
demerger with bioMerieux.
Table 5.9 Pierre Fabre’s Divestment & Demerger (D&D) Strategic Actions
Year Strategic Action
1993 Divestment of Cachou Lajaunie
1996 Divestment of 50% stake in 
Shiseido, France
1999 Divestment of D Medica
2002 Demerger of Pierre Fabre from
bioMerieux
Source: Compiled by the author from various 
issues of Scrip and the Financial Times 1992-2002
The divestment of the sweets firm Cachou Lajaunie appeared to suggest that Pierre 
Fabre was moving to focus on its core areas of pharmaceuticals and cosmetics. In 2002 
Pierre Fabre and bioMerieux demerged (Halpem, 2002), which was Pierre Fabre’s
V
strategic outcome. James (2002) proposed that mergers can present challenges that 
organisations had not been fully able to anticipate pre-merger. This is possibly 
emphasised by the case of Pierre Fabre who realised the need to remain a privately 
owned and controlled firm as it demerged from bioMerieux. Table 5.10 summarises the 
strategic actions that were reported as having been realised by Pierre Fabre.
Table 5.10 Summary of Pierre Fabre’s Strategic Actions
= years that the strategic actions were not realised 
= years that the strategic actions were realised
Source: Compiled by the author
It is noted that Pieire Fabre did not realise strategic actions relating to the External 
Finance Raising strategy.
5.3 LEK
LEK is a generic pharmaceuticals firm based in Slovenia. In 2004 LEK classed itself in
worldwide terms as “a mid size pharmaceutical firm” (LEK, 2004). LEK's main
strategic actions between 1992 and 2002 were for an Organic Growth strategy (Table 
5.11).
Table 5.11 LEK’s Organic Growth (OG) Strategic Actions
Year Strategic Action Cou ntries
1992 Opening of a new plant Poland
1995 Opening of a new tablet 
manufacturing unit
1996 Opening of various 
regional offices
Russia
1998 $4miIlion reconstruction 
of a production plant
\999 Construction of a 
regional production
centre
Macedonia
2001 Construction of a R&D
centre
Ljubljana
2002 Construction of a $l2m 
manufacturing plant
Romania
Source: Compiled by the author from various issues of Scrip 
and the Financial Times 1992-2002
All of LEK's Organic Growth (OG) strategic actions, where the geographical location 
was reported, were based within the Central and Eastern European (CEE) market. 
Various Organic Growth strategic actions were reported from 1992 to 2002 in relation 
to the opening of new production/manufacturing and R&l) facilities Apart from the OG 
strategic actions LEK realised little in terms of further strategic actions until 1999 when 
it started to combine Organic Growth with strategic actions that were more externally 
focused. These were for Merger & Acquisition (M&A), Network & Acquisition Based 
Product Development (NAPBD) and Joint Venture (JV) strategic actions. As shown in 
Table 5.12 LEK was involved with two acquisitions, both of which were in 2001 and 
related to firms in Eastern Europe.
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Table 5.12 LEK's Merger & Acquisition (M&A) Strategic Actions
Year Firms acquired or 
merged with
Notes Geographical 
______ locations
2001 Pharmatech Acquired 90% of 
the capital stock
Romania
2001 Argon Acquired an 
89.45% share
l O I I C  1 C C I 1 P C  n f  t
Poland
Source: Compiled bv the author from van ~***:~1 rr:__
and Mergerstat 1992-2002
LEK acquired majority shares in two CEE based companies in 2001. these were 
Pharmatech (Romania) and Argon (Poland). Following from the acquisition of 
Pharmatech LEK invested $30 million in developing and upgrading the Romanian firm 
(Scrip, 2002a) and was also reported as planning to invest in Argon. Although LEK’s 
M&A activity had a narrow geographical focus its strategic actions relating to network 
and acquisition based product development strategic actions (Table 5.13) allowed it to 
develop relationships with firms in Western Europe through development and 
marketing agreements. 1999 was the first year that LEK entered into an Network and 
Acquisition Based Product Development (NABPD) agreement.
Table 5.13 LEK’s Network & Acquisition Based Product Development (NABPD) Strategic Actions
Year Strategic Action F i r m Product Cou ntry
1999 Collaboration
agreement
Ethical Holdings Lek's narcotic, 
analgesic 
transdermal patch
US, Western 
Europe and 
Japan
2001 Acquisition of 
exclusive 
marketing rights___________ o  o_____
Sofotec Dry powder inhaler 
anti-asthma product
Eastern
Europe
2001 Marketing
agreement
A UK partner Amoksiklav UK
Source: Compiled by the author from various issues of Scrip and the Financial Times 1992-2002
The first agreement in 1999 focused upon Ethical Holdings developing LEK's narcotic,
analgesic transdermal patch with LEK paying Ethical Holdings various milestone
%
payments. Subsequent marketing of the product was to be shared by the firms with LEK
having exclusive access to some of the markets {Scrip, 1999a). The other two
agreements were both cross border agreements. The first was a Western European
partnership with the German firm Sofotec focused upon LEK marketing the partner’s
product in Eastern Europe {Scrip, 2001a). I he collaboration with Sototec allowed LEK
to acquire exclusive Eastern European marketing rights to an inhaler. In comparison to
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the other firms in the sample LEK realised a small number of NABPD strategic actions. 
The last leported marketing agreement involved LEK appointing an organisation to 
market the product that it had developed. Amoksiklav, in the United Kingdom (Scrip, 
2001b). Those NABPD strategic actions that LEK did realise highlight the complexities 
of understanding networks in the pharmaceutical industry, with LEK both having firms 
to market its product and marketing other firms products. There was no reporting of 
LEK developing pioducts for other organisations although this may be in relation to 
LEK being a generics rather than a branded manufacturer. Table 5.14 shows that LEK's 
only Joint Venture w'as in 1999 with Sanofi-Syntelabo.
Table 5.14 LEK’s Joint Venture (JV) Strategic Actions
Year Strategic action Who the JV 
was with
JV name Geographical
location
1999 JV
9  t  1  «  a «
Sanofi-
Svnthelabo
Sanofi-Synthelabo-
LEK
Ljubljana
Source: Compiled by the author from various issues of Scrip and the Financial Times 
1992-2002
As I able 5.15 shows LEK's only Organic Concentric Diversification'(OCD) strategic 
action was the 1996 establishment of LEK US Inc.
Table 5.15 LEK's Organic Concentric Diversification (OCD) Strategic Actions
Year Strategic Action Country
1996 Establishment of LEK
US Inc.
US
Source: Compiled by the author from various issues 
of Scrip and the Financial Times 1992-2002
There was only one example reported of LEK being involved in a licensing out 
agreement (Table 5.16). This agreement was for Gideon Richter to be able sell and 
market the antibiotic Aktil. There were no examples of product divestments.
Table 5.16 LEK’s Product Divestment & Licensing Out (PD&LO) Strategic Actions
Year Strategic
Action
Firms Involved Products
involved
Cou ntries
1997 Licensing out 
agreement
Gideon Richter
m  A
Aktil
*  *  i . i  i • V t
Source: Compiled by the author from various issues of Scrip and the Financial Times 
1992-2002
The issuing of shares (Iable 5.17) refers to the protracted privatisation of LEK that 
arose as a result of government action.
Table 5.17 LEK’s External Finance Raising (EFR) Strategic Actions
Year Strategic
Action
Firms Involved Products
involved
Countries
1992-
1994
Shares issued 
as part of the 
privatisation 
process
N/A N/A Slovenia
1996 Issuing of a 
second round 
of shares
f t  f t  f t  f t  ^  _
N/A N/A Slovenia
Source. Compiled by the author from various issues of Scrip and the Financial Times 
1992-2002
In the initial privatisation shares were purchased by foreign partners, employees and 
financial institutions. Fujimoto Seiyaku was one of the international firms to buy shares 
in LEK in 1992 appearing to build upon a relationship that they had had for the previous 
ten years (Scrip, 1992a). There was no evidence of LEK raising finance from external 
sources after 1996.
In 2002, in a cross border acquisition, LEK was acquired by the Swiss firm Novartis, 
one of the world’s largest pharmaceutical firms that focused upon both brand name and 
generics products (Scrip, 2002f). Table 5.18 summarises the strategic actions realised 
by LEK from 1992-2002.
Table 5.18 Summary Of Lek’s Strategic Actions
□
 = years that the strategic actions were not realised
= years that the strategic actions were realised
LEK did not realise strategic actions relating to the strategies of Divestment & 
Demerger or Retrenchment.
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5.4 Asta Medica
Asta Medica was a German firm established in 1919 (Hoppenstedt
Firmeninfoimationen, 200a). I he firm was the pharmaceuticals division of Degussa. In
1992 Asta Medica s coie business was focused upon "branded generics, original
products and OTC drugs (Scrip, 1992b:9). lable 5.19 illustrates three acquisitions
made by Asta Medica during 1992 to 1998, although there were none reported after this 
date.
Table 5.19 Asta Medica’s Merger & Acquisition (M&A) Strategic Actions
Year
1992
1996
1997
Firms acquired or 
merged with
Muro
Pharmaceuticals
Muro 
Pharmaceuticals
German Remedies
1998 Kampel-Martian
Notes
Acquisition 
of a minority 
stake
Completed 
full
acquisition
Geographical
locations
US
US
Asta Medica 
increased 
share by 70%
Acquisition 
of one-third 
share
India
Argentina
Source: Compiled by the author from various issues of Scrip, 
the Financial Times and Mergerstat, 1992-2002
All three of these acquisitions contributed to the firm developing its international 
presence by focusing upon the Americas and India. German Remedies was an Indian 
manufacturing and marketing firm for large German pharmaceutical companies (Scrip, 
1997c). The initial investment in the US firm Muro in 1992 was Asta's “first acquisition 
in the US market” (Scrip, 1992c: 15) although it already had licensing agreements with 
US firms. (Scrip, 1992d). The increased investment in German Remedies in 1997 was 
subsequently followed by Asta Medica divesting its share in the firm in 2001 (Table 
5.27). There were no acquisitions reported after 1998. Table 5.20 demonstrates that Asta 
Medica realised network and acquisition based product development strategic actions in 
six out of the eleven years from 1992 to 2002.
Table 5.20 Asta Medica’s Network & Acquisition Based Product Development (NABPD) Strategic 
Actions
Y e a r
1992
S tra te g ic  A c tio n
1 Co-marketing 
agreement
F irm
Fison’s German 
pharmaceutical 
subsidiary
__________________P ro d u c t ___________
1 he anti-asthmatic, nedocromil sodium
C o u n try
Germany
1992 Joint development Nippon Kayaku
^ _____________ •
1 wo anticancers -  NK-121, an 
injectable platinum compound and NK- 
61. an oral and injectable glycoside 
______ podophyllotoxin derivative______
Europe
1993 Co-marketing
agreement
Farmitalia Corinfar R Uno Germany
1995 Development and 
marketing
_____agreement_____
3M Pharmaceuticals Products for use in obstructive 
respiratory disease
Germany i
1995 Development and 
marketing 
agreement
Sugen Potential oncology products based on 
Sugen’s HF.R2 and RaF cell signal 
transduction programme
It is a European 
agreement and Sugen 
_____ is American_____
1995 Co-promotion
agreement
Probios, the Portugese 
subsidiary of the 
Spanish company 
Prodesfarma
______________________________ _  B
Branded and generic oncology products Portugal
W
1997 Licensing in 
agreement
Andrx The calcium channel antagonist, dilazep. 
for limiting haematological toxicity 
associated with anticancer or anti 
___________ retroviral drugs
Exclusive worldwide 
rights
1997 Acquisition of 
marketing and 
distribution rights
Harvard Scientific Harvard's liposomal prostaglandin E-l 
product for male erectile dysfunction
Eastern and Western 1 
Europe
1997 Development and 
marketing 
collaboration
Wyeth-Ayerst Asta's anti-epileptic compound,
retigabine
1997 A “link-up" Scotia Thioctyle-gammalinolenate
1998 Sales agreement FH Faulding __________ Hospital products_______ The Netherlands 1
2001 Entering into a co- 
marketing 
agreement
Aventis Asta Medica’s Phase la diabetes 
product dexlipotam
vWorldwide apart from 1 
North America and
Japan |
Source: Compiled by the author from various issues of Scrip and the Financial Times 1992-2002
The agreements up until 1995 were focused upon the European market, but the 1997 
licensing agreement with Andrx was for worldwide marketing rights. The strategic 
actions reported in Table 5.20 relate to a number of different types of cooperative 
agreement including marketing, development, licensing in, sales agreeements and 
distribution rights. The acquisition of marketing and distribution rights to Harvard's 
liposomal prostaglandin E-l product illustrates an example of such an arrangement. As 
Table 5.21 shows Asta Medica became involved in a number of international joint 
ventures in Europe, Japan and the US.
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Table 5.21 Asta Medica’s Joint Venture (JV) Strategic Actions
Year
1992
1992
1995
1997
1998
1998
2000
Strategic action
Establishment of a
JV
Establishment of 
the Tumour 
Biology Centre 
Establishment of a
______ JV ____
Establishment of a
JV __ _
Establishment of a
JV
Collaboration for 
the sale and 
marketing of 
injectable 
pharmaceutical 
products 
Establishment of a
JV
JV Partner
Prodesfarma
Ciba Geigy and 
Schering AG
Nippon Kayaku
Frankgen
Carter Wallace
FH Faulding
I E Ulagay
JV name
Pras Faring
rumour Biology Centre
Kayaku Asta Medica Co
Ltd
Main Gen
Wallace
Laboratories/ASTA
_____Medica_____
Division Faulding Asta
Medica
Countries
Spain 
Germany
Japan
Germany
France
Turkey
Source: Compiled by the author from various issues of the Financial Times and Scrip 
1992-2002.
The joint venture with Nippon Kayaku was an extension of an existing collaboration 
(see Table 5.20) providing Asta with a direct entry path into the Japanese
V
pharmaceutical market. Prior to this joint venture Asta Medica accessed this market by 
using licensees (Scrip, 1995a). Asta Medica and Ulagay had been involved in a long-
term manufacturing and marketing agreement prior to the establishment of the JV 
(Scrip, 2000a). As shown in Table 5.22 in 1992 Asta Medica established two firms in 
the US.
Table 5.22 Asta Medica’s Organic Concentric Diversification (OCD) Strategic Actions
Year Strategic Action Count ry
1992 Establishment of Asta 
Medica Inc and Abkit
Inc
US
1994 Establishment of 
various new companies
Poland, the Slovak 
Republic, Bulgaria, 
Romania, Russia, the 
Ukraine, China,
• Australia, and the 
Philippines
1997 New sales and 
marketing company 
called Asta Medica 
______AWD GmbH_____
_  m  9
Germany 
•  1 1 1
Source: Compiled by the author from various issues ol Scrip and the
Financial Times 1992-2002
In 1994 Asta Medica established a number of new companies both in the CEE market 
and the lest ot the woild . Despite the establishment of various new companies in 1994 
there was no further evidence ol OC D strategic actions being realised for international 
expansion after 1994. The onl\ other OCD strategic action related to Germany with the 
formation of the new sales and marketing company. During 1992-1997. alongside the 
GCD stiategic actions, Asta Medica realised various strategic actions relating to organic 
growth although none were reported after 1997 (Table 5.23).
Table 5.23 Asta Medica’s Organic Growth (OG) Strategic Actions
Year
1992
1994
1994
1994
1997
Strategic Action
Opening of experimental cancer research facility 
Inauguration of a new European production facilit
Establishment of three new business units -  neurology,
neumology and oncology 
Opening of representative offices
Establishment of a branch
Countries
Germany 
France
Czech Republic and Hungary
Latvia
Source: Compiled by the author from various issues of Scrip and the Financial Times 1992-2002
Again, the majority of these were situated outside of Germany (Asta Medica's home 
country) but were confined to Europe rather than further afield, with particular emphasis 
from 1994 on Eastern Europe. As Table 5.24 indicates due to it being a subsidiary (as 
well as a parent company) Asta Medica did not directly seek external finance for its 
pharmaceutical operations, instead this was channelled through Degussa.
Table 5.24 Asta Medica’s External Finance Raising (EFR) Strategic Actions
Year Strategic Action Firms
Involved
Products
involved
Cou ntries
1996 Degussa’s request to 
shareholders for DM40m of 
new capital to strengthen 
its pharmaceutical activities
— — -
2001 IPO for Zentaris Zentaris North 
America 
and Japan |
Source: Compiled by the author from various issues of Scrip and the Financial Times
1992-2002
As Table 5.25 indicates there was no reporting of Asta Medica entering into licensing 
out agreements until 2000. although the expansion of the licensing agreement with 
Serono would suggest that this had originally been entered into in a previous yeai.
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Table 5.25 Asta Medica’s Product Divestment & Licensing Out (PD&LO) Strategic Actions
Year
2000
2000
2001
2001
Strategic
Action
Licensing out 
agreement
Expansion of 
licensing out 
agreement
Divestment of 
roduct rights 
Licensing out 
agreement
Firms
Involved
Products
involved
Countries
Teikoku
Hormone
Sole rights 
to
Teverelix, 
the LHRH 
antagonist 
peptide
-
Serono Cetrotide
(cetrorelix
acetate
injection)
Worldwide
excluding
Japan
Zydus
Cadila
Five brands 63 countries
Aventis Asta 
Medica 
Phase 1 
diabetes 
product 
dexlipotam
-
Financial Times 
1992-2002
various issues of Scrip and the
In 2001 Asta Medica divested the product rights to five brands to Zydus Cadila and 
licensed out dexlipotam to Aventis. As illustrated in Tables 5.2 and 5.-3 in 1992, 1994 
and 1997 Asta realised strategic actions relating to internal expansion i.e. Organic 
Growth and Organic Concentric Diversification strategies. Yet, as shown in Table 5.26, 
in 1993, 1995, 1997, 1999 and 2000 it also realised strategic actions relating to 
restructuring and/or rationalisation.
Table 5.26 Asta Medica’s Retrenchment (TR) Strategic Actions
Year Strategic Action
1993 Merging of two subsidiaries : Tender's export business and
Arzneimithelwerk Dresden (AWD)
1995 Closure of Asta Medica's Frankfurt production facility and
warehouse
1997 Rationalisation of sales and marketing activities
1999 Restructuring
2000 Further restructuring and splitting up of Asta Medica into 
four parts: Zentaris, cancer, healthcare and branded 
generics, so that each part could be divested separately.
«  a  a  I f
Financial Times 1992-2002
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This supports Webb and Pettigrew s (1999) findings that firms combine expansion and
withdrawal strategies. As shown in Table 5.27 there were no reports of any divestments 
of Asta Medica subsidiaries prior to 2000.
Table 5.27 Asta Medica’s Divestment & Demerger (D&D) Strategic Actions
Year Strategic Action
2000 Sale of US subsidiary, Abkit
2000 Sale of shareholding in the German company Temmler Pharm
2001 Asta Medica and Heller Vermagensverwaltungs, which were both part 
of the Degussa group, divested their stake in German Remedies of
India
2001 Divestment of Transfarma Medica Indah
2001 Sale of AWD Pharma
2001 Divestment of Asta Medica Onkologie
1992-2002
From 2000 several divestments were made during the following two years, both directly 
by Asta Medica and by Degussa on behalf of Asta Medica. This coincided with 
Degussa’s failed attempt to sell Asta Medica as a complete entity in 2000, and 
subsequent restructuring of Asta Medica into four separate units for divestment. The 
disbanding and divestment of Asta Medica was finalised in December 2002 with the 
completion of the sale of Zentaris (Degussa, 2002). The strategic actions realised by 
Asta Medica for 1992-2002 are summarised in Table 5.28.
Table 5.28 Summary Of Asta Medica’s Strategic Actions 1992-2002
= years that the strategic actions were not realised
= years that the strategic actions were realised
Source: Compiled by the author
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5.5 Shire
pharmaceutical
industry (Balance et al., 1992; Kettler, 2001a) and Shire's 1986 biotechnology start-up 
coincided with this period of change in the pharmaceutical industry. By the beginning 
of the 21 Century Shire had evolved into a speciality pharmaceuticals firm (Guerrera 
and Fim, 2000). As shown in Fable 5.29 from 1992 onwards Shire was active in Merger 
& Acquisition (M&A) activity.
Table 5.29 Shire’s Merger & Acquisition (M&A) Strategic Actions
Year Firm Acquired or Merged With Geographical 
Location of firm 
acquired/merged
w i t h
1992 Acquired Rybar Laboratories UK
1995 Merged with Imperial 
Pharmaceutical Services Ltd
' England
1997 Acquired Richwood 
Pharmaceuticals
US
1997 Acquired Pharmavene Inc US
1999 Acquisition of Fuisz Technologies
units
Germany, France v 
and Italy
1999 Merged with Roberts 
Pharmaceutical
US .
2001 Merged with Biochem Pharma Inc Canada
Source: Compiled by the author from various issues of the 
Financial Times, Scrip and Mergerstat: 1992-2002.
M&A started with the acquisition of Rybar Laboratories in 1992, followed by the 1995 
merger with another British firm, Imperial Pharmaceutical Services Ltd. All future 
acquisitions were outside of the LJK. 1 he acquisition of Richwood Pharmaceuticals in 
1997 provided Shire with a “US marketing base" (Scrip, 1997d:9). Shire expanded its 
M&A activity to the US with the acquisition of Pharmavene Inc. and in 1999 it merged 
with the US firm Roberts Pharma. M&A activity was completed in 2001 with the 
second cross border merger, which was with Biochem Pharma. Table 5.j 0 outlines the 
large number of strategic actions that Shire realised in relation to a Network &
Acquisition Based Product Development (NABPD) strategy.
Table 5.30 Shire’s Network & Acquisition Based Product Development (NABPD) Strategic Actions
Year [Strategic Action
1995
1995 
1995
1995
1996
1997
1997
1997
1998
Firm
1994 |Agreement on development
rishts
Synaptec
1994 | Agreement on development
rights___________________
MacFarlanSmilh
1995 20-year licensing agreement
1995 Marketing agreement Sigma-Tau
Collaboration agreement for 
third-part} manufacturing
1995 Acquisition of marketing rights
Joint development agreement 
Acquisition of rights
Acquisition of worldwide 
marketing rights
Co-development and marketing 
agreement 
Acquisition of distribution rights
in the UK____________
Acquisition of exclusive
distribution rights_____
(Shire & Janssen)acquisition of 
worldwide manufacturing and 
supply rights of synthetic 
galanthamine and marketing 
rights to Waldheim's version of 
Nivalin
Regent 
Laboratories
Nycomed
Product
Galantahmine, an acetylcholinesterase 
inhibitor for Alzheimer’s disease
Galantahmine, an acetylcholinesterase 
inhibitor tor Alzheimer's disease 
Development licence relating to 
bisphosphonate neridronate
Combined oestrogen-progestogen 
hormone replacement therapy 
Calcium products
Acquisition of exclusive 
worldwide rights______
Seiksui 
Obtained from an 
individuaLDr Fob
Snorrason_____
Co-development 
project with 
Johnson Matthey 
Janssen
Hoechst Marion 
Roussel 
Recordati
Waldheim 
Pharmazeutika
Neurosearch
fransdermal delivery system 
Galanthime in ME
A phosphate binding agent
C.ou ntry
Worldwide rights outside NAFTA 
countries, Japan and four Far East 
territories
Scotland
10 EU countries plus 
Switzerland,Australia, New Zealand 
and South Africa
Shire to market the product in UK and 
Ireland
South Africa and certain territories in 
the Middle East and Asia
Rights outside Japan
Potential Alzheimer's therapy-  
galanthamine.
A range of gynaecological products
Urge incontinence therapy. Unispas
(tlavoxate)_____________________
Synthetic galanthamine and Nivalin
Worldwide
A series of AMPA antagonists for the 
treatment of CNS disorders
Worldwide
United Kingdom
UK, Ireland, South Africa, Thailand
and 11 other countries___________
Worldwide for synthetic galanthamine 
and Nivalin for Austria and certain 
Eastern European countries
Worldwide
1998
1998
Acquisition (buy back) of 
worldwide rights
Elan's Athena
Neuroscience
subsidiary
Carbatrol (sustain-released 
carbamazepine)
Agreement to develop an 
improved formulation
Searle Product not specified'
Worldwide rights
1999 Acquisition of intellectual 
property rights
Arenol (Shire's 
former supplier)
For the manufacture of the active 
ingredient of its two most important
drugs.
2000 Product acquisition Suivay Gastrointestinal product Spain
2000 Licensing in
2000
2001
D-Pharm Valproic acid analogue DP-VPA
2000 Acquisition of rights
Pharmaceuticals
The ulcerative colitis product. Colazide 
(balsalazide disodium)
2000 Licensing agreement Cortex Development of Cortex 's ampakine 
molecules for the treatment of attention 
deficit hyperactivit} disorder4________
Licensing in CeNeS
2001 Vaccine deal Berna Biotech
2001 I Research and licensing
agreement______
CeNeS
2001 Licensing in Devco
Pharmaceuticals
Acquisition of marketing and 
sales rights
2002 I Licensing in marketing and
development rights
ML Laboratories
Giuliani
2002 [Licensing in of rights
Source: Compiled by the author from
Parkinson's compound SPD 451
Worldwide development and 
marketing rights__________
Thirteen European countries plus 
Ireland
Worldwide
Vaccines
Dopamine D1-agonist programme for 
the treatment of Parkinsons disease
The product was a Dopamine, fHT and 
noradrenaline re-uptake inhibitor
Adept 
Mesa I azi ne tech nology
Europe
Throughout Europe
North America, Europe, (excluding 
Italy) and Japan
Solar_______ Actinic keratosis treatment
various issues of the Financial Times and Scrip: 1992-2002
European marketing rights
3 Shire lost an agreement signed with Searle in the previous year to develop an improved formulation of one of the US company’s 
products alter it ended development of the chemical entity. 1 his strategic action w as terminated in 1999
4 Shire Pharmaceuticals terminated a licensing agreement with Cortex Pharmaceuticals covering 
ampakine molecules for the treatment of attention deficit hyperactivity disorder
the development of Cortex’s
A laige proportion of Shire s NABPD strategic actions related to acquisition of rights 
and licensing in agreements. I hey were focused upon development, marketing and 
distribution lights. Shires NABPD agreements included those with biotechnology 
companies such as the licensing in agreement with the Israeli firm D-pharm. There was 
only evidence of two ol Shire s alliances being prematurely terminated (with Searle and 
Cortex Pharmaceuticals) despite Kettler’s (2001b) findings that nearly one third of 
biotechnology-pharmaceutical alliances fail. As Table 5.31 illustrates, prior to 2002
Shire realised only two organic growth strategic actions, both relating to increasing the 
size of its salesforce.
Table 5.31 Shire’s Organic Growth (OG) Strategic Actions
Year Strategic Action Countries
1997 Hiring of a second UK salesforce United Kingdom
1999 Increase in US salesforce US
2002 Investment of $18.5 m in a new global vaccine research centre at its
existing site in Quebec
Canada
Source: Compiled by the author from various issues of the Financial Times and Scrip: 1992-2002
V /
It was suggested that the establishment of Shire’s own global vaccine research centre in 
2002 was to allow Shire to develop its competence with regard to internal Research & 
Development (R&D). It had been previously criticised for its reliance on an in-
licensing strategy in order to develop its late stage product development pipeline (Scrip, 
2002b:9). Table 5.32 shows that Shire only realised one OCD strategic action, relating 
to the new Spanish subsidiary.
Table 5.32 Shire’s Organic Concentric Diversification (OCD) Strategic Actions
Y e a r S t ra te g ic  A c t io n F ir m  created C o u  n t ry
operating subsidiary 
in Madrid
subsidiary
Source: Compiled by the author from various issues of Scrip and 
the Financial Times 1992-2002
As shown in Table 5.33 Shire was involved in a variety of PD&LO strategic actions 
focused upon licensing out agreements. I hese included marketing arrangements and the
licensing out of patent rights.
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Table 5.33 Shire’s Product Divestment & Licensing Out (PD&LO) Strategic Actions
Year
1997
1997
1997
1999
2002
2002
Strategic action
Licensing out 
agreement
Licensing out of 
marketing rights"
Licensing out 
agreement
Sale of 30 non-strategic
products6.
Licensing out of patent
rights
Sale of four products
Firms involved
Searle
Janssen
Athena
Neurosciences 
Integrity 
Pharmaceuticals
Emory University 
and the University 
of Georgia 
Research 
Foundation 
Purdue Pharma
Products involved
Betarange line
Nivalin
Carbatrol
Amdoxovir
Countries
UK, Ireland, South 
Africa and a further 
36 countries in 
African and the 
Middle East
Austria and Eastern 
_____ Europe_____
US
Source: Compiled by the author from various issues of Scrip and the Financial Times 1992-2002
Licensing out agreements and product divestments were a source of income generation 
for Shire. For example. Shire received royalties from Janssen for the licensing out of 
marketing rights to Nivalin. Another possible reason for the product divestments was 
Shire needing to reduce any possible overlaps in its product line as a result of its merger
V
and acquisition activity during 1992-2001 (Table 5.29). Shire's retrenchment (TR) 
strategic actions (Table 5.34) focused upon the discontinuation of two R&D projects in 
1998 and a further three R&D programmes in 2000.
Table 5.34 Shire’s Retrenchment (TR) Strategic Actions
Year Strategic action
1998 Discontinuation of two R&D projects: control led-release versions 
of dihydroergotamine for migraine and acicolvir for herpes
infections
1999 Sale of US to Integrity Pharmaceuticals
2000 Closure of sites in the United States and United Kingdom
2000 Discontinuation of three R&D programmes: LY 315535,
tazofelone and ProAmatine
Source: Compiled by the author from various issues of the Financial Times 
and Scrip: 1992-2002.
The reasons for the 1998 rationalisation of the product line were stated as being as a 
result of a review of the product portfolio after the “acquisitions of Pharmavene and
This refers only to the taking over of marketing by Janssen, the rest ot this co-development deal referied
to in Table 5.30.
Richwood Pharmaceutical” (Scrip, 1998b: 10). The closure of the sites in the US and the 
UK were part oi the integration process following the acquisition of (merger with) 
Roberts (Set ip, 2000b). No reason was reported lor the discontinuation of the three 
R&D piogiammes in 2000. But, in the pharmaceutical industry high R&D costs are 
coupled with a high iisk of failure with many developments not making it to market 
(Kettler, 1998, Cunningham, 2001; Orsenigo et al., 2001). Therefore, it may be 
preferable to reverse decisions than to make commitment to areas that show possible 
signs of failure or no longer have a strategic fit. As shown in Table 5.35 Shire was 
floated on the London Stock Exchange in 1996. The issue of shares raised £40m for the 
company and gave Shire a market capitalisation of £107 million (Scrip, 1996a).
Table 5.35 Shire’s External Finance Raising (EFR) Strategic Actions
Year Strategic action Firms involved Products involved _____ Countries_____
1996 Floatation on the 
London Stock Exchange
N/A N/A United Kingdom
1998 Initial public offering on 
the US stock exchange
N/A N/A US
2001 Placement of an 
offering of $35 million 
guaranteed convertible
notes
n Ta N/A Placed with 
institutional 
investors largely in 
_______the US_______
2002 $3.5 million 
government grant 
towards the cost of a 
new research centre
N/A N/A v Canada
Source: Compiled the author from various issues of the Financial Times and Scrip-. 1992-2002.
From 1996 onwards Shire appeared to support its expansion through External Finance 
Raising (EFR) strategic actions. As was seen in Table 5.33 Shire also had an additional 
income stream from product divestments and licensing out agreements as well as 
revenue from product sales. As part of the EFR strategic actions Shire sought to 
strengthen its position in the US market through an Initial Public Offering (I.P.O.) on 
the US stock exchange in 1998 and the placing of guaranteed convertible bonds 
primarily with US institutional investors.
6 Also see Table 5.34 sale of US plant to Integrity Pharmaceuticals
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Shire s strategic outcome was its 2001 merger with the Canadian firm Biochem Pharma. 
The reasons for the merger were stated as:
This merger ... will further broaden and diversify our revenue base, strengthen 
our early-phase product pipeline and provide greater financial strength to 
capitalise on our search and development capability. ”
Rolf Stahel, Shire's CEO cited in Scrip, 2000c:6
Table 5.36 summarises the strategic actions realised by Shire during 1992-2002.
Table 5.36 Summary of Shire’s Strategic Actions
= years that the strategic actions were not realised
= years that the strategic actions were realised
It is noted that Shire did not realise strategic actions relating to the strategies of Joint 
Venture and Divestment & Demerger.
5.6 Galen
The Northern Ireland integrated pharmaceutical company Galen was founded in 1968
(Galen Holdings pic, 2001). Galen was included in the sample because it had survived
without being acquiied or merged. In 1992 Galen was reported as having a
pharmaceuticals stiategy focused upon competing with branded generics, with its
products distributed throughout the UK and other geographical markets (Scrip. 1992d).
Until 1997 Galen primarily realised strategic actions relating to Organic Growth (Table 
5.37).
#
Table 5.37 Galen’s Organic Growth (OG) Strategic Actions
Y e a r S t ra te g ic  A c t io n C o u n t r ie s
1992 New antibiotics plant Northern Ireland
1994 £7.3 million expansion 
programme
1 9 9 5 -  1997 3 year £17.4 million 
expansion programme •
1997 Establishm ent o f a clinical 
trials operation
US
2 0 0 0 Expansion o f UK 
salesforce
UK
Source: Compiled by the author from various issues of Scrip 
and the Financial Times 1992-2002
Galen was active in investing finances in OG strategic actions, particularly during the 
period of 1994 -  1997 when in excess of £17.4 million was invested. The 1994 
expansion programme focused upon new facilities for R&D and production, and was 
planned to lead to the creation of 116 new jobs (Scrip. 1994b). The expansion 
programmes during 1995 -  1997 included providing a new clinical trials services 
company in Northern Ireland, creating more jobs and the provision of new- 
manufacturing facilities (Scrip, 1995b). The year 2000 saw expansion of the UK 
salesforce as the firm prepared for new product launches (Scrip, 2001c). As shown in 
Table 5.38 there was only evidence of one strategic action relating to the Organic 
Concentric Diversification (OCD) strategy, this related to the establishment of Syngal in
1997.
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Table 5.38 Galen’s Organic Concentric Diversification (OCD) Strategic Actions
Year
1997
Strategic Action
Establishment of a 
new division
Name
Syngal
Country
Source: Compiled by the author from various issues of Scrip 
and the Financial Times 1992-2002
Apart from the divestment of cough and cold products in 1992 Galen did not appear to 
have been involved in either product divestment or licensing out (Table 5.39).
Table 5.39 Galen’s Product Divestment & Licensing Out (PD&LO) Strategic Actions
Year Strategic action
1992 Divestment of cough and cold
products
Source: Compiled by the author from various issues of Scrip and 
the Financial Times 1992-2002
As Table 5.40 shows Galen did not enter into any mergers or acquisitions until 1998. 
From then it focused upon concentrated M&A activity with the majority of the acquired 
firms based in the US. The acquisitions of J Dana, Interactive Clinical Technologies, 
Applied Clinical Concepts and the pharmaceutical division of the US Duke Clinical 
Research Institute were in order for Galen to develop its range of clinical trials 
businesses and expand the services that it offered (Scrip, 1999b:2000d). The $372.1 
million acquisition of Warner Chilcott and the acquisition of the hormone replacement 
therapy business from Bristol Myers Squibb expanded the products that Galen offered 
in women's healthcare.
Table 5.40 Galen’s Merger & Acquisition (M&A) Strategic Actions
Year
1998
1999
1999
2000
2000
2000
2001
Firms acquired or merged with
___________ Acquired J Dana
Acquired Interactive Clinical Technologies
Acquisition of three companies associated with a product range and
development acquisition from Bartholomew Rhodes
Acquired Warner Chilcott
_____________ Acquired Applied Clinical Concepts
Acquired Pharmaceutical division ot the US Duke Clinical Research
Institute
Geographical
locations
UK
Acquisition of hormone replacement therapy business from Bristol
Myers Squibb _________
Source: Compiled by the author from various issues of Scrip, the f inancial Times and Me/get.stat 199_
2002
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Just as the acquisitions referred to were not reported as starting until 1998 a similar
situation occurred with regard to Galen’s Network & Acquisition Based Product 
Development (NABPD) strategic actions (Table 5.41).
Table 5.41 Galen’s Network & Acquisition Based Product Development (NABPD) Strategic Actions
Year
1998
1999
2002
2002
Strategic Action
Acquisition of
rights
Acquisition of 
product range 
and development 
pipeline
Acquisition of 
US rights to two 
roducts
Acquisition of 
US sales and 
marketing rights
Bartholomew 
Rhodes
Bristol Myers 
Squibb
Product
Controlled release 
antiarthritic/analgesic 
product for night pain 
The range included 
sustained-release 
cardiovascular and anti- 
inflammatory products 
The antibiotic Duricef 
and Moisturel, an over- 
the-counter skin cream
Sara fern
Countr
UK
US
US
Source: Compiled by the author from various issues of Scrip and the Financial Times 1992-2002
None of Galen’s NABPD strategic actions related to Galen engaging in collaborative 
R&D projects or licensing in technologies that could be used for internal research and 
development. This suggested that development was either internal or through 
acquisitions rather than collaboration. This suggestion was borne out through the 
following quote: “supplement internal growth through selective acquisition” (Galen 
Holdings pic. 2000:4). As illustrated in Table 5.42 the majority of Galen's strategic 
actions relating to Divestment & Demerger (D&D) were realised in 2002.
Table 5.42 Galen’s Divestment & Demerger (D&D) Strategic Actions
Year Strategic Action
1997 Chemists business sold 
before floatation
2002 Disposal of Galen's clinical 
trial services unit (CTS)
2002 Sale of Interactive Clinical 
Technologies (ICT)
2002 Divestment of Chemical 
Synthesis Services
Source: Compiled by the author from various issues 
of Scrip and the Financial Times 1992-2002
Of specific interest here is that all of the divestments listed tor 2002 were to a group
headed by Allen McClay, the founder of Galen, who had left in the autumn of 2001
(.Financial Times, 2002c). The sale of CTS helped Galen to become a pharmaceutical
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product focused company (Scrip, 2002c). The sale of ICT meant that Galen was no
Synthesis
part of Galen’s clinical trials businesses (Jenkins Interactive Clinical
Technologies was a US firm purchased in 1999 (see Table 5.40). As shown in Table
5.43 Galen did not realise any External Finance Raising (EFR) strategic actions until 
1997 apart from a capital grant in 1992.
Table 5.43 Galen’s External Finance Raising (EFR) Strategic Actions
Year Strategic Action Countries
1992 Capital grant from the Northern Ireland 
Industrial Development Board
Northern Ireland
1997 Floatation on the London Stock Exchange UK
1999 Share sale and share placing UK & Ireland
2001
« m m
Share offering UK and US
Source: Compiled by the author from various issues of Scrip and the Financial Times 1992-2002
In 1997 Galen started realising EFR strategic actions. From 1998 to 2002 this was 
combined with the M&A and NABPD strategic actions, with only one OG strategic 
action being reported in this time. Galen was floated on the London Stock Exchange in
This
apart
V
Galen had not raised finance from external sources. The floatation and subsequent share 
offerings coincided with the period where Galen placed an emphasis upon their un n n uai ] 
acquisition of products and companies based in the US. Table 5.44 
strategic actions realised by Galen during 1992-2002.
summarises
Table 5.44 Summary Of Galen’s Strategic Actions
= years that the strategic actions were not realised
= years that the strategic actions were realised
M&A
NABPD
OCD
OG
D&D
PD&LO
EFR
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002
Source: Compiled by the author
It is noted that Galen did not realise any strategic actions relating to Joint Ventures 
Retrenchment.
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5.7 Bioglan
I he Biitish firm Bioglan was founded in 1932 by Menzies Sharp as a vitamins 
company. 1 iffy years later (1982) Terry Sadler borrowed £176.000 in order to buy the 
firm. £30,000 of the money was borrowed from three credit cards {Scrip, 1997e; 
Financial Times, 1999). Explaining the decisions affecting the purchase Mr Sadler said:
The strategy was simple......... We had to sell more o f the existing product
range and expand the portfolio. I also decided to start generic drug 
development. I chose this area because generics were relatively simple to 
develop, required smaller promotional expenditure compared with branded 
products, and they can be fast cash generators. ”
(Brimicombe, 1999:17)
Terry Sadler provides an example of the entrepreneurial spirit that Rogowsky (1996) 
claimed was partly responsible for directing firms in the pharmaceutical industry to 
develop competitive niches. By 1989 Bioglan was operating in both generics and
V
dermatology. Bioglan had also acquired a range of products and started on the R&D 
process. In 1994 it “diversified into drug delivery“ (Brimicombe. 1999:17). Table 5.45 
contains the empirical data relating to BioglaiTs Network and Acquisition Based 
Product Development (NABPD) strategic actions for 1992-2002.
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Table 5.45 Bioglan’s Network & Acquisition Based Product Development (NABPD) Strategic 
Actions
Year
1997
1998
1998
1998
1999
1999
2000
2000
2000
2000
2000
2001
2001
Strategic action
Co-promotion agreement
Acquisition of licence and
rights
Collaboration
Global drug delivery deal
Acquisition of sales and 
development rights
Acquisition of a US 
dermatology range
Firm
Altana's Savage division
Zeneca
SmithKline Beecham 
Consumer Healthcare 
Novo Nordisk7 
Allergan
Acquisition of development 
and market rights
Exclusive licence for the 
commercialisation of doxepin
Licensing in
Acquisition o f five anti-
inflammatory dermatologicals
Medicis Pharmaceuticals
CeNeSX
Winston Laboratories
arm a
Novartis
Product
Micanol 
Long-term licence for Hibitane 
obstetric and antiseptic creams as 
well as Zeneca's rights to the 
Synalar range of steroids
EsGel
Biosphere delivery system 
Zorac (tazorotene)
"selected compounds using 
CeNes's Depocore Drug 
Delivery System” -  Moraxen a 
rectal slow-release morphine
formulation 
Doxepin
Solaraze
Five prescription steroid 
products, including Locacorten 
Locasalen and Sicorten
Collaboration
Acquisition of pain products
Acquisition of marketing rights 
to Solaraze in the US. Canada
and Mexico
Cou ntr
Global 
UK, Ireland. 
Denmark. Sweden 
Finland and other 
countries 
United States
European 
marketing rights
UK, Europe and 
some Asian 
countries 
European rights
German rights
Glaxo Wellcome
Pharmacia
Skyepharma
Crystacide
Immediate release morphine
products
Solaraze
Latin America, 
Caribbean 
Pharmacia sold the 
products in Sweden 
US, Canada and 
Mexico
2001 Dermatology product portfolio Hexal 12 products including treatments 
for acne and eczema
Germany
2001
2001
Expansion of dermatology 
franchise. Bioglan acquired 
the option to acquire rights 
from Novartis to steroid 
products in an additional 35 
countries to those it already 
held in Germany
Novartis Locacorten and Sicorten A further 35 
(geographical) 
markets including 
Italy, Spain, the 
Middle East. 
Africa. Asia and 
Australasia
Development and 
commercialisation agreement
Arakis AD 177 antiproiferative treatment
for Psoriasis
Source: Compiled by the author from various issues of the Financial Times and Scrip: 1992-2002.
The first network and acquisition based product development strategic action realised 
was the co-promotion agreement between Altana's Savage Division and Bioglan for the 
product Micanol. From 1998 onwards the number of related strategic actions reported 
increased from two and three each year (1998 to 1999) to live in 2000 and 2001. I he
Agreement was terminated in 2001
8 This agreement was terminated in 2001
} North America rights were subsequently sold to Quintiles I ransnational in 2001. Skyephaima bought 
back the European rights in 2002 for a nominal sum and subsequently sold the European distribution
rights to Shire Pharmaceuticals
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increased number of network-based strategic actions from 1997/1998 onwards concurs
with the empirical lesearch conducted by Pammolli and Riccaboni (2001:48) of a
relatively lecent phenomenon of a growing division ol labour between the companies
and organisations that discover new' products and the companies that develop and 
market them”.
Some ol the arrangements focused upon cooperative partnerships relating to product 
development such as the Novo Nordisk global drug delivery deal in 1998 for the 
Biosphere drug delivery system. NABPD strategic actions also included co-promotion 
and collaborations, but predominantly focused upon the acquisition of products and 
product portfolios. These included the US dermatology range acquired from Medicis 
Pharmaceuticals in 1999 and the acquisition of pain products from Pharmacia in 2001. 
In addition to outright acquisition of products Bioglan purchased rights, such as the 
German rights to the dermatology franchise from Novartis in 2000, which was 
expanded to an option for an additional 35 countries in 2001.
Bioglan appears to have taken a knowledge-based approach to its product development 
strategy, such that it could learn from alliance partners as well as from- its own internal 
experiences of both developing product and marketing products for other firms. Bogner 
and Thomas (1996) identified an approach to resource based management that combines 
both internal and external learning through the development of network relationships. 
This appears to match the description of Bioglan’s product development strategy. This 
approach enables a firm to establish "the flexibility needed to continually reposition 
itself in a rapidly changing environment.” (Bogner and Thomas, 1996:175). Child and 
Faulkner's (1998:314) view of network relationships was that "the evolution of 
alliances can proceed along different paths and lead to quite different outcomes. It can 
incur periodic crises and often leads to termination of the cooperation .
The data indicated that of twelve network based relationships entered into by Bioglan
only two of these were terminated. 1 he agreement with CeNes was terminated by
CeNes in 2001 as was the agreement with Novo Nordisk. Although the press speculated
that Skyepharma would terminate the agreement for Solaraze this did not happen.
although Bioglan did have to transfer the North American rights to Quintiles. The
actions of both Cenes and Novo Nordisk demonstrated how, in a ciisis situation these
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partneis will focus on their own survival even if it means the demise of the 
coopeiative partner, lable 5.46 refers to Bioglan’s Merger & Acquisition (M&A)
strategic actions.
Table 5.46 Bioglan’s Merger & Acquisition (M&A) Strategic Actions
Year
1994
1995
1995
1996
1997 
1997
1998
1999
2000
2000
2000
2000
Firms acquired
Hydro Pharma 
Tripharma 
Biogram
Goldham 
Pharmasol 
Euro derm a
Mosaique (holding company of
Laboratoire CS) 
Winston Laboratories
Mosaique (holding company of
Laboratoire CS)
CeNeS Pharmaceuticals 
United Nordic Pharma 
Laegm idde 1 forsyn i ng
Notes
Renamed Bioglan AB
26% share 
50% interest
50% share
19% share 
Remaining 50% share
1.1% minority share
Dansk Lagem idde I forsyn ing 
was an associated company of 
United Nordic Pharma
Geographical 
locations
Sweden 
Ireland 
Sweden 
Germany
United Kingdom 
United Kingdom 
France
United States 
France
US
Denmark
Denmark
Source: Compiled by the author from various issues of Scrip, Financial Times and Mergerstat: 1992- 
2002.
As shown in Table 5.46 Bioglan placed its emphasis on acquisitions focused primarily 
on buying companies outside of the United Kingdom. The acquisitions were focused 
upon its four core therapeutic areas of generics (e.g. Tripharma), drug delivery (e 
Biogram, a biotechnology company), pain management (e.g. Winston Laboratories) and 
dermatology (e.g. Hydro Pharma). Sales and marketing capability was also developed 
through the acquisition of Dansk Lagemiddelforsyning. There was no evidence that 
Bioglan Pharma pic had attempted to diversify outside of pharmaceuticals via 
acquisitions. In the majority of acquisitions Bioglan Pharma pic appeared to attain 
complete control of the companies with the exception of Goldham, Winston 
Laboratories, Biogram and CeNeS. As shown in Table 5.47 Bioglan realised only two 
strategic actions with regard to Organic Concentric Diversification (OCD).
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Table >.47 Bioglan’s Organic Concentric Diversification (OCD) Strategic Actions
Strategic Action
Establishment of a US 
subsidia
Establishment of a wholly 
owned subsidiary
Firm created
Bioglan Pharma 
GmbH
Countr
United States
Germany
Source: Compiled by the author from various issues of Scrip and Financial Times: 1992-2002.
glan Pharma
GmbH, which was responsible tor marketing dermatological products in Germany. 
This purchase showed a change in direction because originally products in Germany had 
been sold by the firm Goldham which Bioglan acquired a 50% share of in 1996 (Table 
5.46) and then sold to Sanochemia Pharmzeutika in 1999/2000 (Table 5.50). Bioglan 
Pharma GmbH was established to allow Bioglan to reacquire the rights to Crystacide. 
Micanol and Furacin, products which had originally been owned by Goldham Bioglan. 
As shown in Table 5.48 Bioglan s Organic Growth (OG) strategic actions were focused 
upon the development of its sales and marketing infrastructure during 1999-2001.
Table 5.48 Bioglan's Organic Growth (OG) Strategic Actions
Year Strategic action
------------- *---------------------
Countries
1999 Establishment of a salesforce in the
United States
United States
2001 Increase in dermatology salesforce in
Germany
Germany
2001 Building up of marketing infrastructure •
Source: Compiled by the author from various issues of Scrip and the Financial Times: 1992-2002
The 2001 data supports the view that Bioglan was expanding in order to support the 
proposed acquisition of the Bristol Myers Squibb skincare division by "building up the 
marketing infrastructure to support sales of the BMS range'* (Croft, 2001:26). As shown 
in Table 5.49, Bioglan restructured its generics subsidiary in 1999 and then proceeded 
in 2001 to undertake an organisation wide restructuring.
Table 5.49 Bioglan’s Retrenchment (TR) Strategic Actions
Year
1999
2001
Strategic Action
Restructuring and rebranding of the generics business
Bioglan Generics Ltd
^ ---------------------------------------------------------------------------------
Restructuring which included 15% reduction in the 
workforce and reduction in the research and development
budget____________________
Source: Compiled by the author from various issues of Scrip and Financial limes. 1992-2002.
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This restructuring, together with divestments in 2001/2002 (Table 5.50), demonstrates 
an inciease in leversals in strategic actions both prior to and after Bioglan's liquidation
in 2002. fi rm
that is lacing problems and refer to it as a turnaround strategy. They note that its
success does depend upon the severity of the situation. For Bioglan the strategic actions 
were insufficient for it to be able to survive
Table 5.50 Bioglan’s Divestment & Demerger (D&D) Strategic Actions
Year
1999
2000
Strategic Action
2001
2001
2002 -  prior to Bioglan going into
Divestment of 50% of Goldham Bioglan Pharma GmbH to
Sanochemia Pharmazeutika____________
Divestment of a further 25% of Goldham Bioglan Pharma
GmbH to Sanochemia Pharmzeutika____
Divestiture of Genplus Ltd (a telesales business)
Putting its generic drugs contract manufacturing and pain
______________ medicines up for sale___________
Sale of Bioglan's Scandinavian generic drug operations to
2002 - prior to Bioglan going into 
____________receivership____________
Divestment of United Nordic Pharma and Dansk
Laegmiddelforsyning
2002 -  after Bioglan went into
receivership
^ __________
2002 Divestment of Bioglan Phanrra Inc
2002 Divestment of Bioglan Generics Ltd
2002 Divestment of CS Dermatologies
2002 Divestment of Bioglan Laboratories
2002 Divestment of Bioglan Pharma GmbH
2002 Divestment of the entire Swedish drug delivery business
2002 Divestment of Bioglan AB
Source: Compiled by the author from various issues of Scrip and the Financial Times: 1992-2002
A comparison of the M&A strategic actions (Table 5.46) with those for D&D (Table 
5.50) shows that with the exception of Goldham Bioglan Pharma GmbH none of the 
other businesses that had been acquired were put up for sale or divested until November 
2001. The reasons for the move to divestment strategic actions in December 2001 
appears to be summed up in the following "the debt forced Bioglan to put its generic 
drugs contract manufacturing and pain medicines up for sale in an effort to save its coie 
dermatology division" (Financial Times, 2001:14). “Skyepharma has acquired
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Bioglan s entire Swedish drug delivery business...the move is pail; of the continuing 
sell-off of Bioglan s assets by its administrators {Scrip, 2002e:13). The remaining 
assets were sold off, as evidenced by the divestment of firms such as CS, Bioglan 
Pharma Inc and Bioglan Generics Ltd as going concerns. The use of external sources of 
raising finance was a frequent theme oi Bioglan's strategy from 1996 until it went into 
administration in February 2002. This is illustrated in Table 5.51.
Table 5.51 Bioglan's External Finance Raising (E F R )  Strategic Actions
Year Strategic action Firms involved (where 
applicable)
Products 
involved (if 
applicable)
1996 _______ Private placement_______
Novo Nordisk1998 Agreement leading to a 
$5million investment in Bioglan
Biosphere 
drug delivery 
system
1998 Institutional placing on the 
London Stock Exchange and the 
placing of £20 million ($32 
million) shares
I -
1999
(June/Ju ly)
2-for-23 placing and open offer 
of 6.8 million shares
Re: Acquisition of 
product range from 
Medicis
-
1999(December) Issue of 3.9 million new shares Fund 19% acquisition of 
Winston Laboratories.
-
2000 Block listing of 4,500.000 
shares on the London Stock 
Exchange and an identical 
listing on the Irish Stock
exchange
V
-
2001 Issuing of 1.854.169 new shares As part of a funding 
arrangement to acquire a 
dermatology portfolio 
from Hexal
Source: Compiled by the author from various issues of Scrip, Financial Times and Mergerstat 
1992-2002
From the initial placing on the London Stock Exchange in 1998 the subsequent years 
saw the issuing of new shares or block listing of shares every year preceding it being 
forced into liquidation. The external financing strategic actions demonstrate how some 
of Bioglan’s product acquisitions were financed. For example, a 2-for-2j placing and 
open offer were made so that Bioglan could purchase a product range from Medicis. 
External finance was also used to make firm acquisitions such as the issuing of j .9 
million new shares so that Bioglan could purchase 19% ol \\ inston Laboiatoiies. I able 
5.52 shows the Product Divestment & Licensing Out (PD&LO) strategic actions
realised by Bioglan.
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Table 5.52 Bioglan’s Product Divestment &  Licensing Out (P D & L O ) Strategic Actions
Year
1995
1995
1996
1998
1999
2000
2000
2001
Strategic action
Licensing out of marketing rights
Licensing out of rights to Micanol
for France
Firms involved 
where applicable
Oclassen 
Pharmaceuticals 
Medeva
Products involved 
where applicable
Micanol (anthralin)
Micanol
Licensing of two dermatologicals Medeva
Marketing deal which provided 
Elan with UK rights to the
products
Micanol (dithranol) 
and Crystacide
Elan
Licensing and supply agreement Glaxo Wellcome
Extended marketing rights CeNeS
Licensing agreement Sakai
A cream used to 
treat the pain of 
osteoarthritis and 
another for 
discomfort caused 
by eczema 
Crystacide 
(hydrogen 
■eroxide) 
Aerosol
formulation of an 
opiate analgesic 
ES-Gel
2002 - prior to 
going into 
receivership
Licensing agreement Skyepharma Crystalip, 
Dermastick and 
ES-Gel
Divestment of rights Quintiles
Transnational
Solaraze
Source: Compiled by the author from various issues of Scrip and the Financial Times: 1992-2002
As well as the acquisition of firms and products a number of the strategic actions shown
confirm that Bioglan had entered into agreements for other firms to market its products.
This is illustrated by the licensing out of (marketing) rights for Micanol to Oclassen in
1995 and to Medeva (for France in 1995 and then a further agreement in 1996). Other
examples include the marketing deal with Elan in 1998 and with Sakai in 2000 for ES-
Gel. As was seen by the strategic actions relating to Divestments (Table 5.50) and
Retrenchment (Table 5.49) prior to February 2002 the Board of Bioglan appeared to be
implementing strategic actions that would enable Bioglan Pharma pic to survive as an
organisation. But eventually the lender decided that it •could no longer continue to
finance Bioglan Pharma Pic. In February 2002 Bioglan went into administration and
this was followed by the liquidation of the business and the selling oil of the various
companies. Pearce 11 and Robinson (1994) argued that liquidation is a giand stiategy as
a firm attempts to liquidate certain assets. However, in the case of Bioglan the decision
to liquidate was not made bv the Board ol Directors but by external stakeholder, in this
case the lenders when they would not continue financing the film s operations. I able
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5.53 summarises, in chronological order, the strategic actions realised by Bioglan 
during 1992-2002.
Table 5.53 Summary of Bioglan’s Strategic Actions
H = years that the strategic actions were not realised = years that the strategic actions were realised
It is noted that Bioglan did not realise any Joint Venture strategic actions.
5.8 Chapter Summary
As was discussed in the introduction the aim of this chapter was to present the results 
relating to the strategic actions realised by the firms in the sample. This was achieved 
by identifying and chronologically ordering strategic actions that had been reported in 
Scrip, the Financial Times and Mergerstat during the period January 1st 1992 to 
December 31st 2002. During the chapter chronological summaries were presented of 
the strategic actions realised by each firm and were categorised with regard to relevant 
grand strategies.. These were presented in relation to six firms that had arrived at 
different strategic outcomes. The tabulated results also referred to, where appropriate, 
the geographical location of the realised strategic actions. These results will now be 
discussed in Chapter Six with regard to patterns in the evolution of the strategic actions 
and grand strategies and also how they relate to internationalisation strategies. This
addresses the sub questions R2 and R4.
CHAPTER SIX
GRAND STRATEGIES: SELECTION AND EVOLUTION
6.1 Introduction
As discussed in Section 2.8. evolutionary theory underpins the concepts of incremental 
and emergent strategy which are two of the strategies on the 'continuum of strategy 
processes' discussed in Chapter Two (Section 2.3). That section concluded that in order 
to understand the strategy process scholars need to explore what firms actually did 
rather than what they had planned. As detailed in Chapter Four a methodological 
framework was designed. This allowed the qualitative collection and analysis of 
longitudinal data on the strategic actions that were realised by the firms in the sample 
during 1992-2002. In Chapter Five these results were chronologically presented for six 
firms that had arrived at different strategic outcomes, namely LEK (acquired). Shire 
(merged). Pierre Fabre (demerged). Bioglan (liquidated). Asta Medica (disbanded and
V
divested) and Galen (survived without being acquired or merged). In Chapters One and 
Four a set of sub questions were presented, labelled R1 to R4. Question R1 was 
addressed in Chapter Four with the development of a categorisation of a detailed set of 
strategic actions and grand strategies realised by firms in the pharmaceutical industry. 
Section 6.2 discusses the grand strategies that w'ere realised by each of the firms in the 
sample. In Section 6.3 this is developed into a discussion about how the grand 
strategies and strategic actions evolved (Question R2). This includes the presentation of 
an Empirical Typology of Pharmaceutical Grand Strategy Evolution. Section 6.4 
proceeds to address the sub question R4 through exploring the strategic actions realised 
in relation to how internationalisation strategies evolved during 1992-2002. Section 6.5 
contextualises the data about how the grand strategies and strategic actions evolved. 
Finally, Section 6.6 presents the conclusions drawn from the empirical data with regard 
to strategy evolution in the pharmaceutical industry during 1992-2002.
6.2 Grand Strategy Selection
As discussed in C hapter l our, the categorisation of strategic actions used for the 
empirical data collection was based upon an adaptation of Pearce II and Robinson’s 
(1994) set of grand strategies. Pearce II (1982:31) said that "grand strategies are 
typically formulated to promote synergy in operations over a period of at least five 
years. This has been interpreted as meaning that a grand strategy was realised for five 
years if relevant strategic actions were realised in at least three years of any live year 
period. Therefore, with regard to the empirical data, this has been defined as 'strategic 
actions are considered to form the relevant grand strategy if they are realised for at least 
three years in any five year period*.
Pearce II (1982:29) developed a "grand strategy selection matrix** which was devised in 
order to guide managers as to the most appropriate combination of grand strategies to 
select. For example, an internal emphasis or external focus in order to overcome 
weaknesses or maximise strengths. However. Pearce IPs (1982) matrix is prescriptive 
rather than descriptive of the grand strategy selections that firms had realised. Also, his 
selection matrix only highlights a maximum of four grand strategies for each of the four 
quadrants. The other key concern is that although it allows for a turnaround strategy 
(quadrant II) it does not show how strategies should or could evolve over time. For this 
thesis, rather than using Pearce IFs (1982) matrix, the grand strategies realised by each 
of the firms in the sample were modelled to identify similarities and differences in 
grand strategy selection for each of the firms during 1992-2002. As well as identifying 
patterns in grand strategy selection it also discusses the realised strategies in relation to
the strategic group literature.
As shown in Figure 6.1, of the nine grand strategies that were identified as being 
realised by the firms in the sample LEK only realised two of these, those relating to 
External Finance Raising (EFR) and Organic Growth (OG). LEK was the firm that was 
acquired and it selected the smallest number of grand stiategies of any firms in the 
sample. It was also only one of two firms in the sample that realised an Oiganic
Growth strategy, the other being Galen.
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Figure 6.1 A Model of LEK’s Grand Strategy Selection 1992-2002
Source: Compiled by the author
As shown in Figure 6.2 as well as realising an Organic Growth (OG) strategy, like LEK 
Galen also realised an External Finance Raising (EFR) strategy.
Figure 6.2 A Model of Galen’s Grand Strategy Selection 1992- 2002
Source: Compiled by the author
However, in comparison to LEK. over the period 1992-2002 Galen combined these two
strategies with Merger & Acquisition (M&A) and Network and Acquisition Based
Product Development (NABPD) strategies. Galen combined grand strategies with an
external emphasis (M&A and NABPD) with one of an internal emphasis (Organic
Growth) with the funding from an External Finance Raising (EFR) strategy. In
comparison. LEK did not realise either formal (M&A) or collaborative (NABPD)
strategies, in other words those strategies that had an external emphasis. LEK did raise
finance from external sources through its EFR strategy. Galen was the firm that 
survived without being merged or acquired.
As shown in I iguie 6.3, like Galen. Asta Medica also realised four grand strategies 
during 1992-^0(G. In comparison to Galen. Asta Medica did not realise grand strategies 
relating to External Finance Raising (EFR) or Organic Growth (OG). Asta Medica 
focused upon a Joint Venture (JV) strategy in addition to the other external emphasis 
strategies of Merger and Acquisition (M&A) and Network and Acquisition Based 
Product Development (NABPD). Asta Medica was only one of two firms in the sample 
to realise a Retrenchment (TR) grand strategy, the other being Shire (Figure 6.6). 
Although Webb and Pettigrew (1999) suggested that it is a viable option for a firm to 
combine growth and retrenchment strategies these did precede Asta Medica being 
disbanded and divested by its parent company, Degussa.
159
Figure 6.3 A Model of Asta Medica’s Grand Strategy Selection 1992-2002
Source: Compiled by the author
As shown in Figure 6.4, like all of the other firms in the sample, apart from LEK, Pierre 
Fabre realised grand strategies relating to Merger and Acquisition (M&A) and Network 
and Acquisition Based Product Development (NABPD). Pierre Fabre was one of only 
two firms that did not realise an External Finance Raising (EFR) strategy, the other
being Asta Medica. However, unlike Asta Medica, Pierre, Fabre did not realise a Joint 
Venture (JV) or Retrenchment (TR) strategy.
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Figure 6.4 A Model of Pierre Fabre’s Grand Strategy Selection 1992-2002
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Source: Compiled by the author
As shown in Figure 6.5, unlike Pierre Fabre Bioglan realised grand strategies for 
External Finance Raising (EFR) and Divestment & Demerger (D&D). Also, Bioglan 
was the only firm that realised a Product Divestment and Licensing Out (PD&LO) 
strategy. Bioglan realised five different grand strategies in comparison to the two 
realised by Pierre Fabre. Bioglan’s strategic outcome was its liquidation.
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Figure 6.5 A Model of Bioglan’s Grand Strategy Selection 1992-2002
Source: Compiled by the author
Like Bioglan and Galen, the other UK speciality niche pharmaceutical firm, Shire
___ V
(Figure 6.6) realised grand strategies of Merger and Acquisition (M&A), Network and
Acquisition Based Product Development (NABPD) and External Finance Raising
(EFR). However, Shire did not realise any of the other grand strategies implemented by
either Bioglan or Galen. Shire did realise a retrenchment strategy, which was not a
strategy selected by either Bioglan or Galen. Shire’s strategic outcome was its merger 
with Biochem Pharma.
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Figure 6.6 A Model of Shire’s Grand Strategy Selection 1992-2002
Source: Compiled by the author
As has been discussed, each of the firms in the sample packaged their grand strategies in 
a different way for the period 1992-2002. Also, Pearce II (1982) suggested four 
combinations in his grand strategy selection matrix, but as has been shown six 
combinations were shown in the above models, one for each of the firms. A possible 
reason for the difference between the results of this thesis and Pearce II’s (1982) matrix 
was that he had focused upon prescriptive selections whilst I have shown the grand 
strategies that were actually realised by firms. This adds weight to the suggestion in 
Chapter Two that strategy researchers should explore what has happened, been realised, 
rather than that which is planned or prescribed. What the results from the models do 
indicate is that firms realised unique patterns of strategy evolution, as indicated in each 
of the firms combining different grand strategies into their overall realised strategy for 
1992-2002. This supports the findings of Balance et al. (1992) that in the 
pharmaceutical industry firms will only realise a few of the many strategic options 
available to them. Also, as the models show each firm in the sample realised a different 
grand strategy mix and arrived at a different strategic outcome thus suggesting a 
possible link between grand strategy selection and strategic outcome. Table 6.1 
summarises the grand strategies and strategic actions that were realised by each of the 
firms in the sample, based upon the empirical data in Chapter Five. Table 6.1 indicates 
where firms realised a relevant strategy, using the definition given in section 6.2.
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However, despite the definition of strategic actions that constitute a grand strategy this 
still leaves the issue of strategic actions that were realised but that were not necessarily 
part ot an overall grand stiategy, i.e. that there was no consistency in action (Kay, 1993;
Mintzberg */ a t, 1998). These have been classed as incremental strategic actions
(Lindblom. 1959; 1979; Quinn, 1980; 1991). Incremental strategic actions were those
strategic actions that were not realised with the frequency required to be interpreted as 
being a strategy.
As can be seen from Table 6.1, of the available grand strategies, strategic actions 
constituting a strategy were realised for eight of the nine potential grand strategies. 
Strategic actions were also realised with regard to Organic Concentric Diversification 
(OCD) but these were insufficient to demonstrate a strategy. As discussed none of the
firms
sample. Evach packaged them in a unique way not only with regard to the number and 
type ot grand strategies but sometimes with regard to the chronological ordering. For
Growth
(M&A)/Network
Acquisition Based Product Development (NABPD) but with no further Organic Growth 
(OG) strategic actions.
The strategic group literature proposed that firms that were homogenous in nature
followed similar strategies (Porter. 1979; Mascarenhas, 1989; McGee and Segal-Horn,
1990; McGee et al., 1995; Thomas and Pollock. 1999). But, as can be seen with regard
to Bioglan, Shire and Galen, the three British speciality pharmaceutical firms, all had
realised M&A/NAPBD/External Finance Raising (FFR) strategies but then differed
with regard to the other five strategies of Organic Growth (OG), Divestment &
Demerger (D&D), Retrenchment (TR). Product Divestment & Licensing Out (PD&LO)
and Organic Concentric Diversification (OCD). The same could be applied to LEK and
Galen who were both focused upon generic pharmaceutical products at the beginning of
the study. This is possibly because the strategic group literature focused upon
competitive rather than grand strategies. However, as Pearce II (1982) argued, grand
strategies themselves can potentially create competitive advantage. Despite being very
different types of firm Asta Medica had selected a set of grand strategies that were
similar to Shire with regard to M&A/NAPD/TR but differed with regard to Joint
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Venture (JV) and External Finance Raising (EFR). This, therefore, demonstrates how 
the pre-selection of variables for analysis, as used in Strategic Group Analysis (SGA), 
can distort the results showing similarities that may not exist. However, as will be 
discussed in Section 6.5, although some of the firms share some similar characteristics, 
they were all unique, i.e. heterogeneous in nature. This is a point that is not referred to 
in the Strategic Group literature as its emphasis is upon identifying similarities.
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6.3 Grand Strategy Evolution
As is shown in Table 6.1, all of the firms in the sample have combined grand strategies 
with incremental strategic actions. However, this still does not help to explain how, in 
overall terms, the strategies evolved during the eleven years for each of the firms. 
Strategy has been considered as a linear or sequential plan (Chandler, 1962; Ansoff. 
1968, Chaffee, 1985; Andrews, 1991). However, emergent strategy appears to imply 
that firms are not necessarily moving in a “forward” direction. Evolutionary theory 
underpins both emergent and incremental strategies and thus the discussion of findings 
will contribute to current understanding about how grand strategies evolved, i.e. 
changed, over an eleven year period. When interpreting how the grand strategies have 
evolved, added to this interpretation is the view that firms undergo turnaround 
strategies. Pearce II and Robinson (1994) referred to turnaround strategies as being 
retrenchment strategies which can also be combined with divestment strategies, 
discussed previously Pearce II (1982) based his grand strategy selection matrix on 
whether emphasis w'as upon an internal or external focus. This evolution of strategies in 
the pharmaceutical industry with regard to internal/external emphasis is particularly
moved from an historical base of largely organic growth 
(Coombs and Metcalfe, 2002) to one with a high level of merger activity (Allen el al., 
2002) and is characterized by its complex system of network relationships which have 
led to the sharing of capabilities and knowledge (Bower, 1993; Henderson and 
Cockburn,1994; Kettler, 1997; Walsh and Lodorfos, 2002). In interpreting the empirical 
data it was found that strategies relating to
focused whilst those with an emphasis upon OG/OCD were internally focused, 
same related to whether or not firms had placed emphasis upon an EFR strategy. The 
following summarises how the data was interpreted in order to identify similarities and 
differences between the firms in how the strategic actions and grand strategies identified 
from the empirical data have evolved:
M&A/NABPD/PD&LO/JV
Emergent -  grand strategies combined with incremental strategic actions that 
provide an overall consistency in actions based upon whether they had an
internal/external emphasis and whether firms had realised an external finance 
raising strategy;
Incremental -  
grand strategy;
forming
Turnaround a stiategy ot retrenchment and/or divestment & demerger-
Linear direction no evidence of a retrenchment or divestment & demerger
(D&D) strategy or the premature termination of strategic actions;
firms
actions, an approach that can be compared with the concept of emergent strategy
(Mintzberg and Waters. 1985; Mintzberg, 1987). From these interpretations the findings
were developed into an Empirical Typology of Pharmaceutical Grand Strategy
Evolution (Figure 6.2) that reflects the dynamic nature of how strategies and strategic 
actions are realised.
Table 6.2 An Empirical Typology of Pharmaceutical Grand Strategy Evolution
Emergent
strategy
External 
emphasis with 
external finance
External 
emphasis with 
internal finance
Internal 
emphasis with 
external finance
Internal 
emphasis 
with internal 
finance
Incorporating 
turnaround 
strategy of 
divestment
Bioglan
— •
•
-
Incorporating 
turnaround 
strategy of 
retrenchment
Shire Asta Medica
- -
Incorporating 
isolated 
turnaround 
strategic actions
Galen Pierre Fabre
-
Linear direction LEK
Source: Compiled by the author
pharmaceutical
As summarised in Table 6.2, there are similarities and differences in how each of the 
tirms realised their strategies. Bioglan. Shire and Galen evolved strategies that towards 
the end the 1992-2002 period had an external emphasis that were accompanied by 
external finance raising strategies. This therefore supports the view of the strategic 
group literature that firms that are homogenous in nature, i.e. the three speciality
firms, will follow similar strategies. However, an area that appears to 
be neglected in the strategic group literature, is that firm strategies can evolve in
different ways with regard to the extent to which they include turnaround strategies such 
as divestment or retrenchment or isolated strategic actions, as illustrated for these three 
firms in Table 6.2. By including these factors in the analysis it can actually be seen that 
firms were not that similar with regard to their realised strategies, thus disagreeing with 
the strategic group literature. 1 hese differences can be related to Deephouse's (1999) 
discussion about whether firms should be different or the same, and to the proposal that 
all firms are unique (Penrose. 1959; Hannan and Carroll. 1995; Kaplan and Johnson, 
1998), which is discussed in Section 6.5. It can also be related to the weaknesses of 
analytical techniques used in Strategic Group Analysis and other quantitative 
approaches which were discussed in Section 4.4.2. Asta Medica and Pierre Fabre both 
realised strategies with an external emphasis that was financed internally rather than 
externally, again the difference was how the strategies evolved. LFK was the only firm 
in the sample to have an internal emphasis and to evolve its strategy in a linear manner.
As was discussed in Chapter Four the firms in the sample were chosen because they had 
arrived at different strategic outcomes. As can be seen with regard to Figures 6.1-6.6 
and Table 6.2 they have also realised their grand strategies and strategic actions in 
different ways. This would suggest that it is possible to tentatively suggest that there are 
relationships between strategy evolution and strategic outcome. This could be illustrated 
from Table 6.2 with regard to Bioglan. An emergent strategy that includes divestments, 
external emphasis and external finance leads to a strategic outcome of liquidation. 
Another example illustrated in Table 6.2 relates to LEK. An emergent strategy that has 
a linear direction which includes an internal emphasis with external finance leads to a 
strategic outcome of being acquired.
It is not possible from this qualitative exploratory study to confirm whether there is a
causal relationship between the strategy process and the strategic outcome. 1 his could
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be tested by other researchers but does not fall within the scope of this thesis. As will
be discussed in Section 6.6 there are other factors that could have potentially shaped the
strategic outcome of the firm as well as the evolution of its grand strategies and strategic
actions. As discussed in the literature review the pharmaceutical industry has evolved
into a global oligopoly. Section 6.4 seeks to develop an understanding of the
globalisation process in the pharmaceutical industry through exploring the evolution of 
strategic actions with regard to internationalisation.
6.4 Evolution of Internationalisation Strategic Actions and
Strategies
Internationalisation was given a high prominence by Webb and Pettigrew (1999) who 
identified it as one of the key strategy types that they explored as part of their study into 
temporal patterns of strategy development in the UK insurance industry. Although 
Pearce and Robinson (1994) did not class globalisation as a grand strategy they did refer 
to it with regard to a market development strategy, although they did not discuss it in 
terms of strategy evolution. Similarly, Ansoffs (1968) description of market 
development was prescriptive rather than descriptive of what firms had done. The 
discussion in this section therefore helps to develop understanding of the evolutionary 
processes for this type of strategy and thus addresses the sub question R4.
During the coding of the data to identify how the grand strategies had evolved it became 
clear that there were four key geographical themes with regard to 
internationalisation/globalisation markets. These were:
• Western Europe
• Central and Eastern Europe (CEE)
• US
Rest of world
From the tabulated results given in Chapter Five, summaries of the internationalisation
strategic actions tor each firm are provided; these are illustrated using the colour key in 
Table 6.3.
Table 6.3 Colour Key for Summaries of Internationalisation Strategic Actions
The purpose of this section is to explore and compare similarities and differences in the 
internationalisation of the strategies in comparison to the overall grand strategies 
discussed in Section 6.3. I have, therefore, underpinned the discussion with the same 
theory in order to focus upon strategy evolution. The strategic actions have been 
interpreted by applying a similar definition to that used for identifying when strategic 
actions form a grand strategy. In summary, ‘strategic actions are considered to form a 
strategy for the relevant geographical market if they are realised for at least three years 
in any five year period'. Further research, which does not fall within the scope of this 
thesis, could discuss these in relation to specific theories of internationalisation.
It is recognised that there are internationalisation strategic actions that do not relate to 
grand strategies, e.g. exporting, but for the purposes of this study internationalisation 
strategic actions are only those that were identified during the coding of the empirical 
data in relation to grand strategies. This discussion only refers to expansion into 
international markets as issues of withdrawal and retrenchment have already been 
discussed in relation to the grand strategies. Specifically, these are strategic actions 
relating to Merger & Acquisition (M&A), Network & Acquisition Based Product 
Development (NABPD), Joint Venture (JV), Organic Concentric Diversification (OCD) 
and Organic Growth (OG). Consideration was also given to including PD&LO but as 
this included product divestments it was considered that this could not be fully 
considered as an expansion strategy within this discussion.
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6.4.1 Pierre Fabre
Pierre Fabre commenced its internationalisation strategic actions in 1992 with strategic 
actions related to both the Western European and C.E.E markets (Table 6.4).
Table 6.4 Summary of Pierre Fabre’s Internationalisation Strategic Actions
All internationalisation strategic 1 
actions |
|” us q CEE Market qWestern Europe | Rest of world |□ No relevant strategic actions H
Source: Compiled by the author
Pierre Fabre used the following strategic actions to extend its geographical markets: 
Joint Ventures (JVs), Acquisitions (M&A), Organic Concentric Diversification (OCD) 
and Network & Acquisition Based Product Development (NAPBD) strategic actions. 
Various ad hoc strategic actions were subsequently realised with regard to the CEE 
market. With the exception of 2001. no strategic actions were reported in relation to the 
US market. In comparison strategic actions relating to the Western European market 
were realised for the majority of the year 1992 -  2002. Although it realised strategic 
action(s) relating to the “rest of the world” in 1995 Pierre Fabre did not start to realise a
ttrest of the world” strategy until the late 1990’s.
Pierre Fabre therefore appeared to have developed its most local market. Western 
Europe, before progressing onto a wider “rest of the world” strategy that excluded the 
US, despite the US being regarded as the largest market for pharmaceutical sales 
(Walton, 2001). By 2002 Pierre Fabre was operating in 130 countries with 45% of sales 
and 74% of employees being overseas (Pierre Fabre, 2002). Pierre fabre s
internationalisation strategy appeared to be driven by its concern that it was “too 
dependent on the French market” (Scrip, 1998c: 11).
6.4.2 LEK
As shown in Table 6.5 LEK’s relevant strategic actions with regard to 
internationalisation. These started with the CEE market in 1992 followed by the US
market in 1996. None were reported with regard to Western Europe or the Rest of the 
world until 1999.
Table 6.5 Summary of LEK’s Internationalisation Strategic Actions
Source: Compiled by the author
LEK focused upon developing specific strategic actions in the CEE market from 1992 
but. until 2001, these had been focused upon organic growth. LEK only realised 
strategic actions for the US market in 1996, with the establishment of a US company, 
and a collaboration agreement with Ethical Holdings in 1999. LEK only realised one 
strategic action with regard to the “rest of the world” which was a collaboration 
agreement with Ethical Holdings that included the Japanese market.
6.4.3 Asta Medica
Table 6.6 provides a summary of the strategic actions that Asta Medica realised that 
contributed to its internationalisation.
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Table 6.6 Summary of Asta Medica Internationalisation Strategic Actions
All internationalisation strategic i 
actions nr ®  |j CEE Market 1nWestern Europe 1 Rest of world |d No relevant strategic actions |d
1999 2000 2001 2002
Source: Compiled by the author
Asta Medica started realising internationalisation strategic actions in 1992 through the 
use of M&A and OCD to access the US market and NABPD and JV for Western 
Europe. Asta Medica did not realised any more strategic actions for the US market
V
until 1996 when it added to its minority share in Muro Pharmaceuticals to enable a full 
acquisition. This was followed in 1997 with a licensing in agreement for Andrx. This 
agreement related to worldwide rights, and therefore was recorded as a strategic action 
for all geographical markets. In 1998 Asta Medica completed its strategic actions for 
the US market with the establishment of the joint venture Wallace Laboratories/ASTA 
Medica. The strategic actions for Western Europe evolved from 1992-2001. These 
were mainly through NABPD and Joint Venture strategic actions. The exception was in 
1994 with the new plant facility in France. Asta Medica only realised incremental 
strategic actions for the CEE market. These were realised in relation to OG and 
NABPD strategic actions. Asta Medica realised a strategy for the “rest of the world” 
market that started in 1994 with relevant strategic actions realised up to 2001.
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6.4.4 Shire
As shown in Table 6.7, Shire started implementing strategic actions to develop itself 
the CEE market consistently during the period 1994 — 2002
in
Table 6.7 Summary of Shire’s Internationalisation Strategic Actions
All internationalisation strategic 
actions
US
Western Europe
CEE Market
Rest of world No relevant strategic actions
M&A
NABPD
OG
Summary of 
internationalisation 
strategic actions
1992 1993 1994 1995 1996 1997 1998
m>%
•
■ ■ v. ■
Source: Complied by the author
1999 2000 2001
■
El
2002
There is sufficient consistency in behaviour to tentatively suggest a specific CEE 
market development strategy using NABPD strategic actions. However, an 
examination of the specific strategic actions demonstrates that those relating to the CEE
part of an overall European/worldwide agreements. A large number
country
origin) including Middle East, Asia, Australia and New Zealand and thus
contributed to the globalisation of the organisation’s business. In 1997 Shire acquired 
two US firms, Richwood Pharmaceuticals and Pharmavene. Entry into the US market 
via acquisition has been shown to be more likely to result in exit from the market rather 
than entry through Greenfield investments (Li, 1995). Yet, Shire appeared to build upon
1997 acquisition with its Pharmaceutical
developed its presence in the US. Its other strategic actions in relation to the “rest of the 
world” did not occur until 2001 with its merger with the Canadian firm Biochem
Pharma
Canada
6.4.5 Galen
shown
until 1997. From 1997 all ot Galen’s internationalisation strategic actions were focused 
upon the US, primarily in the form of acquisitions.
Table 6.8 Summary of Galen’s Internationalisation Strategic Actions
All internationalisation strategic 
actions
Western Europe
US
Rest of world
CEE Market
No relevant strategic actions
NABPD
JV
OCD
OG
Summary of 
internationalisation 
strategic actions
Source: Compiled by the author
Although Galen was a British firm all of Galen’s reported acquisition activity, apart 
from the companies associated with Bartholomew Rhodes, related to firms based in the 
United States. This was concentrated in the period 1998 to 2000 which appears to have 
been a very intense period for Galen’s acquisition strategy. Galen did not realise any 
strategic actions with regard to the CEE, Western Europe or “rest of the world” markets.
6.4.6 Bioglan
As shown in Table 6.9, Bioglan did not realise any strategic actions relating to 
international markets until 1994. Prior to 1998 these were focused upon the Western 
European and US markets.
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Table 6.9 Summary of Bioglan’s Internationalisation Strategic Actions
All internationalisation strategic 
actions
Western Europe
| US
□
CEE Market |
1 Rest of world |□ No relevant strategic actions |
1992 1993
M&A
NABPD
JV
OCD
OG
Summary of 
internationalisation 
strategic actions
1997 1998 1999 2000 2001 2002
Source: Compiled by the author
The majority of Bioglan’s strategic actions for Western Europe related to acquisitions 
and its NABPD strategy. In addition there were OG and OCD strategic actions relating 
to Germany. These were the 1999 establishment of a German subsidiary and the 2001 
increase in Bioglan’s salesforce for Germany. With regard to the US market Bioglan 
also combined M&A, NABPD, OCD and OG strategic actions. In 1998 strategic 
actions also began to be realised for the CEE and “rest of world” markets. For both of 
these markets Bioglan only realised strategic actions relating to a NABPD strategy. In 
summary, Bioglan realised strategic actions that related to internationalisation strategies 
for all of the markets apart from the CEE
In Section 6.3 the grand strategies selected by the firms for 1992-2002 were compared. 
The conclusion was drawn that each firm had realised a unique package of grand 
strategies. The discussion now proceeds to explore whether the same applies to the 
internationalisation strategy selections for 1992-2002. As Figure 6.7 shows Shire 
realised internationalisation strategies for all four markets that were identified through 
the empirical analysis. Shire was the only firm in the sample to realise 
internationalisation strategies for all four markets. All firms realised internationalisation 
strategic actions but some placed more, and in the case of Galen, all oi their strategic 
attention on specific geographical markets for the grand strategies.
Figure 6.7 Shire’s International Strategy Selection
US
Market
Source: Compiled by the author
As shown in Figure 6.8, Asta Medica realised internationalisation strategies for all of 
the markets apart from the CEE market
Figure 6.8 Asta Medica’s Strategy Selection
CEE
Market
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In comparison LEK only realised internationalisation strategy was for the CEE market
(Figure 6.9).
Figure 6.9 LEK’s International Strategy Selection
'Rest of
World’
Market
US
Market
Western
Europe
Market
Source: Compiled by author
Galen also only realised a strategy for one market, the US (Figure 6.10)
Figure 6.10 Galen’s International Strategy Selection
CEE
Market
Source: Compiled by author
Western
Europe
Market
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comparison
strategies for either the US or CEE markets bat did realise them for the “rest of the
Europe (Figure
Figure 6.11 Pierre Fabre’s International Strategy Selection Mix
Source: Compiled by author
us
Market
So for the five firms compared so far each chose a unique international strategy 
selection for 1992-2002. However, as can be seen from Figure 6.12 Bioglan’s 
international strategy selection mix is the same as that for Asta Medica (Figure 6.8).
Figure 6.12 Bioglan’s International Strategy Selection
US
Market
‘Rest o f
World’
Market
Bioglan’s
International
---------------- »
, ! CEE
Strategy
Selection
| i Market
1 1 f  1
1
1
Western
Europe
Market
Source: Compiled by author
This means that the two firms that failed to survive, Asta Medica and Bioglan, had
similar international selection mixes whilst those that survived packaged their choices in 
different ways.
With regard to R4 all of the firms in the sample realised strategies outside their country 
of domicile. With some firms this was directed at specific international markets, e.g. 
Galen and the US, for others there appears to be evidence of a sequential 
internationalisation strategy development approach starting with the closest 
geographical market e.g. Western Europe and then progressively developing other 
markets. These findings support the view that the grand strategy strategic actions 
contributed to the internationalisation of the pharmaceutical industry.
6.5 Contextualising the Strategy Evolution Process
As identified in Section 6.3, each of the firms selected different grand strategy packages 
and realised them in different ways. Each of the firms had been considered 
heterogeneous in nature, particularly because they had each arrived at different strategic
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outcomes. But. as has been discussed, there were also some similarities. For example, 
Galen, B.oglan and Shire were all British niche speciality pharmaceutical firms. 
However, as discussed in C hapter Two, every firm is unique (Penrose. 1959; Hannan 
and Carroll. 1995; Kaplan and Johnson. 1998). The uniqueness of organisations results 
irom various factors such as their history, the way in which they were started as well as 
their consequent evolution. Referring to the literature reviewed in Chapter Three, in 
order to understand the nature of strategic change in the pharmaceutical industry, it is 
important to consider factors that have the potential to shape the strategies of firms. As 
discussed in C hapter 1 hree the pharmaceutical industry is one in which there is a high 
level of risk because of the role of technology and its associated risks. There is also the 
threat front generic substitutes as patents expire and the industry has been the subject of 
regulatory change. Cockburn et a/. (2000:1123) suggested that the key to competitive 
advantage in the pharmaceutical industry may be how and when firms “identify and 
respond to environmental cues”. Although from the empirical data it is not possible to 
identify how firms did respond to environmental cues it was possible to identify factors 
that could potentially create a breakpoint (Strebel. 1990) in the firm's operating
firm
potential to shape the strategy evolution process.
Pierre Fabre considered 1995 to be a "transitional year" as it split its activities into two 
divisions (Scrip. 1995c: 13) yet there was little reflection of this change with regard to 
its grand strategies w ith the only change in strategy being the start of a PD&LO strategy 
in 1997. In 1999 Pierre Fabre announced that he would step down from his role as 
chairman. Pierre Fabre had to make strategic decisions in relation to regulatory changes. 
Specifically these involved restructuring both French and Italian operations due to 
national regulatory changes in each of these countries. In 1999 Pierre Fabre 
restructured itself with the firm appearing to indicate that this was because of healthcare 
reforms in France (Scrip, 2000d).
The evolution of grand strategies explored for LEK coincides with a major change for
this organisation and its operating environment. TEK was a generics pharmaceutical
firm based in Slovenia. The early 1990s signalled change for pharmaceutical firms in
Slovenia with regard to economic and healthcare reforms, and in 1994 LEK became a
public company (LEK, 2004). LEK was based in Slovenia, one of the “first transition
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growth resumed (Centre For Co-Operation With The Economies In 
Transition, 1997:2). However, in 1999 LEK was facing a number of potential problems
including “economic difficulties in Russia, the war in Kosovo and a suspension of three 
of its products in the US” (Scrip, 1999d:14).
During the mid 1990s, Asta Medica encountered a number of problems including
increased competition from generic substitutes, the loss of its rights to beta-interferon
(Scrip, 1999d) and the "emerging markets crisis” (Firn. 2000:33). This was
accompanied by Asta having a history of fluctuating sales and profits. Part of the reason
tor Asta Medica s internationalisation strategy may be because of German health
reforms which were reported during the 1990s as affecting Asta Medica in its domestic 
market (Scrip, 1993; Scrip, 1998d).
In 2002 Shire s top selling product Adderall was also facing generic competition (Scrip, 
2002g). a problem faced by a number of pharmaceutical firms during the 1990s/early 
21 Century as products came off-patent. The start of the TR strategic actions 
coincided with an explosion at Arenol in 1998. Arenol was the supplier of Shire's two 
top selling products and the fire meant that the company had te temporarily stop 
supplying the products. This appears to support Stebefs (1992) view that breakpoints in 
a firm’s operating environment can lead to a change if the aim of the firm is to maintain 
strategic fit with its environment. It is noted that Shire continued with its expansion 
strategies of M&A. NABPD. OCD and OG, thus supporting the findings of Webb and 
Pettigrew (1999) that firms can simultaneously combine expansion and withdrawal 
strategies. This appears to have led to Shire’s share price dropping by one third because 
the explosion severely affected its ability to supply its top two products to the market 
(Scrip, 1998e).
In 2002 Galen faced problems with regard to its relationship with another speciality 
pharmaceutical firm, Elan, which had been facing problems due to allegations of 
accounting mispractice (Jenkins, 2002a). In the same year there was also a cancer fear 
with regard to hormone replacement therapy, one of the therapeutic markets served by 
Galen. Galen's share price underwent a variety of ups and downs. For example, in 2002 
it fell as shareholders were concerned about Galen's relationship with Elan (Scrip, 
2002h) but, in the same year, the share price also increased “after the regulator issued an
183
approval letter lor the company's menopause treatment” (Jenkins, 2002b:22) but, as
this was the final year of data collection, it was not possible to ascertain if this
potentially shaped Galen s grand strategies. Alongside these changes, as was discussed
in Section 5.6 Allen McClay, the founder of Galen, left in the autumn of 2001 (Jenkins, 
2002a).
Bioglan s main breakpoint appeared in 2001 due to both its failure to acquire the Bristol
Myers Squibb skincare division and its financial problems that were identified in the
same year. 1 he data suggests that part of the reason for the ending of Bioglan Pharma
Pic was due to Bioglan and Bristol Myers Squibb not being able to reach agreement
about the proposed acquisition of BMS's skincare division whilst BMS was making
strategic decisions not to proceed with the agreement. These decisions were being made
whilst Bioglan built up its marketing infrastructure in anticipation of the acquisition but
this did not result in an agreement being made. In turn this led to the press highlighting
financial difficulties at Bioglan. During the same period the agreements with both
CeNes and Novo Nordisk went into reverse with both firms cancelling their agreements 
with Bioglan (Scrip, 2001 d).
As summarised in Table 6.10, all firms in the sample faced forces that had the potential 
to shape both strategy evolution and strategic outcomes. In some cases these were 
unique for the relevant firm, for example, the departure of the Chairman/Founder or a 
product specific problem. In other situations firms were affected by the same or similar 
changes such as the 'emerging markets crisis’ or healthcare reforms. As Table 6.10 
indicates, all the Western European firms that realised External Finance Raising 
strategies, faced financial problems and/or volatile share prices.
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The Shire-Biochem partnership therefore appears to support the view that mergers have 
been used to overcome problems relating to patent expiry (James, 2002). It was also 
reported that analysts were concerned in 2001 that Shire did not have sufficient new 
products in its pipeline (Anon, 2002). Pursche (1996) suggested that the reasons for
in the pharmaceutical industry were to reduce costs but for Shire, as 
highlighted by the merger with Biochem, the benefit appeared to be linked to high 
growth rates as three years after the merger Shire reported “the growth rates for 
revenues were 19% lor 2003 over the prior year” (Shire, 2004a:). This is a different 
finding from the perspective of Heracelous and Murray (2001) that the majority of 
pharmaceutical mergers led to reduced rather than increased market share post merger. 
In contrast to Heracelous and Murray (2001), Koenig and Mezick (2004) found that 
pharmaceutical firms that had merged were more productive after the merger. Yet by 
2004 Shire described itself as “one of the world's fastest
pharmaceutical companies (Shire, 2004b: 1) thus suggesting that the merger with 
Biochem Pharma appears to have been a successful cross border merger.
growing speciality
The aim of this section was to contextualise the data with regard to details about
environment
finns
evolution process. These include healthcare reforms (Pierre Fabre, LEK and Asta 
Medica), product specific problems (Asta Medica. Shire and Galen) and increased 
competition from generic substitutes (Asta Medica and Shire).
As well as these factors each firm also differed with regard to its founding and its 
internal decision makers and this highlights how strategy evolution can be path 
dependent for each firm. As Nelson and Winter (1982) proposed, evolution is path 
dependent but there are many variables that can shape this path dependency and the 
final strategic outcome. Path dependency is a factor that is discussed further in Chapter 
Seven with regard to coevolution.
In conclusion, all firms in the sample evolved their grand strategies during 1992-2002, 
with all encountering problems that could potentially shape the evolutionary process. 
This section has highlighted some of the potential forces for change, which are both 
internal and external to the firm. As was discussed in Chapter Two, there has been
debate as to whether it is the environment that determines the fate of the organisation or
the strategic choices that the firm makes. In Chapter Seven, this is explored further with 
iegard to the application ol coevolution theory.
6.6 Chapter Summary
The aim ot this Chapter was to address the sub questions R2 and R4. Following on 
from a discussion about how the overall grand strategies had evolved for each of the six 
firms in the sample, the findings led to an Empirical Typology of Pharmaceutical Grand
firms
had emerged thus seeking to overcome what Webb and Pettigrew (1999:2) classed as 
the static nature of other forms of strategy typology such as those by Ansoff (1987) and 
Porter (1980). As was seen in this chapter all of the firms in the sample realised 
emergent strategies that incorporated incremental strategic actions.
Firms varied in the number of grand strategies that they realised and the length of time
that they followed each one. Firms sometimes realised strategic actions but with little
consistency so they could not be classed as strategies but instead were referred to as
incremental strategic actions. However, no firm in the sample followed an overall
incremental strategy (Lindblom, 1959:1979; Quinn. 1980; 1991) as all firms realised an
emergent strategy (Mintzberg and Waters, 1982;Mintzberg 1987) to some extent. There
was no clear support for the view that strategy is realised in a linear one way direction
(a planned approach) with the exception of LEK. In contrast there were examples of
strategic reversals, e.g. termination of Bioglan's agreements with CeNeS and Novo
Nordisk, and Pierre Fabre's demerger from bioMerieux and turnaround strategies being
evolved at the same time as expansion strategies such as M&A. Although all of the
firms had the same strategic choice set of grand strategies they selected and packaged
them in different ways even when the firms were similar in nature. In addition they all
arrived at different strategic outcomes. Taggart (1993) proposed that regulatory changes
related to the 1992 single market changes meant that only globally focused
pharmaceutical firms would survive. All the firms in the sample did realise strategic
actions outside their country of domicile, but as the findings that have been discussed
show, the firm in the sample that survived, Galen, had focused its internationalisation
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strategies purely on the US market, thus disagreeing with the proposal made by Taggart
(199j ). However, the term ‘survive- is not simple to define because as Carroll and
Hannan (2000) acknowledged mergers and acquisitions can be classed as ending or
beginning events. Instead, a perspective could be applied that they are neither but the
result is a new organisational form as firms have sought to adapt to the changing
environment. This will be explored further in Chapter Seven which develops the study
into a focus on temporal patterns of strategy development and how the strategic actions 
coevolved for each of the firms in the sample.
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CHAPTER SEVEN
FROM EVOLUTION TO COEVOLUTION
7.1 Introduction
Chapter Six explored how the realised strategic actions of the firms in the sample 
evolved during 1992-2002. This chapter proceeds to explore these in more depth 
through the discussion of the results in relation to temporal patterns in, and processes of. 
strategic action coevolution. It therefore addresses the sub question R3. Understanding 
how strategic actions changed in these middle sized firms can lead to understanding of 
the dynamics relating to the bipolarisation of an industry, particularly as it has been 
argued that this size ot firm will either be acquired or fail to survive (Kurdas, 1998; 
Hannan and Freeman, 1997). This in turn relates to theories of environmental 
determinism (i.e. for those that fail to survive) and strategic choice (the strategic actions 
that were realised). Coevolution theory has been proposed as an integrating theory in 
the environmental determinism versus strategic choice debate. Lewin and Volberda 
(1999) proposed that coevolution provides a theoretical lens that will unify studies into 
understanding processes of adaptation and determinism. For this thesis it leads to a
model of coevolution in the pharmaceutical industry (Figure 7.3) which is discussed in 
Section 7.5.
7.2 Temporal Patterns and Coevolution: Strategic Actions
The purpose of this section is to explore the strategic actions that were realised by the 
firms in the sample in order to identify patterns of temporal development and 
coevolution. Specifically, this section addresses the sub question R3. This is achieved 
by comparing the strategic actions that were realised by each ot the firms during the 
period 1992-2002 and analysing these in relation to:
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• Patterns of strategy coevolution
Patterns of convergence and divergence with regard to each grand strategy
• First movers and last movers for each grand strategy
Before exploring whether there were processes of coevolution in the strategic actions 
that were realised it is first important to identify the definition of coevolution that is 
being applied in this thesis as there have been various interpretations in the management 
literature about what is meant by the term (Murmann. 2003) and how it can be explored. 
Lewin and Volberda (1999:527) proposed that coevolution is “conditions of 
simultaneous evolution that persist over long time periods” although they do not define 
what is meant by a "long time . As was discussed in Chapter Six, Pearce 11 (1982) 
proposed that actions constituting a grand strategy should happen over a minimum 
period of five years, and this minimum period therefore forms the same basis for the 
analysis of coevolution. It therefore encompasses and extends the definition of strategy 
used for discussing the results in Chapter Six to be ‘strategic actions are considered to 
be coevolving if the strategic actions relating to a specific grand strategy are 
simultaneously realised between two firms in at least three years in any five year 
period'. Whilst exploring how the strategic actions coevolved the discussion will also 
explore what Webb and Pettigrew (1999) described as temporal patterns of strategy 
development. This involves identifying whether there were first movers or last movers 
for different strategies and periods of divergence/convergence of the strateg ies. This 
therefore contributes towards a richer picture of strategy evolution and coevolution for 
Bioglan. Galen, Shire, Asta Medica. Pierre Fabre and LEK.
7.2.1 Merger & Acquisition (M&A) Strategic Actions 
All the firms in the sample realised strategic actions relating to Merger and Acquisition
(M&A) (Table 7.1).
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Table 7.1 Merger & Acquisition (M&A) Strategic Actions
H_ >’cars that * e  strategic actions were not realised -  years that the strategic actions were realised
As shown in Table 7.1 Shire and Asta Medica were first movers with regard to M&A 
strategic actions with LEK being the last mover. Bioglan, Galen, Pierre Fabre and Asta 
Medica entered into periods ot M&A strategic action coevolution at various periods 
during 1992-2002. A period of convergence was noted in 1998 when four of the six 
firms were involved in M&A activity. In 1999 the same number of firms were also 
involved. This was followed by a distinct period of divergence in 2002 when no firms 
were realising M&A strategic actions. This supports Webb and Pettigrew’s (1999) 
findings that strategy development within an industry can witness ebbs and flows when 
observed over a period of years.
7.2.2 Network & Acquisition Based Product Development (NABPD) Strategic
Actions
As illustrated in Table 7.2, Pierre Fabre and Asta Medica were first movers with regard 
to strategic actions relating to NABPD strategic actions. The last mover was LEK in
Table 7.2 Ne.work *  Acqul.ilkm Baaed Pr„d„,l Development (NABPD) Strategic Actions
years that the strategic actions were not realised
-  years that the strategic actions were realised
Bioglan
1992
Shire
Asta
Medica
—
-  •
Pierre
Fabre
LEK
Galen
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002
Source: Compiled by the author
____________________________
two or three firms
subsequent years saw the number of firms realising these strategic actions increase and 
in 1998, 1999 and 2001 all firms except Galen were realising relevant strategic actions. 
Five of the firms in the sample coevolved their strategic actions for NABPD with each 
of them coevolving with three to four other firms. The exception was LEK.
7.2.3 Joint Venture (JV) Strategic Actions
As indicated in Table 7.3, only three firms realised strategic actions relating to JV with 
Asta Medica being both the first mover and the most active with regard to this strategy.
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Table 7.3 Joint Venture (JV) Strategic Actions
years that the strategic actions were not realised
years that the strategic actions were realised
Bioglan 
Shire 
Asta 
Medica 
Pierre 
Fabre 
LEK
Galen________________
Source: Compiled by the author
----—93__ 1994 ^995 1996 1997 199K 1QQQ ?nnn 2001 2002
t
The other two firms were Pierre Fabre and LEK, who was the last mover, only realising 
relevant strategic actions in 1999. There was little evidence of convergence with just 
two firms realising relevant strategic actions in 2000 and no evidence of coevolution.
7.2.4 Organic Concentric Diversification (OCD) Strategic A ctions
All firms in the sample realisec
Diversification (OCD) (Table 7.4).
Table 7.4 Organic Concentric Diversification (OCD) Strategic Actions
= years that the strategic actions were not realised 
= years that the strategic actions were realised
1992 1993 1994 1995
Bioglan
Shire
Asta
Medica
Pierre
Fabre
LEK
Galen
2000 2001 2002
Source: Compiled by the author
firms
strategic actions but from 2000 onwards there were no OCD strategic actions realised.
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Asta Medica was the first mover with regard to OCD and Shire the last mover. There 
was no evidence of coevolution.
7.2.5 Organic Growth (OG) Strategic Actions
As shown in Table 7.5, all firms in the sample realised Organic Growth (OG) strategic
actions.
Table 7.5 Organic Growth (OG) Strategic Actions
years that the strategic actions were not realised
= years that the strategic actions were realised
Bioglan
Shire
Asta
Medica
LEK
Galen
1992 1993 1994 1995 1996
_____________________________________________________
1997
—
Source: Compiled by the author
1998 1999 2000
d
2001 2002
________________
LEK and Galen were the only two firms that entered into a period of coevolving these 
strategic actions in comparison to five firms for NABPD (Table 7.2). Punctuated 
intervals of convergence were noted with three firms (but not necessarily the same 
firms) realising OG strategic actions in each of the years 1992, 1995, 1997 and 1999 in 
comparison to no firms in 1993 and only one firm in 1998 and 2000. Galen, Asta 
Medica and LEK were all first movers with Bioglan being the last mover.
7.2.6 Divestment & Demerger (D&D) Strategic Actions
As illustrated in Table 7.6. there was no evidence of Divestment & Demerger (D&D)
strategic actions coevolving.
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Table 7.6 Divestment & Demerger (D&D) Strategic Actions
j j years 1*lat the strategic actions were not realised
In comparison to the M&A strategic actions (Table 7.1) there was lower overall D&D 
activity in the first halt of the timescale with only Galen and Pierre Fabre realising 
D&D strategic actions prior to 1999. If the argument that M&A was not as beneficial as 
pharmaceutical firms had perceived it to be (Henderson, 2000) then the Pierre 
Fabre/bioMerieux demerger appears to support that view. However, there appears to be 
a stronger argument, when considering the low level of D&D in comparison to M&A 
that M&A does have benefits. However, there may be time lags between M&A and 
D&D that were outside the scope of the timescale for the empirical data that was 
collected. The highest number of firms realising this strategic action in any one year 
was in 2002 (three firms).
7.2.7 Product Divestment & Licensing Out (PD&LO) Strategic Actions
As illustrated in Table 7.7, Galen was the first mover with regard to PD&LO but 
Bioglan was the firm in the sample that realised relevant strategic actions for the longest
period of time.
195
Table 7.7 PD&LO Strategic Actions
years that the strategic actions were not realised 
-  years that the strategic actions were realised
Bioglan 
Shire
Asta
Medica
Pierre 
Fabre 
LEK
Galen
1992 1993 1994 I 1995 I 1996 I 1997 1998 1999 2000 I 2001 2002
Source: Compiled by the author
Asta Medica was the last mover. There was a definite period of convergence with
regard to PD&LO from 2001-2002 with three firms realising PD&LO strategic actions
in each year, although not necessarily the same firms. This compares to 1993-1994
when none of the firms were realising relevant strategic actions. There was no evidence 
of coevolution for PD&LO.
7.2.8 Retrenchment (TR) Strategic Actions
firms realised Retrenchment
Growth
(Table 7.5).
Table 7.8 Retrenchment (TR) Strategic Actions
= years that the strategic actions were not realised 
= years that the strategic actions were realised
1992 1993
Bioglan
Shire
AstaMedica
PierreFabre
LEK
Galen
1994 1995 1996 1997 1998 1999 2000 2001 2002
Source: Compiled by the author
The
firms
-  — -  ^ ' * * * * i u v  u i i i i u i i u i i w u j i  y
growing other parts of the business. This was also referred to with regard to the
Pharmaceutical
—  -  X  ------------ 7  — -------------------—
6.2). Asta Medica was a first mover with its retrenchment strategic actions and Bioglan 
the last mover. There was no evidence of coevolution for the TR strategic actions.
7.2.9 External Finance Raising (EFR) Strategic Actions
As Table 7.9 shows LEK and Galen were the first firms in the sample to report strategic
actions relating to the raising of external finance, although these appear to be very firm 
specific.
Table 7.9 External Finance Raising (EFR) Strategic Actions
-  years that the strategic actions were not realised 
= years that the strategic actions were realised
Source: Compiled by the author
For Galen the 1992 strategic action refers to a development grant rather than investment 
by individuals or firms gaining a financial interest in the firm. It is particularly 
interesting to note that no firms realised EFR strategic actions in 1995 yet there were 
periods of convergence in the year immediately following (1996) and in 2001 with four 
firms realising the strategic actions. There was no evidence of coevolution for the EFR 
strategic actions and Pierre Fabre did not realise any relevant strategic actions. In 
comparison to the other firms Asta Medica’s EFR strategic actions were driven through 
its parent company (Degussa). There appears to be a similar pattern with regard to EFR 
strategic actions for Bioglan and Shire. This started in 1996 when Bioglan made a 
private placement and Shire floated on the London Stock Exchange. They were both 
still realising EFR strategic actions in 2001, with Shire continuing into 2002. The third
British speciality pharmaceutical firm in the sample, Galen, also followed a similar 
route with an IPO in 1997, a share sale in 1999 and a share offering in 2001. In contrast 
the piivately owned Piene Fabre did not report any strategic actions with regard to the 
raising of external finance either before or after its merger with bioMerieux.
This section has piesented the results with regard to patterns of temporal development 
and coevolution foi the grand strategies realised by the firms in the sample. The next 
section presents results in a similar way, but with regard to how the strategic actions 
related to internationalisation in each ot the geographical markets that were identified in 
the coding.
7.3 Internationalisation Strategies: Patterns
Development and Strategic Action Coevolution
of Temporal
The key focus of this section is to explore temporal patterns of strategy development 
and coevolution of strategic actions relating to internationalisation. These will be 
compared and contrasted in relation to the findings of the grand strategies discussed in
V
the last section.
7.3.1 The Western Europe Market
As illustrated in Table 7.10. the first movers into the Western European market were 
Pierre Fabre. Asta Medica and Shire who were all realising relevant strategic actions in
1992.
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Table 7.10 Summary of Strategic Actions Relating to Western Europe Market
years that the strategic actions were not realised 
years that the strategic actions were realised
Source: Compiled by the author
Of the firms that realised these strategic actions the last mover was the Slovenian firm 
LEK. Galen did not realise any strategic actions relating to the Western European 
market. There was a period of convergence in 2001 (five firms). The one firm that 
diverged from this process was Galen who survived without being acquired or merged. 
Four of the firms coevolved their strategic actions for the Western European market; 
Bioglan, Pierre Fabre, Asta Medica and Shire.
7.3.2 The US Market
The picture for the US market is different to that of internationalisation into Western 
Europe, as shown in Table 7.1.
Table 7.11 Summary of Strategic Actions Relating to the US Market
= years that the strategic actions were not realised 
= years that the strategic actions were realised
Bioglan
Galen
LEK
Asta
Medica
Shire
Source: Compiled by the author
199
Asta Medica was a first mover in 1992. Apart from this for the period 1992-1995 no 
othei stiategic actions weie realised with regard to the US market. The exception was 
Shire who started a US strategy from 1995 that continued through until 2002. The 
situation from 1996 onwards was very different to that for 1992-1995. From 1996 at 
least three films realised relevant strategic actions in each of the subsequent years with a 
period of convergence (four firms) in 1998-1999. It is also noted that Pierre Fabre only 
realised US strategic action(s) in 2001 and was the last mover with regard to the US 
market. Three firms were involved in periods of coevolution with regard to their US 
strategic actions. These were Bioglan. Galen and Shire, the three speciality 
pharmaceutical firms.
The US was a country in which Walton (2001:97) argued that it was important for 
pharmaceutical firms to develop a "marketing presence”. Walton (2001) explained that 
although there was concern in the US in 1994 about possible healthcare reforms in 
Europe, the reality was that healthcare reforms were actually being implemented. The 
findings from the empirical data do not support this with regard to a reduction of 
internationalisation strategies in Western Europe but do appear to support it with regard 
to expansion into the US as noted by the 1998/1999 period of convergence. Therefore a 
conclusion can be drawn that regulatory changes in Europe were shaping the strategies 
of European firms so that they developed a presence in the US.
7.3.3 The Central and Eastern Europe (CEE) Market
With regard to the CEE market the first movers were Pierre Fabre, LEK and Asta 
Medica with the last mover being Bioglan (1 able 7.12).
Table 7.12 Summary of Strategic Actions Relating to the CEE Market
years that the strategic actions were not realised
= years that the strategic actions were realised
Source: Compiled by the author
There was a period of convergence in 2001 (4 firms) with a period of divergence in 
1993 (0 firms). Although five out the six firms in the sample realised strategic actions 
relating to the CEE market there was no process of coevolution. The only firm not 
realising strategic actions relating to the CEE market was Galen. It is noted that some 
of the strategic actions that led to development in the CEE market were actually 
worldwide agreements that related to all of the geographical markets discussed in both 
this and the previous chapter. The only firms that implemented specific strategic actions 
were the Slovenian (CEE) firm LEK. and the German based Asta Medica. They both
V
realised Organic Concentric Diversification (OCD) and Organic Growth (OG) strategic 
actions in relation to the market. LEK was the only firm to make acquisitions (in 2001).
7.3.4 The Rest o f World Market
shown
Medica, Pierre Fabre and Shire, although none ol these realised lelevant strategic
actions until 1994.
Table 7.13 Summary of Strategic Actions Relating to the Rest of World Market
= years that the strategic actions were not realised
= years that the strategic actions were realised
1992 1993
Bioglan
Pierre
Fabre
Galen
LEK
Asta
Medica
Shire
Source: Compiled by the author
This compares to all of the other markets where at least one firm was involved in each 
from 1992. The last mover was LEK who only realised relevant strategic actions in one 
year. Galen did not realise any relevant strategic actions. There was a period of 
convergence in 2000 to 2001 (four firms). There were periods of coevolution for Asta 
Medica, Shire and Bioglan.
7.4 Temporal Patterns and Coevolution in the Pharmaceutical Industry
A summary of the findings from the discussion of temporal patterns and coevolution for 
each of the individual firms is given in Table 7.14.
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7.4.1 Temporal Patterns o f Strategy Development
Webb and Pettigrew (1999) identified a clear first mover with regard to the strategies 
they discussed. In contrast, the findings for this thesis failed to identify any one firm 
that was a first or last mover tor all of the strategies. Asta Medica was first mover for 
six of the nine grand strategies and there was no clear overall last mover. These findings 
may differ because the data has been collected from the pharmaceutical industry rather 
than the insurance industry context of Webb and Pettigrew’s (1999) research. This is 
possibly because industries have different patterns of industry evolution as path 
dependency results from different trajectories. For example, technological developments 
such as biotechnology and genomics for pharmaceuticals, which in turn can shape 
different patterns of interdependence as illustrated by the number of firms in the sample
formal
informal coevolving networks of actors.
Asta Medica was a first mover for all of the geographical markets but there was no 
overall last mover. Specific periods of convergence were noted for each of the
V
geographical markets. Although there was little strategic activity with regard the US 
market until 1995 there was period of convergence in 1998/1999 with a total of five 
firms in the sample realising relevant strategic actions in this period. 1 his was followed 
in 2000 with four firms realising strategic actions for the rest of the world. In 2001 tour 
firms were realising strategic actions for both the CEE and rest of the world markets. 
2001 was the period of convergence for the Western European market with five of the 
firms realising relevant strategic actions. There was a higher number for this market 
than for any other geographical area in this year. This may have been due to European 
regulatory changes during the 1990s, such as the creation of the European single market 
and the creation of the European Medicines Evaluation Agency (EMEA) (Taggart, 
1993; Matraves, 1999; Braithwaite and Drahos, 2000). These regulatory changes had 
the potential to encourage more strategic activity within Western Europe from European
pharmaceutical firms, including the Eastern European firm LEK. Periods of strategic
Q “mimptir isomorphism” (Mintzberg et al., 1998:295) as action convergence suggest a mimetic isoi i
, ■ • u, inotitiitinnalised within the environment which ledthe firms have become increasingly institi
r i ;n(, fUp ctratemc actions realised by other firms, tor exampleto a process of them copying the strate&
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with regard to internationalisation development in the Western European market (Table 
7.10).
Bioglan, the firm that was liquidated, was the only firm not to be a first mover for any 
oi the giand stiategies or any ol the internationalisation strategies. This therefore 
suggests institutionalisation with regard to Bioglair s strategic actions. Asta Medica. the 
fiim that was disbanded and divested, was a first mover for more grand strategies than 
any other firm. It was also the only firm to be a. first mover for all of the 
internationalisation grand strategies. I his therelore suggests that an emphasis upon 
being a first mover is not a source of competitive advantage in the pharmaceutical 
industry. In contrast as was shown with regard to the strategic actions for Western 
Europe, Galen, the firm that survived, was the only firm in the sample not to realise 
strategies for this market instead concentrating on the US market. From this perspective 
Galen was not conforming to industry recipes (Spender, 1989) about how to conduct 
business and could be regarded as being revolutionary (Hamel. 1996) with its overall 
internationalisation strategy rather than becoming institutionalised. There were no other 
clear patterns of temporal strategy development or coevolution that could be related to 
the strategic outcomes of the firms in the sample.
7.4.2 Grand Strategy Strategic Action Coevolution
As discussed earlier, Lewin and Volberda (1999) proposed that coevolution provided a 
theory that could bridge the gap in the environmental determinism versus strategic 
choice debate. Figure 7.1 presents all of the grand strategies and maps them with regard 
to how firms had coevolved relevant strategic actions. For example. Shire coevolved 
strategic actions in relation to the grand strategy ot Network & Acquisition Based 
Product Development (NABPD). The grand strategies that aie boxed with a dashed line 
illustrate those where there was no evidence ot strategic actions coevolving. Ihese 
relate to the grand strategies ot Organic Concentiic Diversification (OCD), 
Retrenchment (TR). Joint Venture (JV), Divestment & Demerger (D&D), Product 
Divestment and Licensing Out (PD&LO) and External Finance Raising (EFR).
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Figure 7.1 A Model of Firms and Grand Strategy Strategic Actions That Coevolved
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With regard to the strategic actions that were realised processes of coevolution were 
seen for those relating to the strategic actions of Merger & Acquisition (M&A), 
Network & Acquisition Based Product Development (NABPD) and Organic Growth 
(OG). All of the firms were involved in processes of grand strategy strategic action 
coevolution. Galen was involved in periods of coevolution for three of its grand 
strategies in comparison to LEK who only entered into a period of coevolution for one 
strategy.
Processes of coevolution were seen in all of the internationalisation markets with the 
largest number of firms (four) involved in coevolution processes for Western Europe
and all three pharmaceutical firms
the US. This is illustrated in Figure 7.2.
Figure 7.2 A Model of the Coevolution of Internationalisation Strategic Actions
As illustrated in Figure 7.2, all firms apart from LEK were involved in processes of 
strategic action coevolution with regard to the identified international regions. These 
processes were seen for all of the geographical markets apart from Central and Eastern
V
Europe (CEE). The only firms to coevolve strategic actions in the US were the three 
speciality pharmaceutical firms, suggesting a similar strategy for firms that shared some 
homogeneous characteristics. However, as discussed in Chapter Six, they realised their 
grand strategies in different ways and only entered into periods of coevolution for a 
limited number of grand strategies. They also only did not enter into periods of 
coevolution for the CEE or “rest of the world” markets. Again, this is in disagreement 
with the SGA literature that proposes that firms that are homogeneous in nature will 
overall follow similar strategies. There was no clear evidence that any one firm was 
coevolving with the overall globalisation of the pharmaceutical industry, with different
firms example
Medica was a first mover for all of the geographical markets whilst Galen only focused
this strategy until 1997. Having explored the findingsand did not start
with regard to strategic action coevolution, the chapter continues to focus on two 
concepts that have been proposed as being extremely important in understanding 
processes of coevolution. These are interdependence and path dependence.
207
7 4.3 Interdependence
It has been argued that a significant factor of the coevolution process is interdependence 
(Carney and Gedajlovic, 2002). This links with the work by McKelvey et al (2004:112) 
and their research into pharmaceutical innovation. They proposed that actors in the 
pharmaceutical industry were coexisting and that this in turn leads to dynamics of 
further interaction with other relevant parties. As Futuyma and Slatkin (1983:3) 
proposed with coevolution “reciprocal genetic changes might be expected to occur in 
two or more ecologically interacting species" or, as Roughgarden (1983:57) suggested, 
that “coevolution may influence several interacting species and possibly even an entire 
community". It has been argued that this process of interaction needs to exist for 
coevolution to take place and that the firms must be different from each other in some 
way (Volberda and Lewin, 2003). For example this can be related to the ‘webs of 
influence’ (Braithwaite and Drahos, 2000) or 'policy networks’ (Rhodes, 1999) that 
have been proposed occur with regard to regulation. It also relates to the interaction of 
firms with regard to, for example. NABPD and JV strategic actions. v
Firms can evolve into different organisational forms as a result of M&A activity. Also,
form
established (Djelic and Ainamo, 1999), which was identified through the NABI D and 
JV strategic actions in Chapter Four. McKelvey et al. (2004.112) state that learning
and selection principles within a population of actors.........affect the long-term
outcomes of the system”. A process of coevolution could occur with each informal and 
formal partnership as the evolution of each firm is shaped in some way from its 
experiences with the alliance/merged/acquired partners. Focusing upon alliances and 
joint ventures Koza and Lewin (1998) suggested that alliances would shape various 
factors in a firm including strategy and the environments within which it operated. As 
was shown in Table 6.1, all of the six firms in the sample realised NABPD and M&A 
strategic actions. This therefore links to the interdependence perspective of coevolution 
proposed by Carney and Gedajlovic (2002) and is illustrated by the Bioglan example 
from the empirical data. As the following illustrates the findings of the empirical
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leseaich suggest, tentatively, that the realised strategic actions of Bioglan did coevolve 
with the strategic actions of other firms and that had some impact upon its strategic 
outcome, although this is not inferring a direct cause and effect relationship. The data 
suggests that part ol the reason for the ending of Bioglan Pharma Pic was due to 
Bioglan and Biistol Myers Squibb (BMS) not being able to reach agreement about the 
proposed acquisition of BMS' skincare division. The strategic actions were coevolving 
whilst Bioglan built up its marketing infrastructure in anticipation of the acquisition but 
this did not result in an agreement being made. However, it did lead to the press 
highlighting financial difficulties at Bioglan. During the same period, as discussed in 
Section 6.5, the agreements with both CeNes and Novo Nordisk. instead of continuing 
to coevolve went into reverse with both firms cancelling their agreements with Bioglan 
(Sl lip, 200Id). Skyepharma was also put into a position where it had to reacquire 
European marketing rights to Solaraze from Bioglan and then sold them to Shire 
(Jenkins, 2002c). I his illustrates how the strategic actions of Bioglan. Skyepharma and 
Shire had coevolved: if Bioglan had not relinquished the European marketing rights to 
Solaraze then Shire would not have been able to acquire them. With regard to the 
Solaraze product the process of coevolution is made even more interesting in the case of 
Bioglan Pharma. Quintiles acquired the US marketing rights to Solaraze and then, 
following Bioglan's break up. proceeded to buy the assets of the US subsidiary. This 
therefore also emphasises the nature of interdependence in coevolving relationships 
such as NABPD agreements.
At the micro level this has been shown with the case of Bioglan where its
interdependence related not just to customers but also to firms with which it was
cooperating and not necessarily competing. As was seen from the longitudinal tracking
of Bioglan's grand strategies from 1992-2002 there are various examples of its strategic
actions and strategies coevolving with the strategic decisions of other firms. With
Bioglan it was possible to see how coevolution happened in relation to other firms.
These are most clearly articulated with regard to other pharmaceutical firms with
acquisition (products and firms) and network based arrangements, and with other
stakeholders through the external finance raising stiategy. Similarly the stiategic
choices of other stakeholders, namely lenders, also had an impact upon the strategic
outcome of Bioglan. As discussed it was the decisions of the lenders as to when
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Bioglan Pharma pic ceased trading. Finally the data also showed Bioglan’s strategies
had also coevolved with the evolution of the pharmaceutical industry as it became a
global oligopoly. As can be seen with the case of Bioglan strategies both evolve and
coevolve thus supporting the view that coevolution theory adds an extra dimension to
our understanding of the strategy process.
With legaid to technological coevolution a process of interdependence can be shown.
As was discussed in Chapter Three, Kurdas (1998) and Rothermel (2000) illustrated
how symbiotic relationships occurred between pharmaceutical firms and biotechnology
companies as they worked together to develop biopharmaceutical products. In a similar
vein there was evidence from the empirical data that pharmaceutical firms had started to
enter into interdependent relationships with genomics specialists. This is illustrated by
Pierre Fabre's agreements with Genfit and Celera Genomics. As was identified in
Chapter Five a number of the internationalisation strategic actions were as a result of
forms
mergers, acquisitions and PD&LO strategic actions. This supports the view of
McKelvey et al. (2004) whose study into sectoral patterns in the pharmaceutical
industry identified that interdependency moved forward the internationalisation of the
pharmaceutical industry.
7.4.4 Path Dependence
Internationalisation strategies can change the structure of an industry, and if they are
%
focused upon expansion (rather than withdrawal) they can lead to it becoming
increasingly globalised. Similarly mergers acquisitions can lead
consolidation of an industry and, as has been seen, the pharmaceutical industry has
become a global oligopoly. This process of strategies shaping industry structure can be
linked to Carney and Gedajlovic’s (2002) view that path dependency is an important
component for understanding the coevolution process. They argue that the outcomes of
organisational strategies can shape the local environment which in turn affects the
actions of other actors affected by this environment. So. loi example, established
pharmaceutical firms entered into mutually beneficial relationships with biotechnology
firms
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have potentially led to pharmaceutical firms being unable to survive. This process of
path dependency can be related to the S-C-P paradigm (perspective) that industry
structure shapes firm strategies (Bain. 1956; Mason. 1959) which in turn shape industry 
structure (Scherer, 1980).
As discussed previously the pharmaceutical industry had become increasingly 
consolidated and internationalised as it had emerged into a global oligopoly thus 
suggesting that firms in the industry had increasingly realised consolidation strategies 
such as mergers and acquisitions, and internationalisation strategies, for example 
entering into new geographical markets. These grand strategy strategic actions could in 
turn shape the structure of the industry (S-C-P paradigm), a process of path dependency. 
This was illustrated by the periods of convergence for M&A. NAPBD and PD&LO 
strategic actions. Also with regard to these strategies it was shown that all firms were 
altering their organisational form either as a result of acquiring more firms, merging 
with partners and/or developing their organisational form with regard to a network form 
or joint venture. This therefore suggests a process of adaptation as the industry was 
evolving into a global oligopoly and suggests that firms were coevolving their strategic 
actions as the industry structure evolved, i.e. being path dependent.
In turn this process can lead to further industry consolidation as all of the firms in the 
sample were involved with mergers or acquisitions and these were spread over a 
number of years. These were strategies that shaped the pharmaceutical industry 
structure by reducing the number of firms and increasingly the size of those that had 
made the mergers and acquisitions. These findings would suggest that individual firm 
strategies did shape industry structure with regard to consolidation, thus supporting the 
path dependency perspective that strategies shape the industry environment. However, 
firms did not all adapt at the same time. For example Pierre Fabre did not implement 
any cross border mergers or acquisitions until 1997. Galen did not until 1998 (and those 
were all focused on the US market) and LEK did not until 2001. In contrast to this Asta 
Medica showed evidence of M&A activity in 1992 but did not engage in any cross
border acquisitions after 1998.
As was shown by the empirical data all the firms in the sample realised 
internationalisation strategic actions. In turn these strategies increase the globalisation 
of the industry structure leading to a process of path dependency as firms sought to 
increase their geographical coverage. For some, (for example Asta Medica) this 
resulted in strategic actions for all the geographical markets. For others (such as Galen) 
it led to increased presence in a particular international market with a move away from 
strategic actions focused upon the country of origin. It can also be seen from the 
empirical data that there was a process of path dependency with regard to the 
internationalisation of firms and their strategies. This is illustrated with all of the firms 
realising internationalisation strategic actions by 1997 although some did limit the 
geographical markets that they were involved with. I his suggests that a process of 
partial coevolution was occurring as the pharmaceutical industry structure 
internationally evolved leading to what was termed by the beginning of the 21st Century 
as a global oligopoly (Kettler. 2001b).
With regard to national path dependency McKelvey et a1 (2004:113) said that 
“institutional/country-specific factors are particularly important for explaining the 
different patterns visible at different levels”. This view is supported by the example of 
LEK. the only non-Western European firm. TEK realised the lowest level of strategic 
actions with regard to Western Europe. A possible reason for this was that it has been 
noted in the literature that the standards of products in CEE countries were not 
necessarily as high as in Western markets, but with the potential accession to the E.U. 
of countries such as Slovenia emphasis was placed upon increasing product quality to 
meet these standards. This may explain why LEK. despite becoming an international 
company did not begin its strategic actions with regard to Western Europe until 1999 
and were quite limited in comparison to the previous firms mentioned. Also. LEK was 
the only firm in the sample to have an internal emphasis rather than the external 
emphasis of all of the other firms in the sample. As shown in Figure 7.1 LEK also 
coevolved strategic actions relating to a smaller number of grand strategies than those of 
the other firms in the sample. However, the findings of Galen contradict this view. 
Galen was one of three British firms and yet of all the firms in the sample it was the 
only one to focus solely on the US market with its grand strategies whilst all of the other 
firms realised strategies in at least two of the geographical markets that were identified.
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7.5 Model
The following section synthesises the findings from discussions in Chapters Six and 
Seven. I he result is a model that depicts a theory of coevolution in the pharmaceutical 
industry. The model (Figure 7.3) summarises the empirical data from the thesis in order 
to address the research question: How did the realised strategies of a heterogeneous set 
ot firms coevolve during the period of pharmaceutical industry consolidation from 
1992-2002? As the model shows the emphasis is upon the strategy process and how this 
lelates to stiategic actions evolving and coevolving into grand strategies. It also
illustrates that the strategic actions coevolved with changes in the pharmaceutical 
industry structure as it consolidated and globalised.
213
Figure 7.3 A Model Of Pharmaceutical Industry Coevolution
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A Firm's Strategic Choices: Firms make strategic choices as to the strategic actions and 
grand strategies that are going to be implemented. However, these strategic choices 
may not necessarily become realised strategic actions. For this reason the empirical data 
for this thesis focused upon those strategic actions that were actually realised rather than 
those that were planned, and this is depicted in the model of pharmaceutical industry
coevolution.
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Realised Strategic AcU o n s E y o lv e j^  As was shown from the empirical data
all firms in the sample realised strategic actions during 1992-2002. These strategic 
actions were related to grand strategies and also discussed in terms of
internationalisation strategies. These strategic actions were either incremental or were 
realised so that they formed the relevant grand strategy (Table 6.1). As was shown in 
Figure 7.1 the empirical data showed that strategic actions coevolved for Merger & 
Acquisition (M&A), Network & Acquisition Based Product Development (NABPD)
Growth
legaid to internationalisation. This process of coevolution of strategic actions was also 
highlighted in Section 6.4.2 with the example of Bioglan and the Solaraze product. It is 
noted that not all strategic actions coevolve and not all amount to a strategy which 
demonstrates consistency over time. Although each of the firms in the sample arrived at 
a different strategic outcome the data has shown that all firms coevolved at least one 
strategic action lor at least one grand strategy with that of another firm in the sample, 
thus strongly suggesting that firms in the pharmaceutical industry were coevolving 
grand stiategies duiing 1992-2002. As was illustrated in Figure 7.1 there were no firms 
that entered into a period of coevolution for all of their grand strategies and some 
strategies were not found to have any periods of strategic action coevolution.
Unique Patterns of Grand Strategy Evolution: The model depicts the empirical data 
which showed that for all firms these strategic actions resulted in the evolution of two or 
more grand strategies. No firm realised its package of grand strategies in the same 
pattern as any other firm in the sample (Section 6.3) and thus grand strategy evolution 
was unique for each of the firms. As was discussed in Chapter Six, although all of the 
firms in the sample had the same strategic choice set they chose to build the strategic 
actions into different patterns of emergent strategy. Therefore, as well as showing that 
heterogeneous firms do coevolve their strategic actions the empirical data from this 
thesis has shown that firms follow unique patterns of strategy evolution and 
coevolution.
In discussions about core competences, resources and skills, reference has been made to 
how firms package these in unique ways in order to achieve competitive advantage 
(Barney, 1991; Porter, 1996) and their work suggests that ‘unique’ equals ‘successful’. 
Flowever, unique does not necessarily mean successful. As has been seen in the
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empirical findings although each firm followed a unique patterns of strategy evolution
and coevolution these preceded different strategic outcomes, which included liquidation 
and being disbanded.
Industry Structure Coevolves: Consolidation and Globalisation- As well as strategic 
actions forming unique patterns of strategy evolution and coevolution it was also found 
that they coevolved with the structure of the pharmaceutical industry as it globalised 
and consolidated. Specifically these relate to strategic actions which related to Merger 
& Acquisition and Internationalisation Strategic Actions (MAlSAs). As was discussed 
previously the pharmaceutical industry structure became increasingly globalised and all 
firms in the sample realised internationalisation strategic actions. This suggests a 
process ol coevolution with firms strategic actions and the increasingly global structure 
of the pharmaceutical industry as it evolved into a global oligopoly. Similarly, all firms 
in the sample realised strategic actions relating to mergers and acquisitions, each action 
reduced the numbei ol firms in the industry and thus contributed to the consolidation of 
the pharmaceutical industry. I hus the findings strongly suggest that as the 
pharmaceutical industry evolved into a global oligopoly a process of coevolution was 
occurring between the MAISAs. Although it is possible that other areas of industry 
structure may have coevolved with other strategic actions this was not an area explored 
in this study, and thus is not depicted in the model.
Strategic Outcomes: As discussed in Chapter Three the pharmaceutical industry evolved 
into a global oligopoly as incumbent firms arrived at a number of different strategic 
outcomes. Some of these strategic outcomes (which can sometimes be the same as 
strategic actions) can potentially coevolve with the industry structure. For example, a 
cross border merger contributes to global consolidation and similarly the liquidation of 
a firm increases the concentration of the industry. But (as noted on the model through 
the dotted line) this may not always be the case, dependent upon what the firm’s 
strategic outcome actually was.
As the model has indicated there are various factors that although endogenous to firms 
within the pharmaceutical industry, have the ability to coevolve with changes both in 
the pharmaceutical industry structure and with the strategy dynamics of individual
firms. These factors include regulators, financial institutions and biopharma
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organisations which includes firms that can be involved in the discovery, development, 
marketing and/or manufacturing of products for the biopharmaceutical industry.
Regulators and Financial InMitufions: Regulatory change can both affect how firms
behave and be affected by firms' attempts to influence the regulatory decision process,
for example, through policy networks (Nunan, 1999; McKelvey el al, 2004). Section
6.5 illustrated regulatory changes and healthcare reforms that related specifically to
firms including Pierre Fabre, LEK and Asta Medica. With regard to financial
institutions, as was shown by the empirical data (Chapter Five) five out of the six of the
firms realised strategic actions relating to the raising of external finance. This highlights
the reliance of pharmaceutical firms upon the financial markets as they seek to resource
expensive and risky product development programmes. The financial markets have also
been responsible tor driving the globalisation of industries due to an increase in 
financial concentration (Chesnais, 1993).
Biopharma Organisations: As discussed in Chapter Two as well as the S-C-P paradigm 
stating that changes in industry structure can shape the conduct of the firm, it also 
proposed that the conduct (strategy) of incumbent firms can shape the industry 
structure. Therefore incumbent firms have the ability to shape the strategic actions 
realised by other firms. Interdependence (Section 7.4.3) also highlights the ability of 
incumbent firms to shape the strategic actions of other firms, and hence the coevolution 
of the pharmaceutical industry. For example, all of the firms in the sample were 
involved in NABPD agreements with partners including other pharmaceutical firms, 
genomics firms, universities and government bodies. Also, as illustrated in Table 6.10. 
firms' strategic actions are potentially shaped by the actions of competitors. For 
example, for a manufacturer of branded pharmaceutical products the competitors could 
include the producers of generic substitutes (Chapter Three, Chapter Six and Table 
6. 10).
The model supports the concept of the S-C-P paradigm (Bain. 1956; Mason. 1959;
Scherer, 1980) but proposes that it is extended to a paradigm of coevolution thus
supporting the work of other management researchers seeking to develop an
understanding of coevolution in relation to changes in firms and their environments
(Lewin and Volberda, 1999; Murmann, 2003). The testing of the model does not fall
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within the remit of this thesis but it does provide a basis for future research into industry 
and firm coevolution. Suggestions tor future research are outlined in Chapter Eight 
The model proposes, based upon the thesis findings, that the above factors lead to a 
cyclical process of coevolution as pharmaceutical structure, firm strategies and strategic 
outcomes create a dynamic environment. Firms will not all adapt and coevolve with the 
changed environment simultaneously (Carney and Gedajlovic. 2002). This helps to 
explain why, as shown in the model, there appear to be unique patterns of strategy 
evolution. However, as shown in the exploration of patterns in temporal strategy 
development there was some evidence of institutionalisation (mimetic isomorphism) as 
shown by periods ol strategic action convergence. Although it was found that some 
firms coevolved strategic actions for the same grand strategies (for example. Asta 
Medica and Pierre Fabre both coevolved strategic actions with regard to M&A and
NABPD) they did not follow exactly the same pattern with regard to how they realised 
all of the relevant strategic actions tor each of these grand strategies.
As can be seen in figure 7.3. forces that are endogenous and exogenous to each firm, 
coevolve with a cyclical process of changes in industry structure preceding patterns in 
the evolution and coevolution of grand strategies which in turn precede different 
strategic outcomes. The overall nature of the coevolutionary process, which includes 
factors of interdependence and path dependency, highlights problems with a planned 
linear approach to strategy because of the difficulties in ascertaining how strategic 
decisions will coevolve. As it is difficult to identify which coevolving processes will 
have strongest impact (Carney and Gedajlovic, 2002) it would appear that firms are 
disadvantaged if they focus upon being a first mover, as shown by the Asta Medica 
example. That is not to say that being a last mover is advantageous as Galen was the 
only firm that was not a last mover for any of the grand or internationalisation 
strategies. It did not appear to be institutionalised into following industry rules, for 
example, it was the only firm to focus its internationalisation strategy purely on the US 
market. This suggests the possibility that Galen was the firm that was able to survive 
without being acquired or emerged because its management were better able to respond 
to the changing nature of coevolving forces.
Although the focus of the analysis has been upon the strategic actions and grand
strategies that were realised, it must be noted that these were actioned by actors within
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each firm. In other words everything realised by the firm was as a result of decisions
made by actors directly involved with the organisation. These may be internal actors
such as managers or key stakeholders who have a financial investment in the
organisation. It must be accepted that it is these actors who make the choices as to how
the firm adapts to changes in its external environment. Their ability to respond to
change and make these decisions can differ from company to company (Penrose, 1959;
Hamel and Prahalad, 1993; Jarzabkowski. 2001) which helps to explain why firms
evolve and coevolve their strategies in different ways. In addition actors, whether they
aie managers within the organisation, political policy makers or other key stakeholders
such as bankers and competitors have the ability to influence strategy development
within an oiganisation. I he role ot actors in the coevolutionary process could be
explored further by future researchers as could the testing of the model outlined in
Figure 7.j . This is discussed further in Chapter Eight, the concluding chapter of this 
thesis.
7.6 Chapter Summary
V
Lewin and Volberda (1999) had proposed that coevolution theory provided a unifying 
theoretical lens with regard to the environmental determinism debate. As shown in 
Chapter Four the six firms chosen for the sample had arrived at different strategic 
outcomes, including those that had not survived and those that undergone organisational 
transformation as a result of being acquired or merged. Thus they provided appropriate 
units of analysis to explore whether coevolution theory did provide the insight 
suggested by Lewin and Volberda (1999). In order to investigate this Chapter Seven 
has focused upon addressing sub question R3 and the main research question. This has 
been achieved through exploring temporal patterns in strategy development and 
processes of strategic coevolution, with regard to both the grand strategies and 
internationalisation. The discussion also focused upon interdependence and path 
dependence, as these are considered to be important parts of the coevolution process. 
The key conclusions with regard to coevolution were that:
• All firms in the sample coevolved strategic actions
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All firms m the sample realised strategic actions relating to internationalisation
which, in turn, coevolved with the structure of the pharmaceutical industry as it 
became increasingly globalised
All firms in the sample realised strategic actions relating to M&A which, in
turn, coevolved with the structure of the pharmaceutical industry as it became 
increasingly consolidated
• As all firms also realised NABPD strategic actions this suggests patterns of 
coevolution with the partner firms (Koza and Lewin. 1998)
0
The main lesearch question was: How did the realised strategies of a heterogeneous set 
of firms coevolve during the period of pharmaceutical industry consolidation from 
1992-2002? In response it was found that strategic actions that formed realised 
strategies coevolved both w ith the strategic actions of other firms and with the structure 
of the pharmaceutical industry as it became increasingly consolidated and globalised. 
The Model of Pharmaceutical Industry Coevolution (Figure 7.3) synthesised the thesis 
findings with regard to how strategic actions and grand strategies realised by firms in 
the pharmaceutical industry are part of a coevolutionary process. The next chapter 
concludes this thesis by clarifying its contributions whilst acknowledging the limitations 
of the research. Suggestions are also made with regard to how the thesis findings can 
contribute to future research.
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CHAPTER EIGHT 
CONCLUSIONS
8.1 Introduction
It has been proposed that any doctoral thesis should provide a ‘contribution to 
knowledge and that the author of such a thesis is an ‘apprentice’ (Phillips and Pugh, 
2000). Acknowledging and accepting these perspectives these conclusions address both 
ol these points. Following a summary of the main findings, reasons as to why this thesis 
makes new contributions to existing knowledge and understanding of strategic change 
in the pharmaceutical industry are offered by consideration of:
• The development of a theory of coevolution for the pharmaceutical industry;
• The development of a methodological framework for exploring strategic change 
in the pharmaceutical industry; and
• The development of techniques to help strategic decision making.
Following this, and acknowledging that the doctoral studies have very much reflected 
an apprenticeship, the chapter proceeds to acknowledge and discuss the limitations of 
the research. But. of course, one does not finish working once the apprenticeship has 
ended. This is a beginning rather than the end. Hence, the chapter presents proposals 
for how the key research findings can be developed in the future. This leads into a 
discussion about the personal journey that has been have travelled, a reflection of the 
learning journey during the doctoral studies process, and how this has changed my 
attitudes and behaviour towards the role of being an academic.
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8.2 Summary of Thesis Findings
The overall aim ol this thesis was to identify how the grand strategies of firms in the
pharmaceutical industry had coevolved during the industry consolidation of 1992-2002.
As discussed in C hapters One and Four, four sub questions (R1-R4) were developed in
ordei to address the main research question. This section begins with a discussion about
how these sub questions were addressed. It then proceeds to discuss the main findings 
with regard to the research question.
As the aim ot the thesis was to identify how strategic actions and grand strategies had 
evolved and coevolved during the period 1992-2002 it was felt necessary to have a 
detailed categorisation of strategic actions that had been realised by firms in the 
pharmaceutical industry (Chapter Four). Using a variety of techniques, strategic actions 
realised by pharmaceutical firms were empirically identified and categorised into a 
framework of 23 grand strategies. A summary of the categorisation was presented in 
Table 4.1 and discussed in detail in Appendix B. thus addressing the sub question Rl:
V
What strategic actions were realised by firms in the pharmaceutical industry during 
2001-2002? The discussion of the categorisation includes examples of firms that have 
actually realised relevant strategic actions and the criteria for strategic actions to be 
included/excluded for each of the grand strategies (Langley el at, 2004; Langley el ah, 
forthcoming).
This categorisation was then adapted as a methodological framework for categorising 
the strategic actions of the firms in the sample and chronologically mapping them. The 
adapted categorisation was summarised in Table 4.4 and presented in detail in Appendix 
E. The adapted categorisation was then used to identify the strategic actions realised by 
the firms in the sample. The results were presented in Chapter Five and then discussed 
in Chapter Six in order to address the sub question R2: 'Flow did the realised grand 
strategies of a heterogeneous set of firms evolve during the period of pharmaceutical 
industry consolidation from 1992-2002?’. Specifically R2 was addressed with the 
findings discussed in Section 6.3. In summary it was found that each firm packaged its 
strategic actions and grand strategies in a unique way. 1 his was not only with legard to
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the number and type of grand strategies realised but sometimes with regard to the 
chronological ordering. This thus indicated different patterns in how they combined
grand strategies and how they evolved. This was depicted in Table 6.2 through an 
empirical typology of pharmaceutical grand strategy evolution.
Having explored how the grand strategies and strategic actions had evolved the next sub 
questions, R3, explored how the strategic actions had coevolved: How did the realised 
strategic actions of a heterogeneous set of firms coevolve with each other’s strategic 
actions during 1992-2002? As discussed in Section 7.2 strategic actions are considered 
to be coevolving it the strategic actions relating to a specific grand strategy are 
simultaneously realised between two firms in at least three years in any five year period. 
Tables 7.1 to 7.9 chronologically mapped the strategic actions realised by every firm for 
each ot the grand strategies in order to identify patterns in strategic action coevolution. 
As was shown in Figure 7.1 the empirical data showed that strategic actions coevolved 
for Merger & Acquisition (M&A), Network & Acquisition Based Product Development 
(NABPD), Organic Growth (OG) and External Finance Raising (EFR). Tables 7.10 to 
7.13 chronologically mapped the strategic actions realised by each of the firms in 
relation to the four international markets of the United States (US): Central and Eastern 
Europe (CEE), Western Europe and the Rest of the World in order to identify patterns 
in internationalisation strategic action coevolution. Figure 7.2 illustrated that all firms, 
apart from LEK. were involved in processes of strategic action coevolution with regard 
to the identified international markets. These coevolution processes were seen for all 
markets apart from Central and Eastern Europe.
As well as focusing upon how the internationalisation strategic actions coevolved the 
focus of R4 was upon internationalisation strategies: How did a heterogeneous set of 
firms realise internationalisation strategies during the period of pharmaceutical industry 
consolidation from 1992-2002? This sub question was addressed in Section 6.4 where it 
was found that all of the firms in the sample realised strategies outside their country of 
domicile. Some firms focused their internationalisation strategies on one specific 
market, for example, Galen and the US (Figure 6.10) or LEK and the CEE market 
(Figure 6.9). In contrast Shire (Figure 6.7) realised strategies for all of the international 
markets that had been identified in the analysis, whilst the other firms realised strategies 
for two or more of the international markets. These findings showed that all firms
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realised strategic actions outside their country of domicile and thus suggested that the
grand strategy strategic actions contributed to the internationalisation of the 
pharmaceutical industry.
The sub questions were developed in order to address the main research question: ‘How
did the realised strategies of a heterogeneous set of firms coevolve during the period of
pharmaceutical industry consolidation from 1992-2002?’ The findings that led to
addressing the research question were synthesised in the development of a model that
illustrated pharmaceutical industry coevolution (Figure 7.3) which was discussed in
Section 7.5. In summary it was found that strategic actions that formed realised
strategies coevolved both with the strategic actions of other firms and with the structure
ot the pharmaceutical industry as it became increasingly consolidated and globalised.
Patterns of strategic action coevolution were identified for all of the firms in the sample.
but not for all of the strategies or all the geographical markets. These findings were
discussed in relation to issues of interdependence and path dependency. In interpreting
the findings it was found that a number of forces, both external and internal to the
organisation, shaped and were shaped by the strategy evolution process. This suggests a
process of coevolution between these forces and the strategies and strategic actions 
realised by incumbent firms.
The empirical data from the pharmaceutical industry drove the research to develop the 
generic grand strategies of Pearce II and Robinson (1994) into one that was focused 
upon classifying the strategic actions that were actually realised by firms operating in 
the pharmaceutical industry. The extension from 14 to 23 grand strategies emphasises 
that generic frameworks cannot necessarily be applied to all industries, which suggests 
that such tools would be more beneficial to strategic analysts if they were context 
specific.
The findings have supported the literature which asserts that strategy is an evolutionary
process that incorporates incremental strategic actions (Lindblom. 1959; 1979; Quinn.
1991) and is emergent in nature (Mintzberg. 1987; 1994). This has been achieved by
analysing strategic actions and grand strategies in their context, which led to the
Empirical Typology of Pharmaceutical Grand Strategy Evolution, rather than the
generic, static nature of strategic planning models produced by Ansoff (1968), Porter
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(.980) and Pearce I, (1982). As was illustrated in Section 6.2 individual strategy 
evolution was different tor each firm, as they each selected different grand strategy
mixes.
These findings were therefore in disagreement with Pearce II’s (1982)
prescriptive model of grand strategy selection. The empirical data also challenged the
literature that strategy is a linear process (Chandler, 1962; Ansoff, 1968; Andrews,
1991) through its identification of growth and turnaround strategies being combined,
incremental strategic actions that do not demonstrate consistency in behaviour, and
strategic actions being prematurely terminated. With regard to temporal strategy
development the empirical findings for this thesis agreed with those of Webb and
Pettigrew (1999) that strategy development within an industry can witness ebbs and
Hows when observed over a period of years with regard to periods of strategic action 
convergence and divergence (Section 7.2.1).
firms
^  ■ M
relation to their strategic outcomes, this would appear to support the proposal in the 
stiategic group literature that it is firms which are homogenous in nature that follow 
similar strategies. However, as was also shown each of the firms in the sample 
coevolved at least one of their strategies thus contradicting the strategic group 
proposition but appearing to support Deephouse’s (1999) proposal that firms attempt to 
achieve a strategic balance between being similar and being different to competing
firms.
Exploring strategic actions realised by firms prior to different strategic outcomes 
provides a depth to the factors that precede transformations and ending events, thus 
overcoming what Davis (1996) had identified as a weakness of the work by population 
ecologists and corporate demographers. This thesis contributes to our understanding 
about how strategies coevolve and suggests that this is an area that requires further 
exploration as we seek to understand the impact of strategy formation on the outcome of 
firms. The research has confirmed that processes of coevolution occur between firms 
and their environment. It therefore supports Lewin and Volberda's (1999) view that 
rather than the outcome of a firm being an issue of strategic choice versus 
environmental determinism it is actually a result of a coevolutionary process. It has also 
confirmed that the strategic actions of firms do coevolve but it has taken this a stage 
further than that achieved in previous studies by focusing upon the grand strategies of
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middle size firms in the pharmaceutical industry which have arrived at different 
strategic outcomes.
0
8.3 Contributions to Knowledge
In this section the contributions of the thesis with regard to theory, method and practice 
are discussed. Previous studies into firm and strategy evolution have tended to be
guided by paradigms. More specifically these related to the Structure-Conduct- 
Perlormance paradigm (Bain, 1956; Mason, 1959; Scherer, 1980). the Strategic Group 
concept (Porter. 1979; McGee and Thomas, 1986; Thomas and Venkatraman, 1988), the 
strategic choice perspective (Astley and Van de Ven, 1983; Hrebiniak and Joyce, 1985; 
Child, 1995), and environmental determinism (Hannan and Freeman. 1977; Astley and 
Van de Ven. 1983; Hrebiniak and Joyce, 1985; Carroll and Hannan, 1995). In the 
strategy literature there have been discussions about whether strategies are planned 
(Chandler, 1962; Ansotf, 1968; Andrews, 1991), emergent (Mintzberg and Waters. 
1985, Mintzberg, 1994), revolutionary (Hamel, 1996) or incremental (Lindblom. 
1959,1979, Quinn, 1991). Ihe aim ot this thesis has been to develop an understanding 
of how realised strategies and strategic actions have evolved and coevolved; to 
understand processes of strategic change that precede different strategic outcomes.
The contributions of this thesis centres around how the realised strategies and strategic 
actions of six heterogeneous middle sized pharmaceutical firms preceded different 
strategic outcomes, and how they coevolved both with other incumbent firms and 
industry structure. This has been achieved through the exploration of how' the strategic 
actions and grand strategies of individual firms were realised and how they evolved 
during 1992-2002. The strategic actions that were empirically derived included both 
those with an external and an internal emphasis incorporating organic, network and 
acquisitive strategic actions. The analysis then proceeded to focus upon strategic 
development relating to temporal patterns and coevolution in grand strategies for the six 
firms in the sample, all of which were operating in the global pharmaceutical industry. 
The research therefore aligned itself with recent recommendations in the literature that, 
rather than working within specific paradigms or defending particular schools of
thought, strategy studies should encompass a multiple theoretical lens perspective 
(Hoskisson et a/., 1999, Lewin and Volberda, 1999; Thomas and Pollock. 1999:127).
In contributing to theories based around the strategic choice versus environmental
firms
firms
necessarily shaped by one or the other, rather that the firm and its strategic actions 
coevolve with changes in the industry structure, the strategic actions of other incumbent 
firms and the decisions made by key stakeholders. Further, firms in the pharmaceutical 
industry can also have their fates affected by technological issues such as new 
technology or product withdrawals and. as shown in the literature review, they can in 
turn shape these issues. Specifically, Chapter Two refers to the symbiotic relationships
and biotechnology companies. In comparison to studies 
which have focused upon the “puzzle of competitive strategy” (Thomas and Pollock,
1999) the emphasis of the research has been on grand, rather than business level, 
strategies which has allowed the analysis to focus upon the coevolution of a number of 
strategic actions, including those relating to internationalisation, networks, mergers and 
acquisitions. In addition, the sample includes firms that have arrived at different 
strategic outcomes such as being liquidated and. therefore, includes those that have 
failed, which Thomas and Pollock (1999) proposed should be an important focus of 
strategy studies in the 2Ll Century. This thesis has therefore contributed to 
understanding of strategic change in the pharmaceutical industry by using coevolution 
theory to explore how firm strategies are shaped and shape changes in the external 
environment.
The thesis has used longitudinal rather than cross sectional data to explore how firms’ 
strategic actions and grand strategies were realised, rather than focusing upon those that 
were planned but not necessarily actioned. The data has been used to explore how 
strategies evolved and thus contributes to the literature on the process of strategy and in 
particular work into realised strategies (Mintzberg and Waters, 1985). It contributes to 
the environmental determinism versus strategic choice debate by using coevolution as 
the theoretical lens (Lewin and Volberda, 1999). It differs from the mainstream 
perspective of the S-C-P paradigm that industry structure shapes business level 
strategies (Bain, 1956; Mason. 1959; Scherer. 1980) by instead placing emphasis on
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grand strategies (Pearce II and Robinson. 1994). I, has provided a different perspective 
to the literature relating to corporate demography (Carroll and Hannan. 2000) by 
exploring the strategies that were realised prior a vital even, rather than focusing 
upon how this affects a number of firms in an industry. With regard to the view that 
middle sized firms are either unable to survive or are acquired as an industry evolves
(Hannan and Freeman. 1997; Kurdas, 1998) I, has demonstrated tha, this is no, a theory
that can be generalised as shown by the demerger of Pierre Fabre and the survival of 
Galen for more than eleven years.
The key contributions of this thesis relate to:
Coevolution theories and perspectives
The research methodology
Strategy theories and perspectives
Its contributions and implications for practice
These are discussed in sections 8.3.1 to 8.3.4 and summarised in section 8.3.5
8.3.1 Coevolution Theories and Perspectives
The overall aim of this thesis has been to identify how the grand strategies of firms in 
the pharmaceutical industry have coevolved during the industry consolidation of 1992- 
2002. Chapter Four presented the development of a categorisation of strategic actions 
realised by firms in the pharmaceutical industry during 2001 to 2002. As Lewin and 
Volberda (1999:527) stated, their vision of coevolution studies that combine 
“microevolution, industry macroevolution. environmental and technological evolution 
and coevolution processes within such as system” were rarely met because of the 
difficulty of collecting appropriate data that can be sequenced and. as they emphasised, 
if coevolution is going to be a unifying framework then a substantial amount of 
empirical research still needs to be conducted. The empirical research for this thesis has
made developments with regard to this ambitious aim. I, has categorised the strategic
fi nn s
that had arrived at different strategic outcomes. This led to the identification of patterns 
in the evolution and coevolution of strategic actions and grand strategies. As well as 
focusing upon these patterns of strategic change forces that had the potential to shape 
the evolution and coevolution process were identified. These findings have been 
considered in relation to McKelvey et a l’s (2004:113) study into sectoral innovation in 
the pharmaceutical industry which proposed that “there is a simultaneous interaction 
among firms; specificities, sectoral actors, national contexts and international trends”. 
The culmination of the research for this thesis has been the development of a model of 
pharmaceutical industry coevolution which was illustrated in Figure 7.3. A summary of
the issues considered in the analysis of the data that led to the development of the model 
of pharmaceutical industry coevolution are listed below:
narrowFirms having a broad strategy focus (e.g. grand strategies) as opposed to 
strategic focus (e.g. network strategies).
The exploration and discussion of patterns in strategy evolution for individual
firms rather than a discussion in general terms or , an aggregation of the 
information.
The exploration and discussion of temporal patterns in strategy development 
(i.e. first and last movers, periods of divergence and convergence).
The identification of patterns of grand strategy strategic action coevolution 
between firms whilst also identifying grand strategies where the strategic actions 
did not coevolve.
A discussion of patterns of strategy development in relation to strategic 
outcomes that included firms that had failed to survive the period of study. 
Related patterns of strategy evolution of incumbent firms and how the relevant 
strategic actions coevolved with changes in industry structure.
A discussion of patterns in strategy evolution and coevolution in relation to 
issues of path dependence and interdependence.
A review of academic papers that have researched strategy coevolution (Djelic and 
Ainamo, 1999; Koza and Lewin, 1999; Carney and Gedajlovic, 2002; Flier et al, 2003;
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Lampel and Shamsie, 2003) explored how the authors had considered these issues. The 
• /% -
1review found that even when the papers had resulted in the development of models of
coevolution no one study had considered all of the above issues. This does not appear to
have been achieved in any other research, particularly in relation to the pharmaceutical
• 1  m i  t  «  .
industry. This thesis has therefore made a significant contribution to existing knowledge
t  • I  •  A
by considering all of these issues in its analysis of the empirical data and using this to
develop a model of pharmaceutical industry coevolution.
With regard to coevolution theory, the thesis makes its contribution by demonstrating
that coevolution is part of an overall cyclical process. It was identified that during this
process each firm realises a unique pattern of strategy evolution and coevolution, that
these precede a number of different outcomes which in turn shape the industry structure.
Rather than adopting the approach of the S-C-P paradigm which focuses upon
performance
stiategy and strategic action evolution and coevolution. The principle of S-C-P that
firms
helps to explain why the pharmaceutical industry evolved from being highly fragmented
to that of a global oligopoly. This thesis has extended this concept further by identifying
that the strategic actions, relating to firm conduct, coevolve with both with the structure
fi rm s
Five this is a very complex process where coevolution occurs not just as a result of
these processes but by forces of interdependence and path dependency and including the
coevolutionary actions of a variety of industry stakeholders including the firms
themselves, regulators and those involved with the financial markets. Furthermore, at
different times different firms are either leaders or followers with regard to strategy
implementation, despite operating within the same industry structure. Thus,
coevolution process is also shaped by temporal patterns in strategy development.
These findings therefore propose a more complex theory ol coevolution than that
suggested by writers such as Djelic and Ainamo (1999), Koza and Lewin (1999),
Carney and Gedajlovic (2002), Flier et a/ (2003) and Lampel and Shamsie (2003). This
thesis has thus contributed to and developed our understanding of the simple question
‘How do firm strategies coevolve? 1 his has helped to biidge divides in the ecology
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literature about how incumbent snecies anH ,species and their communities coevolve and the
economics literaturp ahrmt ^ i „ * : -  . . .
firm
8.3.2 Research Methodology
The design ot the methodological framework has helped to develop understanding of 
strategic actions realised by firms in the pharmaceutical industry. This was achieved 
through the collection of empirical data that could be used to compare and contrast 
realised strategic actions and grand strategies for a number of different firms using the 
same basis tor analysis. As was discussed in the previous section this thesis has made a 
contribution to existing knowledge about coevolution by exploring and explaining how 
strategic actions and grand strategies evolved for firms in the sample prior to their 
strategic outcomes. It then used this information to explore temporal patterns and 
periods of coevolution, patterns in path dependency and interdependence and discussed 
them in relation to the coevolving actions of other key stakeholders. The findings 
therefore ollered a level of depth that had not been covered by the papers referred to in
the previous section where the contribution to coevolution was discussed. As this
>
approach had not been followed before for middle sized firms in the pharmaceutical 
industry a unique research methodology had to be designed that would allow the 
collection of the appropriate data and its subsequent qualitative analysis.
The strategic variables were not pre-selected but allowed to emerge during the data 
collection process, firstly through the development of the methodological framework 
and then through the adaptation of the framework to a sample of six firms that had 
arrived at different strategic outcomes. It did not use any ‘forcing' of variables into 
specific categories and if. during the data collection process, strategic actions had 
emerged that could not be accommodated in the adapted methodological framework 
then a new categorisation would have been added (although this was not necessary).
The empirical data collected to produce the categorisation (Chapter Four) also 
illustrated that pharmaceutical firms realised a far wider range of strategic actions than 
that proposed by researchers who had focused upon the source ot competitive advantage 
in the pharmaceutical industry as being either marketing 01 R&D based. As Pearce II
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(1982) proposed, grand strategies ean be a source of competitive advantage and as was 
shown in Table 4.1 strategic actions relating to twenty three grand strategies were 
.dent,fled as having been realised by firms in the pharmaceutical industry during 
January 1“ 2001 to December 31” 2002 (Langley e, 2004, Langley «
forthcoming). This categorisation therefore provides the basis of a methodological
framework for developing existing understanding of strategy development in the
pharmaceutical industry. This methodological framework was then adapted and applied 
to the data collection for the six firms in the sample.
8.3.3 Strategy Theories and Perspectives
firms
In Chapter Two, different perspectives on the strategy process were reviewed. The 
empirical findings challenge the view that strategy should follow a linear plan. 
Referring to Table 6.2 only one of the firms (LEK) supported the view that strategy is a 
linear process, and even this was combined with what appeared to be ad hoc 
incremental strategic actions. In comparison, the five other
emergent strategies combined with incremental strategic actions. The findings also
>
supported the work of Webb and Pettigrew (1999) that strategies for expansion can be
combined with strategic withdrawals. The findings for Bioglan, Shire and Asta Medica
supported Pearce 11 and Robinson's (1994) proposal that firms can undertake 
turnaround strategies.
Another body of literature that focuses upon realised strategies is that relating to 
Strategic Group Analysis (SOA) (see Chapter Two). In summary this literature 
proposes that it is not the industry that shapes the performance of firms but the strategic 
groups in the industry which have their own levels of performance and mobility 
barriers. The argument is centred on firms being allocated to each strategic group on the 
basis that they are homogeneous in nature and will therefore follow broadly similar 
strategies. In contrast, the findings from this thesis challenge the Strategic Group 
perspective. All the firms were different from each other on the basis of factors such as 
age, main products, nationality and/or they arrived at different strategic outcomes. Yet. 
despite these differences, they all entered into periods of strategy coevolution at some 
point during the timeframe studied. In other words, they all at some point realised at
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least one grand strategy that was the same as that of another firm despite the 
heterogeneous nature of the firms in the sample. The firms that were the most similar in 
nature, i.e. the three British speciality pharmaceutical firms of Bioglan. Shire and Galen, 
as with the other firms in the sample, realised unique patterns of strategy evolution. In 
other words, despite sharing similarities they were not homogeneous with regard to the 
realisation ol all grand strategies. Thus, these findings challenge the main argument of 
the Strategic Group literature although it is acknowledged that the focus of Strategic 
Group research has tended to be on business level rather than grand strategies. Although 
SGA studies tocused upon strategy at the business level the one factor that unites the 
literature is that strategy is about competitive advantage, and as it has already been 
argued, grand strategies are also a source of competitive advantage. Therefore, if 
different strategies within the overall grand master strategy mix evolve in different
ways, some with consistency and some without consistency, then this suggests that 
scholars need to retocus our thinking about studying strategic change.
8.3.4 Contribution and Implications for Practice
*
Due to the nature of the findings being context specific it is felt that the findings can be 
adapted to be used as tools and techniques for strategists working within pharmaceutical 
firms. Pearce II (1982) argued that the grand strategies that he had identified1 could be 
selected by firms into an appropriate mix in order achieve certain goals such as 
maximising strengths through an internal emphasis. However, the grand strategies that 
he identified were generic, rather than industry specific. In comparison the grand 
strategies and strategic actions in this thesis were specific to the pharmaceutical industry 
and thus provide firms with a set of strategic choices that are available to them. When 
making decisions as to how they could be applied the empirical typology of 
pharmaceutical strategy evolution (Table 6.2) shows how firms combined an 
external/internal emphasis, extemal/internal finance and emergent strategy with a linear 
direction/turnaround strategic actions and related these to possible strategic outcomes as 
illustrated by each of the six firms. This information could be combined in order to
Also see Pearce II and Robinson (1994)
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show pharmaceutical strategists the strategic choices available to them and the possible
outcomes ol the selections made. It is noted that this is historical data and is designed
provide a guide rather than to be predictive. However, in comparison to some of the
tools currently used in strategic decision making, e.g. Ansoffs (1968) product portfolio
matrix or Porter’s (1980) generic strategies, it is more detailed, industry specific and 
dynamic in nature.
8.3.5 Summary o f Contributions
Table 8.1 summarises the contributions made by this thesis with regard to theory, 
method and practice. It has summarised them with regard to those that it has supported, 
those that it has added new understanding to, those that it has challenged and. more 
significantly the new contributions made by the findings from this thesis.
Table 8.1 Contributions to Theory, Method and Practice
Contributions 
Theory
Method
Practice
Supported Added
Understanding 
about how firms 
and their 
environments 
coevolve
Understanding
Coevolution theory
Theories of emergent 
and incremental 
strategy
Temporal patterns in 
strategy development | about the
relationship 
between strategic 
actions/grand 
strategies, 
strategic 
outcomes and 
industry structure
Use of strategic 
actions to understand 
patterns in strategy 
development
Strategic actions and 
realised strategies 
used by firms in the 
pharmaceutical 
industry
Understanding 
about the range of 
strategic actions 
realised by firms 
in the
pharmaceutical 
industry 
Produced a 
categorisation of 
strategic actions 
specific to the 
pharmaceutical 
industry that 
could be used for 
selecting 
appropriate grand 
strategies
Challenged New
The findings of 
Strategic Group 
Analysis
The perspective 
that strategy is a 
linear process
Theory of 
coevolution in the 
pharmaceutical 
industry
The pre 
selection of 
variables to 
identify realised 
strategies
Methodological 
framework for 
understanding 
strategic change in 
the pharmaceutical 
industry
The use of static 
strategic 
analysis tools 
(e.g. Ansoffi, 
1968; Porter, 
1980)
Techniques to help 
strategic decision 
making in the 
pharmaceutical 
industry focused 
upon evolutionary 
and revolutionary 
processes
Source: Compiled by the author using an adaptation of the Harris et at. (2002) framework
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8.4 Re-visiting the Limitations
When original!, writing the research design the main limitations of the method were
discussed. As the research was actually conducted further limitations were identified, 
and these are discussed in this section.
8.4. I Method Limitation:v
formed
the basis ot the methodological framework it is noted that a limitation of the empirical 
data that was collected was based on material collected from two years of Scrip. The
data contains some bias as it was primarily based upon strategic actions that were 
reported in the media. However, this was supplemented by
literature and triangulated with feedback from two industry experts.
information
An issue that had not been considered in the initial research design was the extent to
%
which data was collected on the “core” firm. This issue was highlighted with the 
analysis of strategic actions implemented by Asta Medica. Asta Medica was both a 
subsidiary (of Degussa) and a parent company (for example of AWD). In turn. AWD 
had its own subsidiaries. A judgement was therefore made that if a strategic action was 
implemented by the direct parent in relation to the firm being analysed then this would 
be appropriately coded as a strategic action for the firm. So, for example, when 
Degussa decided to split Asta Medica up into four firms this was regarded as a strategic 
action of Asta Medica splitting itself up. Equally if a strategic action related directly to 
Asta Medica’s role as a parent, for example by purchasing a subsidiary this would be 
recorded as a strategic action for Asta Medica. but not if one of Asta Medica’s 
subsidiaries had acquired another firm. In this study this was only a limitation with 
regard to Asta Medica because none of the other firms in the sample had a parent 
company prior to their strategic outcomes.
A considerable amount of the data collection was focused upon identifying strategic 
actions in order to develop the categorisation used for the methodological framework. 
As discussed in Chapter Four it was felt that documentary sources were preferable to
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use rather than interviews that may retleet bias or a justification after the event. 
However, it has now been realised that once the data had been analysed the findings 
could have been developed further in order to understand why firms made the decisions 
that they did. Interviews and internal documents could also clarify whether there had 
been any strategic actions that had been prematurely terminated without being reported 
in the media. It is also noted though, that two of the firms no longer existed when the 
data collection process started and. that of the four remaining firms, three had/now have 
their head offices overseas (LEK. Pierre Fabre and Galen)2. However this would have 
made additional data collection through interviews and accessing internal documents
cost and time prohibitive. Although the lack of interviews is acknowledged as a 
limitation these could be lollowed through in further research
8.4.2 Boundary Limitations
This thesis has focused purely on one industry and a set of six middle sized firms. It is 
acknowledged that this could be criticised for a possibly narrow focus by researchers 
who feel that a large number of firms should be studied or that cross industry 
comparisons should be conducted. However, some strategy researchers are beginning 
to think that it is becoming increasingly important for strategy research to be context 
specific. This thesis has focused upon what Pettigrew et al. (2001:699) classed as the 
“contexts of change”. These context specific factors have included:
Endogenous forces involved in the coevolving process shaping the structure of 
the pharmaceutical industry and its incumbent firms (Figure 7.3)
Potential breakpoints that may have affected strategy evolution for each 
individual firm
These contextual factors have been limited because they have not included, for example 
technological information about new product registrations, but they have provided a 
context for understanding how the grand strategies of a heterogeneous set of firms 
coevolved during the pharmaceutical industry consolidation ot 1992-2002.
Galen changed its name to Warner Chilcott in 2004 and has established its headquarters in the US
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This thesis involved three stages of data collection:
• Stage One. Preliminary interviews.
• Stage Two: Development of a methodological framework based upon a
categorisation of all pharmaceutical strategic actions reported in Scrip for a two 
year period.
Stage Three: C hronological mapping and analysis of strategic actions and grand 
strategies for the sample of six firms.
The findings from Stage Two could be generalised to firms in the whole pharmaceutical 
industiy although it is noted that the categorisation was derived from a two year 
timescale. In turn the six firms studied enable the results to be more generalisable to 
European pharmaceutical producers because they were firms spread across four 
different countries and included biotechnology, generic and branded pharmaceutical 
manufacturers. Each of the firms arrived at a different strategic outcome and. to some
extent, had different characteristics. In summary the boundary limitations were that the 
firms in the sample:
• Were all from Europe
• Only included middle sized pharmaceutical firms
• Did not include organisations that were purely research based e.g. university 
departments or organisations that were specifically contract based with regard to 
either pharmaceutical research, manufacturing or marketing.
The research was limited to 1992-2002 which saw the pharmaceutical industry become 
a global oligopoly with a high level of new entrants. This would suggest the possibility 
that strategic actions and strategies would have been ditleient in, for example, the 
1980s. when the industry was highly fragmented and had not witnessed any new
entrants for a long period of time.
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8.5 Areas For Further Investigation
By its nature this thesis has been an exploratory study. It is anticipated that future
research could be conducted to apply and test some of the findings in order to develop
further understanding about strategic and industry change (evolution and coevolution),
particularly in the pharmaceutical industry. This section specifically focuses upon
suggestions tor future investigation with regard to the methodological framework, the
model of pharmaceutical industry coevolution and the empirical typology of 
pharmaceutical strategy evolution.
9
8.5.1 Application o f the Methodological Framework
A categorisation ol strategic actions was developed during the empirical research 
(Chapter Four; Langley et al. 2004. Langley et al., forthcoming). This could be used to 
both continue the research started in this thesis and to explore other areas of strategic 
change. As well as being applied to the pharmaceutical industry it could be used as a 
starting point for exploring processes of strategy evolution and coevolution in other 
industries.
The categorisation can be used by other researchers exploring strategic change in the 
pharmaceutical industry. It can be used to explore patterns in strategy evolution, 
temporal development and coevolution for a wider sample of firms in order test the 
proposition that grand strategies of firms in the pharmaceutical do follow unique 
patterns of strategy evolution and coevolution. Furthermore, the methodological 
framework can be used to collect data from a wider range of published sources than 
those used here. Examples include interviews and internal documentation and it could 
be adapted for both qualitative and quantitative analysis. As was discussed in the 
research design chapter (Chapter Four) the original categorisation of strategic actions 
had to be revised due to the type of data used for the empirical research. In future 
research the data could be expanded. For example, data could be collected on new 
product/New Chemical Entity (NCE) registrations from the US Food and Diug
Administration (FDA) and the European Medical Evaluation Agency (EMEA) in order 
to identify how new products were developed by the organisation (organic product
development) as well that which had already been identified with regard ,o network and 
acquisition based product development
firms
collection ot data from a wider range of sources, means that it can be used as a tool to 
increase our understanding of strategic change in the pharmaceutical industry. By 
adopting the methodological approach used in this thesis researchers could focus their 
attention on collecting and analysing data on the strategic actions realised by specific 
In ms. It is hoped that this will then lead to more researchers undertaking microstate 
adaptation studies to increase our understanding of patterns in strategic change.
W ith regard to applying the research to other industries this is possible through the 
adaptation ot the methodological framework. As acknowledged the strategic actions 
that were identified for the categorisation instrument were specific to the 
pharmaceutical industry. Researchers could test and amend as appropriate the strategic 
actions that were identified for the pharmaceutical industry in,other contexts. This could 
be achieved by identifying if there were examples for each of the strategic actions so as 
to decide whether to include or exclude them for research into the strategies of 
individual firms. This may need to be developed further to incorporate strategic actions 
that were realised in other industries but not in pharmaceuticals. This could be achieved 
by following the stages involved in developing the methodological framework for this 
thesis which are detailed in Langley et a/. (2004) Although, of course, the stages 
identified above w'ould need to be undertaken in order to ensure that the categorisation 
was as detailed as it feasibly could be.
The methodological framework enabled empirical data to be collected that subsequently 
led to the development of an empirical typology of pharmaceutical strategy evolution 
and the model of pharmaceutical strategy coevolution. How these can both be used in 
future investigations is discussed in Sections 8.5.2 and 8.5.J.
8.5.2 The Model of Pharmaceutical Industry Coevolution
The model ol pharmaceutical industry coevolution (Figure 7.3) was developed through 
findings from the empirical data and findings from the literature review. As was argued 
in C hapter Five, actors internal to the firm are responsible for making the decisions that 
lead to the realisation of strategic actions relating to grand strategies, whilst actors (key
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makes. It is therefore proposed that future research should focus upon managers' and 
key stakeholders perceptions as to why they made the decisions that shaped the 
coevolutionary processes that were found in the pharmaceutical industry. The research 
findings could be developed to contribute to these areas of research through a case study 
approach such as. hypothetically, the case of LEK. Why did LEK agree to be acquired 
by Novartis, and in turn what reasons do the managers of Novartis give for acquiring 
LEK? How do the managers of LEK view the regulatory process in relation to the 
strategic actions that they realised? These questions could be focused around a central 
research question ‘'How did the managers of LEK perceive the role of endogenous 
forces in shaping the evolution of their strategic actions during 1992-2002? This case 
study approach could potentially be applied to other firms that survived, e.g. Galen, in 
order to compare findings to identify internal factors such as managerial perceptions, 
leadership and culture that may explain why firms evolved their strategies in unique 
patterns. However, it is noted that there would be limitations in such a project related to
the perceptions of managers (Chapter Four) and that due to the different organisation
0
transformations and strategic outcomes managers that were at the organisation during 
1992-2002 may no longer be contactable.
Lewin and Volberda (1999) proposed that future studies into coevolution could use 
event history analysis in order to develop understanding about microstate adaptation and
coevolutionary processes This method could be used to test the model of
pharmaceutical industry coevolution by exploring relationships between events that 
result from the actions ot regulatory bodies and their relationships with the realisation ol 
strategic actions and grand strategies. By testing the various components of the 
pharmaceutical industry coevolution model over time this could further dtvelop the 
model in order to further define our understanding of the coevolutionary processes 
between endogenous forces, strategic actions, strategic outcomes and pharmaceutical
°  A A
industry structure. Having reviewed the potential options for future development of the 
model of pharmaceutical coevolution the following section outlines proposals for the 
next stages of the research after the thesis.
8.5.3 The Empirical Typology of Pharmaceutical Strategy> Evolution
The empirical typology ol pharmaceutical strategy evolution was based upon empirical 
data collected over a specific eleven year period (1992-2002) focused upon six 
European middle size firms that had arrived at different strategic outcomes. It is 
proposed that the next stages of the research could focus upon the testing and 
development ol this typology by changing the variables that were explored. This would 
involve two new samples:
• Six middle size American pharmaceutical firms that had arrived at the same 
strategic outcomes as the firms in the sample for this thesis.
• Six "large" European pharmaceutical firms that had also arrived at similar 
strategic outcomes.
These findings would in turn test a proposition of this thesis that pharmaceutical firms 
realise “unique patterns in strategy evolution and coevolution”, one of the components 
underpinning the model of pharmaceutical industry coevolution proposed through the 
findings from this thesis. It is known that the data for collecting this information is 
available through accessing the companies pages of Scrip, the Financial Times and 
Mergerstat. Potential ways of developing this research are as follows:
• Pattern matching six American firms that were similar to the six European firms 
in order to identify potential similarities and/or differences in the relationships 
between strategy evolution and strategic outcomes. It would explore further if 
factors relating to geographical origin shape this process. This could be used to
compare and contrast the grand strategies realised by US and European middle 
sized pharmaceutical firms.
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Carrying out a similar exercise to the one above but adapting the original sample 
for six “large” pharmaceutical firms to identify if the relationships between 
strategy evolution and strategic outcomes are potentially shaped by the size of 
the organisation. The first reason for this approach is to test the strength of the 
typology with regard to the complete pharmaceutical industry. Secondly, to 
explore whether there are differences in grand strategy evolution for large firms 
compared to middle sized firms, particularly as it had been proposed that middle 
sized firms have difficult in surviving without being acquired (Hannan and 
Freeman. 1997; Kurdas. 1998). Although, as previously discussed the findings 
from this thesis have challenged this view.
Through the use of pattern matching it will be possible to test the proposition 
that arose from the empirical typology of pharmaceutical strategy evolution 
(Table 6.2) that there are relationships between the evolution of firms' strategic 
actions and grand strategies and the subsequent strategic outcomes. These 
findings could also be used to test and develop the Empirical Typology of 
Pharmaceutical Industry Evolution.
proposition that underpinned the model of pharmaceutical industry
>
coevolution (Figure 7.3) was that pharmaceutical firms realised “unique patterns
of strategy evolution". The above findings could therefore be used to test and
develop the theory of pharmaceutical industry coevolution proposed in this
thesis by exploring issues with regard to a firm’s country of origin and/or its size
and whether there appear to be relationships with these and how firms’ grand 
strategies coevolve.
Findings from further research could be developed into tools for developing strategic
thinking relevant to the strategic choices that need to be made by firms operating in the 
pharmaceutical industry.
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8.6 Learning and Personal Reflection
Prior to commencing this thesis I had personal experience of the strategy making 
process in one organisation. As I became more involved with the organisation I realised 
that in this one organisation most of the decision-making was made behind closed doors 
both by management and directors. Different “splinter" groups had their own objectives 
and individuals sought to use their power in order to gain support for their preferred 
approach. I witnessed phone calls and lunchtime discussions that illustrated how the 
decision making process was mainly being conducted outside of the Boardroom. As the 
organisation's Chief Executive said, "we can write the minutes prior to the meeting”. 
This highlighted how little of the real decision-making was undertaken in the official 
forum of the Board meeting. For example. I noticed that strategic actions were not 
necessarily implemented by senior management in the way that the Board had agreed, 
but instead were adapted in order to fit with departmental agendas.
A new corporate plan meant change. Several of the senior managers either could not 
understand why this was necessary and/or had very fixed views about the changes that 
were required. At this stage the Chief Executive voiced his view that he did not want 
the resulting corporate strategy document to be left to gather dust on a shelf, as it had at 
the last company where he had been employed. It was to be designed so that it could be 
implemented! It took two years of consultation for the final plan before a final version 
was agreed. After this senior managers continued with their original plans, some of 
which had been incorporated into the corporate strategy. With regard to the proposed 
new initiatives, some were started but few were successfully completed. This appeared 
to be as a result of other issues arising, such as pressure to maximise short-term profits 
and changes in staff, as well as the lack of commitment to certain of the initiatives.
As 1 started this thesis I reflected upon these experiences in this organisation, and 
considered them in relation to the strategic planning literature that 1 had been taught at 
undergraduate level. I realised that the formal long-term approach to strategic planning 
was not necessarily the guide to the strategic actions that were implemented and the 
strategy that emerged. I felt that it was important that if one was to research and write
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to a high academic level in a business related discipline, then it was necessary to focus 
upon the realities of the area that one was researching in order to apply theory to 
practice.
My experience emphasised to me the need to study strategies that had been realised 
rather than those that had been planned because this experience had shown that planning 
does not necessarily convert into action. One final point that it highlighted was people’s 
perceptions of the strategy process. Personal experience has shown that managers “talk 
the talk” of strategy. They also justify actions after the event, which may be different to 
factors that affected the decisions whilst they were in progress. This underpinned the 
research method of focusing upon realised strategies that had been reported in the press 
as they had occurred rather than internal documentary sources, such as minutes of 
meetings that may have focused upon actions that w'ere not necessarily implemented. 
How'ever. in the early stages of my doctoral studies I had not realised the importance of 
nan-owing the study so that it could be completed in the equivalent of three full-time 
years. In addition I did not realise how time consuming relatively small amounts of 
research can be. Therefore I decided, in the early stages, that I wanted to map the 
strategic action paths of all of the firms in the pharmaceutical industry from 1976, when 
the biotechnology revolution started, through to the present day.
>
The frustrations incurred during my doctoral studies have helped me in a number of 
ways, both in terms of my own future research and for the supervision of students 
writing undergraduate and postgraduate dissertations (including doctoral theses). These 
lessons are in no particular order. Assess what the student is capable of when they first 
start their research by asking them to write a literature review on a chosen topic within a 
short timescale. Focus the research question and ensure that it is feasible for the data to 
be collected within the required timescales but also understand that research is an 
emergent process and that flexibility is needed in terms of dealing with challenges and 
timescales. Perseverance -  for various personal reasons I always knew that I was 
fortunate enough to have sufficient personal strength to deal with problems and 
challenges and to keep pushing myself -  but 1 never realised that writing the thesis 
would need more energy than finding a house when I was homeless! Writing up has 
taught me to keep going that extra mile and to find an inner strength that I never knew I
had -  but it has also taught me not to burn myself out, which 1 came very close to doing 
several times during the research process. 1 very much feel that a balance needs to be 
achieved between working hard at research and combining this with relaxation in order 
to maximise productivity. Although I do admit that I believe in the work-life balance, I 
am not always successful in achieving it! Added to the above comment, studying for a 
PhD is a lonely process. As I draw to an end with writing it up 1 realise that friends I 
have known for twenty years are more fed up with it than I have sometimes been. From 
this I have learnt that it is important in the future that I have other interests that I can 
discuss with people who are not necessarily related to the academic research I will be 
undertaking. Having a number of options to discuss will, I feel, help me to develop 
networks ot contacts that I work with to develop all areas of my academic career which 
include research, teaching and income generation. I have combined these roles during 
my career to date and it would be satisfying to continue to develop all areas in the 
future.
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Also, when thinking about networks, talking to people who have completed their 
doctoral theses has been an enormous help. Most specifically, when they have 
discussed it from the perspective of problems that they have encountered both with the 
PhD process and balancing other areas of their lives. Talking to them has made me 
realise that I am not the only one who has had problems and doubts during the process, 
and it was further helped by the fact that they had achieved their doctorates despite 
numerous hurdles. These discussions have made me realise the importance of 
becoming involved in external research groups who are studying areas similar to mine
in order to share ideas and be able to overcome problems rather than attempting to 
recreate the proverbial wheel.
Finally, my doctoral studies have helped develop my ability to challenge the views of 
others. 1 have realised that I can contribute a new understanding to areas that have 
already been strongly researched by experienced academics. The presentation of a full 
paper from this thesis at the British Academy of Management conference to writers 
whose papers and books 1 had learnt from made me realise that I have the ability to 
achieve my dreams and ambitions.
8.7 Chapter Summary
This thesis was driven by a desire to understand what was happening at the firm level 
whilst industries were becoming larger and increasingly internationalised, with 
particular refeience to the globalisation and consolidation of the pharmaceutical 
industry. Coevolution provides a theoretical lens that helps to bridge the gap between 
the environmental determinism and strategic choice debates. Thomas and Pollock 
(1999.1 j 8) proposed that in order to understand strategy researchers need to address the 
question with whom and how do firms compete". 1 he findings from this thesis suggest 
that the\ had omitted an important part ol the puzzle. As the thesis has shown there are 
unique patterns ol how strategies and strategic actions both evolve and coevolve, and 
that these stiategies are realised within a coevolving industry environment. Therefore, 
these findings suggest that in order to understand the puzzle of strategy, the emphasis 
needs to be moved to ‘with whom and how do firms coevolve?’
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APPENDIX A
INDICATIVE INTERVIEW PLAN FOR COMPANIES
1 . How would you outline the structure of the pharmaceutical industry as it is at this point in time?
2. What do you feel are considered to be important areas of strategy development for firms in the 
pharmaceutical industry?
j . How do you feel the structure of the pharmaceutical industry has changed during the past twenty
years?
4. What do you consider to be the major changes that have affected the pharmaceutical industry 
during the past twenty years?
5. What do you consider to be the major changes that have affected your organisation during the
past twenty years?
6. What do you feel has caused the changes discussed in points 4 and 5 above?
7. In what ways have these changes affected the strategies of your organisation?
8. What effect do you think Government policy has had on the pharmaceutical industry during the 
past 20 years? >
9. How do you feel that regulation of the pharmaceutical industry has changed during the past 
twenty years?
10. How do you feel that regulatory changes have affected your firm's strategies during the past 
twenty years?
1 1. How do you feel that regulatory changes have affected the strategies of other firms in the 
pharmaceutical industry during the past twenty years?
12. Are there ways in which you feel your organisation is able to influence the UK policy making
process!
Note: All interviews were tape recorded and data treated as confidential.
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i n d i c a t i v e  i n t e r v i e w  p l a n  f o r  a b p i
12 Whitehall, London, SW1A 2DY
Tel: 020 7747 1414
Interviews held on Tuesday 25th September 2001 
Stage 1 questions -  General Industry Structure
1. How would you outline the structure of the pharmaceutical industry as it is at this point in time?
2. On what basis do you feel that firms in the pharmaceutical industry compete?
j. How do you feel the competitive environment of the pharmaceutical industry has changed during 
the past twenty years?
4. What you consider to be the major changes that have affected the pharmaceutical industry during 
the past twenty years?
5. What do you feel has caused these changes?
%
6. What effect do you think Government policy has had on the pharmaceutical industry during the 
past 20 years?
>
7. Is there anyone else in the industry who you would suggest that 1 speak to?
Stage 2 Questions -  Regulatory Changes
1. There are various Government departments involved in the policy making process with regard to 
the pharmaceutical industry, eg Department of Health, Dti, the Treasury etc. What do you 
consider each of their objectives to be for the pharmaceutical industry and have these changed
during the past twenty years?
2. Who would you describe as the main actors/interest groups/government officials/departments 
involved in the policy making process for the pharmaceutical industry?
3. How does this vary with the areas of policy under consideration?
4. How would you describe the relationship between the government and the various interest 
parties in developing/refining regulation?
Regulation of the pharmaceutical industry is aimed at various stages of the product pipeline from 
NCE development through to marketing and monitoring of products. Could you please outline 
the main pieces of regulation that affect each stage of development?
The pharmaceutical industry has been subjected to increased regulation in some areas and de- 
regulation or re-regulation in others. How would you describe the main direction of industry 
specific regulation during the past twenty years (e.g. has it been to focus more on improving 
safety, reducing profits, moving the cost from the government to the individual?)
Is there anyone else who you would suggest that I speak to?
APPENDIX B
THE FINALISED CATEGORISATION OF STRATEGIC
ACTIONS
AND GRAND STRATEGIES
Grand Strategy Definition of
Grand Strategy
Cooperative 
concentration 
(market 
penetration) 
strategy
Organic
concentration
(market
penetration)
strategy
Actions relating to an 
existing product in an 
existing therapeutic 
market that involves 
some form of 
cooperative 
arrangement.
Criteria for 
Exclusions/ 
Qualifications______
Must be focused upon an 
existing dominant 
technology (Pearce and 
Robinson, 1994). This 
must be a
pharmaceuticals product 
and not one involvingo
biotechnology, genomics 
or proteomics.
Cooperative 
arrangements include 
strategic alliances, 
licensing in agreements, 
co-promotion, co- 
marketing, franchising, 
consortia and 
outsourcing.
Strategic Actions 
Derived From The 
Text Analysis
Product refined and 
relaunched; product 
withdrawal for commercial 
reasons; use of a contract 
salesforce to sell an 
existing product; patent 
extension strategic actions 
e.g. appeal to court for 
patent extension or legal 
action against a firm in 
respect of a patent; 
salesforce to sell another 
firm’s products that 
complement its own 
products; re-branding of an 
existing product: price cut 
or price increase; 
divestment of a single 
product, product line or 
product portfolio.I lowever this category 
does not include 
cooperative arrangements 
relating to the external 
raising of finance. This 
means those that involve 
the firm having equity 
placed in it by the partner 
firm or licensing out
agreements.___________
Actions relating to an I Must be focused upon an I Product refined and
existing product in an 
existing therapeutic 
market that have been 
implemented by the 
firm itself
existing dominant 
technology (Pearce and 
Robinson, 1994). This 
must be a
pharmaceuticals product 
and not one involving 
biotechnology, genomics 
or proteomics
relaunched; product 
w ithdrawal for commercial 
reasons; patent extension 
strategic actions e.g. appeal 
to court for patent 
extension or legal action 
against a firm in respect of 
a patent; re-branding of an 
existing product, price cut 
or price, increase; 
divestment of a single 
product, product line or 
product portfolio
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Cooperative
market
development
strategy
Strategic actions 
relating to entry into 
a new therapeutic 
market through a 
cooperative 
arrangement
Strategic actions relating 
to entry into a new
therapeutic market 
through a cooperative 
arrangement. The source 
must make reference to 
this being a new
therapeutic market for the 
firm.
Cooperative 
arrangements include 
strategic alliances, 
licensing in agreements, 
co-promotion, co- 
marketing, franchising, 
consortia and 
outsourcing.
Launching a product into a 
new therapeutic market
Organic market
development
strategy
M&A market
development
strategy
M&A product 
development 
Strategy
Strategic actions 
relating to entry into 
a new therapeutic 
market that have been 
implemented by the 
firm itself
Strategic actions 
relating to entry into 
a new therapeutic 
market through M&A 
activity
Acquisition rather 
than internal 
development or a 
product or process 
using technology that 
was already used by 
the firm.
However this category 
does not include 
cooperative arrangements 
relating to the external 
raising of finance. This 
means those that involve 
the firm having equity 
placed in it by the partner 
firm or licensing out
agreements.________
The source must make 
reference to this being a 
new therapeutic market 
for the firm.
The source must make 
reference to this being a 
new therapeutic market 
for the firm.
This does not include 
biotechnology, 
proteomics, genomics or 
gene libraries. The 
source must not state that 
the technology was new 
to the firm.
Launching a product into a 
new therapeutic market
Acquisition of a single 
product, product line or 
product portfolio.
Acquisition of a single 
product, product line or 
product portfolio.
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Cooperative
product
development
(R&D)strategy
The cooperative 
development of an 
existing product or 
process using 
technology that was 
already used by the 
firm.
This does not include 
biotechnology,
proteomics, genomics or 
gene libraries. The source 
must not state that the 
technology was new to 
the firm.
Product gains regulatory 
approval, has patent 
granted or is launched onto 
the market for the first 
time. •
Organic product 
development 
(R&D) strategy
The development of 
an existing product or 
process using 
technology that was 
already used by the 
firm.
Cooperative 
arrangements include 
strategic alliances, 
licensing in agreements, 
co-promotion, co- 
marketing, franchising, 
consortia and 
outsourcing.
However this category 
does not include 
cooperative arrangements 
relating to the external 
raising of finance. This 
means those that involve 
the firm having equity 
placed in it by the partner 
firm or licensing out 
agreements.
This does not include 
biotechnology, 
proteomics, genomics or 
gene libraries. The 
source must not state that 
the technology was new 
to the firm.
Product gains regulatory 
approval, has patent 
granted or is launched onto 
the market for the first 
time.
Cooperative 
innovation (R&D) 
strategy
Organic Innovation 
(R&D) strategy
Cooperative 
development of a 
product or process, 
through a cooperative 
arrangement, relatingo
to biotechnology, 
proteomics, genomics 
and gene libraries or 
any technology that 
the source states as
This can also include 
development of a new 
chemical entity (NCE), 
and development of a ' 
class of product that had 
not existed prior to the 
beginning of the study 
(1st January 1992) e.g. a 
super statin.
being new to the firm. Cooperative
Internal development 
of a product or 
process, relating to 
biotechnology, 
proteomics. genomics 
and gene libraries or 
any technology that 
the source states as
arrangements include 
strategic alliances, 
licensing in agreements, 
co-promotion, co- 
marketing, franchising, 
consortia and 
outsourcing.
However this category 
does not include 
cooperative arrangements 
relating to the external 
raising of finance. This 
means those that involve 
the firm having equity 
placed in it by the partner 
firm or licensing out
agreements.__________
This can also include 
development of a new 
chemical entity (NCE), 
and development of a 
class of product that had 
not existed prior to the 
beginning of the study 
(P 1 January 1992) e.g. a
Product, process or NCE 
gains regulatory approval, 
has patent granted or is 
launched onto the market 
for the first time.
Product, process or NCE 
gains regulator}' approval, 
has patent granted or is 
launched onto the market 
for the first time.
being new to the firm, super statin.
Cooperative
innovation
(Information
Technology)
strategy
Actions that relate to
information
technology,
ecommerce or
ebusiness through a
cooperative
arrangement
Cooperative 
arrangements include 
strategic alliances, 
licensing in agreements, 
co-promotion, co- 
marketing, franchising, 
consortia and 
outsourcing.
Launch of an internet site, 
development of new 
software, advertising on the 
internet, accessing a global 
database
However this category 
does not include 
cooperative arrangements 
relating to the external 
raising of finance. This 
means those that involve 
the firm having equity 
placed in it by the partner 
firm or licensing out 
agreements
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Organic innovation 
(Information 
Technology) 
Strategy
Horizontal
integration
information 
technology, 
ecommerce or 
ebusiness througho
internal development
Merger or acquisition 
involving a firm that 
is broadly similar but 
that is not in the same 
supply chain e.g. a 
pharmaceutical firm 
acquiring a 
pharmaceutical firm.
Vertical integration Merger or acquisition 
involving a firm that 
is a customer or 
supplier eg a 
pharmaceutical firm 
acquiring a marketing 
organisation.
M&A concentric
diversification
strategy
Merger or acquisition 
of a firm that “may be
w
related to some 
distinctive 
competence or asset 
of the core business" 
(Mintzberg, 1991 
p79) e.g. a 
pharmaceuticals firm 
acquiring a generics 
business.
This is focused upon the 
merger or partial or full 
acquisition of a business
The text must be 
interpreted in light of the 
firm's main area of 
activity
The text must report that 
the relevant paperwork 
has been signed or 
regulatory approval given 
for the merger or
acquisition_________
This is focused upon the 
merger or partial or full 
acquisition of a business
The text must be 
interpreted in light of the 
firm’s main area of 
activity
The text must report that 
the relevant paperwork 
has been signed or 
regulatory approval given 
for the merger or
acquisition___________
This is focused upon the 
merger or partial or full 
acquisition of a business
Launch of an internet site, 
development of new 
software, advertising on the 
internet, accessing a global 
database
Successful completion of a 
merger or acquisition of a 
business
Successful completion of a 
merger or acquisition of a 
business
Successful completion of a 
merger or acquisition of a 
business
It does not include a 
business that is broadly 
similar or part of the 
supply chain
The text must be
Organic concentric 
diversification 
strategy
Conglomerate
diversification
strategy
Retrenchment
strategy
Internal generation of 
a separate business
Involving a firm that 
is completely 
unrelated to the 
pharmaceutical 
technology or 
healthcare industry 
and that does not fit 
the criteria for 
concentric 
diversification.
A strategy focusing 
upon restructuring, 
asset and cost 
reduction but does 
not include the sale of 
any parts of the firm
1 he spin off or creation 
of a new business which 
must be solely owned
This is focused upon the 
merger or partial or full 
acquisition of a business
The text must be 
interpreted in light of the 
firm’s main area of 
activity
The text must report that 
the relevant paperwork 
has been signed or 
regulatory approval given 
for the merger or
acquisition_____
To be interpreted 
alongside strategic 
actions that have been 
coded as reversed.
Spin off of a company, 
creation of subsidiary, 
affiliate company, new 
business or business unit
Successful completion of a 
merger or acquisition of a 
business
Closure of a plant, 
implementation of a 
redundancy programme.
Organic growth 
strategy
Divestment 
strategy
Liquidation
strategy
Corporate expansion 
activities which 
include an increase in 
assets and 
expenditure.
The sale of complete 
businesses ie business 
units, subsidiaries etc 
as going concerns.
This does not include the 
acquisition or merger of 
businesses or increases 
that are product specific
This does not include the 
selling off of parts of the 
firm e.g. a plant or a 
product line.
This does include a 
demerger.
Increase in staff, opening 
or acquisition of a new 
plant, opening of a new 
R&D facility, expansion of 
facilities or assets eg plant, 
workforce
Divestment of a business, 
subsidiary, spin off. wholly 
owned business or business
unit
The selling off of 
parts of a company as 
a result of the actions 
of an administrator. 
This includes the sale 
of complete 
businesses ie business 
units, subsidiaries, 
spin offs, or wholly 
owned businesses as 
going concerns as 
well as plants and 
product lines.
It may also include a firm 
dissolving subsidiary 
companies or assets but 
not include the sale 
(divestment) of complete 
businesses i.e. business 
units, subsidiaries, spin 
offs, or wholly owned 
businesses as going 
concerns by the company 
itself.
Divestment of a plant 
facility
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Joint venture
External finance 
raising strategy
The creation of a 
third “daughter” firm 
by two partner firms.
This form of strategy 
focuses upon how
pharmaceutical firms 
have raised 
investment through 
arrangements with
external 
organisations, 
firm or licensing out 
agreements.
Text will refer to either 
joint venture or jointly 
owned affiliate company,
business, business unit or 
spin off
Includes any cooperative 
arrangement where the 
firm has had equity 
placed into it by the 
partner firm.
Does not include the 
selling (liquidation or 
divestment) of assets
Spin off of a company, 
creation of subsidiary, 
affiliate company, new 
business or business unit
Gaining equity investment 
as a result of a cooperative 
arrangement, bank loan, 
Initial Public Offering 
(IPO), further issuing of 
shares, debenture 
investment, licensing out 
arrangements.
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DISCUSSION OF THE CATEGORISATION
Concentration (Market Penetration) Strategies
• Organic concentration (market penetration)
• Cooperative concentration (market penetration)
Strategic actions tor market penetration strategies are those that relate to an existing 
product in an existing theiapeutic market. From the empirical data market penetration 
stiategies were categorised as cooperative concentration and organic concentration 
stiategies. For the purposes of analysing strategic change these are considered to be 
pharmaceuticals/biotechnology products that do not incorporate genomics or proteomics 
technology which are categorized under innovation R&D below.
Relevant strategic actions identified for organic market penetration included products 
being refined and relaunched, such as Roche relaunching the weight-loss drug Xenical. 
This may also refer to product withdrawal for commercial reasons, such as 
IntemMune’s action with regard to lnfergen. Although the majority of product 
withdrawals were because of issues such as safety, firms also discontinued products 
during the development stage for commercial reasons. For example, this was the reason
why YM Biosciences stopped development of the vaccine EGF-P64k. despite its
0
completion of what appeared to be a successful Phase II study. Japan Tobacco decided 
to concentrate primarily on prescription products rather than its originally wider focus 
that had included over-the-counter and consumer healthcare products, although it did 
not completely divest all of the non-core products. Chugai also appeared to be taking 
action to increase its concentration on prescription drugs rather than other medical 
areas.
Patent extension strategic actions are also relevant to organic market penetration
strategies as they are used to extend the life of a product. This may be achieved through
an appeal to court for patent extension or legal action against a firm in respect of a
patent. This is illustrated by Pharmacia having brought a patent infringement suit
against Alcon with regard to the Xalatan trademark. Gideon Richter also brought a case
against five Japanese generics firms with regard to famotidine.
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Relevant strategic actions for cooperative concentration also included use of a contract 
saiesforce to sell an existing product e.g. Lilly sought to develop US sales of Evista by 
searching lor a "contract sales force" or a saiesforce to sell another firm's products that 
complement its own products and co-marketing arrangements, e.g. the agreement for 
Merck KGaA to co-market Novartis’ product Starlix.
Market Development Strategies
#
• Organic market development
• Cooperative market development
• M&A market development
Market development strategies are those which facilitate a firm's movement into a new 
therapeutic market. From the empirical data market development strategies were 
identified relating to organic, cooperative arrangements and product acquisition. For 
organic market development it was considered that strategic actions must relate to entry 
into a new therapeutic market that had been implemented by the firm itself. This is 
illustrated by Ranbaxy entering into the area ot diabetes. In comparison cooperative 
market development strategic actions related to those where a partnership was entered 
into. For example. Pfizer and Serono had a copromotion’agreement which allowed 
Pfizer to enter into the multiple sclerosis market. A R&D based collaboration with XTL 
Biopharmaceuticals provided Dyaz with entry into the area of infectious disease 
products. Serono entered into the psoriasis market through the granting of a license 
from Genentech to market Raptiva.
%
Product acquisitions (M&A market development) are another popular source of market 
development strategic action for firms in the pharmaceutical industry. This could relate 
to the acquisition of a single product or product line (portfolio) but not acquisitions of 
complete organisations. Bioglan realised a relevant strategic action to enter into the 
"moderate to severe pain control market’’ through the purchase of a product portfolio
from Pharmacia.
Product Development Strategies
• Organic product development (R&D)
• Cooperative product development (R&D)
• M&A product development
The development of an existing product or process using technology that was already 
used by the firm. Product development strategic actions do not refer to products or 
processes based upon relatively ‘new’ technologies such as genomics or proteomics. 
Also, the source must not state that the technology is new to the firm. Product 
development strategies have been categorised as those that are organic, cooperative and 
acquisition based. Relevant strategic actions can include products gaining regulatory 
approval, ha\ ing patents granted and/or launched onto the market for the first time.
M&A based product development strategic actions are those that meet the product 
development criteria and refers to acquisitions of a single product, product line or 
product poittolio. It does not lefer to the acquisition of whole firms. Relevant examples 
included King Pharmaceuticals extending its hypertension and women’s healthcare 
product line through the acquisition of rights to four Bristol-Myers Squibb products and 
Alpharma increasing its portfolio of generic liquid pharmaceuticals through the 
acquisition of eight approved ANDAs from UDL Laboratories. Cooperative product 
development was illustrated by Tanabe granting rights to Senju for developing, 
manufacturing and marketing the tablet form of bepotastine into an ophthalmic 
formulation. Another example refers to Choong Wae developing a compound from 
Janssen into a new formulation which resulted in a patent being granted for itraconazole 
for the local South Korean market. Organic product development includes firms 
developing various products in the R&D/product pipeline based upon a specific 
technology. This was illustrated through the example of RTP Pharma and the
application of its IDD technology.
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Innovation (R&D) Strategies
• Organic Innovation (R&D)
• Cooperative innovation (R&D)
Innovation R&D strategies refer to the development of a product or process relating to a 
change in technology. This may be a technology that is new to the firm or one based 
upon new technologies such as proteomics or genomics. Strategic actions can include 
the product, process or new chemical entities gaining regulatory approval, having a 
patent granted or being launched onto the market for the first time. This can also include 
development ot a class ol product that had not previously existed, such as a superstatin 
illustrated by AstraZeneca's development and launch of Crestor. These strategic actions 
were categorised on the basis of whether they applied to an organic innovation (R&D) 
strategy or those that related to cooperative agreements. No empirical examples were 
found to support a categorisation for acquisition-based innovation (R&D) strategies.
With regard to organic innovation (R&D) strategic actions, genomics research examples 
reported in Scrip during 2001-2002 included the setting up of subsidiaries to focus upon 
genomics and proteomics research. These included the establishment of the genomics 
focused CenoFunction by the Japanese firm Hisamitsu. Another new subsidiary was 
ZoeGene Corp. established by Mitsubishi Chemical to focus upon both proteomics and 
genomics research. Other firms, such as Sumitomo Pharma started building new 
pharmaceutical R&D facilities that could incorporate genomics research.
There were also a number of different types of strategic action that referred to 
cooperative innovation (R&D) strategic actions. These included pharmaceutical firms 
entereing into licensing in arrangements to access technology for genomic research, 
such as GlaxoSmithKline’s agreement with Valentis for its ‘-gene regulation platform 
technology”. Firms such as GlaxoSmithKline and Novo Nordisk licensed a gene library 
from the Swedish firm Biolnvent International. Entry into proteomics agreements 
included an alliance between MediChem Life Sciences and Celgene and a drug 
discoverv partnership between Oxford GlycoSciences and the I S based Institute loi
Systems Biology.
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Innovation (Information Technology) Strategies
Organic innovation (Information Technology) 
Cooperative innovation (Information Technology)
to actions realised b>Innovation (information technology) strategies refer 
pharmaceutical and biotechnology firms that relate to information technology, e- 
commerce or e-busmess through internal development. Innovation (information 
technology) stiategies were identified both as organic and as cooperative. Relevant 
cooperative strategic actions included the formation of a software company by Pfizer, 
IBM and Microsoft targeted at producing software products to provide doctors with 
electronic services for activities such as prescribing. With regard to organic innovation 
(information technology) strategic actions Aventis set up an internet site to help doctors 
communicate with patients by allowing them to carry out a number of activities online, 
such as 01 dering repeat prescriptions and making appointments. The internet was also 
used by some firms as part of their advertising campaigns, for example Nycomed 
Amersham used this medium as part of its promotion for OncoSeed.
Integration Strategies
Horizontal integration 
Vertical integration
Both horizontal and vertical strategic actions were identified. Horizontal integration 
refers to merger or acquisition involving a firm that is broadly similar but that is not in 
the same supply chain e.g. a pharmaceutical firm acquiring a pharmaceutical firm. This 
is focused upon the merger or partial or full acquisition of a business and is illustrated 
by Shire's acquisition of BioChem Pharma and Amgen’s acquisition of Immunex 
which led to the creation of the “world's largest biotech company”.
Vertical integration refers to the acquisition of a firm that was in a different part of the 
supply chain from the acquisitive firm, usually a customer or a supplier. For example.
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the outsouicing firm Global Health Care Partners (GHCP) acquiring the contract
manufacturer Laboratoires Thissen. Nextpharma acquired Thissen as part of its business 
filling a missing gap in Nextpharma’s supply chain.
Diversification Strategies
• Joint venture
• Organic concentric diversification
• M&A concentric diversification
• Conglomerate diversification
Joint venture refers to the creation oi a third '‘daughter** firm by two or more partner 
firms such as the firm formed by Schering-Plough and Merck & Co. In comparison 
organic concentric diversification refers to an organisation diversifying through the 
creation of new businesses. I hese could include the spin off of a company, creation of 
subsidiary, affiliate company, new business or business unit. Examples from the 
empirical data included the creation of Gencell, a company spun off by Aventis Pharma 
and Takeda America holdings establishing the subsidiary company Takeda Research 
Investment (TRI). M&A concentric diversification strategic actions relate to merger 
with or acquisition of a firm that “may be related to some distinctive competence or 
asset of the core business'* (Pearce II and Robinson, 1994:79) e.g. a pharmaceuticals 
firm acquiring a generics business. It does not include a business that is broadly similar 
or part of the supply chain. In contrast conglomerate concentric diversification refers to 
merger and acquisition activity involving a firm that is completely unrelated to the 
pharmaceutical technology or healthcare industry and that does not fit the criteria for 
concentric diversification. Bayer’s acquisition of the crop science business of Aventis
meets this criteria.
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Organic growth
Organic giowth refers to coipoiate expansion activities which include an increase in 
assets and expenditure. 1 his does not include the acquisition or merger of businesses or 
increases that aie product specific. Strategic actions identified from the empirical data 
included an increase in staif, opening or acquisition of a new plant, opening of a new 
R&D facility and expansion ol facilities or assets. Examples include the expansion of 
production facilities by EMS Sigma Pharma, Sumitomo Pharma’s expansion of its 
pharmaceutical R&D lacilitiy in Osaka and the establishment of new “genotyping 
facility and an increase in employees by Sequenom.
Retrenchment
Retrenchment refers to a strategy focusing upon restructuring, asset and cost reduction. 
Relevant strategic actions include closure of a plant or implementation of a redundancy 
programme but do not include the sale of any parts of the firm. This type of strategy can 
be illustrated by restructuring at firms such as Aventis, ICN and GlaxoSmithKline.
r
Divestment Strategy
A divestment strategy relates to strategic actions that involve the sale of complete 
businesses such as business units or subsidiaries as going concerns. This does not 
include the selling off of parts of the firm e.g. a plant or a product line but does include 
demergers. Relevant strategic actions include Akzo Nobel’s divestment of Rosemont 
Pharmaceutical and Pierre Fabre’s demerger from bioMerieux,
Liquidation Strategy
It has been argued that liquidation is a grand strategy as a firm attempts to liquidate 
certain assets (Pearce II and Robinson. 1994:79). As part of this strategy a firm may 
dissolve subsidiary companies or assets, but this does not include those that are sold off 
(divested) as going concerns. For example Nexell Therapeutics’ decision to liquidate
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Oxford Molecular, and Japan Tobacco dissolving Lifix. Liquidation may also refer to 
the selling off of parts of a company as a result of the actions of an administrator. This 
includes the sale of complete businesses i.e. business units, subsidiaries, spin offs, or 
wholly owned businesses as going concerns as well as plants and product lines. For 
example, after Bioglan went into receivership in 2002 various parts of the firm 
including Bioglan Pharma Inc, Bioglan Generics and Bioglan AB were sold.
External Finance Raising Strategy
An external finance raising strategy refers to strategic actions that focus on financing 
arrangements through external organisations. These can include equity partnerships 
and/or licensing agreements. This includes any cooperative arrangement where the firm 
has had equity placed into it by the partner firm. This does not include the selling 
(liquidation or divestment) of assets. Relevant strategic actions include gaining equity 
investment as a result of a cooperative arrangement, bank loans, Initial Public Offering 
(IPO), further issuing of shares, debenture investment and licensing out arrangements.
During 2001-2002 Skyepharma was one of the firms that issued new shares and Teva
#
Pharmaceutical industries placed a debenture offering. Initial Public Offerings were 
made by a number of firms including Far East Pharmaceutical Technology and 
biotechnology companies such as the German firm Morphochem. Sources of raising 
external finance through network based relationships included licensing out 
arrangements by Pierre Fabre with Cypress Bioscience and Lilly. Celltech placed 
equity finance into NeoGenesis as part of a research collaboration, and similarly Atrix 
Laboratories received an equity investment from Pfizer as part of an alliance agreement.
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APPENDIX C
EUROPEAN PHARMACEUTICAL FIRMS
Company Name
Active Biotech
Akzo Nobel_______
Almirall-Prodesfarma 
Amarin 
ASTA Medica 
AstraZeneca 
Aventis 
Bayer
Country of origin
Sweden
The Netherlands 
Spain
Germany 
UK
Position In Top 200 
Ranking Of 
Pharmaceutical 
Companies By 
Tu mover For Year 
2000
Bial___________________________ Portugal 141
Bioglan UK______________ 143
Biora Sweden 175
Biotest Germany 1 19
Boehringer Ingelheim Germany 18_______________ i
Byk Gulden Germany "45
Cangene Canada 153
Celltech UK 96
CeNeS Pharmaceuticals UK 186
Cerep France 195
Chiesi Italy 193
Cortecs UK 179
DSM The Netherlands 79
Elan Ireland 56
Esteve Spain 95
F Hoffmann-La Roche Switzerland 1°
Faes Spain 123
Ferrer Spain 117
Flamel Technologies France 182
Forest Laboratories_______________ US_______________ 53_______________
Fournier France ~86
Galen__________________________ UK______________ 140______________
Gerolymatos _______ Greece 166
GlaxoSmithKline________________ UK______________ 1
Grunenthal _________________ Germany 68
Innosenetics Belgium "T89
IsoTis __________ The Netherlands 197______________
Itafarmaco _____________ Italy 122
KRKA_________ _______________ Slovenia__________ 107______________
Lacer_________ _______ _________ Spain_____________ 128
Lafon_________________________ France ~\3\
LEK_______________ ___________ Slovenia 1 1 1
Lundbeck _ Denmark 66
M L Laboratories ______ UK 177 __________ 1
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Medivir
Merck KGaA
ModexCorp
Norgine Europe 
Novartis
Novo Nordisk
Nycomed Holdings 
Orion Pharma
Pierre Fabre
Pliva
Polifarma
Provalis
Reckitt Benckiser
Recordati 
Rhein Biotech 
Richter_______
Sanofi-Synthelabo
Schering AG 
Schwarz Pharma 
Serono
Servier
Shire________
Siegfried Group
Sigma_____
SkyePharma
Solvay
ST A DA 
Theramex
UCB
Valpharma
Vianex
Zambon
Sweden
Germany
Switzerland
fhe Netherlands
Switzerland
Denmark 
Denmark 
Finland 
France 
Croatia
Italy 
The Netherlands 
Hungary 
France 
Germany 
Germany 
Switzerland
Switzerland
Belgium
Germany 
Principality of 
Monaco
Belgium
Republic of San 
Marino
Greece
Source: Compiled by the author from Scrip Pharmaceutical League Tables 2001
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APPENDIX D
EUROPEAN FIRMS IN THE SAMPLE AND DETAILS
STRATEGIC OUTCOMES REPORTED IN SCRIP
DURING THE PERIOD
JANUARY 1st  2001 DECEMBER 31 ST 2002
Company Name in Scrip 
Pharmaceutical League Table 
( 2 0 0 0 )
Active Biotech 
Akzo Nobel
Almirall-Prodesfarma
Amarin
ASTA Medica
AstaZeneca
Aventis
Bayer 
Bial 
Bioglan
Biora
Biotest____________
Boehringer Ingelheim
Byk Gulden
Cangene
Celltech
CeNeS Pharmaceuticals
Results of Search into Name 
Change
No name change 
No name change 
No name change
Changed its name in 1999 from 
Ethical Holdings
No name change
No name change 
No name change 
No name change 
No data available 
No name change
No data available 
No name change 
No name change
Strategic Outcome Recorded
Changed name to Altana
Pharma_______
No name change
No name change
No name change
No change 
No change 
No change 
No change
Disbanded and divested by 
Degussa 
No change 
No change
No change_____
No data available_________
Went into administration and 
then liquidated 
No data available 
No change 
No change 
No change
No change
No change
No change
Cerep No name change No change
Chiesi
Cortecs
DSM
Elan
Esteve
F Hoffmann-La Roche
Faes
Ferrer
Flamel Technologies 
Fournier
Galen
Gerolvmatos
GlaxoSmithKline
Grunenthal 
Innogenetics
IsoTis
Itafarmaco
KRKA
No name change No change
No name change No change
Name changed to Royal DSM No change
No name change
No name change
No name change
No name change
No change
No change
No change
No name change
No change
No name change
No name change
No name change
No data available
No name change
No change
No change
No change
No change
No data available
No change
No name change 
No name change
No change
No change
No name change
No data available 
No name change
Merged with Modex 
Therapeutics 
No data available
No change
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Lacer
Lafon
LEK
Lundbeck
ML Laboratories
Medivir
Merck KGaA
Modex Corp (also referred to as 
Modex Therapeutics)
Norgine Europe 
Novartis
Novo Nordisk
Nycomed Holdings (also 
referred to as Norgine Pharma)
Orion Pharma 
Pierre Fabre 
Pliva 
Polifarma
Provalis 
Reckitt Benckiser 
Recordati
Rhein Biotech
Richter_________
Sanofi-Synthelabo 
Schering AG 
Schwarz Pharma 
Serono 
Sender
Shire_________
Siegfried Group
Sigma-Tau
No data available
No name change
No name change
No name change
No name change
No name change
Rebranded as EMD in North 
America and Merck elsewhere
Changed name to IsoTis 
No data available
No name change
No name change 
No name change 
No name change 
No data available 
No name change 
No name change 
No name change_______
To trade under the name Berna 
Biotech
SkyePharma
No name change 
No name change 
No name change 
No name change 
No name change 
No name change 
No name change 
No name change
No data available
Acquired by Cephalon
Acquired by Novartis
No change
No change
No change
No change
Merged with IsoTis
No data available 
No change
No change
Acquired by a consortium of 
investors led by CSFB Private 
Equity 
No change
Demerged from BioMerieux 
No change 
No data available 
No change 
No change
No change 
Acquired by Berna Biotech
No change 
No change
No name change
No change 
No change 
No change 
No change 
Merged with Biochem Pharma 
No change
No name change
No change
No change
Solvay No name change No change
STADA No name change No change
Theramex No data available No data available
UCB No name change
Valpharma No data available
Vianex No data available
No name change
No change
No data available
No data available
No changeZambon
Source: Compiled by the author based on data from various issues of Scrip 2001-2002
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APPENDIX E
CATEGORISATION USED FOR
CODING
Grand
Strategy
Network and 
acquisition 
based product 
development 
strategy
Definition of 
Grand Strategy
Cooperative
innovation
(Information
Technology)
strategy
Organic 
innovation 
(Information 
Technology) 
Strategy
Refinement of an 
existing product or 
development of a 
new product or 
licensing in a 
product through a 
cooperative 
arrangement. This 
includes internal 
development of a 
product, chemical. 
New' Chemical 
Entity (NCE) or 
process, through a 
cooperative 
arrangement. 
Innovative equals 
products that have 
been developed 
using
biotechnology, 
proteomics, 
genomics and other 
gene therapies. This 
includes products 
that are in clinical 
trials but have not 
yet been launched
Actions that relate 
to information 
technology, 
ecommerce or 
ebusiness through a 
cooperative 
arrangement
Actions that relate 
to information 
technology, 
ecommerce or 
ebusiness through 
internal 
development
Criteria for
Exclusions/qualifications
Cooperative arrangements 
include strategic alliances, 
licensing in agreements, 
co-promotion, co- 
marketing. franchising, 
consortia and outsourcing.
However this category 
does not include 
cooperative arrangements 
relating to the external 
raising of finance. This 
means those that involve 
the firm having equity 
placed in it by the partner 
firm or licensing out 
agreements.
Cooperative arrangements 
include strategic 
alliances, licensing in 
agreements, co-
promotion. co-marketing, 
franchising, consortia and 
outsourcing.
However this category 
does not include 
cooperative arrangements 
relating to the external 
raising of finance. This 
means those that involve 
the firm having equity 
placed in it by the partner 
firm or licensing out 
agreements.
Strategic Actions Derived from The Text Analysis
Product refined and relaunched; use of a contract 
salesforce to sell an existing product; patent extension 
strategic actions e.g. appeal to court for patent extension 
or legal action against a firm in respect of a patent; 
salesforce to sell another firm’s products that 
complement its own products; licensing in a product in 
order to market it, re-branding of an existing product; 
price cut or price increase;, launching a product into a 
new' therapeutic market
Product gains regulatory approval, has patent granted or 
is launched onto the market for the first time.
Launch of an internet site, development of new software, 
advertising on the internet, accessing a global database
Launch of an internet site, development of new softw are, 
advertising on the internet, accessing a global database
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Merger & 
Acquisition
This
incorporates:
Horizontal
integration
Vertical
integration
M&A
concentric
diversification
strategy
Merger or 
acquisition 
involving a firm 
that is broadly 
similar but that is 
not in the same 
supply chain e g. a 
pharmaceutical firm 
acquiring a 
pharmaceutical 
firm.
Merger or 
acquisition 
involving a firm 
that is a customer or 
supplier e.g. a 
pharmaceutical firm 
acquiring a 
marketing 
organisation.
I his is focused upon 
the merger or partial or
full acquisition of a 
business
The text must be 
interpreted in light of
the firm's main area of 
activity
I lie text must report 
that the relevant 
paperwork has been 
signed or regulator} 
approval given for the 
merger or acquisition 
This is focused upon 
the merger or partial or 
full acquisition of a 
business
The text must be 
interpreted in light of 
the firm’s main area of 
activity
Successful completion of a merger or acquisition of 
business
a
Successful completion of a merger or acquisition of a 
business
Merger or 
acquisition of a firm 
that "may be related 
to some distinctive 
competence or asset 
of the core 
business” 
(Mintzberg, 1991 
p79) e.g. a 
pharmaceuticals 
firm acquiring a 
generics business.
The text must report 
that the relevant 
paperwork has been 
signed or regulatory 
approval given for the 
merger or acquisition 
This is focused upon 
the merger or partial or 
full acquisition of a 
business
It does not include a 
business that is broadly 
similar or pait of the 
supply chain
The text must be 
interpreted in light of 
the firm’s main area of 
activity
The text must report 
that the relevant 
paperwork has been 
signed or regulatory 
approval given for the
Successful completion of a merger or acquisition of a 
business
Organic Internal generation 1 The spin off or creation i Spin oil of a company, creation of subsidiary, affiliate
concentric
diversification
strategy
of a separate 
business
of a new business 
which must be solely 
| owned |
company, new business or business unit
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Conglomerate
diversification
strategy
Involving a firm 
that is completely 
unrelated to the 
pharmaceutical 
technology or 
healthcare industry 
and that does not lit 
the criteria for 
concentric 
diversification.
1 his is focused upon 
the merger or partial or 
full acquisition of a 
business
The text must be 
interpreted in light of 
the firm's main area of 
activity
The text must report 
that the relevant 
paperwork has been 
signed or regulatory 
approval given for the 
merger or acquisition
Retrenchment A strategy focusing To be interpreted
strategy upon restructuring, alongside strategic
asset and cost actions that have been
reduction but does 
not include the sale 
of any parts of the 
firm
coded as reversed.
Organic Corporate T his does not include f
growth expansion activities the acquisition or
strategy which include an merger of businesses or
increase in assets increases that are
and expenditure. product specific
Liquidation The selling off of Does not include the T
strategy parts of the firm sale of complete
e.g. a plant or a businesses ie business
product line by an units, subsidiaries, spin
administrator offs, or wholly owned 
businesses as going 
concerns.
Divestment & The sale or partial This does not include
Demerger sale of complete the selling off of parts
strategy businesses ie of the firm e.g. a plant
business units, 
subsidiaries etc as
or a product line.
going concerns. This does include a 
demerger.
This does not include 
divestments that have 
occurred due to the 
company going into 
administration.
Joint venture The creation of a Text will refer to either 1 :
third “daughter” ioint venture or jointly i
firm by two partner owned affiliate
firms. company, business, 
business unit or spin off
Successful completion of a merger or acquisition of a 
business
C losure of a plant, implementation of a redundancy 
programme.
Increase in staff, opening or acquisition of a new plant, 
opening of a new R&D facility, expansion of facilities or 
assets eg plant, workforce
Divestment of a plant facility 
Divestment of a business, subsidiary , spin off. w holly 
owned business or business unit because the company has 
gone into administration
Divestment of a business, subsidiary , spin off, w holly 
owned business or business unit
271
External 
finance raising 
strategy
Product 
divestment 
and licensing 
out strategy
This form of 
strategy focuses 
upon how
pharmaceutical
firms have raised 
finance through 
arrangements with 
external 
organisations.
This form of 
strategy relates to a 
firm entering into or 
expanding licensing 
out agreements, the 
granting of 
marketing rights to 
products or 
divesting products
Does not include the 
selling (liquidation or
divestment) of assets or
licensing out 
agreements.
I his category does not 
include cooperative 
arrangements relating to 
the external raising of 
finance which involve 
the firm having equity 
placed in it by the 
partner firm.
This does not include 
divestment of a 
complete firm and does 
not include using 
another firm’s 
salesforce to sell the 
product. It does include 
cooperative agreements 
which involve 
payments being 
received from the 
partner firm(s), for 
example milestone 
payments.
Gaining equity investment as a result of a cooperative 
arrangement, bank loan. Initial Public Offering (IPO), 
further issuing of shares, debenture investment.
Divestment of a single product, product line or product 
portfolio or entering into/expanding licensing out 
agreements related to pharmaceutical products e.g.
granting a firm access to marketing rights to a product or 
patent rights.
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APPENDIX F
PUBLICATIONS AND CONFERENCE PAPERS
PtaT r S Were,based uP°n the literature review, data eolleetion and data 
anal\sis conducted loi my doctoral studies.
Peer Reviewed Conference Proceeding
Langley A.. Kakabadse. N. and Swailes, S. (2004). ‘A Methodological Framework 
or nalysing Strategic Change In The Pharmaceutical Industry’. British Academy of
Management Conference. 19 pages.
Forthcominu Publication
Langley, A., Kakabadse, N. and Swailes, S. (Forthcoming). ‘Grand Strategies and
Strategic Actions In The Pharmaceutical Industry: 2001-2002’, Technology Analyst 
& Strategic Management. 33 pages.
Papers Under Review
Langley, A., Kakabadse, N. and Swailes, S. The Evolution & Coevolution Of 
Realised Strategies Prior To Liquidation: The Case Of Bioglan Pharma Pic.,30 pages.
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